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Summary 
Malaria is a serious global health problem and in the absence of an effective vaccine, access 
to safe and effective treatment still remains the mainstay in the control of the disease. 
However, the efficacy of this control strategy is hampered by the emergence and spread of 
drug resistant malaria which may lead to excess of mortality. One of the greatest challenges 
for health authorities of malaria endemic countries is thus to decide on when and how 
antimalarial drug policy should be changed, so that most of the patients will fully recover 
from the disease and will be cleared from parasites. 
The current ‘gold standard’ for the assessment of antimalarial resistance is the estimation of in 
vivo drug efficacy, whereas in vitro drug sensitivity tests and the analysis of molecular 
resistance markers in the parasite serve as complementary tools. 
In the present study, we assessed the relevance of a new appraisal approach for malaria 
resistance: community-based cross-sectional surveys versus clinical malaria studies, and the 
usefulness of a new molecular technology for the identification of molecular markers in 
different parasite genes. The frequencies of single nucleotide polymorphisms (SNPs) in given 
resistance marker genes, as well as genotype patterns were analyzed in clinical samples and 
their role in predicting in vivo treatment response was investigated. Furthermore, community 
drug resistance profiles were correlated with the incidence risk of clinical treatment failure in 
order to evaluate the relevance and usefulness of such a novel approach in the management of 
drug use. 
In Papua New Guinea (PNG), the 4-aminoquinoline drugs amodiaquine (AQ) and chloroquine 
(CQ) have been first-line treatment against uncomplicated malaria until the late 1990s. At the 
same time, resistance of Plasmodium falciparum and P. vivax to these drugs had reached 
unacceptably high levels and health authorities were prompted to revise antimalarial treatment 
policy in 1997. First efficacy trials with the combination of AQ or CQ plus SP conducted 
between 1998 and 1999 showed good efficacy against falciparum and vivax malaria and the 
PNG Department of Health chose these combination regimens to replace the monotherapy 
with AQ or CQ as the standard first-line treatment against uncomplicated malaria in 2000. 
The in vivo studies we conducted between 2003 and 2005 were the first ones to assess the 
therapeutic efficacy of the newly introduced combination regimen against P. falciparum and 
P. vivax malaria using the revised WHO standard protocol. In our studies conducted in three 
different areas over the period of three consecutive years, we observed PCR-corrected 
treatment failure rates up to 28% for P. falciparum and 12% for P. vivax malaria. 
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Regarding former drug history in PNG (i.e., long lasting 4-aminoquinoline use and sporadic 
use of SP as mass chemprophylaxis or partner drug with quinine for second-line treatment), 
we found a genetic background in the parasite population that is associated with high CQ as 
well as moderate pyrimethamine resistance. We also observed the emergence of mutations 
concordant with a sulphadoxine resistant phenotype, indicating that the efficacy of the sulpha 
component is already compromised. Further results that identified key pfdhps mutations to be 
most relevant in predicting treatment failure with the current first-line regimen corroborated 
our findings that AQ and CQ as inefficacious partner drugs of SP in the new standard 
treatment were not able to curb both, the progression of pyrimethamine resistance as well as 
the emergence of sulphadoxine resistance in PNG. 
We have shown that our community-based molecular monitoring approach was feasible in 
PNG and that molecular monitoring of parasite resistance can indeed be a valuable 
supplementary tool in malaria resistance surveillance. However, our data also clearly 
highlighted several drawbacks of the presently applied methods for the assessment of 
resistance, the most important being the lack of standardised methods that are applicable in 
different epidemiological settings. In addition, our data indicate that currently suggested 
public health models for the molecular monitoring of parasite resistance are not suitable for 
universal application in settings which are different with regard to several factors such as 
malaria endemicity, transmission intensity and drug use patterns. 
To summarize, decreasing in vivo efficacy of the current first-line regimen in PNG and the 
molecular drug resistance profile of the parasite population consistent with a CQ and SP 
resistant phenotype strongly indicate that a policy change to artemisinin-based combination 
therapy (ACT) has to be considered in the near future. We have shown that a careful baseline 
evaluation of the molecular resistance background is needed for the identification of the most 
relevant molecular markers for longitudinal monitoring in a given area. The novel DNA 
microarray-based method which allows the parallel analysis of multiple drug resistance-
associated SNPs has been proven to be a valuable tool to assess the usefulness of each known 
molecular marker in a particular region with specific drug use. Moreover, the new technology 
enabled the assessment of molecular markers on an epidemiological scale and hence opened 
the avenue for the investigation of a more comprehensive community-based monitoring 
programme. 
To conclude, the novel technical tool for the assessment of molecular markers of parasite 
resistance presented in the current study is cheap, easy to use, and applicable in laboratories 
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with limited infrastructure. Moreover, the technology is highly versatile and allows rapid 
adaptation to specific monitoring needs, the most important at the moment being the close 
monitoring of resistance to the highly effective artemisinin derivates and potential partner 
drugs in ACTs. Though molecular markers have been proven to be useful as an early warning 
system, their usefulness in predicting treatment response and the progression of resistance is 
still limited. Hence, currently suggested public health models based on molecular data will 
have to include additional parameters for important determinants of parasite resistance and to 
be evaluated in varying epidemiological settings before molecular methods may eventually 
replace in vivo efficacy studies for the surveillance of resistance. 
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Zusammenfassung 
Malaria ist nach wie vor eine Tropenkrankheit mit immenser gesundheitspolitischer 
Tragweite. Da ein wirksamer Impfstoff in absehbarer Zeit nicht zur Verfügung stehen wird, 
ist die korrekte Diagnose der Krankheit und eine erfolgreiche Behandlung immer noch die 
wichtigste Kontrollstrategie gegen diese Infektionskrankheit. Die Strategie wurde aber in den 
letzten Jahren durch das Auftreten und die Verbreitung medikamenten-resistenter Parasiten 
stark beeinträchtigt und könnte in den nächsten Jahren die durch Malaria bedingte Morbidität 
und Mortalität erhöhen. Daher ist die Entscheidung, wann und wie die nationale 
Behandlungsstrategie gegen Malaria geändert werden soll, eine der grössten 
Herausforderungen für die Gesundheitsbehörden in Malaria-endemischen Gebieten. 
Der Goldstandard zur Bestimmung der Medikamentenresistenz ist immer noch die 
Durchführung von klinischen Studien zur Erfassung der Wirksamkeit eines Präparats. 
Laborverfahren zur Bestimmung der in vitro-Resistenz gegen einzelne Wirkstoffe in 
Parasitenkulturen oder molekularer Resistenzmarker im Parasiten werden heute als 
zusätzliche Methoden eingesetzt. 
In der vorliegenden Arbeit wurden zwei neue Ansätze zur Erfassung der 
Medikamentenresistenz untersucht. Zum einen wurden klinische Studien zur Bestimmung der 
Wirksamkeit des gegenwärtigen Behandlungsstandards in Papua Neuguinea (PNG) an 
mehreren Gesundheitszentren durchgeführt und von Querschnittsstudien in den 
Dorfgemeinschaften der entsprechenden Einzugsgebiete begleitet. Zum anderen wurde eine 
neue molekulare Methode zur Bestimmung von Punktmutationen in verschieden 
Parasitengenen entwickelt und getestet. Hiermit wurde die Häufigkeit einzelner 
Resistenzmarker sowie auch die Muster unterschiedlicher Marker in klinischen Proben 
bestimmt, um diese Marker potentiell zur Vorhersage des Behandlungsausgangs zu 
verwenden. Gleichzeitig wurde das Muster der Resistenzmarker in Parasiten in Proben der 
jeweiligen Querschnittsstudien bestimmt. Die verschiedenen Resistenzprofile der 
verschiedenen Regionen wurden mit der Inzidenz von Behandlungsmisserfolgen an den 
jeweiligen Gesundheitszentren verglichen. Hierbei war es Hauptziel, die Relevanz und 
Nützlichkeit eines solchen Ansatzes (Querschnittsstudien zur Bestimmung des molekularen 
Resistenzmusters in der Parasitenpopulation) zur Überwachung der Resistenzsituation 
abzuschätzen. Zusätzlich sollte beurteilt werden, inwiefern ein solcher Ansatz bei der 
Erstellung von Behandlungsstrategien hilfreich sein könnte. 
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In PNG wurden bis Ende der 90iger Jahre zur Behandlung klinisch unkomplizierter Malaria 
fast ausschlieslich Medikamente der 4-Aminoquinolin-Gruppe, Amodiaquin (AQ) und 
Chloroquin (CQ), verwendet. Gleichzeitig entwickelte sich Resistenz dagegen in Plasmodium 
falciparum und P. vivax. Nachdem die Resistenz ein nicht mehr akzeptables Ausmass 
angenommen hatte, waren die Gesundheitsbehörden in PNG 1997 schliesslich gezwungen, 
die Behandlungsstrategie gegen Malaria zu revidieren. Nachdem erste klinische Studien mit 
der Kombinationstherapie AQ oder CQ plus Sulfadoxin-Pyrimethamin (SP) zwischen 1998 
und 1999 gute Wirksamkeit gegen falciparum- und vivax-Malaria gezeigt hatten, wurde diese 
Kombinationstherapie dann schliesslich im Jahr 2000 vom Gesundheitsdepartement offiziell 
zum neuen Behandlungsstandard erklärt. 
Die hier vorgelegten klinischen Studien waren die ersten, welche die Effizienz der neuen 
Kombinationstherapie unter Berücksichtigung des neu revidierten Protokolls der 
Weltgesunheitsorganisation (WHO) bestimmt haben. In diesen Studien, die zwischen 2003 
und 2005 in drei verschiedenen Regionen PNGs durchgeführt wurden, wurden 
Behandlungsmisserfolgsraten von bis zu 28% für P. falciparum und 12% für P. vivax 
gemessen. 
Bedingt durch die bisherige Behandlungsstrategie in PNG (langanhaltender Gebrauch von 4-
Aminoquinolinen und sporadischer Einsatz von SP während Massenbehandlungskampagnen) 
wurde auf molekularer Ebene ein hoher Grad an CQ-Resistenz und das Vorkommen von 
Pyrimethamin-Resistenz beobachtet. Gleichzeitig belegen die vorliegenden Daten das 
ansteigende Auftreten genetischer Parasitenresistenz gegen Sufadoxin. Mutationen im P. 
falciparum dhps-Gen, welches hauptverantwortlich für die Sulfadoxinresistenz ist, waren 
auch die Marker mit dem besten Vorhersagewert für Behandlungsmisserfolg. Diese Daten 
zeigen, dass die pharmakologische Wirkung von AQ/CQ in der jetzigen Kombination nicht 
genügend war, um sowohl das Ausbreiten der Resistenz gegen Pyrimethamin, als auch das 
Entstehen der Resistenz gegen Sulfadoxin zu verhindern. 
Es konnte auch gezeigt werden, dass die Erstellung eines genetischen Resistenzprofils der 
Parasiten in Querschnittsstudien in PNG erfolgreich eingesetzt werden kann und dass 
molekulare Marker wichtige Hinweise zur Wirksamkeit verschiedener Medikamente geben 
können. Die hier vorliegende Arbeit verdeutlicht allerdings auch die Probleme der gängigen 
Methoden zur Bestimmung der Resistenz, wie zum Beispiel das Fehlen von standardisierten 
Protokollen, die in Regionen mit unterschiedlicher Malariaepidemiologie gleichermassen 
angewendet werden können. Bisher vorgeschlagene Modelle zur molekularen Überwachung 
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von Medikamentenresistenz scheinen zudem nicht universell anwendbar zu sein. Dies ist 
möglicherweise auf Unterschiede in wichtigen epidemiologischen Eigenschaften wie 
Krankheitsendemizität, Übertragungsintensität, oder Gebrauch von Medikamenten zurück zu 
führen. 
Zusammenfassend haben die klinischen und molekularen Resultate dieser Arbeit gezeigt, dass 
die Effizienz der heutigen Behandlungsstrategie in PNG sehr wahrscheinlich nur noch von 
kurzer Dauer sein wird und dass ein Wechsel zu einer auf Artemisinin-Derivaten basierenden 
Kombinationstherapie in Betracht gezogen werden muss. 
Die Studie zeigte, dass eine umfassende Bestimmung der molekularen Marker und deren 
Einfluss auf den Behandlungserfolg wichtig ist, um geeignete Marker für die longitudinale 
Resistenzüberwachung zu identifizieren. Die hier vorgestellte DNA-Mikroarray Technologie 
zur Bestimmung von mehreren Punktmutationen in verschiedenen resistenz-assoziierten 
Genen hat sich als ideales Werkzeug für diesen Zweck erwiesen. Wichtige Kriterien, zum 
Beispiel einfache Handhabung und tiefe Kosten, machen die Methode praktikabel für 
Laboratorien mit beschränkten Mitteln. Sie ermöglicht einen grossen Probendurchsatz und ist 
daher für epidemiologische Studien geeignet. Als wichtiger Punkt sei die hohe Flexibilität des 
Systems erwähnt, da das Einschliessen verschiedenster Punktmutationen eine Überwachung 
der Resistenzdynamik von P. falciparum gegen bereits verwendete und/oder zurückgezogene, 
als auch gegen momentan empfohlene und bisher noch nicht verwendete Medikamente 
erlaubt. 
Obwohl sich molekulare Resistenzmarker als Frühwarnsystem hilfreich erwiesen haben und 
verschiedenste Marker und/oder Markerkombinationen für die Überwachung der Resistenz 
gegen diverse Medikamente schon vorgeschlagen wurden, zeigt die Diskrepanz der Daten, 
dass auch wichtige andere epidemiologische Faktoren die Resistenzdynamik in einer 
bestimmten Region bestimmen. Daher wird es zunehmend wichtig, dass bestehende Modelle 
zur Resistenzdynamik, welche molekulare Daten verwenden, zusätzliche Faktoren 
einschliessen, um dann in Regionen mit unterschiedlichen Misserfolgsraten der Behandlung 
und mit unterschiedlichem Medikamentengebrauch getestet zu werden. Abgesehen von der 
Prävalenz der molekularen Resistenzmarker werden in zukünftigen Modellen auch 
Indikatoren für andere wichtige Determinanten der Resistenzdynamik, wie zum Beispiel 
Übertragungsintensität oder Medikamentengebrauch berücksichtigt werden müssen. 
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1. The burden of malaria 
Malaria is one of the most important infectious diseases in the world, affecting mainly the 
tropics and the sub-tropics. At present, about 100 countries or territories are considered 
malarious, with nearly 50% of them in Sub-Saharan Africa. Globally, approximately 3 billion 
people corresponding to 40% of the world’s population are at risk of infection (Hay et al., 
2004). Malaria is a vector-borne parasitic disease caused by intracellular protozoan parasites 
of the genus Plasmodium. Four species, P. falciparum, P. vivax, P. malariae and P. ovale, 
infect humans. The parasites multiply asexually in the human host and go through sexual 
reproduction in the anopheline mosquito vector (Figure 1). Each type of infection causes 
debilitating febrile illness, but approximately 90% of clinically manifest infections are caused 
by P. falciparum. P. vivax accounts for nearly 10% of the global malaria incidence. The main 
causes of mortality are severe anaemia and cerebral malaria caused by P. falciparum. Recent 
estimates suggest that between 500 million and 5 billion clinical episodes and up to 3 million 
deaths occur each year due to malaria, with Sub-Saharan Africa having 90% of this mortality 
burden. Moreover, the devastating consequences of malaria are a major obstacle to social and 
economic development in affected regions (Breman et al., 2004; Mendis et al., 2001; Snow et 
al., 2005). 
In the 1950s and early 1960s, elimination of malaria seemed possible and the World Health 
Organization (WHO) launched the Global Malaria Eradication campaign with a main focus 
on indoor residual spraying (IRS) with dichlorodiphenyltrichloroethane (DDT) and mass drug 
administration (MDA) with chloroquine (CQ) or pyrimethamine (PYR). The eradication 
strategy was not only abandoned due to logistical, social and political reasons, but mainly 
because of the occurrence of chemoresistance in both, the vector and the parasite 
(D’Alessandro & Buttiens, 2001). Thereafter, the world was facing a rapid resurgence of the 
disease. This has been attributed to several factors, such as the change of agricultural practices 
creating new vector breeding sites, political crises leading to a weakening of public health 
systems, and long-term climate changes favouring malaria transmission (Sachs & Malaney, 
2002). 
In the absence of an effective vaccine, current control efforts of the global partnership 
program Roll Back Malaria (RBM) clearly focus on reducing malaria morbidity and 
mortality. Methods include the reduction of transmission by either lowering vector densities 
using insecticides or biological measures and reducing their contact with humans by the use 
of insecticide-treated mosquito-nets. A further element is the early detection or forecasting of 
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malaria epidemics and rapid application of appropriate control measures. But the cornerstone 
in the control of the disease is the reduction of malaria cases by early diagnosis followed by 
prompt and effective treatment and prophylaxis of people at greatest risk (i.e., infants and 
pregnant women) (WHO, 2005a; RBM, 2006). 
However, the efficacy of this control strategy is hampered by the emergence and spread of 
drug resistant malaria which is the major challenge in the control of the disease at present. 
Therefore, research efforts into the design and development of new antimalarial drugs, which 
are safe, effective and affordable, have to be sustained. Important measures to prevent or 
delay the spread of resistance include the protection of currently used and newly introduced 
drugs by combination therapy (White, 1999) and improvement of access to prompt and 
effective treatment (Panosian, 2005). Further critical elements to detain resistance include the 
adoption of adequate methods to assess and monitor drug resistance in order to deploy 
evidence-based drug policies (Olliaro & Taylor, 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The life cycle of the malaria parasite (Source: Phillips, 2001) 
Chapter 1: Introduction   4
2. Antimalarial chemotherapy 
The elimination of malaria from most regions in Europe and North America lead to a loss of 
interest in malaria for more than 25 years. Between 1975 and 1999, only 4 of 1393 newly 
developed drugs were antimalarials (Trouiller et al., 2002). Because of the limited armoury of 
drugs in endemic countries and a lack of affordable new drugs, malaria control has heavily 
relied on a restricted number of medicaments mainly belonging to the quinolines and the 
antifolates. It has been only recently that the artemisinin-based compounds have been 
introduced widely. Because the useful therapeutic life (UTL) of many of the currently used 
drugs is severely compromised by drug resistance and newly introduced drugs have to be 
protected, combination therapy using compounds belonging to different drug classes is 
strongly recommended (Kremsner & Krishna, 2004; WHO 2001; WHO, 2006). The most 
common antimalarials used in malaria control programmes, either as mono- or combination 
therapy and their mode of action are summarised in Table 1. 
 
2.1 Quinolines 
The 4-aminoquinolines chloroquine (CQ) and amodiaquine (AQ) and the related quinoline 
methanols quinine (QUIN) and mefloquine (MEF) have been the mainstay of malaria 
chemotherapy during much of the past 40 years. Halofantrine (HAL), another related 
phenanthrene methanol, is no longer recommended due to the occurrence of fatal 
cardiotoxicity, low bioavailability and its high cost (Nosten et al., 1993). The new analogue 
lumefantrine (LUM) was developed and is now a component of the combination regimen co-
artemether (Riamet®, Coartem®; van Vugt et al., 2000). Primaquine (PRIM) is an 8-
aminoquinoline which is highly active against gametocytes of all malaria species in humans 
and the hypnozoites of the relapsing species P. vivax and P. ovale. It is recommended as 
antirelapse treatment and gametocytocidal drug against P. falciparum in low or non-
transmission areas only (WHO, 2006). Despite extensive studies and the proposition of 
various mechanisms (reviewed in O’Neill et al., 1998), the mode of action of these drugs is 
not completely understood. However, the commonly accepted hypothesis is that quinoline-
containing drugs accumulate in the digestive vacuole (DV) of the intraerythrocytic parasite 
and primarily interfere with haemoglobin metabolism. Degradation of haemoglobin by the 
parasite produces toxic byproducts, the most important being ferriprotoporphyrin IX (FPIX or 
haem) and free oxygen radicals, which have to be detoxified by a series of parasite-specific 
processes (Francis et al., 1997). The major mechanisms postulated to be involved in CQ 
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accumulation are 1) trapping of the weak base CQ in the acidic DV through passive diffusion 
down a pH gradient, 2) active uptake of CQ by specific transporters, and 3) binding of CQ to 
the intravacuolar receptor haem (reviewed in Foley & Tilley, 1998). The build-up of CQ-
haem complexes subsequently interferes with DV functions eventually leading to parasite 
death through the following mechanisms. CQ interferes with haem detoxification by the 
inhibition of its polymerization to β-haematin and sequestration as malaria pigment 
haemozoin (Bray et al., 1999; Egan et al., 1994; Slater, 1993). The inhibition of peroxidase 
degradation (Loria et al., 1999) and glutathione-dependent degradation of unpolymerized 
haem (Ginsburg et al., 1998; Zhang et al., 1999) leads to peroxidative damage of parasite 
proteins and lipids and membrane disruption. The closely related AQ has been suggested to 
exert its activity by a similar mechanism (Foley & Tilley, 1998) because efficiency of haem-
binding and inhibition of haem-polymerization have been shown to be comparable to CQ 
(O’Neill et al., 1997; Slater, 1993). Data are conflicting as to whether the mode of action of 
quinoline/phenantrene methanols is similar to that of CQ (Foley & Tilley, 1997). However, 
there are several lines of evidence that the interaction with haem is also central to the activity 
of QUIN, MEF and HAL (Bray et al., 1999; Mungthin et al., 1998; Slater et al., 1993). Drug 
action of 8-aminoquinolines seems to be different from that of 4-aminoquinolines (Meshnick 
& Marr, 1992) and PRIM has been proposed to exert its activity by interfering with 
mitochondrial function (Beaudoin & Aikawa, 1968; Boulard et al., 1983). 
 
2.2 Antifolates 
In contrast, the primary targets of another important drug class, the antifolates, have long been 
established. Antifolates exert their antimalarial action by disruption of the de novo 
biosynthesis of folate, an important co-factor in the amino acid, purine and pyrimidine 
pathways, which eventually leads to blockage of DNA synthesis and lowered production of 
glycine and methionine (Krungkrai et al., 1989). There are two important groups of 
antifolates: 1) the sulpha drugs, such as sulphadoxine (SDX) and dapsone (DAP), which are 
structural analogues of para-aminobenzoic acid (pABA) and inhibit dihydropteroate 
synthetase as part of a bifunctional protein with hydroxymethylpterin pyrophosphokinase 
(PPPK-DHPS), and 2) pyrimethamine (PYR) and proguanil (PG), which is metabolised in 
vivo to the active form cycloguanil (CG), both inhibiting dihydrofolate reductase as part of the 
bifunctional enzyme with thymidylate synthetase (DHFR-TS) (Yuthavong, 2002). Due to 
their marked synergistic effect (Chulay et al., 1984), DHFR and DHPS antagonists are mainly 
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used as combination regimens, the most common being SDX plus PYR (SP, Fansidar™) and 
PG plus DAP (Lap-Dap™) (Watkins, 1997). 
 
2.3 Artemisinins 
An important new and entirely different class of compounds originates from the Chinese herb 
qinghao (Artemisia annua) from which the parent compound artemisinin was first isolated in 
the 1970s. Since then, several analogues, such as dihydroartemisinin, arteether, artemether 
and artesunate, with better bioavailability have been developed. Artesiminins are 
endoperoxide-containing sesquiterpene lactones. A number of studies have shown that the 
endoperoxide-bridge can be cleaved by reductive interaction with iron, yielding free radicals 
that lead to parasite death, possibly by alkylation of different plasmodial targets (Meshnick et 
al., 1996; Olliaro et al., 2001). The formation of covalent adducts between artemisinins and 
haem and several plasmodial and host proteins have been described, but the precise 
mechanisms involved in antimalarial activity are still to be resolved (Krishna et al., 2004; 
Meshnick, 2002). More recently, an alternative hypothesis for the mode of action has been 
proposed, based on structural similarities between artemisinin and thapsigargin, a potent 
inhibitor of sarcoendoplasmic reticulum Ca2+-ATPases (SERCAs) in a variety of organisms 
(Eckstein-Ludwig et al., 2003). Evidence in favour of this hypothesis included the specific 
inhibition of the SERCA of P. falciparum (PfATPase6) by artemisinins, the interference of 
thapsigargin with the action of artemisinins, the iron-dependent inhibition of PfATPase6, and 
the strong positive correlation between inhibition of PfATPase6 and death in cultured 
parasites. The artemisinins have considerable advantage over other antimalarials because they 
kill parasites more rapidly and affect a broader range of asexual blood stages (Hien & White, 
1993). Unlike 4-aminoquinolines and antifolates, which exert their antiparasitic action on 
schizonts, artemisinins also impede gametocytes, which limits transmission to new hosts 
(Price et al., 1996; Targett et al., 2001). Moreover, they inhibit important pathophysiological 
processes, such as cytoadherence and rosetting, more effectively than other drug classes 
(Udomsangpetch et al., 1996). 
 
2.4 Other drug classes 
Atovaquone (ATQ) is a naphthoquinone derivate and a structural analogue of coenzyme Q 
(ubiquinone). ATQ acts by specifically binding to the ubiquinone oxidation site in the 
cytochrome bc1 complex (CYT bc1) in the electron transport chain and collapsing 
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mitochondrial membrane potential in the parasite (Srivastava et al., 1999a). Though 
inappropriate as monotherapy due to rapid selection of resistant parasites, ATQ is clinically 
successful when used in combination with the synergistically acting partner drug PG 
(Malarone™) for both, chemoprophylaxis and therapy of P. falciparum malaria 
(Looareesuwan et al., 1999; Hogh et al., 2000; Srivastava et al., 1999b). 
A number of antibiotics, such as tetracycline (TET) and doxycycline (DOX), are effective, 
though slow-acting, antimalarial compounds. They are suggested to inhibit different steps of 
prokaryote-like protein synthesis in the apicoplast of the parasite (Ralph et al., 2001). 
However, they are currently used in combination with other dugs or as chemoprophylactic 
agents in non-immune travellers only (WHO, 2005b). 
 
Table 1: Mode of action of current antimalarial drug classes 
 
Drug class Members Target location Target molecule Efficacy 
Antifolates 
PYR, PG 
SDX, DAP 
Cytosol 
DHFR, 
DHPS 
Blood-stage schizonticide 
Quinolines 
CQ, AQ, QUIN, 
MEF, HAL, LUM 
PRIM* 
Food vacuole 
Haem, 
Others? 
Blood-stage schizonticide 
Gametocytocide* 
Tissue-stage schizonticide* 
Artemisinins 
Dihydroartemisinin 
and derivates 
Food vacuole 
PfATP6 
Others? 
Blood-stage schizonticide, 
Gametocytocide 
Naphthoquinones ATQ Mitochondrion Cytochrome bc1 Blood-stage schizonticide 
Antibiotics DOX, TET Apicoplast Apicoplast ribosome Blood-stage schizonticide 
 
PYR, pyrimethamine; PG, proguanil; SDX, sulphadoxine; DAP, dapsone; DHFR, 
dihydrofolate reductase; DHPS, dihydropteroate synthase; CQ, chloroquine; AQ, 
amodiaquine; QUIN, quinine; MEF, mefloquine; HAL, halofantrine; LUM, lumefantrine; 
PRIM, primaquine; * PRIM has tissue-schizonticidal and gametocytocidal activity; 
PfATPase6, Plasmodium falciparum ATPase6; ATQ, atovaquone; DOX, doxycycline; TET, 
tetracycline 
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3. Drug resistant malaria 
3.1 Epidemiology 
The parasite’s ability to develop resistance affects all currently available drugs except the 
artemisinin derivates, although the degree of resistance varies depending on different drugs 
and regions (Bloland, 2001). 
After the introduction in 1943, CQ came into universal use as therapeutic and prophylactic 
agent against malaria. The success has been based on high clinical efficacy, good safety and 
tolerability, ease of use and cost-effective production. However, resistance to CQ was first 
described at the Thai-Cambodian border in the late 1950s (Harinasuta et al., 1965) and in 
Colombia and Venezuela in the 1960s (Payne, 1987). A further focus emerged in the 1970s in 
Papua New Guinea (PNG) (Grimmond et al., 1976). In Africa, CQ resistance was first 
documented in the late 1970s in Kenya (Fogh et al., 1979) and Tanzania (Campbell et al., 
1979), and spread first to the central and southern parts before arriving in West Africa in 
1983. By 1989, CQ resistance was widespread in Sub-Saharan Africa (Wernsdorfer & Payne, 
1991). Today, P. falciparum resistance to CQ occurs everywhere except in Central America, 
the island of Hispaniola and some regions of Southwest Asia (WHO, 2005b). Recent data 
from population genetic surveys suggest that CQ resistance emerged independently at a 
limited number of sites: two in South America (Cortese et al., 2002; Wootton et al., 2002), 
one in PNG (Mehlotra et al., 2001), and one on the Philippines (Chen et al., 2003). These data 
had shown similarities of parasites from Asian and African origin, but differences from those 
from South America and PNG, supporting the hypothesis that parasite migration played a 
critical role in the spread of CQ resistance (Wellems & Plowe, 2001). 
Despite the widespread use of CQ, resistance of P. vivax has been very limited, apparently 
having originated in PNG (Rieckmann et al., 1989; Schuurkamp et al., 1992). CQ resistant P. 
vivax malaria may be characterized as endemic to the Indonesian archipelago, sporadic in the 
rest of Asia, and rare in South America (Baird, 2004). 
The spread of CQ resistant malaria has led to increasing use of the combination regimen 
sulphadoxine-pyrimethamine (SP) as standard first-line regimen in many countries. Antifolate 
resistance emerged almost instantaneously and independently from several areas where the 
drug had been introduced on national level. First reported at the Thai-Cambodian border in 
the late 1960s (Björkman & Phillips-Howard, 1990), high-level SP resistance was rapidly 
spreading in southeast Asia and the Amazon Basin and moderate frequencies were observed 
on the Pacific coast of South America, in southern Asia and Oceania (Bloland, 2001). In 
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Africa, sensitivity started to decrease in the late 1980s, with the highest levels reported from 
the eastern part of the continent (Wongsrichanalai et al., 2002). Similar to CQ resistance, 
molecular data suggest that resistance to antifolates has arisen at only a few independent foci 
and was followed by inter- and intracontinental spread of resistant parasites (Cortese et al., 
2002; Nair et al., 2003; Roper et al., 2004). 
Reports of clinical resistance to QUIN have been started to accumulate since the mid-1960s, 
especially from the Thai-Cambodian border. High levels of resistance were described in 
Thailand in the 1980s, where the introduction of QUIN monotherapy as interim therapy 
against SP resistant malaria has led to a rapid decrease in sensitivity to the drug (Wernsdorfer, 
1994). Therefore, QUIN has been used in combination with other drugs during the following 
decades and is currently recommended as second-line regimen against uncomplicated malaria 
and treatment of severe cases only (WHO, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Malaria transmission areas and reported drug resistance in 2004 
  (Source: WHO, 2005a) 
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Resistance to MEF was first reported from the Thai-Cambodian border in the late 1980s, five 
years after it has been introduced (Wongsrichanalai et al., 2001). The high level of MEF 
resistance in Thailand was most probably due to the heavy use of the chemically related drug 
QUIN (Brasseur et al., 1992). Though there have been sporadic reports of clinical failure 
from the Amazon Basin, Bangladesh and India (Wernsdorfer, 1994), and reduced in vitro 
sensitivity of P. falciparum strains in Africa has been observed (Jelinek et al., 2001), MEF 
resistance is rare outside Southeast Asia. 
Resistance to ATQ developed in 1996, the same year when the drug was introduced 
(Looareesuwan et al., 1996) and is currently used as fixed-dose combination with PG 
(Malarone™) only. 
Foci of established multidrug resistant malaria, defined as resistance to more than three 
operational antimalarial compounds, are found at the border region of Thailand and Cambodia 
and Myanmar, respectively, and some focal areas in the Amazon Basin (Wongsrichanalai et 
al., 2002). 
 
3.2 Molecular basis of parasite resistance to antimalarial drugs 
Advances in the understanding of the mechanisms of drug action during the last two decades 
have led to the identification of the putative molecular targets and the genetic basis 
responsible for parasite resistance to antimalarial drugs. Genetic events conferring resistance 
include single point mutations in or changes of copy numbers of genes encoding drug targets, 
such as important enzymes or transporters regulating intraparasitic drug concentrations. 
 
3.2.1 Resistance to quinolines 
Recent molecular analyses strongly argue for multiple genes and epistasis, rather than a single 
genetic determinant, to be involved in CQ resistance (Anderson et al., 2005; Duraisingh & 
Refour, 2005). The two main characteristics that distinguish CQ resistant from CQ sensitive 
parasites are diminished accumulation of CQ in the parasite’s digestive vacuole (DV) and 
reversal of resistance through chemosensitization by verapamil (VP) or other Ca2+-channel 
blockers (Krogstad et al., 1987; Martin et al., 1987). These observations suggested that CQ 
resistance is most probably associated with altered drug transport processes into the DV and 
several genes encoding candidate proteins involved in the transport of CQ into or out of the 
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DV have been proposed: P. falciparum multidrug resistance gene 1 (pfmdr1), candidate gene 
2 (cg2), and P. falciparum chloroquine resistance transporter (pfcrt or cg10). 
Pfmdr1, which is localized on chromosome 5, encodes a P-glycoprotein homolog (Pgh1) and 
has been localized to the parasite DV (Foote et al., 1989; Wilson et al., 1989; Cowman et al., 
1991). Pgh1 has a typical structure shared by members of the ATP binding cassette (ABC) 
transporter family (Endicott & Ling, 1989). Initial sequence analysis of the full-length pfmdr1 
revealed five polymorphic residues that appear to be dimorphic: N86Y, Y184F, S1034C, 
N1042D, and D1246Y (Foote et al., 1990a). In the same study, pfmdr1 mutations were 
strongly linked to the CQ resistant phenotype, but several subsequent studies failed to confirm 
the association (Wilson et al., 1993; Basco & Ringwald, 2002). Moreover, analysis of the 
progeny of a genetic cross between a CQ resistant and a CQ sensitive parasite line found no 
association between inheritance of the CQ resistant phenotype and the pfmdr1 locus (Wellems 
et al., 1990). However, more recent experiments utilizing newly available transfection 
methods have shown that pfmdr1 mutations can increase resistance levels to CQ (Reed et al., 
2000). In field studies, most attention has been given to the investigation of the pfmdr1 N86Y 
allelic variant which is widespread in Africa and Asia. Several studies have demonstrated the 
selection of the mutant allele following treatment with CQ or AQ (Duraisingh et al., 1997; 
Sutherland et al., 2002). A positive, though incomplete, association has also been found 
between pfmdr1 N86Y and in vivo CQ resistance by several authors (Basco et al., 1995; 
Nagesha et al., 2001; von Seidlein et al., 1997). Nevertheless, numerous other studies have 
demonstrated contradictory results (Bhattacharya et al., 1997; Basco & Ringwald, 1997; 
Haruki et al., 1994; Pillai et al., 2001). The allelic variant pfmdr1 N86Y has not been 
observed in a large number of South American strains. In contrast, the triple mutation 
S1034C, N1042D, plus D1246Y is more prevalent on this continent, but was seen in CQ 
resistant and CQ sensitive parasites (Foote et al., 1990a; Huaman et al., 2004; Povoa et al., 
1998). Variation in copy number of the pfmdr1 gene was observed in a number of CQ 
resistant isolates (Foote et al., 1989; Barnes et al., 1992), but this correlation could not be 
confirmed in a wide variety of field and laboratory strains (Basco et al., 1995; Wellems et al., 
1990). 
A series of highly systematic experiments using the progeny of the genetic CQ resistant-CQ 
sensitive cross led to the discovery of the cg2 gene family on chromosome 7. Different 
members were screened for polymorphisms that might correlate with the CQ resistant 
phenotype in a large array of laboratory-adapted P. falciparum strains from around the world. 
An initially promising candidate, cg2, showed a complex pattern of polymorphism that was 
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tightly, but not perfectly, linked with CQ resistance (Su et al., 1997). Though the weak 
association between allelic variants of cg2 and CQ resistance were confirmed by some studies 
(Basco & Ringwald, 1999), others found no correlation (Sharma et al., 2001). Moreover, 
transfection experiments, where the cg2 gene from CQ resistant parasites was replaced with 
the variant from their CQ sensitive counterparts, showed no effect on the level of CQ 
resistance in the transformed parasites (Fidock et al., 2000a). 
Further analysis of the progeny of the genetic cross of Wellems et al. (1990) localized the CQ 
resistance determinant to a 36kb segment on chromosome 7 (Su et al., 1997; Wellems et al., 
1991). Subsequent studies of the segment identified a highly interrupted gene with 13 exons, 
termed pfcrt, encoding a putative transporter protein that was localized to the DV membrane 
of the parasite. Several polymorphisms in pfcrt showed linkage to the CQ resistant phenotype 
in a large set of laboratory-adapted P. falciparum lines from Africa, South America, and 
Southeast Asia, but with considerable variations depending on the geographical region 
(Cooper et al., 2002; Fidock et al., 2000b). Furthermore, an allelic exchange approach 
replacing the endogenous pfcrt allele of a CQ sensitive strain with pfcrt from CQ resistant 
lines from different origins provided conclusive evidence that mutant haplotypes of the pfcrt 
gene product confer CQ resistance with characteristic VP-reversibility and reduced CQ 
accumulation (Sidhu et al., 2002). The mutation K76T seems to play a major role in 
determining the CQ resistant phenotype since it was invariably found in all CQ resistant 
strains so far. The mutation is usually not isolated, but associated with other single nucleotide 
polymorphisms (SNP) at other codons, C72S, M74I, N75E, H97Q, A220S, Q271E, N326S/D, 
I356T/L and R371T/I, the role of which is not very well defined. It was suggested that these 
mutations might play a critical role in maintaining important functional properties of the 
protein in CQ resistant parasites (Wellems & Plowe, 2001). The importance of the K76T 
mutation has been further corroborated by several clinical studies which have shown a higher 
prevalence of the K76T mutation in post-treatment than in pre-treatment samples, which 
alludes to a strong selection towards the mutant allele under CQ treatment (Djimde et al., 
2001a; Schneider et al., 2002). Moreover, the presence of the mutant allele has been shown to 
be present in all P. falciparum isolates which failed treatment with CQ (Basco et al., 2002; 
Djimde et al., 2001a; Thomas et al., 2002). However, the mutation has also been observed in 
CQ sensitive isolates (Kyosiimire-Lugemwa et al., 2002) which suggest that either additional 
mutations in pfcrt or other genes may be involved in the determination of the CQ resistant 
phenotype. Interestingly, it has recently been shown that pfcrt K76T mediated parasite 
resistance was reversed by concomitant carriage of the pfcrt mutation S163R, and further 
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modified by the additional mutation in pfcrt T152A (Johnson et al., 2004). Currently, there is 
no evidence that alterations in gene copy number or expression levels of pfcrt are involved in 
CQ resistance (Durrand et al., 2004). 
Regarding the proposed similar, though not equal, mode of action of the related quinoline 
drugs MEF, QUIN, HAL and LUM, molecular studies on parasite resistance to these drugs 
have mainly focused on the two membrane transporter genes pfcrt and pfmdr1. Mutations in 
pfcrt have been shown to be associated with resistance to QUIN (Mu et al., 2003). In addition, 
several in vitro studies could demonstrate that point mutations in pfmdr1 modulate resistance 
to MEF, QUIN and HAL (Reed et al., 2000; Duraisingh et al., 2000). However, more recent 
in vivo studies conducted in Peru and Gabon did not provide evidence for an association 
between pfmdr1 mutations and MEF resistance (Mawili-Mboumba et al., 2002; Pillai et al., 
2003). Interestingly, the presence of the pfmdr1 wild-type allele N86 has been found to be 
associated with in vitro resistance to MEF (Duraisingh et al., 2000; Price et al., 1999) and 
more recently, with in vivo resistance to LUM (Sisowath et al., 2005). 
Amplification of the pfmdr1 gene copy number has been found to be associated with 
resistance to MEF and HAL in both, laboratory (Cowman et al., 1994, Peel et al., 1994) and 
field (Price et al., 1999; Wilson et al., 1993) isolates. Though amplification of pfmdr1 seems 
not to be a prerequisite for increased MEF resistance (Lim et al., 1996; Chaiyaroj et al., 
1999), its important role in predicting in vitro and in vivo MEF failure has been shown in 
Thailand (Price et al., 2004). Moreover, recent experiments using pfmdr1 knockdown clones 
of the parasite could provide further evidence for this gene modification to be important in 
mediating resistance to MEF, QUIN, and HAL (Sidhu et al., 2006). 
More recent studies have demonstrated that other genes, such as pfmrp (multidrug resistance 
protein) or pfnhe1 (sodium hydrogen exchanger), and as yet not fully characterised loci 
encoding other transporter molecules, are involved in conferring resistance to quinolines 
(Ferdig et al., 2004; Klokouzas et al., 2004; Mu et al., 2003). These findings further 
underscore the current hypothesis that phenotypic resistance to this drug class requires the 
involvement and interaction of many different genes (Bray et al., 2005; Duraisingh & 
Cowman, 2005). 
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Table 2: Genetic changes in P. falciparum associated with resistance to quinolines in clinical 
use as antimalarials 
 
Drug Genea Molecular markersb 
CQ, (AQ) pfcrt C72S, M74I, N75D/E, K76T, A220S, Q271E 
 pfmdr1 N86Y, Y184F, S1034C, N1042D, D1246Y 
MEF, QUIN, HAL, LUM pfmdr1 Copy number > 1; wild-type N86 
 pfcrt Mutations affect in vitro resistance to differing 
degrees in different strains 
 
a
 Genes encoding known targets (it can not be excluded that there are as yet unidentified 
additional targets); b Most commonly observed amino acid changes associated with in vivo 
resistance; bold, key mutations. The relative importance of the other mutations (i.e., 
interference with drug binding or maintenance of protein function) is not yet fully assessed; 
CQ, chloroquine; AQ, amodiaquine; pfcrt, Plasmodium falciparum chloroquine transporter; 
pfmdr1, Plasmodium falciparum multidrug resistance gene 1, MEF, mefloquine; QUIN, 
quinine; HAL, halofantrine; LUM, lumefantrine 
(Source: adapted from Hyde, 2005a) 
 
3.2.2 Resistance to antifolates 
Though the detailed molecular basis of parasite resistance to antifolates is not yet completely 
clear, a variety of studies, including genetic analyses, biochemical assays and transfection 
experiments, have contributed to a better understanding of the molecular events involved in 
resistance to the individual antifolate compounds. 
Resistance to PYR is caused by mutations in the pfdhfr gene, which lead to weaker drug 
binding, but maintain enzyme activity (Chen et al., 1987; Cortese & Plowe, 1998; 
Sirawaraporn et al., 1997). Several studies have shown the key role of the S108N mutation in 
conferring the PYR resistant phenotype in P. falciparum (Cowman et al., 1988; Peterson et 
al., 1988). Additional mutations at codons N51I, C59R and I164L progressively enhance 
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resistance to the drug (Basco & Ringwald, 2000; Wang et al., 1997a). Triple mutants 
S108N+N51I+C59R are mainly seen in Africa and Southeast Asia, where they are responsible 
for high level PYR resistance (Hyde, 1990; Sibley et al., 2001). Though relatively uncommon 
in Southeast Asia and South America (Berens et al., 2003; Biswas et al., 2000; Plowe et al., 
1997), and only sporadically reported from single foci in Africa (Alker et al., 2005; Hastings 
et al., 2002; Staedke et al., 2004), quadruple mutants (plus I164L) represent the severest form 
of resistance and are responsible for high level resistance to the DHFR inhibitors PYR and 
CG. The allelic variation A16V coupled with an alternative change at position 108 (S108T) is 
involved in resistance to CG, with only moderate loss of sensitivity to PYR (Foote et al., 
1990b; Peterson et al., 1990). Amino acid changes C50R/I and V140L in pfdhfr are rare and 
were only observed in isolates originating from single foci in South America (Vasconcelos et 
al., 2000). Pfdhfr mutations have been shown to segregate with the drug resistant phenotypes 
in a genetic cross (Peterson et al., 1988) and final proof for their role in PYR resistance has 
been obtained by parasite transfection experiments (Wu et al., 1996). Though never been 
demonstrated in vivo, chromosomal rearrangement and gene amplification were demonstrated 
under drug pressure in vitro (Thaithong et al., 2001) and can not yet be ruled out as 
contributory factors to clinical resistance. 
Similarly to pfdhfr, resistance to SDX and other sulpha drugs is associated with decreased 
drug binding and has been linked to mutations in pfdhps (Triglia et al., 1999). Amino acid 
changes at five different sites, S436A/F, A437G, K540E, A581G and A613S/T, have as yet 
been reported (Brooks et al., 1994; Triglia & Cowman, 1994; Triglia et al., 1997; Wang et al., 
1997a). As done for pfdhfr, the role of these mutations in conferring resistance to sulpha 
drugs has been demonstrated in cross-mating and allelic exchange experiments (Triglia et al., 
1998; Wang et al., 1997b). Whereas the S108N change in pfdhfr seems to be a prerequisite 
for further accumulation of mutations which results in a progressive increase in PYR 
resistance, a similar, but less clear-cut, situation is assumed for pfdhps, since the A437G 
mutation, alone or in combination with additional mutations in the gene, predominated in 
field isolates (Sibley et al., 2001). 
An important aspect of antifolate resistance is the rapid selection of resistant parasites due to 
pharmacologically sub-optimal amounts of drugs persisting in the body after treatment, the 
reason being that PYR and SDX have long elimination half-lives of 116 h and 81 h, 
respectively (Diourte et al., 1999; Watkins et al., 1997). Selection pressure exerted by the 
short-acting antifolates CG and DAP has been shown to be lower (Curtis et al., 1998; Nzila et 
al., 2000a). 
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The question how much mutations in pfdhfr and pfdhps contribute to the level of in vivo 
antifolate resistance has been and still is a matter of debate. Laboratory and field studies 
dealing with this question are difficult for many reasons. Systematic investigations are 
hampered by the fact that antifolate drugs are frequently used in combination and act 
synergistically. Furthermore, numerous different pfdhfr/pfdhps haplotypes are observed in 
field samples (Plowe et al., 1997). However, there is ample evidence for a positive correlation 
between the number of mutations in both genes and the level of prior SP usage. In the Middle 
East for instance, where little SP has been used, all isolates had wild type pfdhfr and pfdhps, 
whereas most isolates from Southeast Asia were highly mutated in both genes (Wang et al., 
1997a). Also a number of sites in Africa, where SP has been widely used within the last 
decade, reported high prevalence rates of triple-pfdhfr plus double-pfdhps genotypes, such as 
in Northern Tanzania where rates up to 60% were measured in community surveys (Pearce et 
al., 2003). 
The overall tendency is to consider that the triple-pfdhfr mutation could be a useful genetic 
marker for in vivo resistance to SP and that point mutations in pfdhps play a secondary role in 
determining treatment failure (Basco et al., 1998; Mockenhaupt et al., 2005; Mugittu et al., 
2004). However, there are several other authors who claim mutations in pfdhps to be equally 
or even more important in predicting treatment response to SP (Berens et al., 2003; Dorsey et 
al., 2004). Reports are conflicting because host factors confound the association between 
molecular resistance markers and in vivo drug response. In addition, the investigation of a 
relationship is further complicated by the fact that many, but not all, Plasmodium strains have 
the ability to use exogenous folate from the host. This salvage pathway (i.e., exogenous folate 
utilization via a pathway that obviates the need for DHPS), which is believed to provide only 
a minority of folate production in the parasite, the majority being produced by de novo 
biosynthesis, can be blocked by PYR (Wang et al., 1997b; Wang et al., 1999). This might not 
only be a possible explanation for the observed synergy of drug action between PYR and 
SDX, it could also be a putative explanation for the asymmetric selection of mutations in 
pfdhfr and pfdhps, which has been demonstrated in many in vitro and field studies (Mberu et 
al., 2000; Nzila et al., 2000b; Plowe et al., 1997). Selection for mutations in pfdhfr occurs 
first and mutations in pfdhps are only selected if parasites carry at least a double mutation in 
pfdhfr. It therefore seems that mutations in pfdhps become important once resistance in pfdhfr 
has reached a degree where therapeutic levels of PYR are not sufficient anymore to kill the 
parasite by the inhibition of DHFR alone (Sims et al., 1999). Though the exact genetic basis 
for this ‘folate effect’ is not fully elucidated at this time, current molecular hypotheses assume 
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the locus for the differences in folate utilisation to be closely linked to pfdhfr (Wang et al., 
1997b; Wang et al., 2004). However, data about the prevalence of this capacity in natural 
parasite populations and its contribution to a SP resistant in vivo phenotype are still scarce 
(Dzinjalamala et al., 2005). More recently, the conversion of SDX by DHPS to sulpha-pterin 
adducts, which have inhibitory effects further downstream the folate biosynthesis pathway, 
has been shown (Mberu et al., 2002). The effect was independent of mutations in pfdhfr or 
pfdhps and led to the hypothesis that sulpha drugs could inhibit the parasite by mechanisms 
other than the blockage of DHPS and therefore, resistance could be mediated by other genes 
(Patel et al., 2004). Moreover, the assumption that these drug adducts have detrimental effect 
on folate synthesis led to the speculation that sulpha drug resistant parasites may be selected 
on the basis of lower production of these toxic adducts rather than reduced competition for 
binding to DHPS (Hyde, 2005b). 
 
Table 3: Genetic changes in P. falciparum associated with resistance to antifolates in clinical 
use as antimalarials 
 
Drug Genea Molecular markersb 
PYR pfdhfr C50R, N51I, C59R, S108N, I164L 
PG (CG) pfdhfr A16V, N51I, C59R, S108T/N, I164L 
SDX, DAP pfdhps S436A/F, A437G, K540E, A581G, A613S/T 
 
a
 Genes encoding known targets (it can not be excluded that there are as yet unidentified 
additional targets); bold, key mutations. The relative importance of the other mutations (i.e., 
interference with drug binding or maintenance of enzyme function) is not yet fully assessed; b 
Most commonly observed amino acid changes associated with in vivo resistance; PYR, 
pyrimethamine; pfdhfr, Plasmodium falciparum dihydrofolate reductase; PG, proguanil; CG, 
cycloguanil; SDX, sulphadoxine; DAP, dapsone; pfdhps, Plasmodium falciparum 
dihydropteroate synthase 
(Source: adapted from Hyde, 2005a) 
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3.2.3 Resistance to other drug classes 
Atovaquone (ATQ) has been shown to inhibit the cytochrome bc1 (CYT bc1) complex of the 
electron transport chain of malaria parasites. Mutations in P. falciparum CYT bc1 were 
associated with ATQ resistance in vitro (Korsinczky et al., 2000) and were reported in a small 
number of in vivo failures with Malarone™ (Fivelman et al., 2002; Wichmann et al., 2004). 
Interestingly, mutations in CYT bc1 were found to be associated with a loss of fitness in P. 
falciparum, which could suggest that the prevalence of resistant parasites may decrease after 
drug usage is discontinued (Peters et al., 2002). 
Up to date, clinical resistance to artemisinin and its derivates, when used in combination with 
other drug classes, has not yet been observed. However, there are several lines of evidence 
that drug resistance to this drug class emerges. These include 1) a clinical study that 
demonstrated decreased in vitro sensitivity to artemisinin in P. falciparum isolates from 
patients who failed treatment with artesunate monotherapy (Menard et al., 2005), 2) 
experiments that showed increased in vitro resistance to artemether for isolates from French 
Guiana (Jambou et al., 2005), and 3) a report of the development of genetically stable and 
transmissible resistance to artemisinin and its derivates in P. chabaudi chabaudi (Afonso et 
al., 2006). Most current models suggest a multiple-target model for the mode of action of 
artemisinins (Golenser et al., 2006), and several findings from molecular studies investigating 
parasite resistance to this drug class are in support of this hypothesis. Drug assays using 
mutant pfcrt lines showed that these CQ resistant strains were also slightly less susceptible to 
AQ, but more susceptible to QUIN, MEF and artemisinin (Duraisingh et al., 2000; Sidhu et 
al., 2002). This implicates pfcrt to govern parasite susceptibility to a variety of compounds 
including the newly introduced drug class of artemisinins. Likewise, increased copy number 
of pfmdr1 has been found to be associated with artemisinin resistance in isolates from patients 
who failed treatment with combination therapy of MEF plus artesunate (Price et al., 2004). 
More recently, molecular studies have found mutations at codons 263 and 769 in pfATPAse6, 
a putative target for artemisinin derivates, to be associated with decreased drug susceptibility 
in vitro (Jambou et al., 2005; Uhlemann et al., 2005). 
These findings further emphasise the need to use artemisinins in combination with other 
companion drugs to which high-grade resistance has not yet been developed, in order to 
prolong the useful therapeutic life (UTL) of this highly effective drug class (Duffy & Sibley, 
2005; WHO, 2006). At the same time, continued research efforts are needed, not only to 
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consolidate recent molecular findings, but also further elucidate the genetic basis of drug 
action of and parasite resistance to artemisinins. 
 
Table 4: Genetic changes in P. falciparum associated with resistance to other drug classes in 
clinical use as antimalarials 
 
Drug Genea Molecular markersb 
ATQc CYT bc1 Y286S/N 
Artemisinin 
and 
derivatesd 
pfmdr1 
 
pfATPase6e 
Status of pfmdr1 modulates level of in vitro sensitivity 
 
L263, S769N, (E431K, A623E) 
DOX, TET Pf mitochondrion Not yet characterised 
 
a
 Genes encoding known targets (it can not be excluded that there are as yet unidentified 
additional targets); b Most commonly observed amino acid changes associated with in vivo 
resistance; c only in clinical use in combination with proguanil (Malarone™); d clinical 
resistance to artemisinin-based combination regimens not yet observed; e shown by in vitro 
experiments only; ATQ, atovaquone; CYT bc1, cytochrome bc1 complex; pfmdr1, 
Plasmodium falciparum multidrug resistance gene 1; pfATPase6, Plasmodium falciparum 
ATPase 6; DOX, doxycycline; TET, tetracycline 
(Source: adapted from Hyde, 2005a) 
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3.3 Assessment of resistance 
3.3.1 Classical tools 
Two methods have been widely used to assess the level of drug resistant malaria: 
I. In vivo drug efficacy studies which are based on WHO standardised Day 7, 14, or 28 
monitoring of patients after treatment for uncomplicated malaria using parasitology 
alone (S/RI/RII/RIII levels of resistance), or parasitology and symptoms (adequate 
clinical response, early or late treatment failure) as outcome(s) (Table 5), and 
II. In vitro assays to measure intrinsic sensitivity of P. falciparum parasites to antimalarial 
drugs. 
At present, in vivo therapeutic tests still remain the gold standard for monitoring antimalarial 
drug efficacy and guiding drug policy. These in vivo test systems were developed and 
introduced shortly after the first reports of CQ resistance in 1965. Thereafter, protocols were 
simplified, revised and standardised for the assessment of antimalarial drug efficacy in infants 
and young children in areas with high malaria transmission (WHO, 1996). Though the 
methodology has recently been revised and includes now several modification and 
adaptations for low to moderate transmission areas as well as a common classification for all 
transmission areas (WHO 2002; WHO, 2003), it is still a subject of debate with no consensus 
on several issues, such as length of follow-up, etc. (White, 2002). Apart from several 
advantages of in vivo studies, such as the generation of easily interpretable results and a 
minimal requirement for equipment and supplies, they are afflicted with several drawbacks. 
These include the interference of host factors (e.g. immunity or drug uptake and metabolism) 
with treatment outcome, strongly reduced compliance because of long follow-up periods, the 
assessment of resistance to one drug regimen only, and poor ability to compare different 
studies because local adaptations and modifications of the standard protocol are usually made. 
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Table 5: Definitions of in vivo therapeutic efficacy and parasitological resistance 
 
Parasitological resistance outcomes (WHO, 1996)a 
Sensitive Asexual parasite count reduces to 25% of the pre-treatment level within 48 hours after initiation of treatment 
and complete clearance on Day 7, without subsequent recrudescence up to Day 28 
RI Asexual parasitaemia reduces to <25% of pre-treatment level within 48 hours after initiation of treatment, 
but reappears between Day 7 and Day 28 
RII Marked reduction in asexual parasitaemia (decrease >25% but <75%) within 48 hours after initiation of 
treatment, without complete clearance on Day 7 
RIII No or minimal reduction in asexual parasitaemia, (decrease <25%) or an increase in parasitaemia within 48 
hours after initiation of treatment 
Therapeutic efficacy outcomes (WHO, 2003)b 
ETF 
• Danger signs or severe malaria on Day 1, 2, or 3, or 
• Parasitaemia on Day 2 higher than on Day 0, or 
• Parasitaemia on Day 3 ≥25% of Day 0 count, or 
• Parasitaemia on Day 3 with axillary temperature ≥37.5°C 
LCF 
• Danger signs or severe malaria after Day 3, or 
• Parasitaemia with axillary temperature ≥37.5°C (or history of fever) from Day 4 to Day 28 
• Without meeting any of the criteria for ETF 
LPF • Parasitaemia from Day 7 to Day 28 without axillary temperature ≥37.5°C (or history of fever) 
• Without meeting any of the criteria for ETF or LCF 
ACPR • Absence of parasitaemia on Day 28, 
• Without meeting any of the criteria for ETF, LCF or LPF 
 
a
 Outcomes for extended test protocol (i.e., Day 14 or Day 28 follow-up); R, resistance; b 
Protocol based on Day 14 follow-up for high transmission areas and Day 28 follow-up for 
low to moderate transmission areas; ETF, Early treatment failure; LCF, Late clinical failure; 
LPF, Late parasitological failure; ACPR, Adequate clinical and parasitological response 
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Several in vitro assay systems are available and differ with regard to end-point measurement. 
These include the WHO mark III test (microscopic examination of blood films for assessment 
of schizont maturation), radioisotopic tests (incorporation of radio-labelled nucleotide 
precursors), ELISA (Enzyme-linked immunosorbent assay) tests based on antibodies against 
Plasmodium lactate dehydrogenase (production of enzyme) or histidine-rich protein 2 
(secretion of soluble antigen) (reviewed in Noedl et al., 2003). In vitro assays have several 
advantages, such as the ability to assess simultaneously several drugs (including experimental 
compounds) and host confounding factors are avoided. However, the main problems 
encountered with in vitro sensitivity tests are that they require expensive equipment and 
supplies, there is partial lack of standardised protocols, threshold values for resistance are not 
determined for all drugs, and the correlation with therapeutic efficacy tests is not yet fully 
established. Therefore, they are not readily amenable to large scale epidemiological mapping, 
especially in low-resource countries, and are recommended to be used as adjunct to in vivo 
efficacy studies (WHO, 2005b). 
 
3.3.2 New tool: molecular monitoring of parasite resistance 
Advances in the understanding of the mechanism of drug action allowed the identification of 
the putative molecular targets responsible for resistance. At present, the assessment of 
molecular markers is still considered as complementary tool for monitoring antimalarial 
resistance (WHO, 2003; WHO, 2005b). Though the advantages of the molecular tests are 
similar to those of in vitro assays (i.e., detection of true parasite resistance without interfering 
host factors, ability to perform multiple analyses with a single patient sample), they are 
limited with regard to many aspects. Most of the work has been focused on CQ and SP, both 
available and cheap drugs widely used in malaria endemic areas worldwide. Therefore, 
molecular markers are only available for a limited number of drugs. Furthermore, the role of 
molecular markers in predicting in vivo therapeutic outcome has been controversial and the 
correlation has not been fully established. Presently, a number of methods exist for SNP 
analysis in antimalarial drug resistance genes, but each has its disadvantages. Many are based 
on PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) 
analysis of selected loci or on sequence specific amplification or hybridisation (Ranford-
Cartwright et al., 2002; Sangster et al., 2002). These techniques are limited in the number of 
samples and SNPs which can be analysed simultaneously. They are usually quite costly and 
often limited by available restriction sites. Other available techniques, such as MALDI-TOF 
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based systems (Marks et al., 2004), pyrosequencing (Nair et al., 2002), molecular beacons 
(Durand et al., 2000), real-time PCR (Alker et al., 2004; de Monbrison et al., 2003), or 
clamped-probe PCR (Senescau et al., 2005), are also prohibitively expensive and complex. 
Taken together, there is a lack of standardised protocols for sample collection and DNA 
extraction as well as standard operating procedures (SOP) for further downstream molecular 
analyses. In addition, most of these technologies require a high infrastructure laboratory and 
equipment and supplies which are expensive. Hence, they are not feasible in many field 
laboratories in countries with limited resources. In order to provide a monitoring system based 
on the analysis of various SNPs in a timely manner on a large scale (i.e., numerous 
populations and sites), new tools have to be developed and validated. 
 
4. Rationale, aims and objectives 
4.1 Rational of the current study 
One of the greatest challenges for health authorities of malaria endemic countries is to decide 
on when and how drug policy should be changed (i.e., at which level of parasite resistance or 
treatment failure should a malaria control program change the first-line drug). A number of 
criteria, such as the level of parasite resistance (RIII resistance 5-30%) (Bloland, et al., 1993; 
Sudre et al., 1992) or in vivo treatment failure (total failure rate ≥25% and clinical failure rate 
≥15%) (WHO 2005b; WHO, 2006) have been suggested. But even if these criteria are agreed 
on, several questions remain: 
I. What is the best way to assess these outcomes? 
II. How do these outcomes differ from one country to the other (i.e., between different 
epidemiological settings)? 
III. Which alternative drug(s) should be used? 
IV. How should the development of parasite resistance to newly introduced and/or 
withdrawn drug(s) be monitored? 
The difficulties in determining parameters for drug policy change are mainly attributable to 
the limitations of the currently applied tools. The routine methods for the assessment of 
resistance (i.e., in vivo drug efficacy studies and in vitro sensitivity tests) are demanding in 
terms of personnel, equipment, costs and time. Moreover, the lack of standardised protocols 
and procedures applicable to different epidemiological settings makes comparability between 
studies difficult. In recent years, the growing body of knowledge about the molecular 
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mechanisms involved in parasite resistance has led to the advocacy for molecular monitoring 
of parasite resistance as a supplementary tool to in vivo drug efficacy studies (Plowe, 2003; 
Quaye & Sibley, 2002; WHO, 2003). The role of several point mutations at different loci in 
conferring resistance in vivo has mainly been inferred from studies showing predictive 
association of particular mutations with treatment failure and from overrepresentation of 
mutations in recrudescent infections after treatment. However, on an individual level, an 
association of specific molecular markers with in vitro resistance does not allow prediction of 
resistance in vivo or of the therapeutic response. A number of other parameters, such as the 
use of drug combinations, the level of prior immunity which is closely linked to transmission 
intensity, compliance to treatment, etc., play a role in clearing symptoms and parasites 
(White, 2004). Hence, direct proof of a causal relationship between single or a combination of 
markers and clinical failure has remained elusive and most models now postulate a multigenic 
basis of resistance (Anderson et al., 2005; Mu et al., 2003). As yet, such clinical-based studies 
were conducted in a relatively small number of sentinel sites and at infrequent time intervals 
because of the high cost and resources required. In addition, these studies usually investigated 
symptomatic patients in a restricted age group (i.e., children ≤ 5 years of age) and were thus 
assessing a biased sub-sample of the whole parasite population. In most instances, the large 
parasite reservoir circulating in the untreated asymptomatic population, which might play an 
important role in the development and spread of parasite resistance, was not investigated. 
The analysis of point mutations on population level and the establishment of correlations 
between the molecular drug resistance profile in parasites and in vivo parasitological and 
clinical outcome could give a more comprehensive appraisal of the status and longitudinal 
dynamics of resistance. Several population-based molecular surveys have already been 
conducted, but only two studies in Mali (Djimdé et al., 2001b) and Uganda (Talisuna et al., 
2002; Talisuna et al., 2003) have investigated the correlation with the level of clinical failure 
in health facilities of the same region. Moreover, these studies have only assessed one locus, 
which considerably limits the conclusions that can be drawn for further drug policy 
implementation. 
Studies on an epidemiological scale are mainly limited by the currently applied methods for 
the analysis of molecular resistance markers. Although the procedures to determine these 
drug-related parasite genotypes are relatively simple and already in use in several laboratories 
in sub-Saharan Africa, Asia, and South and Central America, their capacity to analyse 
multiple SNPs in several genes simultaneously is limited. Moreover, in the few studies that 
dealt with this issue, haplotype frequencies have been estimated from individuals with single 
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infections, discarding the ones with multiple infections. Since a vast majority of parasitaemic 
individuals harbour multiple infections, especially in areas of high transmission, this approach 
is of only limited applicability. For all these reasons, an accurate and complete picture of the 
genetic resistance pattern in an area is difficult to get. 
In the current project, we evaluate a new approach that should overcome these problems. We 
make use of a high throughput system to analyse all known molecular markers of resistance in 
samples collected in community-based cross-sectional surveys. By using different 
combinations of SNPs in several marker genes we should be able to assess the relationship 
between the genetic drug resistance background in the parasite population and treatment 
failure rates more accurately. A series of rapid assessments using cross-sectional surveys of a 
sub-sample of the general population could be performed in several sites and the frequencies 
of point mutations (and combinations of mutations) in multiple marker genes in the 
community could then be used to predict the clinical response at health facilities. If 
reproducible results can be obtained in different geographical areas with different levels of 
endemicity, rapid age-balanced cross-sectional surveys in the community could eventually 
allow overcoming resource-consuming in vivo studies to assess the level of Plasmodium 
resistance to various drug regimens. These surveys could also be conducted in remote areas 
that are not well served by health facilities and have been left aside in the past. An informed 
and rationale decision could thus be made by health authorities on the best time to change 
drug policy and on the best drug to choose. Moreover the monitoring of the development of 
resistance to the newly introduced drug(s) as well as of the reversal of resistance to previous 
drug(s) abandoned could be assessed. Finally, quick surveys for the longitudinal assessment 
of frequencies of markers would allow to capture the dynamics of resistance and to construct 
predictive models for different areas with different levels of transmission. 
 
4.2 Aim and specific objectives 
This study aimed to bring directly together data from community-based molecular surveys 
and data derived from health centre-based studies. Since the routine tools for the assessment 
of antimalarial resistance (i.e., in vivo and in vitro studies and current methods for the analysis 
of molecular resistance markers in parasites) are too cumbersome and difficult to use on a 
large scale, we assessed the relevance of a new appraisal approach: Community-based cross-
sectional surveys versus clinical studies (population versus patient), and the usefulness of a 
new molecular technology (DNA microarray versus PCR-RFLP or sequencing) for the 
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identification of relevant SNPs in different parasite genes. The frequencies of SNPs in given 
resistance marker genes as well as genotype patterns were analyzed in clinical samples to 
investigate their role in predicting in vivo treatment response. Furthermore, corresponding 
community drug resistance profiles were correlated with the incidence risk of clinical 
treatment failure in order to investigate the relevance and usefulness of such a novel approach 
in the management of drug use. 
 
The specific objectives of the present PhD project were as follows: 
 
1. To assess the treatment efficacy of sulphadoxine-pyrimethamine (SP) plus 
amodiaquine (AQ) or chloroquine (CQ) against uncomplicated P. falciparum and P. 
vivax malaria in Papua New Guinea (Chapter 2) 
2. To develop and validate a DNA microarray-based technology for the assessment of 
molecular markers of drug resistant malaria (Chapter 3) 
3. To assess the genetic drug resistance profile in clinical samples and to determine 
useful molecular markers in P. falciparum for predicting treatment outcome with 
combination therapy of AQ or CQ plus SP (Chapter 4) 
4. To test the hypothesis that the parasite population circulating in the community has the 
same genetic profile of resistance markers as the population circulating in malaria 
patients attending health facilities (Chapter 5) 
5. To estimate the frequency and patterns of molecular markers in community samples 
and to compare them with the incidence risk of clinical failure in the health centres 
serving these communities (Chapter 6) 
6. To assess the dynamics of molecular markers in the parasite population under standard 
treatment regimen over a period of two to three years (Chapter 6) 
7. To assess and investigate the role of molecular markers in P. vivax for predicting 
treatment outcome with combination therapy of AQ or CQ plus SP (Chapter 7) 
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5. Study design and methodology 
5.1 Study area 
Studies were conducted in Papua New Guinea (PNG) which is a patchwork of different 
geographical and ecological zones and inhabited by a population of approximately 5.7 million 
people characterized by exceptional cultural and linguistic diversity. PNG features complex 
variations in vector and malaria epidemiology. All four Plasmodium species that infect 
humans are found in both, lowland and highland areas, with P. falciparum and P. vivax being 
the predominant species. Malaria intensity ranges from unstable low-level endemicity where 
outbreaks are common to high transmission comparable with most endemic regions in Sub-
Saharan Africa. Malaria is the commonest cause of outpatient presentation and accounts for 
27% of all attendances at health facilities (Müller et al., 2003). Studies were conducted 
between October 2002 and March 2005 at three different sites in PNG. These sites included: 
I) The Sigimaru health centre (HC) in the Karimui area (Simbu Province), a rural 
region in the highland fringe area of PNG located at an altitude of 700 to 1200 m, 
II) The Kunjingini HC in the South Wosera area (East Sepik Province), a remote 
region located in the floodplain of the Sepik river in the North-eastern part of the 
country, and 
III) The Mugil HC at the North Coast of the country (Madang Province), a rainforest 
region located near the provincial capital town of Madang (Figure 3). 
Though malaria transmission is perennial with limited variations between wet (October to 
April) and dry (May to September) season at all three sites, areas cover different levels of 
transmission intensity and drug use patterns. Transmission intensity decreases significantly 
with increasing altitude (Müller et al., 2003) and is higher in the lowland regions of the 
Wosera and the North Coast than in the Karimui area. There is little socioeconomic 
stratification between and within sites, with most of the inhabitants being subsidence farmers, 
but there are differences with regard to health care provision and drug use patterns (Benet et 
al., 2004; Genton et al., 1995; Hii et al., 2001; Mehlotra et al., 2002; Müller et al., 2004). 
Scientific approval and ethical clearance for the studies were obtained from the Medical 
Research and Advisory Committee (MRAC) of the Ministry of Health in PNG. Informed 
consent was first requested from all the communities involved and prior to recruitment, 
individual consent was obtained from each study participant and parents or legal guardians. 
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Figure 3: Map of Papua New Guinea presenting the location of study sites 
 
 
5.2 Methods 
The project used data collected at two different levels: 
I) Repeated in vivo drug efficacy studies were conducted at the three health centres 
over the period of three consecutive years to estimate the incidence risk of 
treatment failure with the current first-line regimen of AQ or CQ plus SP against 
uncomplicated malaria. We used the newly revised WHO standard protocol for 
low to moderate transmission areas (WHO, 2003) and applied genotyping methods 
for the distinction of recrudescences and new infections and corrected failure rates 
accordingly (Cattamanchi et al., 2003; Slater et al., 2005). The method is 
described in detail in Chapter 2 and study forms are found in Appendix II. 
II) Repeated community-based cross-sectional surveys were conducted in the 
catchment areas of the corresponding health centres in order to determine the 
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frequencies and patterns of drug resistance markers in a random sample of the 
parasite population. Apart from clinical assessment, collected information included 
demographic characteristics, history of sickness (onset, type and duration of 
symptoms), health facility attendance, purchase or consumption of drugs outside 
health facilities, and antimalarial treatment courses received in the preceding year. 
Methodology is described in detail in Chapters 5 and 6. Study forms and 
characteristics of the study populations are found in Appendix II and IV, 
respectively. 
 
Molecular analyses were done for: 
I) The assessment of the number of infecting clones per sample. The multiplicity of 
infection (MOI) was determined by genotyping the highly polymorphic msp2 
(merozoite surface protein 2) locus of P. falciparum (Felger and Beck, 2002). 
II) The assessment of the molecular drug resistance profile in clinical and community 
samples. For this purpose, we used a newly developed DNA microarray-based 
technology. The method is described in detail in Chapter 3 and standard operating 
procedures (SOP) are found in Appendix III. 
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ABSTRACT 
Due to increasing resistance to 4-aminoquinolines in Papua New Guinea (PNG), 
combination therapy of amodiaquine (AQ) or chloroquine (CQ) plus sulphadoxine-
pyrimethamine (SP) was introduced as first-line treatment against uncomplicated malaria in 
2000. It was the aim of this study to assess the in vivo efficacy of the combination therapy 
against P. falciparum and P. vivax malaria. 
Studies were conducted between 2003 and 2005 in the Simbu, East Sepik and Madang 
Provinces in PNG according to the revised protocol of the World Health Organization (WHO) 
for the assessment of antimalarial drug efficacy. Children aged 6 months--7 years presenting 
with a clinically overt and parasitologically confirmed P. falciparum or P. vivax malaria were 
monitored up to Day 28 and classified according to clinical and parasitological outcome as 
ACPR (Adequate clinical and parasitological response), ETF (Early treatment failure), LCF 
(Late clinical failure), and LPF (Late parasitological failure). 
Treatment failure rates for P. falciparum malaria up to Day 28 ranged between 16% 
and 30%, depending on the region and the year of assessment. The corresponding PCR-
corrected values after differentiation of true recrudescences from new infections by parasite 
genotyping were 12% and 28%, respectively. Overall treatment failure rate in P. vivax malaria 
was 12%. 
Our results suggest that the current first-line treatment in PNG is not sufficiently 
effective. According to the new WHO guidelines for the treatment of malaria, a rate of 
parasitological resistance above 10% in the two dominant malaria species in the country 
justifies a change in treatment policy. 
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INTRODUCTION 
Malaria is a serious health problem in Papua New Guinea (PNG) and access to safe 
and effective treatment still remains the mainstay in the control of the disease. The 4-
aminoquinoline drugs amodiaquine (AQ) and chloroquine (CQ) have been first-line treatment 
against uncomplicated malaria until the late 1990s. However, resistance of Plasmodium 
falciparum to CQ was first documented in 19761,2 and numerous studies done since then in 
different provinces at different times showed the problem to be widespread. Within two 
decades, resistance to the 4-aminoquinolines AQ and CQ increased gradually with a slow 
shift from RI to RII and RIII types.3--9 The first documented evidence for P. vivax resistance 
in PNG was reported in 198910,11 and showed a similar increasing trend as for P. falciparum.12 
Although pyrimethamine in combination with CQ has been used in mass drug 
administration campaigns in the 1960s,13 the combination of sulphadoxine-pyrimethamine 
(SP) was not previously part of the standard treatment against uncomplicated malaria and was 
used only in combination with quinine to treat severe or treatment failure malaria in the 
country. Despite the low use of SP, resistance of P. falciparum to this drug combination was 
first described in PNG in 1980.14 Thereafter, P. falciparum-resistance to SP as well as 
reduced efficacy of SP against P. vivax has been reported in the Madang province.15--18 
In view of the low efficacy of the 4-aminoquinolines used as first-line regimen against 
malaria, PNG health authorities were prompted to revise antimalarial treatment policy in 
1997. Combination therapy for uncomplicated malaria has been advocated for some years to 
improve clinical effectiveness and to delay the development and spread of resistance to the 
individual drugs.19,20 Though evidence for the success of the combination regimen of AQ or 
CQ plus SP was scarce at that time21 and there was evidence for in vivo as well in vitro 
resistance against either of the drugs in the country, the decision to investigate the possible 
change to this combination regimen was made. Based on efficacy trials conducted between 
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1998 and 1999, that showed that the combinations were efficacious with treatment failure 
rates below 5%,22 the PNG Department of Health chose these combination regimens to 
replace the monotherapy with AQ or CQ as the standard first-line treatment against 
uncomplicated malaria in the year 2000. 
Since the introduction of the new drug policy, little data has been collected on the 
efficacy of the new standard treatment. Two studies conducted at health facilities in Maprik 
and Madang in 2001 recorded treatment failure rates up to Day 14 of 3% and 8%, respectively 
(JC Reeder, personal communication). These data showed clinical resistance to the 
combination regimen only one year after introduction and this has been further substantiated 
by more recent molecular studies showing a high prevalence of mutations in CQ resistance 
associated marker genes Pfcrt (P. falciparum chloroquine resistance transporter gene) and 
Pfmdr1 (P. falciparum multidrug-resistance gene 1), and also a low prevalence of mutations 
in the gene encoding Pfdhfr (P. falciparum dihydrofolate reductase) known to confer 
resistance to SP.23,24 
Therefore, the principal aim of this study was to assess the status of the clinical 
efficacy of the current first-line regimen of AQ or CQ plus SP against P. falciparum and P. 
vivax malaria in PNG after its official implementation in the year 2000. Within the framework 
of a project for the clinical and molecular monitoring of drug resistant malaria in PNG, we 
conducted in vivo drug efficacy studies in three different areas in PNG between 2003 and 
2005. 
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MATERIALS AND METHODS 
Patients and study sites. The studies were conducted at the Sigimaru health centre 
(HC) in the Karimui area (Simbu Province), the Kunjingini HC in the South Wosera area 
(East Sepik Province), and the Mugil HC in the North Coast area of the Madang Province. In 
Karimui, the studies were run between October and April in three consecutive years (2002, 
2003, and 2004). In the Wosera, the study period was between December and June in two 
following years (2003 and 2004). The study at the North Coast was conducted between April 
2004 and February 2005. Though all the three areas are rural places and endemic for malaria, 
they differ with regard to malaria epidemiology, level of health care provision and history of 
drug use.25--30 
Scientific approval and ethical clearance for the study was obtained from the Medical 
Research and Advisory Committee (MRAC) of the Ministry of Health in PNG and informed 
consent was obtained from parents or legal guardians prior to recruitment of each patient. 
 
Assessment of drug efficacy. Drug efficacy studies were conducted according to the 
standardised WHO protocol for low to moderate transmission areas.31 Briefly: children 
between 6 months and 7 years of age were enrolled if they were presenting at the health centre 
with a microscopically confirmed Plasmodium infection (P. falciparum density > 1000 
asexual parasites per microlitre of blood, P. vivax density > 250 asexual parasites per 
microlitre of blood) and clinically overt malaria (axillary temperature ≥ 37.5°C or history of 
fever during the last 24 hours for P. falciparum, or fever during the last 48 hours for P. vivax). 
P. falciparum cases were enrolled regardless of whether they had a concomitant infection 
with any other Plasmodium species, whereas a mixed infection with another species was an 
exclusion criterion for the P. vivax group. However, in mixed P. falciparum plus P. vivax 
infections, drug action was evaluated against both parasites species. 
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Further inclusion criteria were the absence of danger signs for severe or complicated 
malaria32 and no signs of any other disease, malnutrition or anaemia. Standard AQ or CQ plus 
SP first line-treatment (10 mg amodiaquine or chloroquine per kg on Day 0, 1 and 2, and 25 
mg sulphadoxine per kg plus 1.25 mg pyrimethamine per kg on Day 0) was administered 
under supervision over the first three days. Follow-up visits were scheduled on Day 1, 2, 3, 7, 
14, and 28. On every visit, patients were clinically examined and a Giemsa-stained blood 
slide was taken for the microscopic assessment of parasitaemia. 
Patients were advised to come to the health centre on any other day if symptoms 
occurred. Whenever a child was diagnosed as treatment failure, standard second-line 
treatment (5 mg artesunate per kg on Day 1 followed by 2.5 mg artesunate per kg on Day 2 to 
7, and a single dose of 25 mg sulphadoxine per kg plus 1.25 mg pyrimethamine per kg on Day 
3) was given. 
A patient was withdrawn from the study when any of the following occurred during 
the follow-up period: development of a concurrent infection requiring treatment, consumption 
of other antimalarial drugs, or loss of follow-up due to refusal of consent or failure to trace a 
patient on a follow-up visit. 
 
Molecular analyses. Blood samples were taken on Day 0 (pre-treatment sample) and 
on Day 14 and 28 or any day of treatment failure for molecular genotyping purposes. 
Differentiation between recrudescence and new infection with P. falciparum was achieved by 
comparing PCR-RFLP generated genotype patterns of the merozoite surface protein 2 (msp2) 
in pairs of samples obtained at enrolment and at the day of reappearance of parasitaemia, as 
described elsewhere.33,34 
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Data analysis. Data were double entered in EpiData software (version 3.02, Odense, 
Denmark) and analysis was performed using STATA software (version 8.2; Stata Corp., 
College Station, Texas). Patients in the P. falciparum group were classified according to their 
clinical and parasitological responses as follows: Early Treatment Failure (ETF, parasitaemia 
on Day 2 higher than on Day 0 or parasitaemia on Day 3 with axillary temperature ≥ 37.5°C), 
Late Clinical Failure (LCF, parasitaemia with axillary temperature ≥ 37.5°C or history of 
fever from Day 4 to Day 28), Late Parasitological Failure (LPF, parasitaemia from Day 7 to 
Day 28 without axillary temperature ≥ 37.5°C or history of fever) or Adequate Clinical and 
Parasitological Response (ACPR, absence of parasitaemia on Day 28 without meeting any of 
the previously described criteria for early or late treatment failure). For the P. vivax group, a 
patient was classified as treatment failure (TF) when 1) clinical deterioration due to P. vivax 
malaria in the presence of parasitaemia, or 2) parasitaemia between Day 3 and Day 28 with 
axillary temperature ≥ 37.5°C, or 3) parasitaemia between Day 7 and Day 28, irrespective of 
clinical conditions, was observed.35 
Logistical regression analysis was used for the investigation of possible risk factors for 
treatment failure and frequencies were compared by using chi-squared tests or Fisher’s exact 
tests as applicable. 
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RESULTS 
In vivo drug efficacy against P. falciparum. From a total of 687 children eligible for 
the P. falciparum group, 38 (5.5%) were excluded from the analysis population. There were 
no exclusions due to the occurrence of a concomitant infectious disease during the study 
period. All losses were due to withdrawal of consent of parents or guardians during the 
follow-up period (3.6%) or migration and/or absence of families after Day 3 (1.9%). 
Therefore, clinical and parasitological monitoring up to Day 28 was accomplished for a study 
group of 649 (94.5%) children. The baseline characteristics of the children at day of 
enrolment were similar for the three study sites and the corresponding years, except for mean 
parasite density at Day 0 (Table 1). Mean parasite densities were higher in the Wosera (t = 
2.80, p ≤ 0.01) and the North Coast area (t = 3.10, p ≤ 0.01) than in Karimui. 
At enrolment, 555 children (85.5%) presented with a monoinfection with P. 
falciparum and 94 (14.5%) with a mixed infection. Among the mixed infections, 86 (91.5%) 
were simultaneously infected with P. vivax, 7 (7.4%) with P. malariae, and 1 (1.1%) with 
both of the latter species. 
Standard treatment was given under supervision over the first three days and the 
decision on whether children received SP in combination with AQ or CQ was dependent on 
weight (AQ for <14 kg). CQ plus SP was given to 128 (19.7%) children (median age of 6 
years), whereas 521 (80.3%) children were treated with AQ plus SP (median age of 4 years). 
A summary of the classification of the treatment outcomes for P. falciparum at the 
three sites in the different years is shown in table 2. In the Karimui area, treatment failure 
rates up to Day 28 decreased over the three-year period from 30% to 25%, and 18%, 
respectively. This trend remained even after PCR-correction (28%, 18%, and 16%, 
respectively), which identified 11%, 26%, and 9% of recurrences to be new infections (χ2(2) = 
4.81, p = 0.09). The overall decreasing trend in treatment failure rates over the study period 
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was especially so because of a decrease in clinical failures. In the South Wosera area, overall 
failure rate tended to increase from 2003 to 2004 (χ2(2) = 1.19, p = 0.28), from 19% in 2003 to 
28% in 2004, and after genotyping correction from 16% to 22%, respectively, with 24% of 
recurrences in 2003 and 33% in 2004 being new infections. Treatment failure rate up to Day 
28 in 2004 was 16.4% in the North Coast area of Madang, 11.5% after PCR-correction with 
29% of recurrent parasites being new infections. 
From the total of 120 (18.5%) treatment failures in the P. falciparum group, 97 
(80.8%) had a monoinfection with P. falciparum, 20 (16.7%) a mixed infection with P. vivax, 
and 3 (2.5%) a mixed infection with P. malariae at Day 0. In our study, none of known risk 
factors (i.e., age, fever or parasite density at day of enrolment) or the combination regimen 
(SP plus AQ or CQ, respectively) were associated with an increased risk of treatment failure. 
A mixed infection with P. vivax and/or P. malariae at Day 0 showed a slightly increased risk 
of P. falciparum treatment failure (OR=1.53), but this effect did not reach statistical 
significance (p = 0.11). Recurrent parasitaemia with other species was seen in 36 (5.5%) of all 
cases, in 34 (5.2%) with P. vivax, and in 2 (0.3%) with P. malariae. Ten of the 86 patients 
(11.6%) with a mixed infection with P. vivax at Day 0 had recurrence with P. vivax, therefore 
representing P. vivax failure cases (Table 3). From all patients with a P. falciparum 
monoinfection at Day 0, 24 (4.3%) had recurrence with P. vivax, and one (0.2%) with P. 
malariae. From the two patients with recurrent P. malariae, one had a monoinfection with P. 
falciparum, the second a mixed infection with P. falciparum and P. vivax at Day 0. The 
patient with a mixed infection with all three species at enrolment had no recrudescent 
parasitaemia during the follow-up period. 
 
In vivo drug efficacy against P. vivax. To maximize the sample size for analysis, data 
from the P. vivax groups enrolled at all study sites between 2004 and 2005 were pooled. From 
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a total of 106 children with a P. vivax monoinfection at admission day, two were lost due to 
withdrawal of consent. At baseline, the analysis population had a mean age of 3 years (95% 
CI = 2.7--3.4), a mean axillary temperature of 37.7°C (95% CI = 37.4--38.0), a mean 
haemoglobin level of 10.1 g/dl (95% CI = 9.7--10.5), and a mean parasite density of 4182 
asexual parasites per microlitre whole blood (range = 40--50640). CQ plus SP was given to 5 
(4.8%), AQ plus SP to 98 (94.2%) children, and one (1.0%) was treated with primaquine plus 
SP. P. vivax treatment failure, defined as recurrent parasitaemia after Day 3 irrespective of 
clinical symptoms, was seen in 13 (12.5%) of all children (Table 3). There was a significant 
difference of failure rates between sites (χ2(2) = 13.95, p = 0.001): 10/34 (29.4%) P. vivax 
infections in the North Coast area of Madang and 3/46 (6.5%) in the Karimui area failed 
treatment, whereas all 27 infections were successfully cleared in the Wosera area. Recurrent 
parasitaemia with P. falciparum was observed in two (1.9%) patients who had both 
successfully cleared their P. vivax infection. 
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DISCUSSION 
In Papua New Guinea, standard first-line therapy with AQ or CQ against 
uncomplicated malaria was replaced with the combination regimen of AQ or CQ plus SP in 
the year 2000. The current studies conducted between 2003 and 2005 were the first ones to 
assess the therapeutic efficacy of the newly introduced combination regimen against P. 
falciparum and P. vivax malaria using the revised WHO standard protocol. In our studies 
conducted in three different areas over the period of three consecutive years, we observed 
PCR-corrected treatment failure rates up to 28% for P. falciparum and 12% for P. vivax 
malaria. 
There is strong advocacy for artemisinin-based combination therapy (ACT) .36 
However, for economic reasons, many countries have decided on combination regimens 
including more affordable options, such as AQ or CQ plus SP. PNG replaced 4-
aminoquinoline monotherapy with AQ or CQ plus SP in 2000, a decision which was based on 
efficacy levels above 95% assessed by trials using the 14 day follow-up protocol. When we 
restricted the analysis in our studies to the Day 14 outcomes based on clinical and 
parasitological criteria only, we measured treatment failure rates between 2% and 18%. As 
expected, failure rates up to Day 28 were higher, with PCR-corrected values between 12% 
and 28%, depending on the area and the year. In concordance with previous data, our results 
show that in vivo studies with a follow-up period of 14 days are not sensitive enough to assess 
the therapeutic efficacy of the current first-line regimen in moderately to highly endemic 
areas.37,38 Assessment up to Day 14 clearly underestimates the true failure rate because in the 
majority of patients, recurrent parasitaemia appeared after Day 14. Furthermore, late 
recurrences (i.e., appearing after Day 14) have to be expected for regimens including drugs 
with long elimination half-lives, such as SP.39 
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Our results show a two to threefold decrease in efficacy of AQ or CQ plus SP only 
three years after successful implementation of the new first-line regimen. Though clinical 
failure rates were still low (< 10% at all three sites), resistance levels exceeded 12% in all 
three sites. It is commonly accepted that parasitological response should be used as an 
additional indicator for the in vivo efficacy of drugs. Parasitological failure rates are likely to 
translate into clinical failure rates, either within a short term in the infected individual 
depending on the immunological status, or within a long term on population level as parasite 
resistance increases.35,40 Moreover, according to the new WHO guidelines, which recommend 
that a policy change should be seriously considered when efficacy of a combination regimen 
up to Day 28 is below 90%,40 these high levels of in vivo resistance are worrisome. 
Surprisingly, the dynamics of drug efficacy over time in the Karimui and the Wosera 
area showed contrasting trends. Whereas treatment failure rates showed a decreasing trend 
over three years in Karimui, they showed an increasing trend over two years in the Wosera. 
The fact that the decreasing trend in Karimui was mainly attributable to a drop in clinical 
failures up to Day 14 without a change of failures between Day 14 and 28, might suggest the 
quality of the drug batches (i.e., mainly SP) used in Karimui in 2003 to be considerably lower 
than those in the following years. Otherwise, the question remains whether our observations 
are the product of intrinsic regional variations or reflect real trends in the dynamics of 
resistance in these areas. We are aware that the sample sizes and the time intervals between 
the studies might not have been sufficient to detect real trends. Supplementation of the in vivo 
results with additional molecular data, the most important being the level of resistance in the 
circulating parasite population (Marfurt J. and others, unpublished data), and ongoing 
monitoring activities will give further indications about the level and dynamics of drug 
resistant P. falciparum malaria in PNG. 
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In view of the history of drug use in PNG, the observation of increasing failure rates 
with AQ or CQ plus SP is not surprising. In the face of increasing CQ resistance, many 
countries in Africa and Asia had adopted SP as first-line antimalarial between the 1960s and 
the 1980s.41 Thereafter, several countries facing increasing levels of SP resistance had 
introduced the cheap and safe combination of AQ or CQ plus SP as interim option for 
antimalarial therapy. Whereas SP combined with AQ had shown a reduction in clinical as 
well as total failure rates up to Day 28, the combination with CQ has not been associated with 
much benefit over monotherapy with SP.42,43 Considering the high levels of resistance to AQ 
and CQ in PNG and a known history of antifolate use in the country before the introduction of 
the combination regimen, the rapid appearance of resistance had to be expected, because an 
added benefit of combination therapy is heavily dependent on pre-existing efficacy of the 
partner drugs.44 And since resistance levels to AQ and CQ have been known to be high in 
PNG, it was very unlikely that these drugs would have had sufficient capacity to significantly 
curb the development of resistance to SP and therefore prolong its useful therapeutic life. 
CQ resistance of P. vivax, the second dominant species in PNG, was first described in 
198911 and treatment failure rates up to 20% for CQ and 8% for AQ were reported from 
Maprik in the late 1990s.6 Reduced sensitivity of P. vivax malaria to SP has been observed in 
Madang.17 When we evaluated the therapeutic efficacy of AQ or CQ plus SP in 190 patients 
with a P. vivax infection, we measured a total treatment failure rate up to Day 28 of 12%. 
Relapse is an important aspect of P. vivax malaria and refers to clinical malaria caused by 
reappearing parasites which originate from the dormant liver stages called hypnozoites. 
Therefore, circulating asexual stages after blood schizonticidal therapy might either originate 
from asexual parasites that survived therapy, from activated hypnozoites which lead to a 
relapse, or from a new infection. Unlike with P. falciparum infections, where true 
recrudescences can be distinguished from new infections by the use of genotyping methods,45 
current molecular methods used for the genetic analysis of P. vivax46-49 do not allow the 
Chapter 2   
 
60
unambiguous classification of recurrent parasitaemia, in particular the distinction between a 
relapse originating from an antecedent infection and a newly acquired infection during the 
follow-up period, which is critical in the analysis of the therapeutic response. However, recent 
work on the establishment of standard protocols, similar to those developed for P. falciparum 
including multiple polymorphic genes, look promising and might be included in future drug 
efficacy trials.50 Though patients in our study were exposed to the risk of a new infection 
during the follow-up period and parasite genotyping methods were not applied, we have good 
reason to assume that our data represent true P. vivax resistance to treatment. Former studies 
demonstrating that no P. vivax relapses occurred until Day 36 after full compliance to 
treatment with the long half-life drug CQ, most probably due to minimal effective 
concentrations of the drug preventing a first relapse to become patent in the blood, led to the 
proposition that parasitaemia recurring within 28 days after initiation of CQ therapy reflects 
resistance to the drug.51 This concept might be even more relevant with a combination 
regimen containing CQ and a second long half-life drug, such as SP.52 
It has long been thought that SP is less active against P. vivax malaria, an assumption 
which was mainly based on clinical studies failing to demonstrate SP efficacy against this 
species.53 Accordingly, SP has never been recommended for P. vivax malaria. Nevertheless, 
increasing levels of resistance of P. vivax to CQ led to the introduction of SP in many 
countries in South East Asia, Central and South America and other parts of Oceania, where 
both species are endemic, and resistance had developed rapidly in many areas within only a 
few years after its initial deployment as monotherapy.54,55 It has been shown recently that the 
mechanisms of P. vivax resistance to antifolates are similar to those of P. falciparum. Several 
studies have reported an association between single nucleotide polymorphisms in P. vivax 
dihydrofolate reductase (Pvdhfr) and reduced sensitivity to SP.56--59 Moreover, in vivo studies 
conducted in areas with previous history of SP use against P. falciparum have shown that SP 
resistance of P. falciparum was paralleled by the development of resistance of P. vivax.52,60 
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These findings further argue for a similar mechanism of antifolate resistance in both species, 
one that is driven by exertion of selective drug pressure and progresses rapidly. It does 
therefore not come as a surprise that despite the addition of SP, P. vivax failure rates rose 
from 8% with AQ monotherapy6 to 12% with AQ or CQ plus SP combination. High level of 
P. vivax resistance is however still restricted to the Madang area, where P. vivax resistance 
even exceeds the one seen in P. falciparum. 
Occurrence of P. falciparum parasitaemia was seen in two (2%) of all P. vivax 
patients. Cryptic coinfections with P. falciparum after treatment against P. vivax malaria have 
been described in other areas where both species are endemic.61,62 Since appearance of P. 
falciparum in both cases was seen after two weeks of treatment, it may reflect acquisition of a 
new infection. However, a more plausible explanation is that a concomitant P. falciparum 
infection was not recognized at day of admission. This could have occurred because the P. 
falciparum infection was in its hepatic stage, or due to difficulties in differentiating the 
erythrocytic stages of the two species by microscopy. In contrast, occurrence of P. vivax in 
patiens with a P. falciparum monoinfection at admission day was seen in 24 (4.3%) of all 
patients. P. vivax parasites appeared between Day 7 and 28, suggesting that patients had a 
concomitant infection with both species at presentation, either as patent infection which was 
not detected by microscopical diagnosis, or as relapse from intra-hepatic infection shortly 
after initiation of treatment against P. falciparum. In both cases, recurrent parasitaemia would 
represent resistance since circulating drug levels should have eliminated drug sensitive 
parasites. 
In conclusion, the high parasitological failure rates of P. falciparum and P. vivax to the 
combination therapy with AQ or CQ plus SP only after a short time of successful 
implementation suggest that the current first-line regimen in PNG is not sufficiently effective 
and that a policy change needs to be considered. Whilst further monitoring assessing 
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molecular markers for parasite resistance to CQ and SP, and also other drugs, such as the 
artemisinin derivates, is ongoing in PNG, clinical trials to test the safety and efficacy of 
alternative replacement regimens are urgently needed so that a policy change can be rapidly 
initiated. P. falciparum and P. vivax malaria are both endemic in PNG and in most health 
facilities, antimalarial therapy is given based on presumptive clinical diagnosis. Therefore, 
apart from safety, tolerability, practicability and cost, efficacy to both of the prevailing 
species is an important aspect to consider in the evaluation of any future combination 
regimen. 
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TABLE 1: Baseline characteristics of children with a P. falciparum infection at admission day 
Study site 
Karimui area 
(Simbu Province) 
South Wosera area 
(East Sepik Province) 
North Coast area 
(Madang Province) 
Year 2003 2004 2005 2003 2004 2004 
Characteristics (n = 97) (n = 93) (n = 128) (n = 112) (n = 115) (n = 104) 
Weight (mean (95% CI), kg) 14.3 (13.5-15.1) 15.7 (14.4-16.9) 17.1 (15.8-18.3) 14.6 (14.0-15.3) 16.9 (14.3-19.6) 14.7 (11.7-17.7) 
Age (mean (95% CI), yrs) 4.0 (3.7-4.4) 4.2 (3.9-4.6) 4.4 (4.2-4.7) 4.5 (4.2-4.8) 4.7 (4.5-5.1) 3.5 (3.2-3.7) 
Sex: females/n (%) F: 43/97 (44.3) F: 51/93 (54.8) F: 60/128 (46.9) F: 59/112 (52.7) F: 57/115 (49.6) F: 43/104 (41.4) 
Temperature (mean (95% CI),°C) 38.7 (38.5-38.9) 38.7 (38.5-38.8) 38.5 (38.4-38.7) 38.7 (38.4-39.0) 38.0 (37.8-38.3) 38.0 (37.8-38.3) 
Hb (mean (95% CI), g/dl) 9.0 (8.6-9.5) 9.5 (9.1-10.0) 9.6 (9.2-9.9) 9.0 (8.7-9.3) 8.8 (8.5-9.1) 9.3 (8.8-9.7) 
Parasite density (geometric mean (range), per µl) 21937 (1120-329400) 23786 (1040-187440) 19364 (1000-238880) 40526 (280-774400) 37244 (1000-512000) 38706 (1160-261160) 
 
CI, Confidence interval; Hb, haemoglobin 
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TABLE 2: Treatment outcomes for amodiaquine (n = 521) or chloroquine (n = 128) plus sulphadoxine-pyrimethamine against P. falciparum 
malaria 
Study site Karimui area (Simbu Province) 
South Wosera area 
(East Sepik Province) 
North Coast area 
(Madang Province) 
Year 2003 2004 2005  2003 2004  2004 
Class (no (%)) (n = 97) (n = 93) (n = 128) p(χ2(2)) (n = 112) (n = 115) p(χ2) (n = 104) 
Follow-up to Day 14 
ACPR 80 (82.47) 80 (86.02) 126 (98.44)  96 (85.71) 94 (81.74)  97 (93.27) 
TF 17 (17.53) 13 (13.98) 2 (1.56)  16 (14.29) 21 (18.26)  7 (6.73) 
Follow-up to Day 14, PCR corrected 
ACPR 80 (82.47) 83 (89.25) 126 (98.44)  98 (87.50) 96 (83.48)  97 (93.27) 
TF 17 (17.53) 13 (10.75) 2 (1.56) <0.001 14 (12.50) 19 (16.52) 0.39 7 (6.73) 
Follow-up to Day 28 
ACPR 67 (69.07) 70 (75.27) 105 (82.03)  90 (80.36) 83 (72.17)  87 (83.65) 
ETF 2 (2.06) 0 (0) 0 (0)  5 (4.46) 11 (9.57)  0 (0) 
LCF 7 (7.22) 0 (0) 0 (0)  1 (0.89) 0 (0)  4 (3.85) 
LPF 21 (21.65) 23 (24.73) 23 (17.97)  16 (14.29) 21 (18.26)  13 (12.50) 
TF 30 (30.39) 23 (24.73) 23 (17.97)  22 (19.64) 32 (27.83)  17 (16.35) 
Follow-up to Day 28, PCR corrected 
ACPR 70 (72.16) 76 (81.27) 107 (83.59)  94 (83.93) 90 (78.26)  92 (88.46) 
ETF 2 (2.06) 0 (0) 0 (0)  5 (4.46) 11 (9.57)  0 (0) 
LCF 7 (7.22) 0 (0) 0 (0)  1 (0.89) 0 (0)  4 (3.85) 
LPF 18 (18.56) 17 (18.28) 21 (16.41)  12 (10.71) 14 (12.17)  8 (7.69) 
TF 27 (27.84) 17 (18.28) 21 (16.41) 0.09 18 (16.07) 25 (21.74) 0.28 12 (11.53) 
 
ACPR, Adequate clinical and parasitological response; ETF, Early treatment failure; LCF, Late clinical failure; LPF, Late parasitological failure; 
TF, Treatment failure 
Chapter 2           
 
75 
TABLE 3: Treatment outcomes for amodiaquine (n = 174) or chloroquine (n = 16) plus sulphadoxine-pyrimethamine against P. vivax malaria 
Study site 
Class (no (%)) 
Karimui area 
(Simbu Province) 
South Wosera area 
(East Sepik Province) 
North Coast area 
(Madang Province) 
p(χ2(2)) Total 
P. vivax monoinfections (n = 43) (n = 27) (n = 34)  (n = 104) 
ACPR 40 (93.0) 27 (100) 24 (70.6)  91 (87.5) 
TF 3 (7.0) 0 (0) 10 (29.4) 0.001 13 (12.5) 
Mixed P. vivax plus P. falciparum infections (n = 36) (n = 32) (n = 18)  (n = 86) 
ACPR 33 (91.7) 29 (90.6) 14 (77.8)  76 (88.4) 
TF 3 (8.3) 3 (9.4) 4 (22.2) 0.29 10 (11.6) 
 
ACPR, Adequate clinical and parasitological response; TF, Treatment failure 
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ABSTRACT 
 
Plasmodium falciparum resistance to drugs is a public health concern and monitoring 
of drug efficacy is part of national health systems. Drug resistance is mostly 
conferred by SNPs. To monitor the spread of these mutations techniques are 
required facilitating analyses of multiple SNPs. We report a rapid and affordable 
microarray technique for application in epidemiological studies on malaria drug 
resistance. 
All known resistance-associated SNPs in pfdhfr, pfdhps, pfcrt, pfmdr1, and 
pfATPase6 genes were analysed by a single tube mini-sequencing reaction and 
subsequent microarray hybridisation. After evaluation using sequenced parasite 
material, naturally infected samples from Papua New Guinea were analysed. There 
was overall consistency of over 90% and analysis by microarray can be done with 
<10 parasites. 
This fast and cost-effective monitoring system facilitates longitudinal monitoring as 
early warning system and can be applied to detect re-emergence of drug susceptible 
parasites after withdrawal of a drug. 
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INTRODUCTION 
 
Parasite resistance to antimalarial drugs has become a major public health concern 
for endemic areas and a threat to malaria control programs (1). Therefore, monitoring 
of antimalarial drug efficacy has become an integral part of national health systems. 
Efficacy of first-line antimalarial drugs is currently monitored primarily by in vivo 
methods. Such investigations pose major problems in terms of recruitment, costs, 
and adherence to follow-up visits. In highly endemic areas, efficacy studies are 
confounded by new infections during the follow-up period (2). In addition, such a 
monitoring system does not allow the determination of efficacy of drugs which have 
been discontinued as a result of decreased efficacy, and whose efficacy has been 
reported to re-emerge once drug selection pressure had ceased (3, 4). In vivo 
studies may also fail to describe the true drug resistance situation in a country 
because they are usually based on a small and often highly biased sample from the 
population (5). 
 
Single nucleotide polymorphisms (SNPs) have frequently been associated with 
susceptibility to disease (6), with differences in drug metabolism (7), and with 
reduced sensitivity to drugs in microorganisms (8). Drug resistance of the malaria 
parasite Plasmodium falciparum is nearly always conferred by several SNPs. 
Resistance to sulfadoxine-pyrimethamine (SP) is conferred by point mutations at 
codons A16V, N51I, C59R, S108N/T, and I164L in the dhfr (dihydrofolate reductase) 
gene. Resistance is augmented by point mutations in the dhps (dihydropteroate 
synthase) gene (S436A, A437G, K540E, A581G, and A613T/S) (9). Multiple SNPs in 
the transporter genes mdr1 (multidrug resistance gene 1) and crt (chloroquine 
resistance transporter) have been implicated in resistance to 4-aminoquinolines (10, 
11). Recently, mutations in the plasmodial ATPase6 gene have been associated with 
decreased susceptibility to artemisinins (12). 
 
Because molecular monitoring of parasite drug resistance has a potential to become 
a complementary tool for long-term surveillance and for developing predictive models 
on malaria drug resistance (13, 14), a technique is required that facilitates parallel 
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analysis of multiple SNPs. It must be affordable and applicable for studies at 
epidemiological scale. 
 
Presently, a number of methods exist for SNP analysis, but each has its limitations. 
Many are based on PCR-RFLP analysis of selected loci or on sequence specific 
amplification or hybridisation (15). These techniques have limitations in the 
availability of diagnostic restriction sites or the vulnerability to false positive signals. 
In addition, costs are high for these techniques and throughput is low. Other methods 
such as MALDI-TOF (16), pyrosequencing (17), real-time PCR (18, 19), clamped-
probe PCR (20), or molecular beacons (21), are also prohibitively expensive for 
epidemiological studies. Consequently, many previous studies have analysed only a 
few SNPs deemed as primary predictors of resistance. Little attention has been paid 
to mutations that are not directly associated with resistance, but are considered to 
have modulating or compensatory effects. 
 
In order to overcome these limitations, we have developed a parallel SNP analysis 
system for monitoring parasite drug resistance in malaria. Our aim was to develop a 
user-friendly technology that can rapidly and accurately detect multiple SNPs on a 
large scale at low cost. We validated our approach with markers of parasite 
resistance to antimalarial drugs where important criteria are simplicity and robustness 
to allow transfer to countries with limited resources. 
 
We present here a microarray-based system to determine all known SNPs in drug 
resistance associated P. falciparum genes. In relation to previously used techniques, 
costs are significantly lower and large numbers of samples can be analysed in a 
reasonably short time. We have already shown that this technique can be transferred 
and run in laboratories with minimal infrastructure (22, 23). This technology is also 
flexible and adaptable for many other applications requiring SNP analyses. 
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MATERIAL AND METHODS 
 
Our method is based on parallel PCR amplification of the target sequences followed 
by primer extension mediated mini-sequencing using fluorochrome-labelled ddNTPs. 
Subsequent base calling occurs on a microarray upon sequence specific 
hybridisation. The flow chart in figure 1 depicts schematically the principle of the 
parallel SNP analysis system. 
 
Analysed material 
To establish and evaluate the technique both cultured material from strains 3D7 and 
K1, and samples collected during community surveys in Papua New Guinea have 
been used. 
 
Blood samples and DNA preparation 
Blood samples were collected in EDTA Microtainer™ tubes (BD Biosciences, 
Allschwil, Switzerland), plasma was separated by centrifugation and red blood cell 
pellets were stored frozen until used. DNA from cultures and field samples was 
extracted using QIAamp® DNA Blood Kit (Qiagen, Hombrechtikon, Switzerland) 
according to the manufacturer’s instructions. 
 
DNA amplification 
We analysed the following 36 polymorphisms in 5 genes at 32 SNP sites: pfmdr1 
codons N86Y, Y184F, S1034C, N1042D and D1246Y, pfcrt codons C72S, K76T, 
H97Q, T152A, S163R, A220S, Q271E, N326D/S, I356L/T and R371I, pfdhfr condons 
A16V, N51I, C59R, S108N/T and I164L, pfdhps codons S436A, A437G, K540E, 
A581G, A613T/S, I640F, and H645P, and pfATPase6 codons S538R, Q574P, 
A623E, N683K, and S769N. Oligonucleotides for amplification, extension, and 
arraying are shown in supplementary table 1. To cover all SNP sites, we performed 
10 PCR reactions with amplification primers listed in supplementary table 1. The 
amplification reaction contained 1 x PCR buffer with MgCl2 in a final concentration of 
3 mM, 0.2 mM dNTPs, and 0.2 µM of each primer. Reactions were carried out in 50 
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µl containing 2.5 µl DNA and 2.5 U Taq polymerase (Firepol®, Solis BioDyne, Tartu, 
Estonia). Cycling conditions were: 96oC for 3 min followed by 20 cycles of 96oC for 
30 sec, 52oC for 90 sec, and 72oC for 90 sec. 
As our aim was to identify SNPs also in asymptomatic samples from community-
based surveys we performed nested PCR for highest sensitivity. Nested PCR 
reactions were carried out in 100 µl with 5 µl primary PCR products and 5 U Taq 
polymerase. Buffer and cycling conditions were identical as above but nested PCR 
primers were used (supplementary table 1). 
 
Primer extension 
To eliminate non-incorporated nucleotides, all nested PCR products of one blood 
sample were pooled and 5 µl of a 1:10 dilution of the pooled PCR products was 
digested with 2 U shrimp alkaline phosphatase (SAP) (Amersham Biosciences, 
Freiburg, Germany) in a reaction volume of 12 µl for 1 h at 37oC. SAP was 
inactivated by incubating samples for 15 min at 90oC. 
Since most microarray scanners support only dual fluorescence measures 
simultaneously, a strategy of two parallel reactions had to be applied. Per sample, 
two primer extension reactions were carried out. The mixes differed in their 
combinations of Cy3 and Cy5 labelled ddNTPs (Perkin Elmer, Schwerzenbach, 
Switzerland) and extension primers were added as shown in supplementars table 2. 
It was thus possible to detect all possible SNP permutations in all loci using two 
fluorochromes only. All primer extension reactions for one sample were carried out in 
2 x 20 µl containing 1 x Sequenase buffer, extension primer mix 1 or 2, and ddNTP 
mix 1 or 2, respectively (supplementary table 2), and 2 U Thermo Sequenase 
(Termipol®, Solis, Tartu, Estonia). Concentration of ddNTPs in both mixes was 0.25 
µM and primers were diluted to a concentration of 6.25 nM each. The extension 
reaction was cycled 35 times with 94oC for 30 sec, and 50oC for 10 sec, with an initial 
cycle of 1 min at 94oC. After the extension reaction, both mixtures were pooled and 6 
µl denaturing solution (3% SDS in 40 mM EDTA pH 8.0) were added. The sample 
was denatured at 95oC for 60 sec, and subsequently kept on ice until hybridisation 
onto the microarray. 
 
Chapter 3   
 
82 
Chip production 
Microarrays carried short oligonucleotides (20 - 35 bp) corresponding to the 
antisense DNA of the extension primers (supplementary table 1). All oligonucleotides 
possessed a C7-aminolinker and were spotted onto aldehyde activated glass slides 
(Genetix, Munich, Germany). Prior to spotting of oligonucleotides, a mask with 12 
circular wells (diameter 8 mm) was applied onto the surface of the slides (MaProline 
GmbH, Starrkirch-Wil, Switzerland). Oligonucleotides were spotted in triplicates and 
pre-labelled Cy3 and Cy5 anchor oligonucleotides as well as four oligonucleotides 
with a random sequence were added as position and negative controls, respectively. 
Slides were spotted using a VersArray ChipWriterPro system (Bio-Rad Laboratories, 
Hercules, CA). Oligonucleotides were dissolved in 180 mM phosphate buffer pH 8.0 
and 0.5 nl of a 50 µM solution were spotted onto the slides. Slides were stored 
desiccated and in the dark until used for hybridisation. 
 
Chip hybridisation 
Twenty-three µl of the pooled and denatured primer extension reaction were 
transferred to a well of the microarray glass slide and 6 µl of 20 x SSC was added. 
The hybridisation was carried out in a humid chamber at 50oC for 60 to 90 min. After 
hybridisation, the slide was washed at room temperature in 2 x SSC plus 2% SDS for 
20 min, followed by another wash with 2 x SSC for 20 min, and a final wash with 2 x 
SSC plus 2% ethanol for 2 min. The slides were dried with compressed air and 
stored in the dark until scanned. 
 
Data acquisition 
Hybridised slides were scanned at 635 nm and 532 nm using an Axon 4100A 
fluorescence scanner (Axon, Bucher Biotec AG, Basel, Switzerland). Cy3 and Cy5 
images were acquired and analysed using the Axon GenePix® Pro (version 6.0) 
software (www.axon.com). This software generates data points using pixel intensity 
after background subtraction. We developed a software for further analysis of raw 
data. Each signal was classified either as wild type, mutant, or mixed based on the 
expression intensities of the scanned image. The grouping was done according to 
the following algorithm: Flurescence intensities below 9000 (Cy3) or 10000 (Cy5) 
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units (mean intensities minus background) were regarded as negative. For measures 
above these threshold values, we considered the ratio Cy5 to Cy3 intensity to 
discriminate wild-type, mutant, or mixed. 
To determine an optimal algorithm to translate the output of the GenePix® Pro 
software into predictions about the genotypes present in analyzed samples, we used 
two singly infected blood samples which were previously sequenced at 29 SNP sites. 
Sequence data showed that the samples were different at 3 of 29 SNP sites (C59R, 
S108N, and A437G). The samples were analyzed with the chip either single or mixed 
in varying proportions (1:2, 1:4, 1:8, and 1:16). With this approach, we could 
empirically determine the following threshold values: for Cy5 to Cy3 ratios below 0.7 
the sample was classified according to whether wild-type or mutant were labelled 
with Cy3. Ratios between 0.7 and 2.4 were assigned to mixed genotypes, and ratios 
above 2.4 to the Cy5 labelled genotype. 
To estimate the above mentioned threshold parameters and to determine the 
predictive accuracy of our method, we used 3 of 4 identical but independently 
processed microarrays to estimate the threshold value to distinguish positive from 
negative signals so that the results would match the sequence data as close as 
possible. The fourth microarray was then used to apply this algorithm to determine 
the predictive accuracy of the method. This procedure was repeated 4 times in all 
possible combinations. Finally, we applied this algorithm to samples which were 
genotyped by PCR-RFLP and sequence analysis to determine the sensitivity and 
specificity of our method. 
 
Sequencing 
PCR products were purified by size-selective polyethylenglycol precipitation (24) and 
directly sequenced using the respective nested PCR primers. Cycle sequencing (25 
cycles of 96°C for 30 sec, 50°C for 15°C, and 60°C for 4 min) was performed using 
the API PRISM™ Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin 
Elmer, Schwerzenbach, Switzerland) and sequences were analysed using the API 
PRISM™ 310 Genetic Analyzer and the API PRISM™ software. 
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RESULTS 
 
Amplification and sensitivity 
Ten PCR fragments were required to cover all SNP locations. Amplicons sizes were 
637 base pairs (bp) for pfdhfr, 686 bp for pfdhps, 799 bp and 526 bp for pfmdr1, five 
fragments of 630 bp, 548 bp, 476 bp, 304 bp, and 200 bp for pfcrt, and 798 bp for 
pfATPase6. To increase sensitivity we applied a nested PCR protocol and re-
amplified all PCR products (for primers see supplementary table 1). For assay 
validation, DNA was extracted from parasitized erythrocytes added in ten fold 
dilutions to non-infected human blood. Thus, the amount of template per PCR 
reaction corresponded to 1 to 100’000 parasites. All samples were subjected to a 
primer extension reaction and hybridised onto the microarray. Figure 2 shows signals 
obtained from the dilution series at selected SNP sites. Except for pfmdr1 1246, we 
were able to detect 1000 parasites. Eight of 13 primers tested gave a signal with 10 
parasites per reaction, and 6 primers were positive with 1 parasite only. 
 
Mixed infections 
Since naturally occurring blood samples often contain multiple P. falciparum strains, 
we tested whether the presence of 2 different templates would decrease sensitivity of 
detection. We mixed 3D7 parasites and K1 parasites which differ in their genetic 
profile in pfdhfr 59 and 108. While one parasite strain was kept at 1% parasitaemia, 
the other strain was serially diluted from 4% to 0.00125%. When K1 was kept 
constant, 3D7 gave acceptable results even at the lowest dilutions, except with dhfr 
59 with an endpoint at 0.0075%. When 3D7 was kept constant, similar results were 
obtained with decreasing template concentrations of K1. The exception was the loss 
of the K1 pfdhfr 59 signal at a dilution of 0.06%. Figure 3 shows the signals for both 
strains at both SNP positions. This experiment showed that the dynamic range for 
quantification of signals is low. 
 
Specificity 
We have used 12 different culture strains from which we directly sequenced the 
genes pfmdr1, pfcrt, pfdhps, and pfdhfr comprising 16 different SNP sites. Of these 
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192 SNPs analysed, we failed to detect 1 SNP in 1 strain. A mixed signal was 
produced for 4 SNPs, and 7 SNPs gave discrepant results compared to sequencing, 
3 of which at codon 86 of pfmdr1. This gave an overall specificity of 94% compared 
to the ‘gold standard’ of sequencing. After that, we determined the precision of base 
calling in naturally infected blood samples. We compared samples that were 
previously analysed by PCR-RFLP or sequencing with data from microarray analysis. 
Thirty-six PCR positive samples from field studies in Papua New Guinea were PCR-
RFLP analyzed (25, 26, 27) for pfmdr1 86, pfcrt 76, pfdhfr 51, 59, and 108, and 
pfdhps 437, 540, and 581. Mean multiplicity of infection (MOI) in these samples, 
determined by genotyping the polymorphic msp2 (merozoite surface proteine 2) 
locus (28), was 1.56 (range 1-4, 95% CI = 1.29-1.84). Only 10 of these samples were 
positive by microscopy and densities were between 80 and 9440 asexual parasites 
per µl blood with a mean density of 1731/ µl. Table 1 summarises the concordance 
between the microarray and PCR-RFLP analysis. 
In addition, 12 of these samples harbouring a single clone infection were sequenced. 
There was an excellent agreement between the microarray and sequencing results 
(data not shown) 
 
Costs 
Because we developed this microarray system to monitor parasite drug resistance 
against antimalarial drugs in resource restricted countries, it was essential to keep 
costs as low as possible so that the system can be used routinely for drug resistance 
monitoring. Cost calculation included consumables for DNA preparation, PCR 
reactions, primer extension with fluorochromes, and microarray production. But it 
does not take into account acquisition, maintenance and amortisation of equipment, 
nor does it take into account labour costs. We calculated a price of 0.27 EURO (0.33 
US$) per SNP when determining 32 SNP sites per sample and analysing 12 samples 
on one slide simultaneously. 
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DISCUSSION 
 
Monitoring of parasite resistance to antimalarial drugs has become an essential part 
of the malaria control programs in endemic countries. Common standards have been 
in vivo efficacy trials at health facilities (29) which are time and labour intensive. 
These studies are hampered, particularly in areas highly endemic for malaria, by the 
frequent re-occurrence of parasites from new inoculations. This leads to an 
underestimation of drug efficacy (2). 
 
In order to circumvent these problems, systematic molecular monitoring of parasite 
resistance-associated SNPs has been widely promoted and used to complement in 
vivo efficacy studies (6, 7). However, current systems for SNP analysis are either 
extremely cumbersome and limited or expensive, both in terms of equipment and 
running costs. 
 
Therefore, large studies analysing multiple SNPs of multiple genes in parallel have 
never been performed for reasons such as high costs and labour intensity. Here we 
report a novel method that allows the simultaneous analysis of many SNPs in 
hundreds of samples in a very short time (approx. 15h for 4 x 96 well plates) with 
significantly reduced costs. The microarray system was shown to be fast and 
accurate. In particular, the low detection limit of 10 to 100 parasites and the suitability 
for samples containing multiple infections represent added advantages over many 
competing systems. The significantly reduced costs per SNP compares favourably 
with other systems. In resource restricted countries, such as in Sub-Saharan Africa 
where parasite resistance to antimalarial drugs is a major concern (30), only a low 
cost system permits molecular monitoring of drug resistance. 
 
In contrast to the analysis of diploid organisms, the analysis of P. falciparum 
infections represent an additional challenges because multiple infections are 
commonly found leading to a highly skewed distribution of different templates within a 
blood sample (31). In addition, PCR amplification might favour the dominant 
templates. Therefore, it was an important aim to ensure that minor template 
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populations can be detected. We therefore designed an elaborate algorithm to 
determine the detection threshold for genotype calling. But evidently, some low 
density infections may be missed in some individuals whatever threshold will be 
used. Whether this is important in the epidemiological assessments of resistance 
remains to be seen, because it is not clear to what degree these low density 
infections contribute to disease and transmission. 
 
It has been shown that a synergistic action of transmembrane transporters is 
involved in parasite resistance to antimalarial drugs. In addition to pfcrt, another 
transporter involved in chloroquine resistance (pfmdr1), the homologue to the human 
P-glycoprotein, seems to contribute to resistance against chloroquine, the most 
commonly used drug against malaria (32). Pfmdr1 has also been shown to modulate 
resistance to mefloquine and related drugs (33). But up to date, no clear association 
could be shown between individual SNPs and parasitological failure of a given drug. 
Hence, it is possible that the parallel analysis of all SNPs in several genes might 
identify certain haplotypes suspected to be involved in drug resistance. With the 
prospect of analysing all known drug resistance associated SNPs at once, 
elucidation of the genetic background of drug failure becomes feasible. This 
underscores the need for linking individual SNPs into haplotypes because 
interactions between SNPs from different loci are likely to account for the phenotypic 
effect. However, current algorithms and techniques are yet unable to generate true 
haplotypes of unlinked loci in samples containing multiple infections of P. falciaprum. 
In Tanzania for instance, mean multiplicity of infection (MOI) in children is 5 
concurrent infections per individual (34), considerably complicating or preventing the 
determination of haplotypes of individual P. falciparum clones. The ability of our 
method to semi-quantify signal strength potentially allows the determination of the 
most dominant haplotype. Since parasite density is a correlate of malaria symptoms, 
the most dominant haplotype within a multiple clone infection is likely to represent the 
clone actually causing clinical malaria. 
 
We have now used our microarray system successfully for drug resistance 
monitoring in several sites over three years, in Tanzania (23), Papua New Guinea 
(22), and Solomon islands (unpublished). This demonstrates that standardised and 
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comparable data can be produced at an affordable price. The flexibility of the system 
facilitates prompt inclusion of newly identified point mutations associated with 
parasite resistance. 
 
In conclusion, this method offers unmatched capacity to provide evidence-based data 
on the dynamics of parasite resistance against antimalarial drugs in a cost-effective 
way. This platform can also be widely applied and adapted with ease to other 
genotyping tasks requiring highly parallel multiple SNP analyses. 
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Figure 1: Flow diagram of analytical procedure starting from blood samples collected 
in the field. DNA is prepared from blood samples and target sequences amplified by 
nested PCR. All amplicons are subsequently combined and nucleotides are 
eliminated by SAP. Primer extension is performed in 2 x 20 µl for each sample and 
both mixtures are combined for hybridisation onto the microarray. After washing, the 
array is air dried and scanned and subsequently analysed using GenePix® Pro and 
dedicated analysis software. 
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Figure 2: Sensitivity curves for SNP analysis in parasite samples diluted in 
uninfected blood. All data represent the percentage of fluorescence of the undiluted 
sample containing the genomic equivalent of 100000 parasites per reaction. The 
upper panel represents values obtained for SNPs within the pfdhfr and pfdhps locus. 
The lower panel represents the values for pfmdr1 and pfcrt. 
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Figure 3: Detection of SNPs in mixed parasite infections. The upper panel depicts 
arbitrary fluorescence values obtained when strain K1 was mixed with various 
dilutions of the 3D7 strain. K1 and 3D7 differ at codons 59 and 108 in the pfdhfr 
gene. The lower panel shows arbitrary fluorescence values obtained when strain 3D7 
was mixed with various dilutions of the K1 strain. 
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Table 1: SNP analysis in 36 field samples from Papua New Guinea and agreement 
between data obtained by microarray and PCR-RFLP method, respectively 
 
 N nd 
RFLP 
nd 
array 
Concordant mixed 
RFLP/ 
single 
array* 
mixed 
array/ 
single 
RFLP 
single RFLP / 
single RFLP 
alternative nt 
% 
agreement  
(κ test) 
Locus 36 n=1 n=0 250 nt 86.8% 
25 nt 
8.3% 
8 nt 
2.8% 
5 nt 
1.7% Total: 288 nt 
mdr1 86 36 0 0 36 0 0 0 100 
crt 76 35 1 0 28 6 0 1 80 
dhfr 51 36 0 0 23 13 0 0 63.9 
dhfr 59 36 0 0 29 4 2 1 80.6 
dhfr 108 36 0 0 29 0 6 1 80.6 
dhps 437 36 0 0 34 1 0 1 94.4 
dhps 540 36 0 0 35 0 0 1 97.2 
dhps 581 36 0 0 36 0 0 0 100 
 
N, total number of samples 
nd, not determined 
* identification of mutant or wild type alleles only requires complete digest 
nt, nucleotides 
n, number of samples 
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Supplementary table 1: Oligonucleotide primers used (Operon Biotechnologies 
GmbH, Cologne, Germany) 
 
Name Locus / fragment  Sequence 
 Primary PCR amplification 5’                                                                          3’ 
P5-for dhfr  TTTATGATGGAACAAGTCTGC 
P5-1 rev dhfr  ATTCATATGTACTATTTATTCTAGT 
P8-1 for dhps  ATTTTTGTTGAACCTAAACGTGCTGTTCA 
P8-1 rev dhps  CTTGTCTTTCCTCATGTAATTCATCT 
P1-1 for mdr1, first fragment TTAAATGTTTACCTGCACAACATAGAAAATT 
P1-1 rev mdr1, first fragment CTCCACAATAACTTGCAACAGTTCTTA 
P3-1 for mdr1, second fragment AATTTGATAGAAAAAGCTATTGATTATAA 
P3-1 rev mdr1, second fragment TATTTGGTAATGATTCGATAAATTCATC 
P10-1 for crt, first fragment TTGTCGACCTTAACAGATGGCTCAC 
P10-1 rev crt, first fragment AATTTCCCTTTTTATTTCCAAATAAGGA 
P18-1 for crt, second fragment ACTTTATTTGTATGATTATGTTC 
P18-1 rev crt, second fragment TAACTGCTCCGAGATAATTGT 
P11-1 for crt, third fragment ATTTACTCCTTTTTAGATATCACTTA 
P11-1 rev crt, third fragment TTATATTTTTTAAAAACTATTTCCCTTG 
P16-1 for crt, fourth fragment TCTGTTATTTTTATTTCTTATAGGCTAT 
P16-1 rev crt, fourth fragment CTTGTATGTATCAACGTTTTTCATCC 
P12-1 for crt, fifth fragment AGGAAATAAATATGGGAATGTTTAATTGA 
P12-1 rev crt, fifth fragment TTCTAAGATAATATTTCCTACACGGT 
P17-1 for ATPase6 AATATTGTTATTCAGAATATGATTATAA 
P17-1 rev ATPase6 TGGATCAATAATACCTAATCCACCTA 
 Nested PCR amplification 5’                                                                          3’ 
P5 for dhfr ACAAGTCTGCGACGTTTTCGATATTTATG 
P5 rev dhfr AGTATATACATCGCTAACAGA 
P8 for dhps TTGAAATGATAAATGAAGGTGCTAGT 
P8 rev dhps CCAATTGTGTGATTTGTCCA 
P1 for mdr1, first fragment TGTATGTGCTGTATTATCAGGA 
P1 rev mdr1, first fragment CTCTTCTATAATGGACATGGTA 
P3 for mdr1, second fragment GAATTATTGTAAATGCAGCTTTA 
P3 rev mdr1, second fragment GCAGCAAACTTACTAACACG 
P10 for crt, first fragment CTTGTCTTGGTAAATGTGCTC 
P10 rev crt, first fragment GAACATAATCATACAAATAAAGT 
P18 for crt, second fragment TCCTTATTTGGAAATAAAAAGGGAAATT 
P18 rev crt, second fragment TAAGTGATATCTAAAAAGGAGTAAAT 
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P11 for crt, third fragment ACAATTATCTCGGAGCAGTTA 
P11 rev crt, third fragment CATGTTTGAAAAGCATACAGGC 
P16 for crt, fourth fragment CTTTTTCCAATTGTTCACTTCTTG 
P16 rev crt, fourth fragment TCTTACATAGCTGGTTATTAAAT 
P12 for crt, fifth fragment ACCATGACATATACTATTGTTAG 
P12 rev crt, fifth fragment TTATAGAACCAAATAGGTAGCC 
P17 for ATPase6 AGCAAATATTTTCTGTAACGATAATA 
P17 rev ATPase6 TGTTCTAATTTATAATAATCATCTGT 
 Extension primer at SNP site 5’                                                                          3’ 
16 dhfr 16 GACGTTTTCGATATTTATGCCATATGTG  
51 dhfr 51 GAAATAAAGGAGTATTACCATGGAAATGTA  
59 dhfr 59 TTCACATATGTTGTAACTGCAC 
108 dhfr 108 forward CAAAATGTTGTAGTTATGGGAAGAACAA 
108B dhfr reverse AAAGGTTTAAATTTTTTTGGAATGCTTTCCCAG 
164 dhfr 164 forward GGGAAATTAAATTACTATAAATGTTTTATT 
164B dhfr 164 reverse TTCTTGATAAACAACGGAACCTCCTA 
436 dhps 436  TTATAGATATAGGTGGAGAATCC 
437 dhps  437 reverse TTGGATTAGGTATAACAAAAGGA 
540 dhps  540 AGGAAATCCACATACAATGGAT 
581 dhps  581 GGATACTATTTGATATTGGATTAGGATTTG 
613 dhps  613 forward GGATATTCAAGAAAAAGATTTATT 
613B dhps  613 reverse ATTTTGATCATTCATGCAATGGG 
640 dhps  640 reverse CAATTGTGTGATTTGTCCACAA  
645 dhps  645 ATAAAAATATTGTGGACAAATCAC 
86 mdr1 86 TTTGGTGTAATATTAAAGAACATG 
184 mdr1 184 TGCCAGTTCCTTTTTAGGTTTAT 
1034 mdr11034 ATTGTAAATGCAGCTTTATGGGGATTC 
1042 mdr1 1042 reverse AGAAGGATCCAAACCAATAGGCAAAACTAT 
1246 mdr1 1246 TAATATATGTGATTATAACTTAAGA 
72 crt 72 TTTTAAGTATTATTTATTTAAGTGTA 
76 crt 76 reverse TTTGTTTAAAGTTCTTTTAGCAAAAATT 
97 crt 97 GTTTTGTAACATCCGAAACTCA 
152 crt 152 CCTTCATAGGTCTTACAAGAACT 
163 crt 163 ATCCAATCATTTGTTCTTCAATTAAG 
220 crt 220 TTCTATCATATTTAATCTTGTCTTAATTAGT 
271 crt 271 TATACACCCTTCCATTTTTAAAA 
326 crt 326 AAACCTTCGCATTGTTTTCCTTCTTT  
326B crt 326 reverse ACATAGCTGGTTATTAAATTATCACAAATG 
356 crt 356 TTGTTAGTTGTATACAAGGTCCAGCA 
356B crt 356 reverse GGCTAAGAATTTAAAGTAATAAGCAATTGCT 
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371 crt 371 CTTTTTAATTTTATAGGGTGATGTTGTAA 
538 ATPase6 538 AAATGTAATAAAGCTAATTCGGT 
574 ATPase6 574 TGAAAAAAATACAACACCTGTAC 
623 ATPase6 623 AACCATTCTAATTATACTACAGCTCAGG 
683 ATPase6 683 TGAATGTATTTCTTCTTGGAGAAA 
769 ATPase6 769 ACTTAGCTTTGCTTATAAAAAATTAA 
 Arrayed as antisense oligonucleotides 5’                                                               3’ ---- C7 
16 C-7 dhfr 16 CACATATGGCATAAATATCGAAAACGTC 
51 C-7 dhfr 51 TACATTTCCATGGTAATACTCCTTTATTTC 
59 C-7 dhfr 59 GTGCAGTTACAACATATGTGAA 
108 C-7 dhfr 108 forward TTGTTCTTCCCATAACTACAACATTTTG 
108B C-7 dhfr reverse CTGGGAAAGCATTCCAAAAAAATTTAAACCTTT 
164 C-7 dhfr 164 forward AATAAAACATTTATAGTAATTTAATTTCCC 
164B C-7 dhfr 164 reverse TAGGAGGTTCCGTTGTTTATCAAGAA 
436 C-7 dhps 436  GGATTCTCCACCTATATCTATAA 
437 C-7 dhps  437 reverse TCCTTTTGTTATACCTAATCCAA 
540 C-7 dhps  540 ATCCATTGTATGTGGATTTCCA 
581 C-7 dhps  581 CAAATCCTAATCCAATATCAAATAGTATCC 
613 C-7 dhps  613 forward AATAAATCTTTTTCTTGAATATCC 
613B C-7 dhps  613 reverse CCCATTGCATGAATGATCAAAAT 
640 C-7 dhps  640 reverse TTGTGGACAAATCACACAATTG 
645 C-7 dhps  645 GTGATTTGTCCACAATATTTTTAT 
86 C-7 mdr1 86 CATGTTCTTTAATATTACACCAAA 
184 C-7 mdr1 184 ATAAACCTAAAAAGGAACTGGCA 
1034 C-7 mdr1 1034 GAATCCCCATAAAGCTGCATTTACAAT 
1042 C-7 mdr1 1042 reverse ATAGTTTTGCCTATTGGTTTGGATCCTTCT 
1246 C-7 mdr1 1246 TCTTAAGTTATAATCACATATATTA 
72 C-7 crt 72 TACACTTAAATAAATAATACTTAAAA 
76 C-7 crt 76 reverse AATTTTTGCTAAAAGAACTTTAAACAAA 
97 C-7 crt 97 TGAGTTTCGGATGTTACAAAAC 
152 C-7 crt 152 AGTTCTTGTAAGACCTATGAAGG 
163 C-7 crt 163 CTTAATTGAAGAACAAATGATTGGAT 
220 C-7 crt 220 ACTAATTAAGACAAGATTAAATATGATAGAA 
271 C-7 crt 271 TTTTAAAAATGGAAGGGTGTATA 
326 C-7 crt 326 AAAGAAGGAAAACAATGCGAAGGTTT 
326B C-7 crt 326 reverse CATTTGTGATAATTTAATAACCAGCTATGT 
356 C-7 crt 356 TGCTGGACCTTGTATACAACTAACAA 
356B C-7 crt 356 reverse AGCAATTGCTTATTACTTTAAATTCTTAGCC 
371 C-7 crt 371 TTACAACATCACCCTATAAAATTAAAAAG 
538 ATPase6 538 ACCGAATTAGCTTTATTACATTT 
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574 ATPase6 574 GTACAGGTGTTGTATTTTTTTCA 
623 ATPase6 623 CCTGAGCTGTAGTATAATTAGAATGGTT 
683 ATPase6 683 TTTCTCCAAGAAGAAATACATTCA 
769 ATPase6 769 TTAATTTTTTATAAGCAAAGCTAAGT 
 
 
 
Supplementary table 2: ddNTP and extension primer mixes Combination 1 and 
Combination 2 
 
ddNTP mix Combination 1 Combination2 
 ddATP Cy3 ddUTP Cy3 
 ddCTP Cy3 ddCTP Cy3 
 ddGTP Cy5 ddATP Cy5 
 ddUTP Cy5 ddGTP Cy5 
Extension primer mixes Combination 1 Combination2 
Pfdhps 437, 540, 581, 613, 640 436, 613B, 645 
Pfdhfr 16, 51, 59, 108, 164 108B, 164B 
Pfmdr1 86, 184, 1034, 1042 1246 
Pfcrt 72, 152, 271, 326, 326B, 356, 356B 76, 97, 163, 220, 371 
PfATPase6 538, 769 574, 623, 683 
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ABSTRACT 
 
BACKGROUND In Papua New Guinea (PNG), combination therapy with amodiaquine (AQ) or 
chloroquine (CQ) plus sulphadoxine-pyrimethamine (SP) was introduced as first-line 
treatment against uncomplicated malaria in 2000. 
METHODS The aim of the study was to characterise 24 molecular markers of drug resistance 
in pre-treatment samples collected in two different areas in PNG and to investigate the 
association between infecting genotype and treatment response in order to identify useful 
predictors of treatment failure with combination therapy. 
RESULTS In 2004, overall failure rate up to Day 28 for P. falciparum malaria was 28% in the 
Karimui and 16% in the Wosera area. The strongest independent predictors for treatment 
failure with AQ or CQ plus SP were pfmdr1 N86Y (OR=9.26, p<0.01) and pfdhps A437G 
(OR=3.82, p<0.01). Mutations found in CQ related markers pfcrt K76T, A220S, N326D, and 
I356L did not help to increase the predictive value, the most likely reason being that these 
mutations reached almost fixed levels. Though mutations in SP related markers pfdhfr S108N 
and C59R were not associated with treatment failure, they increased the predictive value of 
pfdhps A437G. The difference in clinical outcome was reflected in the corresponding genetic 
profile of the parasite populations in the two sites, with significant differences seen in the 
frequencies of mutant pfmdr1 N86Y, pfcrt A220S, and pfdhps A437G. 
CONCLUSION The study provides evidence for high levels of resistance to the combination 
regimen of AQ or CQ plus SP in Papua New Guinea and indicates which of the many 
molecular markers analysed are useful for the monitoring of parasite resistance to 
combinations with AQ or CQ plus SP. 
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INTRODUCTION 
 
The effectiveness of the most widely used first-line antimalarials chloroquine (CQ) and 
sulphadoxine-pyrimethamine (SP) has been heavily compromised by the emergence and 
spread of P. falciparum resistance to these drugs. In order to improve treatment efficacy and 
to delay the development and spread of drug resistance, there is strong advocacy for 
combination therapy (White & Olliaro, 1996). Though many authorities recommend the 
combination of 4-aminoquinolines or SP with artemisinin derivates (WHO, 2001) this option 
is expensive and several countries have taken an interim step and chose the inexpensive 
combination of amodiaquine (AQ) or CQ plus SP. 
Monitoring of parasite resistance is essential in directing the rational use of antimalarials. 
Apart from studies assessing in vivo drug efficacy and in vitro drug sensitivity, molecular 
markers have been proposed as a means to monitor drug resistant malaria (WHO, 2003). 
CQ resistance has been attributed to several mutations occurring in the Plasmodium 
falciparum chloroquine transporter gene (pfcrt) and Plasmodium falciparum multidrug 
resistance gene 1 (pfmdr1), both encoding proteins localised in the digestive vacuole of the 
parasite (Fidock et al., 2000; Reed et al., 2000; Sidhu et al., 2002). Correlation between 
molecular markers of CQ resistance and in vivo treatment outcome has been complex. 
Whereas several studies have shown the key role of pfcrt K76T in conferring in vivo 
resistance to CQ (Babiker et al., 2001; Djimdé et al., 2001; Wellems & Plowe, 2001), the 
relationship between phenotypic resistance and other pfcrt polymorphisms (i.e., C72S/R, 
M74I/T, N75E/D/K/I, K76T/I/N, I77T, H97Q/L, A144F/T, L148I, L160Y, I194T, A220S, 
Q271E, N326S/D, I356V/T/L and R371T/I), which have been shown to be associated with 
CQ resistance in vitro (reviewed in Cooper et al., 2005), has been poorly studied in the field. 
Single-base changes in pfmdr1 N86Y, Y184F, S1034C, N1042D and D1246Y have been 
documented in CQ resistant laboratory strains, but a straightforward association of these 
polymorphisms with in vivo CQ resistance has been questioned by several studies (Basco & 
Ringwald, 1998; Haruki et al., 1994; Pillai et al., 2001; Povoa et al., 1998). 
The accumulation of point mutations in Plasmodium falciparum dihydrofolate reductase 
(pfdhfr) and dihydropteroate synthase (pfdhps), two enzymes in the parasite’s folate synthesis 
pathway, is associated with resistance to SP (Cowman, et al., 1988; Peterson et al., 1988; 
Triglia et al., 1997; Triglia et al., 1998). Though the relationship between polymorphisms in 
these genes and resistance to SP has been shown in vitro, the correlation of different 
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genotypes and clinical treatment outcome is controversial. Whereas the triple mutation 
S108N+C59R+N51I in pfdhfr has been found to be a good molecular marker for SP resistance 
by some authors (Basco et al., 1998; Basco et al., 2000; Wang et al., 1997), others did not 
confirm the usefulness of this combination of mutations (Alifrangis et al., 2003; Aubouy et 
al., 2003). The quintuple mutation pfdhfr S108N+C59R+N51I plus pfdhps A437G+K540E 
has been proposed as a useful indicator for monitoring SP resistance in Africa (Nzila, et al., 
2000), in the Amazon region, the quintuple mutation pfdhfr S108N+N51I+I164L plus pfdhps 
A437G+K540E has been shown to be more useful (Kublin et al., 1998). More recently, 
several authors have found the double mutation pfdhfr C59R plus pfdhps K540E to be 
sufficient to predict treatment failure in vivo (Kublin et al., 2002; Kyabayinze et al., 2003; 
Talisuna et al., 2004). The most likely reason for these conflicting reports is the fact that, 
apart from the infecting genotype, response to drug treatment is affected by many factors, 
such as host immunity, which is related to transmission intensity, and history of drug use in a 
given area (Alifrangis et al., 2003; Omar et al., 2001; Staedke et al., 2004). As a consequence, 
the patterns as well as the predictive values of molecular drug resistance markers may vary 
between different geographical regions. Another problem is that most of the studies looked at 
only few markers, which does not allow investigating which of the many known markers are 
the most useful for parasite resistance monitoring to specific drugs. 
After a long history of 4-aminoquinoline use which has been accompanied by accumulating 
reports about increasing levels of AQ and CQ resistance (Müller et al., 2003; Genton et al., 
2006), official drug policy for uncomplicated malaria in Papua New Guinea (PNG) was 
changed to the combination therapy of AQ or CQ plus SP in 2000. Although high levels of 
polymorphisms in CQ relevant genes pfcrt and pfmdr1, and also to a lesser extent in key 
markers responsible for resistance to SP, have already been reported in PNG (Casey, et al., 
2004; Mehlotra et al., 2001; Reeder et al., 1996;), their association with in vivo treatment 
outcome has never been evaluated. 
In this study, we analysed the genetic profile of parasites collected from pre-treatment 
samples of malaria patients attending two health facilities in PNG with known clinical and 
parasitological outcomes after treatment with AQ or CQ plus SP. Twenty-four key markers in 
pfmdr1, pfcrt, pfdhfr and pfdhps were determined using a new DNA microarray-based 
technology. The relation of the parasite genetic output to the treatment response was 
investigated to identify the most useful predictors of failure with the current first-line regimen 
in the country. 
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MATERIALS AND METHODS 
 
In vivo assessment of drug efficacy 
Drug efficacy studies were conducted according to the standardised WHO protocol for low to 
moderate transmission areas (WHO, 2003) and are described in detail elsewhere (Marfurt et 
al., 2006, submitted, Chapter 2). Children between 6 months and 7 years of age were enrolled 
if they were presenting at the health centre with clinically overt and microscopically 
confirmed P. falciparum malaria and no danger signs for severe or complicated malaria 
(WHO, 2000) or signs of any other disease, malnutrition or anaemia. Standard AQ (for 
patients <14 kg) or CQ plus SP first line treatment (10 mg AQ or CQ per kg on Day 0, 1 and 
2, and 25 mg sulphadoxine per kg plus 1.25 mg pyrimethamine per kg on Day 0) was 
administered under supervision over the first three days. Visits for the follow-up were 
scheduled on Day 1, 2, 3, 7, 14, and 28. On every visit, patients were clinically examined and 
a Giemsa-stained blood slide was taken for the microscopic assessment of parasitaemia. A 
blood sample was taken on Day 0 (pre-treatment sample) and on Days 14 and 28 or any day 
of treatment failure for molecular genotyping purposes. At the end of the follow-up, the 
patients were classified according to their clinical and parasitological responses into early 
treatment failure (ETF), late clinical failure (LCF), late parasitological failure (LPF), or 
adequate clinical and parasitological response (ACPR) (WHO, 2003). 
 
 
Study sites and population 
The studies were conducted between October 2003 and April 2004 in the Karimui area 
(Simbu Province) and the South Wosera area (East Sepik Province), two rural places 
mesoendemic for malaria but differing with regard to transmission intensity and drug use 
patterns (Müller et al., 2003). Main characteristics of the study populations and the two sites 
are depicted in table 1. 
Scientific approval and ethical clearance for the study was obtained from the Medical 
Research and Advisory Committee (MRAC) of the Ministry of Health in PNG and consent 
was obtained from parents or legal guardians prior to recruitment of each patient. 
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Laboratory analyses 
DNA was extracted using QIAamp® DNA Blood Kit (Qiagen, Hombrechtikon, Switzerland) 
according to the manufacturer’s instructions. 
Assessment of single nucleotide polymorphisms (SNPs) for drug resistant malaria was done 
for pfmdr1 codons N86Y, Y184F, S1034C, N1042D and D1246Y, pfcrt codons K76T, H97Q, 
T152A, S163R, A220S, Q271E, N326D/S, I356L/T and R371I, pfdhfr condons A16V, N51I, 
C59R, S108N/T and I164L, and pfdhps codons S436A, A437G, K540E, A581G, and 
A613T/S. The method is based on parallel PCR amplification of the target sequences 
followed by primer extension mediated mini-sequencing using fluorochrome-labelled 
ddNTPs. Subsequent base calling occurs on a microarray upon sequence specific 
hybridisation (Crameri et al., 2006, submitted, Chapter 3). 
Assessment of the multiplicity of infection (MOI) in pre-treatment samples and the 
differentiation between true recrudescences and new infections in treatment failure samples 
was done by PCR-RFLP analysis of the merozoite surface protein 2 (msp2) as previously 
described (Cattamanchi et al., 2003; Felger and Beck, 2002; Slater et al., 2005). 
 
 
Statistics 
Statistical analyses were performed by the use of STATA software (version 8.2; Stata Corp., 
College Station, Texas). The strength of association was evaluated by calculating odds ratios 
(OR). We used χ2 tests and Fisher’s exact test and stepwise logistical regression analysis as 
applicable to assess the significance of association between known risk factors and single or 
multiple mutations and treatment failure. 
To estimate the allele frequencies of resistance markers in our sample set, we used a non 
linear statistical model that takes into account the effects of varying multiplicity of infection 
and assumes that resistant and sensitive parasite clones are transmitted independently. The 
likelihood of a sample containing no resistant clones is (1 - p)n, where p is the frequency for 
the mutant allele and n is the multiplicity of infection of the sample. Similarly, the likelihood 
for the sample to contain no wild-type allele is pn and for a mixture of both, a wild-type and a 
resistant allele, is 1 – pn – (1 - p)n. The likelihood over the whole data set for p is computed as 
the product of this likelihood over all samples, using values of n derived from msp2 
genotyping results. A Markov Chain Monte Carlo algorithm (Program Winbugs 1.3) was used 
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to obtain estimates of mutant allele frequencies and credible intervals (Bayesian confidence 
intervals (CI) for p), making use of this likelihood, and assuming a uniform (0.1) prior 
distribution for p (Schneider et al., 2002). 
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RESULTS 
 
In vivo drug efficacy 
A total of 97 patients in Karimui and 112 patients in the Wosera were enrolled into the study 
and treated with AQ plus SP (174/209 (83.25%), median age of 4 years) or CQ plus SP 
(35/209 (16.75%), median age of 6.5 years). Overall treatment failure rate up to Day 28 for P. 
falciparum was 31% in Karimui and 20% in the Wosera. Three of 28 (10.7%) late treatment 
failure cases in Karimui and 4 of 17 (23.5%) in the Wosera were new infections as shown by 
molecular genotyping of the highly polymorphic msp2 locus. Therefore, overall treatment 
failure rates after PCR-correction, classifying infections with new and recurrent strains as true 
recrudescences (i.e., treatment failures), were 28% in Karimui and 16% in the Wosera area 
(Table 2). 
 
 
Prevalence and relationship of pfmdr1, pfcrt, pfdhfr and pfdhps mutations 
Mutation analyses were successfully accomplished in 206 (99%) of all pre-treatment samples 
from both study sites. Polymorphisms were found in pfmdr1 codons N86Y, Y184F, and 
N1042D, pfcrt codons K76T, A220S, N326D and I356L, pfdhfr codons C59R and S108N, 
and pfdhps codons A437G and K540E. None of the other SNPs (11/24) was detected as 
mutated allele in any of the infections analysed. Regarding CQ relevant molecular markers, 
infections harbouring mutated pfmdr1 N86Y and pfcrt K76T, N326D, I356L and A220S 
alleles were with 86%, 91%, 89%, 89%, and 70% very common, whereas 5%, 1%, 1%, 0%, 
and 2% of these infections were mixed with a wild-type allele (Figure 1). The mutated alleles 
in pfmdr1 Y184F and pfmdr1 N1042D were only found in 5 (2%) and 2 (1%) samples, 
respectively, with the latter being detected as mixed allele only. 
Considering relationships of mutated alleles in pfcrt, we found that 1) the mutations N326D 
and I356L were always linked, 2) the double mutation N326D+I356L never occurred without 
a mutated allele K76T, and 3) a mutation A220S never occurred without the triple mutation 
K76T+N326D+I356L. Considering pfmdr1, a mutation N1042D was always linked to a 
mutated Y184F allele, but we never observed these mutated alleles occurring together with a 
N86Y mutation. 
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Regarding SP relevant molecular markers, mutations in pfdhfr S108N and C59R were also 
very common with 79% and 77% of infections having a pure mutant, and 91% and 82% of 
infections having a mutant or mixed allele, respectively. Mutated alleles in pfdhps A437G 
were found in 13% of all infections whereas in 10% of all infections it was detected as a pure 
mutant. The pfdhps K540E mutation was only found in 2 (1%) samples and was only detected 
as pure mutant allele. Pfdhfr C59R was never detected without pfdhfr S108N, and pfdhps 
A437G was strongly linked to the double mutation pfdhfr S108N+C59R with only 2 (7.6%) 
of the samples having the mutant allele without any mutated allele in pfdhfr. Also the pfdhps 
K540E mutation was only found in conjunction with the double mutation pfdhfr 
S108N+C59R. 
 
 
Association between pfmdr1, pfcrt, pfdhfr and pfdhps alleles and treatment outcome 
To maximize our sample size, we pooled the data from both study sites and evaluated the 
association between infections with single and combined mutant alleles in pfmdr1, pfcrt, 
pfdhfr and pfdhps and response to treatment. All patient isolates were coded according to 
presence or absence of mutant alleles and isolates showing both, wild type and mutant allele, 
were treated as mutant. Likewise, infecting genotypes were coded according to the most 
highly mutated pfmdr1, pfcrt, pfdhfr and pfdhps alleles present in the sample. 
Apart from pfmdr1 N86Y (OR=9.26, 95% CI: 1.22-70.08, p<0.01) and pfdhps A437G 
(OR=3.82, 95% CI: 1.62-9.01, p<0.01), there was no independent marker found to be 
significantly associated with treatment failure (Table 3). When we adjusted for known 
confounding factors, such as initial parasite density and age, in a stepwise logistical 
regression model, the significant association for the two above-mentioned markers was 
retained (data not shown). 
In a further step, we established the genetic profile of parasites for each patient sample. With 
regard to mutated gene loci in all four genes analysed, we could discriminate between 24 
different genotypes (Table 4). Among those, eight were observed in treatment failure cases, 
whereas the remaining 16 were exclusively found in patients with an adequate treatment 
response. The investigation of the relationship between these genotypes and treatment failure 
revealed the following. Considering the genotypes with a fully wild-type pfcrt, the risk of 
treatment failure was slightly increased when concurrent mutations in pfmdr1 N86Y and 
pfdhfr S108N+C59R were seen (OR=1.45, 95% CI: 0.27-7.74, p=0.67). When the latter three 
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mutations were observed in conjunction with a triple (K76T+N326D+I356L) or quadruple 
(plus A220S) mutation in pfcrt, the risk of treatment failure was not significantly changed 
(OR=0.83, 95% CI: 0.30-2.35, p=0.73 and OR=1.18, 95% CI: 0.61-2.30, p=0.62 for the pfcrt 
triple and quadruple mutant, respectively). In contrast, the risk of failure with a triple or 
quadruple mutant in pfcrt was significantly increased with the additional mutation A437G in 
pfdhps (OR=3.76, 95% CI: 0.73-19.32, p=0.12 and OR=4.22, 95% CI: 1.56-11.39, p<0.01, 
respectively). In contrast, when the pfcrt quadruple mutant was combined with the double 
mutation pfdhfr S108N+C59R, but showed wild-type alleles in pfmdr1 N86Y and pfdhps 
A437G, the odds ratio for failure was decreased (OR=0.22, 95% CI: 0.03-1.72, p=0.08). 
Furthermore, treatment failures were observed among pfcrt quadruple plus pfmdr1 N86Y 
mutants without any concurrent mutations in pfdhfr or pfdhps (OR=3.04, 95% CI: 0.78-11.85, 
p=0.12). 
To investigate whether the difference in treatment outcome at the two study sites was 
reflected in the drug resistance profile of the corresponding parasites, we calculated the 
mutant allele frequencies for each gene locus. Maximum likelihood estimates of mutant allele 
frequencies found in the two study populations are presented in figure 2. Regarding the allele 
frequencies for the CQ relevant molecular markers, there was no significant difference in 
pfcrt K76T, N326D, and I356L. The only statistically significant differences in allele 
frequencies between the Karimui and the Wosera area were found for pfcrt A220S (0.57 
versus 0.81) and pfmdr1 N86Y (0.99 versus 0.71). A similar picture was observed for the SP 
relevant molecular markers. Whereas the difference in any of the mutated loci in pfdhfr was 
not significant, the genetic profile for pfdhps mutation A437G was significantly different in 
the two parasite populations with an allele frequency of 0.26 in the Karimui area versus 0.02 
in the Wosera area. 
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DISCUSSION 
 
This study investigated the relationship between polymorphisms in four malaria resistance 
related genes in P. falciparum and the in vivo response to treatment with the combination 
regimen of AQ or CQ plus SP. First, therapeutic efficacy was assessed in two rural areas in 
PNG which are different with regard to transmission intensity and drug use patterns, whereby 
we measured treatment failure rates of 28% in the Karimui and 16% in the Wosera area 
(Marfurt et al., 2006, submitted, Chapter 2). The genetic drug resistance profile including 24 
molecular markers was established in pre-treatment samples from both sites by the use of a 
new DNA microarray-based technology (Crameri et al., 2006, submitted, Chapter 3) and its 
relationship with in vivo drug response was analysed in the pooled sample set. The principal 
objectives were to establish the baseline prevalence of polymorphisms in genes related to CQ 
and SP resistance, to assess their relationship with treatment outcome with combination 
therapy, in order to identify and propose useful markers for molecular monitoring of drug 
resistant P. falciparum in the country. 
The analysis of the genetic profile of the parasite population revealed high levels of mutant 
alleles in CQ resistance (CQR) related pfcrt and pfmdr1 genes. Polymorphism in pfmdr1 
N86Y and pfcrt K76T, the most important key markers for CQR, were found in 86% and 91% 
of all patients, respectively. Additional polymorphisms known to be associated with CQR, 
such as pfcrt A220S, N326D and I356L, were found in 70%, 89% and 89% of all isolates. 
The long history of 4-aminoquinoline use as monotherapy in PNG, which was accompanied 
by accumulating reports about increasing levels of in vivo CQR (Müller et al., 2003; Genton 
et al., 2006), has led to a highly CQ resistant genetic background in the parasites as reported 
previously (Chen et al., 2001; Mehlotra et al., 2001; Mehlotra et al., 2005; Nagesha et al., 
2003). Similarly high frequencies of mutated alleles in pfmdr1 N86Y and pfcrt K76T were 
reported recently in a study conducted in PNG between May 2000 and October 2001 (Casey 
et al., 2004), where the analysis of parasites from treatment failure samples collected in town 
clinics in Maprik and Madang had shown mutation rates above 80% for these two CQR loci. 
In addition, our results demonstrated prevalence rates of 91% and 82% for mutant alleles in 
the pyrimethamine related gene loci pfdhfr S108N and C59R, which were higher than those 
reported in the afore mentioned study for Maprik (72% and 51%, respectively) and Madang 
(82% and 74%, respectively). More recently, Mita et al. (2006a) analysed P. falciparum 
isolates from patients attending two town clinics in Wewak, the provincial capital of the East 
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Sepik Province in PNG, and also observed rather high prevalence rates of pfdhfr double 
S108N+C59R mutations (83% in 2002 and 86% in 2003). These high levels of mutation rates 
in pfdhfr appearing only a short time after the implementation of SP as one component of the 
official first-line policy were not surprising. Prior drug exposure to antifolates has been 
thought to be low because SP was only used in combination with quinine as second line 
therapy against treatment failure and severe malaria. However, former drug pressure may 
have been exerted by the use of pyrimethamine (in combination with CQ) in mass drug 
administration campaigns in the 1960s and 1970s (Spencer, 1992). Moreover, cotrimoxazole, 
a combination regimen of trimethoprim-sulphamethoxazole, is a commonly used antibiotic to 
treat bacterial infections at health facilities in PNG. Since cross-resistance between 
pyrimethamine and trimethoprim has been described in vitro and on molecular level (Basco & 
Le Bras, 1997; Iyer et al., 2001; Khalil et al., 2003), widespread use of cotrimoxazole may 
have exerted additional selective pressure on pfdhfr in former years. Recent microsatellite 
analysis in dhfr-flanking regions by Mita et al. (2006a) revealed that the most prevalent dhfr 
haplotype (i.e., S108N+C59R double mutation) was associated with reduced microsatellite 
variability around the gene, an observation which argues for the selection of pre-existing SP 
resistant parasites, rather than the frequent emergence of de novo mutations in this gene 
(Hastings et al., 2002; Pearce et al, 2005). These data further corroborate the hypothesis, that 
former drug pressure has lead to the emergence of pyrimethamine resistant parasites before 
the official introduction of SP in PNG. 
In addition to high prevalence rates of genetic loci reflecting high CQR and moderately 
reduced pyrimethamine sensitivity, we also describe the occurrence of polymorphic alleles in 
the sulphadoxine resistance related gene pfdhps. Until 2003, polymorphic pfdhps loci 
associated with reduced sensitivity to sulpha drugs have only been found in a single P. 
falciparum isolate originating from PNG (Casey et al., 2004; Reeder et al., 1996). In our pre-
treatment samples collected between 2003 and 2004, we measured prevalence rates of 13% 
for A437G and 1% for K540E. Likewise, Mita and colleagues detected mutations in these loci 
in 8% of patient isolates collected in Wewak in the year 2003 (Mita et al., 2006a). In contrast 
to our results, they found a strong linkage between the two mutated dhps alleles and always 
detected them in conjunction with the double mutation S108N+C59R in pfdhfr. Though the 
A437G mutation in pfdhps is thought to be the first selected mutation under sulphadoxine 
pressure (Kyabayinze et al., 2003; Nzila et al., 2000; Triglia et al., 1997), two samples in our 
study harboured dhps genotypes having a single K540E mutation without a concomitant 
A437G mutation. Though very uncommon, the same genotype has been described previously 
Chapter 4   113
in patient isolates from Tanzania, Malawi, and Sudan (Bwijo et al., 2003; Dorsey et al., 2004; 
Wang et al., 1997). In the view that pfdhfr mutations usually predominate over those in 
pfdhps (Wang et al., 1997), the detection of genotypes having a single dhps A437G mutation 
in combination with a pfdhfr wild type allele in two of our samples was rather unusual. 
However, this genotype may well have been selected by sulpha drugs used to treat infectious 
diseases other than malaria. 
Most data concerning the relationship between molecular markers and treatment outcome 
have been produced by the genetic analysis of patient isolates originating from clinical trials 
evaluating the efficacy of a single drug class. Straightforward associations have been rarely 
found and therefore, the elucidation of an association between molecular correlates and 
treatment outcome with combination regimens containing drug classes being effective against 
different parasite targets may be even more complex. In order to propose a suitable marker set 
for the molecular monitoring of P. falciparum against the current first-line combination 
therapy with AQ or CQ plus SP, we investigated the association of single mutations as well as 
infecting genotypes (i.e., combinations of mutated alleles in the respective genes) with in vivo 
treatment response. Regarding CQ relevant markers, the only single marker associated with a 
significantly increased risk of treatment failure was pfmdr1 N86Y. Taking into account 
additional SNPs in pfcrt, neither of the mutated alleles increased the predictive value for 
pfmdr1 N86Y, the most likely reason being that these mutations nearly reached fixed levels in 
the parasite population. Similarly, pyrimethamine relevant markers in pfdhfr did not show a 
significant association with treatment failure. Risk of failure was only increased with 
infections harbouring the A437G mutation in dhps. These observations are in agreement with 
previous studies showing that the prevalence of single molecular markers (e.g. pfcrt K76T or 
pfdhfr S108N) was almost always higher than the level of clinical or parasitological resistance 
to the respective drugs, especially in regions with high transmission intensity and long lasting 
drug pressure (Djimde et al., 2001; Mayor et al., 2001; Rallon et al., 1999) and therefore, 
renders these markers unsuitable for molecular monitoring. Furthermore, the validity of 
molecular markers is dependent on former drug use and may also vary according to the 
malaria epidemiology in a given area (Alifrangis et al., 2003; Omar et al., 2001; Staedke et 
al., 2004). The relevance of these epidemiological characteristics is further illustrated by the 
following conflicting results. Similar to our data, a significant association between pfdhps 
A437G and treatment response with CQ plus SP was found in a study conducted in Laos 
(OR=15.00, 95% CI=1.23-412.69) (Berens et al., 2003). In contrast, the K540E mutation in 
pfdhps was shown to be a better indicator of treatment failure with the same combination 
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regimen in Uganda (Dorsey et al., 2004). The evaluation and assessment of a combination of 
markers (e.g. quintuple mutation pfdhfr S108N+C59R+N51I plus pfdhps A437G+K540E, or 
pfcrt K76T in combination with pfmdr1 N86Y), instead of single markers indicating the 
presence of a highly resistant genotype, have been suggested for the molecular monitoring of 
antimalarial resistance (Jelinek et al., 2002; Khalil et al., 2005; Kublin et al., 2002, 
Kyabayinze et al., 2003; Nzila et al., 2000; Talisuna et al., 2004). In our study, which took 
into account the combined pfcrt/pfmdr1/pfdhfr/pfdhps genotype, the risk of treatment failure 
was clearly associated with the total number of mutations in the analysed genes. But the risk 
was only significantly increased for patients who harboured parasites with the most highly 
mutated genotype (i.e., 8/24 SNPs mutated). 
Unusual findings in our study included the observation of treatment failures with genotypes 
having either a fully wild type pfcrt combined with a mutated pfmdr1 N86Y plus the double 
pfdhfr S108N+C59R mutation, or a fully wild type pfdhfr+pfdhps allele combined with the 
N86Y mutation in pfmdr1 and the quadruple mutation in pfcrt. These results highlight again 
the fact that among many parasite and host factors, the molecular resistance background of P. 
falciparum is only one of several determinants for in vivo treatment outcome. Whereas 
acquired immunity can account for the clearance of drug resistant genotypes, diminished drug 
metabolism may well explain treatment failure in spite of an infection with a susceptible 
genotype (Cravo et al., 2001; Djimde et al., 2003; White, 2002). 
Regarding former drug history in PNG (i.e., long lasting 4-aminoquinoline use and sporadic 
use of SP) which has led to a highly CQ and moderately SP resistant genetic background in 
the parasite population, the relevance of key pfdhps mutations in predicting treatment failure 
was expected. AQ and CQ as inefficacious partner drugs of SP in the new standard regimen 
were not able to curb both, the progression of pyrimethamine resistance as well as the 
emergence of sulphadoxine resistance. It is most likely that in our in vivo studies, we 
measured the clinical efficacy of the sulpha component. Therefore, with ongoing drug 
pressure with the current first-line policy, the assessment of SNPs related to sulphadoxine 
resistance will be an important molecular index for increasing resistance in PNG. However, 
according to our results, also pfmdr1 N86Y plays an important role in predicting a negative 
treatment response. Linkage disequilibrium between the key CQR markers pfcrt K76T and 
pfmdr1 N86Y has been reported by several authors (Babiker et al., 2001; Djimde et al., 2001; 
Fidock et al., 2000; Happi et al., 2006a; Mita et al., 2006b) and has led to the conclusion that 
the latter mutation might either compensate for fitness costs induced by the K76T mutation in 
pfcrt or augment CQR in the parasite (Cooper et al., 2005; Walliker et al., 2005). CQ and AQ 
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are chemically related drugs and cross-resistance has been described in several clinical and in 
vitro reports (Basco & Le Bras, 1993; Olliaro et al., 2003). Though little is known about the 
genetic mechanisms conferring AQ resistance (Meshnick & Alker, 2005), an important role 
has been ascribed to the key CQR markers pfcrt K76T and pfmdr1 N86Y (Dokomajilar et al., 
2006; Ochong et al., 2003). It has been shown recently that in combination with pfcrt K76T, 
the pfmdr1 N86Y polymorphism was predictive for treatment failure with AQ in Nigeria 
(Happi et al., 2006b) and that AQ resistance was associated with the selection of these 
polymorphisms in Kenya (Holmgren et al., 2006). Considering the long use of AQ as 
monotherapy against uncomplicated falciparum malaria in PNG and our observation that 
pfmdr1 N86Y is a strong predictor for treatment failure with AQ plus SP, our data support the 
hypothesis that pfmdr1 N86Y is probably involved in AQ resistance. Several studies have 
shown that both, SNPs and gene amplification of pfmdr1, can mediate resistance to 4-
aminoquinlines and also other drug classes, such as amino alcohols and artemisinin derivates 
(Duraisingh et al., 2000; Foote et al., 1989; Foote et al., 1990; Price et al., 2004; Reed et al., 
2000) However, results from different studies investigating the relationship of these genetic 
alterations in pfmdr1 and in vivo response were often inconsistent (Flück et al., 2000; Happi 
et al., 2003; Pillai et al., 2001; Tinto et al., 2003). Several possible direct (active drug 
translocation) or indirect (modification of biophysical cell parameters) modes of action have 
been proposed for P-glycoprotein homolog 1, the gene product of pfmdr1. But how genetic 
alterations in pfmdr1 and epistatic interactions with other genes finally lead to a multidrug 
resistant phenotype, this question still remains to be resolved (Duraisingh & Cowman, 2005; 
Duraisingh & Refour, 2005; Roepe, 2000). 
Finally, we were interested to see whether the observed difference in clinical outcome 
between sites was reflected in the genetic profile of the corresponding parasite populations. 
By taking into account the varying multiplicity of infection, we estimated and compared allele 
frequencies for all the mutated gene loci measured at both sites. Thereby we could show that 
the levels of treatment failure rate were reflected by statistically significant differences in 
frequencies of pfmdr1 N86Y and pfdhps A437G. These data further confirmed the role of 
these two markers as important predictors for a negative treatment response with AQ or CQ 
plus SP and suggests them to be the most useful resistance surveillance markers with the 
current standard treatment in PNG. 
To recapitulate, with regard to the drug use history in PNG, we describe a genetic background 
in the parasite population that is associated with high CQ as well as moderate pyrimethamine 
resistance. Moreover, the emergence of mutations concordant with a sulphadoxine resistant 
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phenotype indicates that the efficacy of the sulpha component is already compromised. 
Therefore, under sustained drug pressure with both drug classes, close in vivo as well as 
molecular monitoring with the suggested markers is highly recommended so that appropriate 
measures can be taken in due time. We have shown that a careful baseline assessment of 
molecular markers including the investigation of their relationship with treatment response is 
important for the identification of appropriate marker sets. For that purpose, DNA microarray 
technology has been proven to be a valuable and cost-effective tool for the parallel analysis of 
SNPs in multiple genes in a large sample size. However, the use of additional markers could 
become necessary for the longitudinal resistance monitoring in the future, in particular when 
current drug policy will be changed. These may include SNPs in known or as yet 
uncharacterized genes involved in resistance to the commonly used antimalarials (Mu et al., 
2003), or markers against newly implemented drug classes, such as the artemisinins (Jambou 
et al., 2005; Uhlemann et al., 2005). 
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TABLE 1: Baseline characteristics of study sites and patients at enrolment 
 
 
* Assessed by concomitant cross-sectional surveys in both study areas which showed P. falciparum prevalence rates of 11-50% in children aged 2-9 
years (WHO, 2003); § Müller et al., 2003; # proportion of children with enlarged spleen 
 
 Study site 
Characteristics Karimui area (Simbu Province) 
South Wosera 
(East Sepik Province) 
Study sites n=97 n=112 
Endemicity* mesoendemic mesoendemic 
Transmission intensity§ moderate high 
Patients 
Weight (mean (95% CI), kg) 13.8 (12.9-14.6) 14.4 (13.8-15.1) 
Age (mean (95% CI), yrs) 4.0 (3.7-4.4) 4.5 (4.2-4.8) 
Sex: female/n (%) 43/97 (44.3) 59/112 (52.7) 
Temperature (mean (95% CI),°C) 38.7 (38.5-38.9) 38.7 (38.4-39.0) 
Hb ( mean (95% CI), g/dl) 9.0 (8.6-9.5) 9.0 (8.7-9.3) 
Parasite density (geometric mean (range), per µl) 21937 (1120-329400) 40526 (280-774400) 
Multiplicity of infection (=MOI) (mean (95% CI)) 1.48 (1.34-1.63) 1.73 (1.59-1.88) 
Spleen rate# (% (95% CI)) 43.3 (33.3-53.7) 50.9 (41.3-60.5) 
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TABLE 2: Treatment outcomes for amodiaquine or chloroquine plus sulphadoxine-
pyrimethamine against P. falciparum malaria in Papua New Guinea 
 
 Study sites 
 Karimui area South Wosera area 
 n=97 n=112 
Treatment x/n (%) 
AQ plus SP 80 (82.5) 94 (83.9) 
CQ plus SP 17 (17.5) 18 (16.1) 
Outcome* x/n (%) 
ACPRa 70 (72.2) 94 (83.9) 
ETFb 2(2.1) 5 (4.4) 
LCFc 7 (7.2) 1 (0.9) 
LPFd 18 (18.5) 12 (10.8) 
Total TFe 27 (27.8) 18 (16.1) 
New infections 3 (10.7) 4 (23.5) 
 
AQ, amodiaquine; SP, sulphadoxine-pyrimethamine; CQ, chloroquine; * PCR-corrected 
values up to Day 28; a ACPR, Adequate clinical and parasitological response; b ETF, Early 
treatment failure; c LCF, Late clinical failure; d LPF, Late parasitological failure; e TF, 
Treatment failure 
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FIGURE 1: Prevalence of mutations in pfmdr1, pfcrt, pfdhfr and pfdhps in patient samples 
from Papua New Guinea. CQ, chloroquine; SP, sulphadoxine-pyrimethamine; pfmdr1, 
Plasmodium falciparum multidrug resistance gene 1; pfcrt, Plasmodium falciparum 
chloroquine resistance transporter; pfdhfr, Plasmodium falciparum dihydrofolate reductase; 
pfdhps, Plasmodium falciparum dihydropteroate synthase; no mutation was detected in any of 
the other SNP sites analysed (13/24 sites) 
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TABLE 3: Association between mutated single markers in pfcrt, pfmdr1, pfdhfr and pfdhps 
and treatment outcome with amodiaquine or chloroquine plus sulphadoxine-pyrimethamine 
 
Gene polymorphism OR 95% Confidence Interval p (LRT) 
pfcrt K76T 2.37 0.52-10.73 0.22 
pfcrt I356L 3.05 0.69-13.57 0.10 
pfcrt N326D 3.05 0.69-13.57 0.10 
pfcr A220S 1.62 0.75-3.53 0.22 
pfmdr1 N86Y 9.26 1.22-70.08 <0.01 
pfmdr1 Y184F §   
pfmdr N1042D §   
pfdhfr S108N 1.05 0.33-3.35 0.93 
pfdhfr C59R 2.06 0.75-5.64 0.13 
pfdhps A437G 3.82 1.62-9.01 <0.01 
pfdhps K540E §   
 
OR, odds ratio; LRT, likelihood ratio test; pfcrt, Plasmodium falciparum chloroquine 
resistance transporter; pfmdr1, Plasmodium falciparum multidrug resistance gene 1; pfdhfr, 
Plasmodium falciparum dihydrofolate reductase; pfdhps, Plasmodium falciparum 
dihydropteroate synthase; § mutated alleles were not detected in samples from treatment 
failure cases 
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TABLE 4: Association between infecting pfcrt, pfmdr1, pfdhfr and pfdhps genotypes and 
treatment outcome with amodiaquine or chloroquine plus sulphadoxine-pyrimethamine 
 
 
* due to very low mutation rates, genotypes with mutated gene loci Y184F and N1042D in 
pfmdr1 were grouped together with the wild type pfmdr1 genotypes; CQ, chloroquine; AQ, 
amodiaquine; SP, sulphadoxine-pyrimethamine; pfcrt, Plasmodium falciparum chloroquine 
resistance transporter; pfmdr1, Plasmodium falciparum multidrug resistance gene 1; pfdhfr, 
Plasmodium falciparum dihydrofolate reductase; pfdhps, Plasmodium falciparum 
dihydropteroate synthase; P, prevalence; OR, odds ratio; white box, wild-type allele; grey 
box, mutated allele; § the genotype was not detected in samples from treatment failure cases 
 
CQ-relevant markers SP-relevant markers     
pfcrt pfmdr1* pfdhfr pfdhps     
K76T N326D I356L A220S N86Y S108N C59R A437G K540E P (%) OR 95%CI p (χ2) 
         1.46 §   
         0.49 §   
         1.94 §   
         0.49 §   
         0.49 §   
         0.49 §   
         0.49 §   
         0.49 §   
         7.77 0.22 0.03-1.72 0.08 
         0.49 §   
         0.97 §   
         3.40 1.45 0.27-7.74 0.67 
         0.97 §   
         0.97 §   
         1.46 §   
         12.62 0.83 0.30-2.35 0.73 
         2.91 3.76 0.73-19.32 0.12 
         0.49 §   
         4.37 3.04 0.78-11.85 0.12 
         0.97 §   
         5.83 0.31 0.04-2.47 0.20 
         41.26 1.18 0.61-2.30 0.62 
         8.74 4.22 1.56-11.39 <0.01 
         0.49 §   
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FIGURE 2: Maximum likelihood estimates of mutant allele frequencies at the two study 
sites. Error bars denote 95% confidence intervals; * denotes statistical significance at the 95% 
level; CQ, chloroquine; SP, sulphadoxine-pyrimethamine; pfmdr1, Plasmodium falciparum 
multidrug resistance gene 1; pfcrt, Plasmodium falciparum chloroquine resistance transporter; 
pfdhfr, Plasmodium falciparum dihydrofolate reductase; pfdhps, Plasmodium falciparum 
dihydropteroate synthase 
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SUMMARY 
 
OBJECTIVE To test the hypothesis that parasite populations circulating in the community have 
the same genetic profile for resistance markers as the ones collected from malaria patients 
attending health facilities. 
METHODS Assessment of twenty-four molecular markers known to be associated with 
resistance to chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) was done by using a 
novel DNA microarray-based technology. Mutant allele frequencies were estimated by a 
Markov Chain Monte Carlo algorithm and genetic profiles of parasite populations circulating 
in clinical and community samples from two sites in Papua New Guinea were compared. 
RESULTS Different treatment failure rates with the current first-line regimen of CQ plus SP 
observed at the two study sites were reflected in the genetic profile of the corresponding 
parasites in clinical samples. There was no difference in the genetic resistance background of 
parasites collected from clinical or community samples. 
CONCLUSION Molecular monitoring of drug resistant malaria can be accomplished much 
quicker and easier by the use of a community approach and a technology to measure a wide 
array of drug resistance markers in large sample sets. The implementation of a community 
approach enables surveillance to be expanded to remote areas with limited access to health 
care facilities, and thus can contribute to a more comprehensive assessment of parasite 
resistance to antimalarial drugs countrywide. 
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INTRODUCTION 
 
The burden of malaria has been increasing in recent years, the main reason being the 
development and spread of P. falciparum resistance to the most commonly used antimalarial 
drugs, such as the 4-aminoquinolines and the antifolates (Olliaro, 2005; Trape, 2001). 
Knowledge about the level of parasite resistance to drugs through regular surveillance is 
necessary to make decisions on drug policies and treatment strategies. Methods for the 
assessment of parasite resistance in malaria include in vivo drug efficacy studies, which are 
still the gold standard, and to a lesser extent, in vitro sensitivity testing of patient isolates. 
Since parasite resistance is frequently associated with single nucleotide polymorphisms 
(SNPs) within coding genes for important drug targets or transporter proteins, the assessment 
of molecular markers has become an important complementary tool for the monitoring of 
drug resistance (Plowe, 2003; Plowe, 2005; WHO, 2005). 
Apart from the known limitations of in vivo drug efficacy studies, such as the assessment of 
one drug regimen only, and the fact that they are resource- and time-consuming, analysis is 
restricted to a biased sample with regard to study population and area (Fevre & Barnish, 
1999). Considering the study population, analysis is restricted to clinical cases and few age 
categories (i.e., children < 5 years). Parasites circulating in asymptomatic carriers are 
therefore neglected with a health facility-based approach. Moreover, clinical studies are 
usually conducted at selected sentinel sites with good access to health care facilities, and 
remote areas are thus excluded from surveillance. A community-based monitoring approach 
could give a more comprehensive assessment of the genetic profile of the parasite population 
circulating in a given area and contribute to a better understanding of the relationship between 
drug resistance genotypes and level of clinical failure rates as well as the dynamics and spread 
of drug resistant malaria. 
Most molecular analyses have been done in pre-treatment samples collected from clinical 
studies and were limited in the number of molecular markers studied. For the analysis of 
molecular markers in large scale epidemiological studies, such as community surveys 
conducted in several areas, there is a need for new, easy to use and cheap high throughput 
methods which allow the parallel analysis of several SNPs in large sample sets. 
Molecular studies assessing antimalarial drug resistance markers up to date have been done 
with clinical samples and there is as yet no indication whether the molecular profile of 
parasites circulating in the community matches the profile of those observed among patients 
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attending health facilities. In order to evaluate the feasibility of a community-based 
monitoring approach, we tested the hypothesis whether parasite genotypes circulating in the 
whole community were similar to those circulating in clinical malaria cases. For this purpose, 
we first established the molecular drug resistance profile in community and clinical samples 
by using a newly developed DNA microarray-based technology and then compared the 
genetic profiles of the two parasite populations in two sites in Papua New Guinea, which had 
shown different in vivo treatment failure rates with the current first-line treatment of 
amodiaquine (AQ) or CQ plus SP. 
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PATIENTS, MATERIALS, AND METHODS 
 
Studies were done at two sites in Papua New Guinea between October 2003 and April 2004. 
Both selected sites, the Karimui area in the Simbu Province and the South Wosera area in the 
East Sepik Province, are rural places mesoendemic for malaria but differ with regard to 
transmission intensity and drug use patterns (Genton et al., 1995; Mehlotra et al., 2002; 
Müller et al., 2004). 
Clinical samples were collected within drug efficacy studies conducted according to the 
standardised World Health Organization (WHO) protocol for low to moderate transmission 
areas (WHO, 2003), as described in detail elsewhere (Marfurt et al., 2006, submitted; Chapter 
2). Community samples were collected from cross-sectional surveys conducted in the 
catchment areas of the health facilities at both sites using a randomized household approach. 
To obtain a representative sample of the parasite population circulating in the corresponding 
communities (i.e., approximately 100 PCR-positive P. falciparum samples from each 
location), we collected between 300 and 350 blood specimens per community (Mehlotra et 
al., 2002). 
Assessment of SNPs for drug resistant malaria was done for pfmdr1 codons N86Y, Y184F, 
S1034C, N1042D and D1246Y, pfcrt codons K76T, H97Q, T152A, S163R, A220S, Q271E, 
N326D/S, I356L/T and R371I, pfdhfr condons A16V, N51I, C59R, S108N/T and I164L, and 
pfdhps codons S436A, A437G, K540E, A581G, and A613T/S. The method was based on 
parallel PCR amplification of the target sequences followed by primer extension mediated 
mini-sequencing using fluorochrome-labelled ddNTPs. Subsequent base calling occurred on a 
microarray upon sequence specific hybridisation (Crameri et al., 2006, submitted, Chapter 3; 
Marfurt et al., 2006, in preparation, Chapter 4). 
Statistical analyses were performed by the use of STATA software (version 8.2; Stata Corp., 
College Station, Texas). To allow for the varying multiplicity of infection, which was 
determined by genotyping of the highly polymorphic msp2 locus (Felger & Beck, 2002; 
Cattamanchi et al., 2003), a Markov Chain Monte Carlo algorithm was used to obtain 
estimates of mutant allele frequencies (p). Differences of allele frequencies between parasite 
populations in clinical and community samples were assessed by the comparison of Bayesian 
confidence intervals (CI) for p (Schneider et al., 2002; Marfurt et al., 2006, in preparation, 
Chapter 4). 
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RESULTS 
 
PCR-corrected treatment failure rates up to day 28 with AQ or CQ plus SP for P. falciparum 
malaria were 28% in the Karimui and 16% in the Wosera area (Marfurt et al., 2006, 
submitted, Chapter 2). We had previously identified the strongest independent predictors for 
treatment failure with AQ or CQ plus SP to be pfmdr1 N86Y and pfdhps A437G. Moreover, 
we could demonstrate that the difference in clinical outcome was reflected in the 
corresponding molecular drug resistance profile of the parasite populations derived from 
clinical samples. Significant differences between the Karimui and the Wosera area were not 
only seen in the mutant allele frequencies of CQ resistance markers pfcrt A220S (0.57 versus 
0.81) and pfmdr1 N86Y (0.99 versus 0.71). A similar picture was observed for the SP relevant 
marker pfdhps A437G with an allele frequency of 0.26 in the Karimui area versus 0.02 in the 
Wosera area (Marfurt et al., 2006, in preparation, Chapter 4). 
In order to test the hypothesis that there is no difference between the genetic drug resistance 
profile in community and clinical samples, we simultaneously determined the profile of 
molecular markers in the respective community samples. We then compared the estimated 
mutant allele frequencies for each SNP in clinical and community samples. Thereby we 
showed that there was no difference in mutant allele frequency for any of the SNPs analysed 
between community and clinical samples. We also demonstrated the match of these two 
genetic profiles for both study sites which differ with regard to transmission intensity and 
drug use patterns (Figure 2). 
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FIGURE 1: Comparison of mutant allele frequencies between clinical and community 
samples at the two study sites. 
n, number of samples analysed; A, Karimui area; B, South Wosera area; Error bars denote 
Bayesian confidence intervals (95%) for mutant allele frequencies; CQ, chloroquine; SP, 
sulphadoxine-pyrimethamine; pfmdr1, Plasmodium falciparum multi drug resistance gene 1; 
pfcrt, Plasmodium falciparum chloroquine resistance transporter gene; pfdhfr, Plasmodium 
falciparum dihydrofolate reductase; pfdhps, Plasmodium falciparum dihydropteroate synthase 
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DISCUSSION 
 
On an individual level, an association of specific molecular markers with in vitro resistance 
does not allow unambiguous prediction of in vivo therapeutic response, since a number of 
other parameters, such as drug use patterns, level of prior immunity, intensity of transmission, 
or compliance to treatment, play a role in clearing symptoms and parasites (Djimde et al., 
2003; Hastings & Watkins, 2005; White, 2004). Furthermore, most current models postulate 
the molecular basis of antimalarial resistance to be multigenic (Duraisingh & Refour, 2005; 
Mu et al., 2003) However, for regular surveillance of drug resistant malaria, the monitoring of 
molecular markers is considered a valuable complementary tool to the classical methods, such 
as in vivo drug efficacy studies and in vitro sensitivity testing (WHO, 2003; WHO 2005). The 
majority of previous studies investigating molecular correlates of antimalarial resistance have 
been done with samples collected in clinical studies. As a consequence, analysis was 
frequently restricted to a sub-sample of the whole population (i.e., symptomatic cases in the 
age group below 5 years). Therefore, a large parasite reservoir (i.e., parasites circulating in the 
untreated asymptomatic population), which nonetheless plays an important role in the 
development and spread of resistance, was not investigated. Furthermore, most of these 
clinical-based studies were conducted in a relatively small number of sentinel sites and thus 
neglected remote areas with limited access to health care facilities. More recently, the 
comparability of clinical and community molecular data was further challenged by Bwijo and 
colleagues (2003) who put forward the following concept. Because symptomatic patients 
attending health care facilities are more prone to have taken antimalarial drugs before and are 
thus more likely to harbour resistant parasites selected by drug treatment, resistant genotypes 
might be over-represented in clinical samples. Nevertheless, a community-based approach for 
molecular surveillance has been suggested by several authors and based on correlations found 
between population-based molecular data and the level of clinical failure, molecular 
surveillance indices have been proposed (Djimde et al., 2001; Talisuna et al., 2002; Talisuna 
et al., 2003; Pearce et al., 2003). But due to technical limitations, these studies have only 
assessed a small number of gene loci and were therefore considerably limited in drawing 
conclusions for further drug policy recommendations. 
In order to evaluate the validity of a broader community-based surveillance approach, it was 
for us an important prerequisite to show that the molecular drug resistance profile assessed in 
clinical samples does not differ from that in community samples. To cover multiple resistance 
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markers in different genes, we applied a newly developed DNA microarray-based technology 
and simultaneously analysed 24 SNPs in four different genes in a total of 418 samples. We 
demonstrated in the current report that there was no difference in the estimates of mutant 
allele frequencies in parasite populations collected from symptomatic children between 6 
months and 7 years of age or from a random sample of the whole community. In other words, 
the different levels of in vivo resistance, which had previously been shown to be reflected in 
the genetic resistance profile of the corresponding clinical samples, were also mirrored in the 
profile detected in community samples. Thus, molecular monitoring of parasite resistance is 
feasible by using cross-sectional surveys. 
Such community-based cross-sectional surveys applying highly standardized protocols with 
regard to sample size, sentinel sites and genetic analysis can be done in a quick and cost-
effective way by the application of our newly developed DNA microarray-based method and 
provides a new tool as early warning system for drug resistance. This technology does not 
only allow the simultaneous analysis of markers for several different drug classes, but is also 
highly flexible since markers can be easily added or deleted according to specific monitoring 
needs. Such population-based data collected over time could capture the dynamics of 
resistance, such as the emergence and/or disappearance of given genotypes to different drug 
classes (Bwijo et al., 2003; Mita et al., 2003; Laufer & Plowe, 2004) and could significantly 
add to the decision making process on when and where standard treatment should be changed 
and more importantly, on what drug classes an alternative treatment regimen should be based. 
Ongoing studies in different epidemiological settings in Papua New Guinea, the Solomon 
Islands and Tanzania are currently validating the usefulness and feasibility of our proposed 
community-based surveillance approach. 
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ABSTRACT 
 
BACKGROUND Surveillance of drug resistance is an integral part of national malaria control 
programs in endemic countries and molecular monitoring of parasite resistance has become 
and important complementary tool in establishing rational drug policies. The principal aim of 
this study was to evaluate a community-based approach using a novel high throughput 
technology for the analysis of molecular markers in the parasite as a means for monitoring 
antimalarial resistance. 
METHODS Between 2003 and 2005, we determined in vivo drug efficacy of amodiaquine (AQ) 
or chloroquine (CQ) plus sulphadoxine-pyrimethamine (SP) at three different sites in Papua 
New Guinea. We concurrently assessed the genetic drug resistance profile in community 
samples collected in the catchment areas of the respective health facilities by using a novel 
DNA microarray-based method for the parallel analysis of 33 single nucleotide 
polymorphisms (SNPs) in five different P. falciparum resistance associated genes (i.e., pfcrt, 
pfmdr1, pfdhfr, pfdhps, and pfATPase6). We determined mutant allele frequencies and 
genotype patterns and investigated the relationship with corresponding treatment failure rate 
at each site in each year. 
RESULTS PCR-corrected in vivo treatment failure rates with AQ or CQ plus SP were between 
12% and 28%, depending on the respective site and year, and showed variable longitudinal 
trends at two sites. Clinical failure rates with the current combination regimen were reflected 
in the corresponding genetic resistance pattern of parasites from community samples. 
Frequencies of mutated alleles of markers in pfcrt and pfmdr1, known to confer resistance to 
AQ/CQ, were high and did not show significant changes over time. Mutant allele frequencies 
in the pyrimethamine relevant gene pfdhfr were moderate at all three sites and those in pfdhps, 
involved in resistance to sulphadoxine, were still low, but showed different levels between 
sites. The opposing longitudinal trends in clinical response observed at two sites were best 
reflected by the frequencies and genotype patterns of mutations in SP relevant genes pfdhfr 
(S108N plus C59R) and pfdhps (A437G). Mutations in pfATPase6, the gene encoding a 
putative target for artemisinin derivates, were not detected. 
CONCLUSION In areas with high level of background AQ/CQ resistance, the evaluation of the 
frequency of 4-aminoquinoline relevant molecular markers in the community was not helpful 
to predict treatment response towards AQ or CQ plus SP, probably because polymorphisms in 
these genes had already reached fixed levels. In contrast, the estimation of mutation 
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frequencies in relevant SP resistance genes better mirrored treatment failure rates observed at 
nearby health facilities. Thus, indicators based on molecular data have to be considered with 
caution and interpreted in the local context, especially with regard to prior drug usage and 
level of pre-existing immunity. The community approach using relevant molecular markers 
for drugs that are likely to be still partially effective is a complementary tool that should help 
decision-making for the best treatment option and appropriate potential alternatives. 
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INTRODUCTION 
 
The burden of malaria has been increasing in recent years, the main reason being the 
development and spread of P. falciparum resistance to the most commonly used antimalarial 
drugs, such as the 4-aminoquinolines and the antifolates (Olliaro, 2005; Trape, 2001). Drug 
resistance is a major challenge in the control of malaria because effective drugs are the single 
most important tool to treat and control the disease in endemic countries. Rational drug policy 
is therefore a key issue in affected areas and knowledge about the level of parasite resistance 
to antimalarial drugs through regular monitoring is necessary to provide health authorities 
with reliable indicators of drug efficacy. Combination therapy as a means to improve clinical 
effectiveness and delay the emergence and spread of resistance to the individual drugs has 
been advocated for some years and successful implementation has been achieved in several 
countries (Kremsner & Krishna, 2004; White, 1999; WHO, 2006). Rapid, easy to use, and 
affordable surveillance systems are not only important to monitor emergence and spread of 
resistance to the newly adopted artemisinin-containing combination regimens (Adjuik et al., 
2004), but also decreasing resistance to withdrawn drugs, with the prospect of possibly 
reusing the limited number of safe and cheap drugs as partner compounds in antimalarial 
combination regimens (Laufer & Plowe, 2004). In addition, more comprehensive approaches 
are needed in order to assess the impact of new drug-based malaria intervention strategies 
such as intermittent preventive treatment (IPT) in infants and pregnant women (Schellenberg 
et al., 2006). 
Methods for the assessment of drug resistance in malaria include in vivo drug efficacy studies, 
which are still the gold standard, and to a lesser extent, in vitro sensitivity testing of patient 
isolates. More recently, the analysis of molecular markers has been proposed as an alternative 
approach for the evaluation of resistance to treatment (Plowe, 2003; Wernsdorfer & Noedl, 
2003). Indeed, antimalarial resistance is often associated with point mutations in parasite 
genes encoding drug target molecules or transporters. Thus, the presence of specific point 
mutations in these genes can be used as indicators for treatment failure or decreased 
antimalarial efficacy. 
Chloroquine resistance (CQR) is conferred by single nucleotide polymorphisms (SNPs) in 
pfcrt (Plasmodium falciparum chloroquine resistance transporter) and pfmdr1 (P. falciparum 
multidrug resistance 1), both encoding transport proteins localized in the digestive vacuole of 
the parasite (Fidock et al., 2000; Foote et al., 1990; Reed et al., 2000; Sidhu et al., 2002; 
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reviewed in Cooper et al., 2005 and Duraisingh & Cowman, 2005). Resistance to 
sulphadoxine-pyrimethamine (SP) is associated with a stepwise accumulation of mutations in 
pfdhfr (P. falciparum dihydrofolate reductase) and pfdhps (dihydropteroate synthase), both 
encoding important enzymes of the parasite’s folate synthesis pathway (Cowman, et al., 1988; 
Peterson et al., 1988; Triglia et al., 1997; Triglia et al., 1998; reviewed in Gregson & Plowe, 
2005). Artemisinin derivates have been shown to inhibit the sarcoendoplasmic reticulum 
Ca2+-ATPase (SERCA) of P. falciparum (pfATPase6) (Eckstein-Ludwig et al., 2003). A 
finding which was further corroborated by more recent experiments demonstrating that 
decreased in vitro susceptibility to artemisinine derivatives was associated with SNPs in 
pfATPase6 (Jambou et al., 2005; Uhlemann et al., 2005). 
However, the usefulness of these molecular markers has been controversial because 
straightforward associations with in vivo treatment outcome were not consistently found in 
different epidemiological settings (Aubouy et al., 2003; Kublin et al., 2002; Kyabayinze et 
al., 2003; Pillai et al., 2001; Tinto et al., 2003; Wellems & Plowe, 2001). Reports may be 
conflicting because clinical outcome is also dependent on several host factors, such as pre-
existing immunity, pharmacogenetic background determining drug metabolism, and 
compliance to treatment (White, 2004), as well as transmission intensity and drug use history 
in a given area (Alifrangis et al., 2003; Pearce et al., 2003). Furthermore, most previous 
studies focusing on molecular markers as indicators of treatment failure were conducted 
within the framework of clinical trials, and were therefore not only limited to sentinel sites 
with good access to health care facilities, but also investigated predominantly clinical cases 
within a restricted age group (i.e., children between 0.5 and 5 years of age) (Fèvre & Barnish, 
1999). Hence, a large parasite reservoir circulating in asymptomatic carriers that might play 
an important role in the spread of resistance has previously been ignored. Difficulties in 
finding consistent associations may also have arisen because most of the studies primarily 
focused on single genes and markers (Djimdé et al., 2001), rather than multiple markers in 
several gene loci, therefore neglecting mutations that are not directly associated with 
resistance, but compensate for fitness costs induced by resistance related mutations (Hastings 
& Donnelly, 2005; Warhurst, 2001). This is mainly because the most frequently applied 
molecular methods, such as PCR-RFLP (Polymerase chain reaction-restriction fragment 
length polymorphism) analysis or sequencing, are not suitable for the parallel analysis of 
multiple markers in large sample sets (Sangster et al., 2002). 
A monitoring approach on community level could give a more comprehensive assessment of 
the genetic profile of the parasite population circulating in a given area and contribute to a 
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broader understanding of the relationship between drug resistance genotypes and clinical 
failure rates as well as the dynamics and spread of drug resistant malaria. 
Only a few studies used a community-based design for the determination of the genetic 
resistance background in parasites and its correlation with in vivo treatment response 
(Talisuna et al., 2002a; Talisuna et al., 2003a). However, whether the molecular profile of 
parasites circulating in the community matches the one observed among symptomatic patients 
seen at health facilities, has never been demonstrated. 
We have recently developed a novel high throughput method based on DNA microarray 
technology which allows a parallel analysis of multiple SNPs in different genes in large 
sample sets (Crameri et al., 2006, submitted, Chapter 3). Moreover, in a recent pilot study, we 
could demonstrate that there was no difference between the genetic drug resistance profile in 
clinical and community samples (Marfurt et al., 2006, in preparation, Chapter 5). 
It was the aim of the current study to investigate the role and applicability of the molecular 
drug resistance profiles in community samples for monitoring of drug resistant malaria. For 
this purpose, we conducted in vivo efficacy studies with the current first-line regimen 
amodiaquine (AQ) or chloroquine (CQ) plus sulphadoxine-pyrimethamine (SP) at different 
sites in Papua New Guinea (PNG). We established simultaneously the molecular drug 
resistance profile in blood samples collected in the communities from the catchment areas of 
the corresponding health facilities by using the new DNA microarray-based technology for 
the parallel analysis of antimalarial drug resistance markers. We then investigated the 
potential of molecular marker frequencies and genotype patterns to reflect the trends of 
clinical failure in different epidemiological settings and propose a model for surveillance of 
resistance based on the molecular resistance profile of the parasite. 
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MATERIALS AND METHODS 
 
Study areas and design 
In vivo drug efficacy studies and community-based cross-sectional surveys were conducted at 
three different sites in Papua New Guinea (PNG) between October 2002 and March 2005. 
These sites included 1) the Sigimaru health centre (HC) in the Karimui area (Simbu 
Province), 2) the Kunjingini HC in the South Wosera area (East Sepik Province), and 3) the 
Mugil HC in the North Coast area of Madang (Madang Province). In Karimui, a rural region 
in the highland fringe area of PNG, the studies were run between October and April in three 
consecutive years (2003, 2004, and 2005). In the Wosera, located in the floodplain of the 
Sepik river in the North-eastern part of the country bordering Indonesian Papua, the study 
period was between December and June in two following years (2003 and 2004). The study in 
the rainforest area at the North Coast of Madang was conducted between April 2004 and 
February 2005. Malaria transmission is perennial with limited variations between wet 
(October to April) and dry (May to September) season at all three sites. Transmission 
intensity decreases significantly with increasing altitude (Müller et al., 2003) and is higher in 
the lowland regions of the Wosera and the North Coast than in the Karimui area, an elevated 
plateau situated at an altitude of 700 to 1200 m. Whereas there is little socioeconomic 
stratification between and within sites, with most of the inhabitants being subsidence farmers, 
there are differences with regard to health care provision and drug use patterns (Benet et al., 
2004; Genton et al., 1995; Hii et al., 2001; Mehlotra et al., 2002; Müller et al., 2004). 
Baseline characteristics of the study sites are summarized in table 1. 
Scientific approval and ethical clearance for the study was obtained from the Medical 
Research and Advisory Committee (MRAC) of the Ministry of Health in PNG. Informed 
consent was first requested from all the communities involved and prior to recruitment, 
individual consent was obtained from each study participant and parents or legal guardians. 
 
 
Assessment of in vivo drug efficacy 
Drug efficacy studies were conducted according to the standardised WHO protocol for low to 
moderate transmission areas (WHO, 2003) and are described in detail elsewhere (Marfurt et 
al., 2006, submitted, Chapter 2). Children between 6 months and 7 years of age were enrolled 
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if they were presenting at the health centre with clinically overt and microscopically 
confirmed P. falciparum malaria and no danger signs for severe or complicated malaria 
(WHO, 2000) or signs of any other disease, malnutrition or anaemia. Standard AQ (for 
patients <14 kg) or CQ plus SP first line treatment (10 mg AQ or CQ per kg on Day 0, 1 and 
2, and 25 mg sulphadoxine per kg plus 1.25 mg pyrimethamine per kg on Day 0) was 
administered under supervision over the first three days. Visits for the follow-up were 
scheduled on Day 1, 2, 3, 7, 14, and 28. On every visit, patients were clinically examined and 
a Giemsa-stained blood slide was taken for the microscopic assessment of parasitaemia. A 
blood sample was taken on Day 0 (pre-treatment sample) and on Days 14 and 28 or any day 
of treatment failure for molecular genotyping purposes. At the end of the follow-up, the 
patients were classified according to their clinical and parasitological responses into early 
treatment failure (ETF), late clinical failure (LCF), late parasitological failure (LPF), or 
adequate clinical and parasitological response (ACPR) (WHO, 2003). Distinction between 
recrudescence and new infection was accomplished by the comparison of the msp2 
genotyping patterns of Day 0 and treatment failure samples (Snounou & Beck, 1998) and 
failure rates were corrected accordingly (Marfurt et al., 2006, submitted, Chapter 2). 
 
 
Community-based cross-sectional surveys 
Cross-sectional surveys were conducted in the catchment areas of the health centres where in 
vivo studies were run using a randomized household approach. To obtain a representative 
random sample of the parasite population circulating in the corresponding communities (i.e., 
approximately 100 PCR-positive P. falciparum samples from each location), we collected 
between 300 and 350 blood specimens per community (Mehlotra et al., 2002). Overall, a total 
of 2013 individuals from randomly selected villages and households were recruited for the 
community surveys between 2003 and 2005. 
Apart from demographic characteristics, collected information included history of sickness 
(onset, type and duration of symptoms), health facility attendance, purchase or consumption 
of drugs outside health facilities, and antimalarial treatment courses received in the preceding 
year (extracted from health books when available). Axillary temperature was measured with 
an electronic thermometer and spleen size was assessed in the recumbent position using 
Hackett's grading system (Gilles & Warrell, 1993). Blood samples for parasitological 
examination by microscopy, haemoglobin (Hb) level determination (HemoCue®, Ångelholm, 
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Sweden), and molecular assessment of parasite genotypes were collected by venepuncture 
using 2 ml EDTA-Vacutainer™ tubes (BD Biosciences, Allschwil, Switzerland). Plasma was 
separated by centrifugation and red blood cell pellets were stored frozen until further 
processing. 
 
 
Molecular analyses 
DNA was extracted using QIAamp® DNA Blood Kit (Qiagen, Hombrechtikon, Switzerland) 
according to the manufacturer’s instructions. 
Assessment of SNPs for drug resistant malaria in community samples was done for pfmdr1 
codons N86Y, Y184F, S1034C, N1042D and D1246Y, pfcrt codons K76T, H97Q, T152A, 
S163R, A220S, Q271E, N326D/S, I356L/T and R371I, pfdhfr condons A16V, N51I, C59R, 
S108N/T and I164L, pfdhps codons S436A, A437G, K540E, A581G, and A613T/S, and 
pfATPase6 codons S538R, Q574P, A623E, N683K, and S769N. The method is based on 
parallel PCR amplification of the target sequences followed by primer extension mediated 
mini-sequencing using fluorochrome-labelled ddNTPs. Subsequent base calling occurs on a 
microarray upon sequence specific hybridisation (Crameri et al., 2006, submitted, Chapter 3; 
Marfurt et al., 2006, in preparation, Chapter 4). Multiplicity of infection (MOI) for each 
sample was assessed by determining the number of msp2 genotypes (Felger and Beck, 2002). 
 
 
Statistical analyses 
Data were double entered in EpiData software (version 3.02, Odense, Denmark) and analysis 
was performed using STATA software (version 8.2; Stata Corp., College Station, Texas). 
To estimate the allele frequencies of resistance markers in our sample set, we used a non 
linear statistical model that takes into account the effects of varying multiplicity of infection 
and assumes that resistant and sensitive parasite clones are transmitted independently. The 
likelihood of a sample containing no resistant clones is (1 - p)n, where p is the frequency for 
the mutant allele and n is the multiplicity of infection of the sample. Similarly, the likelihood 
for the sample to contain no wild-type allele is pn and for a mixture of both, a wild-type and a 
resistant allele, is 1 – pn – (1 - p)n. The likelihood over the whole data set for p is computed as 
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the product of this likelihood over all samples, using values of n derived from msp2 
genotyping results. A Markov Chain Monte Carlo algorithm (Program Winbugs 1.3) was used 
to obtain estimates of mutant allele frequencies and credible intervals (Bayesian confidence 
intervals (CI) for p), making use of this likelihood, and assuming a uniform (0.1) prior 
distribution for p (Schneider et al., 2002). 
The significance of different proportions was determined by using χ2 test for trend or Fisher’s 
exact test as applicable and differences in allele frequencies were assessed by the comparison 
of 95% confidence intervals. 
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RESULTS 
 
In vivo drug efficacy of AQ or CQ plus SP 
Clinical and parasitological monitoring up to Day 28 between 2003 and 2005 at all three sites 
was accomplished for a study group of 649 children. CQ plus SP was given to 128 (19.7%) 
children (median age of 6 years), whereas 521 (80.3%) children were treated with AQ plus SP 
(median age of 4 years). PCR-corrected treatment failure rates up to Day 28 for P. falciparum 
at the three sites in the different years are shown table 2. In the Karimui area, treatment failure 
rates up to Day 28 decreased over the three-year period from 28% to 18% and 16%, 
respectively (χ2(2)=4.81, p=0.09). In the South Wosera area, overall failure rate tended to 
increase from 16% in 2003 to 22% in 2004 (χ2(2)=1.19, p=0.28). In 2004, treatment failure rate 
after PCR-adjustment was 11.5% in the North Coast area of Madang (Marfurt et al., 2006, 
submitted, Chapter 2). 
 
 
Characteristics of the survey populations 
Key characteristics of the random community sub-samples collected at the three sites between 
2003 and 2005 are depicted in table 1. Whereas age distribution, sex ratio, and mean axillary 
temperature were similar between sites, mean haemoglobin levels were lower in the high 
transmission areas of the Wosera and the North Coast. Microscopic P. falciparum prevalence 
rates ranged between 13% and 27%, depending on the site and the respective year, and 
prevalence rates determined by a positive msp2 PCR result were higher (between 20% and 
41%, respectively). Though mean multiplicity of infection (MOI) was not significantly 
different between and within sites over time (range: 1.5 to 1.8), the proportion of multiple 
versus single infections varied between high and moderate transmission areas (data not 
shown). 
 
 
Mutant allele frequencies of drug resistance markers 
From a total of 2013 collected blood samples, 695 (34.5%) were found to be P. falciparum 
positive by msp2 PCR screening and subsequent mutation analyses were successfully 
accomplished for 633 (91%) of these samples. Polymorphisms were found in pfmdr1 codons 
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N86Y, Y184F, and N1042D, pfcrt codons K76T, A220S, N326D, I356L, and S163R, pfdhfr 
codons C59R and S108N, and pfdhps codons A437G and K540E. None of the other 21 SNPs 
was detected as mutated allele in any of the infections analysed (Table 2). 
Regarding CQ relevant markers in pfcrt, we measured high mutant allele frequencies (MAFs) 
for K76T (0.90 to 1.00), N326D (0.77 to 0.97), and I356L (0.76 to 0.98) at all three sites. 
Mutation rates of A220S were highest at the North Coast (0.95) and significantly lower in 
Karimui (0.48 to 0.63) and the South Wosera (0.61 to 0.81). Mutated pfcrt S163R alleles were 
rarely detected (≤ 0.01) and at the latter two sites only. Whereas MAFs for pfmdr1 N86Y 
reached quasi fixed levels in Karimui (0.99 to 1.00) and at the North Coast (0.93), frequencies 
were significantly lower in the South Wosera (0.69 to 0.72). Pfmdr1 polymorphisms Y184F 
and N1042D were never detected in samples from Karimui, and frequencies were low (0.03 to 
0.07) at the other two sites. 
Regarding SP relevant markers, MAFs for pfdhfr S108N and C59R were high at all three sites 
(0.82 to 0.97 and 0.73 to 0.95, respectively), but were still moderate in pfdhps A437G (0 to 
0.21) and very low in pfdhps K540E (0 to 0.03) (Table 2). 
Looking at the dynamics over time at a single site, significant changes in MAFs were found in 
the Karimui area for pfcrt N326D and I356L, which decreased significantly between 2003 and 
2005, and 2004 and 2005, respectively. By comparing the dynamics of molecular markers 
between Karimui and the South Wosera, we observed reverse trends over time for 
polymorphisms pfcrt A220S and pfdhps A437G. Whereas MAFs for these two gene loci 
decreased significantly between 2004 and 2005 in Karimui (0.63 to 0.48, and 0.10 to 0.04, 
respectively), they increased significantly between 2003 and 2004 (0.61 to 0.81, and 0 to 0.03, 
respectively) in the South Wosera (Table 2). 
 
 
Patterns of drug resistant genotypes 
All patient isolates were coded according to presence or absence of mutant alleles and isolates 
showing both, wild-type and mutant allele, were treated as mutant. Likewise, infecting 
genotypes were coded according to the most highly mutated pfmdr1, pfcrt, and pfdhfr/pfdhps 
alleles present in the sample. 
A single mutation N86Y was the predominant genotype in pfmdr1 at all three sites (72% to 
100%; Table 3). There was a significant difference in prevalence rates between the Karimui 
Chapter 6   154
and the Wosera areas in the years 2003 and 2004 (99% versus 71%, and 100% versus 71%, 
respectively, p<0.001 in both years). Though we observed a slightly decreasing trend in the 
prevalence of the pfmdr1 wild-type allele in the Wosera over time (p=0.43), this was not 
accompanied by an increase of the single N86Y mutation (p=0.97), but the occurrence of 
genotypes with single or double mutations Y184F and N1042D. 
Genotypes with a pfcrt wild-type, single K76T or double K76T+ N326D mutations were only 
observed in the Karimui and the Wosera areas, but they were not detected in any of the 
samples from the North Coast in Madang (Table 4). In this region, we only found genotypes 
with triple (K76T+N326D+N326D) or quadruple (+A220S) mutations. Prevalence rates of 
pfcrt triple and quadruple mutants were relatively stable in Karimui between 2003 and 2005 
(32% to 36%, and 54 to 61%, respectively). This is in contrast to the observations in the 
Wosera, where quadruple mutations increased at the expense of triple mutations between 
2003 and 2004, from 69% to 86% (p=0.001) and 15% to 4% (p=0.002), respectively. 
For SP relevant genotypes (Table 5), the prevalence of fully wild-type pfdhfr/pfdhps alleles 
was low at all three sites (1 to 15%). The predominant genotype was the double pfdhfr mutant 
S108N+C59R, with prevalence rates between 56% and 93%. Whereas genotypes with the 
pfdhps A437G mutation (which always occurred in combination with the pfdhfr double 
mutation S108N+C59R) were detected in 7% to 22% of patient samples from the Karimui 
area, prevalence rates between 0% and 4% were lower at the other two sites. In Karimui, there 
was a significant decrease of this triple pfdhfr/pfdhps mutant between 2003 and 2005 
(p=0.002), which was paralleled by a significant decrease of genotypes with single (S108N) 
and an increase in genotypes having the double (+C59R) mutation in pfdhfr (p=0.003 and 
0.001, respectively). A different longitudinal trend was observed in the Wosera area, where a 
significant increase of triple pfdhfr/pfdhps mutants between 2003 and 2004 (p<0.001) was 
accompanied by an increase of wild-type pfdhfr/pfdhps alleles (p<0.001) and a decrease of 
genotypes with the single and double mutations in pfdhfr (p=0.38 and 0.01, respectively). 
Because it was the aim to use the rate of SNPs within the population, we tested whether the 
genotype failure indices (GFIs), calculated as the ratio between prevalence of different 
genotypes to treatment failure rate, could predict the actual failure rate at a given site in the 
respective year. The trends in treatment failure rate over subsequent years (i.e., decreasing in 
Karimui and increasing in the Wosera) was best reflected by the GFI based on the prevalence 
of the combined pfdhfr S108N+C59R + pfdhps A437G genotype (Table 6). 
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DISCUSSION 
 
In the present study, we investigated the relationship between the genetic drug resistance 
background in parasite populations and clinical drug efficacy at three sites in Papua New 
Guinea (PNG). To clarify the question, whether the observed varying trends of in vivo drug 
efficacy between 2003 and 2005 in these regions reflected intrinsic variations or true 
dynamics of drug resistant malaria, we sought to explain these longitudinal in vivo trends by 
the molecular drug resistance profile assessed in the respective parasite populations. On an 
individual level, we had previously identified the triple mutation pfdhfr S108N+C59R plus 
pfdhps A437G to be a reliable predictor for treatment failure under the current first-line 
therapy with AQ or CQ plus SP (Marfurt et al., 2006, in preparation, Chapter 4). Moreover, 
we could show that the genetic drug resistance profile of parasite populations circulating in 
community samples was representative for the profile detected in clinical samples which was 
indeed reflecting the corresponding in vivo failure rates (Marfurt et al., 2006, in preparation, 
Chapter 5). We therefore used in the current studies a community-based sampling approach 
and applied a novel DNA microarray-based technology which enabled the parallel assessment 
of multiple single nucleotide polymorphisms (SNPs) in several genes in large sample sizes 
(Crameri et al., 2006, submitted, Chapter 3). 
After a long history of 4-aminoquinoline use, which was accompanied by accumulating 
reports of in vivo resistance to this drug class (Genton et al., 2006; Müller et al., 2003), 
treatment policy against uncomplicated malaria in PNG was changed to combination therapy 
with AQ or CQ plus SP in the year 2000. Only after two years of effective implementation, 
we measured treatment failure rates between 12% and 28%, with varying longitudinal trends 
depending on the area and the year (Table 2, Marfurt et al., 2006, submitted, Chapter 2). The 
significant levels of parasitological in vivo resistance were reflected in the genetic drug 
resistance profile of the parasites. High mutant allele frequency (MAF) estimates were 
obtained not only for molecular markers for CQ resistance (CQR) in pfcrt and pfmdr1, but 
also for important markers in pfdhfr and pfdhp, relevant for resistance to antifolates. 
Whereas MAFs for key CQR markers pfcrt K76T, N326D, and N326D reached almost fixed 
levels at all three sites, which was consistent with data from previous studies describing a 
highly mutated genetic CQR background in field isolates from PNG (Chen et al., 2001; 
Mehlotra et al., 2005; Nagesha et al., 2003), MAFs between 0.48 and 0.95 for pfcrt A220S 
varied considerably between sites. More importantly, MAFs in pfcrt A220S, which proved to 
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be indicative for the presence of a highly CQ resistant pfcrt quadruple mutant 
(K76T+N326D+N326D+A220S) in our studies, reflected the longitudinal trends of in vivo 
drug efficacy observed in Karimui and the Wosera. Whereas the decreasing in vivo trend in 
Karimui (28% in 2003, 18% in 2004, and 16% in 2005) was accompanied by MAFs in pfcrt 
A220S of 0.57 in 2003 and 0.63 in 2004, which significantly decreased to 0.48 in 2005, the 
opposing in vivo trend in the Wosera (16% in 2003 and 22% in 2004) was reflected in a 
statistically significant increase in the frequency of the pfcrt A220S mutation (0.61 in 2003 
versus 0.81 in 2004). Though statistically not significant, a similar trend was observed when 
taking into account the complete pfcrt genotype, with the prevalence of pfcrt quadruple 
mutants decreasing between 2003 and 2005 from 60% to 54% in Karimui, and increasing 
between 2003 and 2004 from 69% to 86% in the Wosera. 
Frequencies and genotype patterns of polymorphisms in pfmdr1 (i.e., N86Y, Y184F and 
N1042D) were relatively stable over time in a given area, but prevalence rates for the single 
pfmdr1 N86Y mutant of 99% to 100% in Karimui and 93% in the North Coast area of 
Madang were significantly higher than those of 71% observed in the Wosera. There is ample 
evidence from in vitro experiments that demonstrated single nucleotide polymorphisms 
(SNPs) in pfmdr1 to confer resistance to CQ, but also altered sensitivity to other drug classes 
including quinine, arylaminoalcohols and artemisinin derivates (Duraisingh et al., 2000; Reed 
et al., 2000; Sidhu et al., 2005). Several lines of evidence, such as the lack of a 
straightforward associations between pfmdr1 mutations and in vivo CQR (Basco & Ringwald, 
1998; Haruki et al., 1994; Pillai et al., 2001; Povoa et al., 1998), frequently observed linkage 
disequilibrium between pfcrt K76T and pfmdr1 N86Y in vivo (Adagut et al., 2001; Happi et 
al., 2006, Mita et al., 2006a), and the commonly accepted hypothesis that CQR is mediated 
by multigenic processes (Mu et al., 2003), strongly suggest that SNPs in pfmdr1 play an 
important role in modulating levels of CQR, but may not be sufficient indicators for in vivo 
CQR. Our data confirm that and also showed that pfmdr1 N86Y was strongly linked with 
treatment failure on individual level when found in conjunction with the highly CQ resistant 
pfcrt quadruple mutant (Marfurt et al., 2006, in preparation, Chapter 4). However, this marker 
does not seem to be suitable for longitudinal monitoring of CQR on population level, the most 
likely reason being that this mutation is almost fixed in the parasite population. On the other 
hand, the observed differences in pfmdr1 genotype patterns between sites (i.e., absence of 
pfmdr1 polymorphisms Y184F and N1042D in Karimui) most likely resulted from different 
levels of previous quinine use in the highland versus the lowland areas. Most probably due to 
the fact that P. falciparum, the species responsible for severe malaria requiring treatment with 
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quinine under prior drug policy in PNG, has become the predominant species in the Karimui 
area only within the last two decades (Müller et al., 2006). 
Regarding SP relevant markers, high MAFs for pfdhfr S108N and C59R at all three sites 
(0.82 to 0.97 and 0.73 to 0.95, respectively) were consistent with the observation of parasites 
harbouring the corresponding pfdhfr double mutation being the predominant genotype at all 
three sites. Similarly high mutation rates for the same dhfr genotype (83% in 2002 and 86% in 
2003) were recently reported by Mita and colleagues (2006b) in a study conducted in Wewak, 
the capital town of the East Sepik Province. These high prevalence rates measured after only a 
short time of SP introduction as part of the official first-line regimen in PNG may have arisen 
due to several reasons. These include the 1) use of pyrimethamine (in combination with CQ) 
in mass drug administration campaigns between the late 1960s and the early 1970s (Spencer, 
1992), 2) sporadic use of SP as part of the second-line treatment (together with quinine) 
against severe and treatment failure malaria, and 3) frequent use of cotrimoxazole 
(trimethoprim-sulphamethoxazole) against bacterial infections which may have exerted 
additional selection pressure for resistance conferring mutations in pfdhfr and pfdhps (Iyer et 
al., 2001). Though MAFs of polymorphic pfdhps K540E and A437G were relatively low 
(between 0 and 0.03, and 0 to 0.21, respectively), the longitudinal in vivo efficacy trends were 
best reflected by the latter mutation. Whereas the decreasing treatment failure rates in 
Karimui were paralleled by decreasing MAFs for pfdhps A437G (from 0.21 in 2003 to 0.04 in 
2005), polymorphisms at this SNP site in the Wosera were absent in 2003 and started to 
emerge in 2004, which correlated with the increasing trend in treatment failure rates. The 
importance of the pfdhps A437G mutation in indicating clinical resistance were additionally 
confirmed by the observation that the trends in clinical response were not mirrored in the 
prevalence rates of pfdhfr genotypes alone, but were best reflected by prevalence rates of the 
genotypes having the triple pfdhfr (S108N+C59R) plus pfdhps (A437G) mutation. 
Taken together, we describe here a highly mutated CQR background combined with pfdhfr 
mutations consistent with a moderately pyrimethamine resistant phenotype and the emergence 
of key mutations in pfdhps. Regarding the previously known high levels of in vivo CQR and 
reduced pyrimethamine sensitivity, significant levels of in vivo failure with the combination 
of AQ or CQ plus SP are not surprising. The combination of SP with a nearly 90% 
inefficacious partner drug was not expected to prolong the useful therapeutic life of the 
combination of these two drug classes (Watkins et al., 2005). In fact, our in vivo and 
molecular data suggest that SP, and more specifically sulphadoxine, is the effective 
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component in the current first-line regimen and hence, molecular monitoring of resistance to 
this component is important under constant treatment policy in PNG. 
It is a long-standing goal in malaria control to use molecular markers as a rapid means for the 
surveillance of resistance in order to provide timely and evidence-based information for 
policy formulation. Hence, there is a need for practical models to predict the risk for treatment 
failure based on molecular data collected in different epidemiological contexts using 
treatment regimens consisting of single or multiple drug classes. Determination of a genetic 
failure index (GFI), calculated as the ratio between the prevalence of mutated genotypes and 
treatment failure rate, has been proposed by several authors (Djimdé et al., 2001; Kublin et 
al., 2002; Kyabayinze et al., 2003). We tested the validity of this GFI for different CQR and 
SPR relevant genotypes and identified the GFI based on the combined pfhfr/pfdhps genotype 
to be the most suitable indicator for in vivo drug efficacy. These observations do not only 
further corroborate our previous findings showing this genotype to be the best predictor for 
treatment failure on individual level (Marfurt et al., 2006, in preparation, Chapter 4), they also 
indicate this genotype to be a valuable marker for the level clinical failure on population level 
over time at a given site. Though our results are not consistent with African studies in 
Tanzania (Mugittu et al., 2004; Mutabingwa et al., 2001) and Ghana (Mockenhaupt et al., 
2005), which showed that the pfdhps genotype was not indicative for treatment failure with 
SP monotherapy, recent studies from Uganda (Dorsey et al., 2004) and Laos (Berens et al., 
2003) reported pfdhps mutations to be important markers for unsuccessful treatment response 
to combination therapy with CQ plus SP. These conflicting reports underscore the need for a 
careful baseline assessment of the molecular marker profile in parasite populations, the 
investigation of its relationship with in vivo treatment response, and the monitoring of its 
dynamics over time. They clearly indicate that former drug history is an important 
determinant of the genetic resistance background in parasites and that SP resistance may 
emerge and spread very differently according to whether SP was used as monotherapy or 
introduced as partner component in a combination regimen. 
However, when we compared GFIs with clinical failure rates between sites in 2004 (i.e., 22% 
in the Wosera, 18% in Karimui, and 12% at the North Coast of Madang), the corresponding 
absolute values of the GFI (i.e., 0.2 in the Wosera, 0.6 in Karimui, and 0.1 at the North Coast 
of Madang) did not reflect the respective in vivo efficacy trends. These findings further 
underscore the importance of drug pressure exerted on parasite populations in determining 
molecular resistance dynamics, especially in areas with low to moderate transmission 
intensity (Talisuna et al., 2002b; Talisuna et al., 2003b; White; 2004). Previous drug histories 
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were different at the three sites. The North Coast area had by far the highest CQ pressure due 
to good health care provision as well as easy access to drugs in the nearby town of Madang. 
In contrast, former 4-aminoquinoline use is assumed to be lower in the remote regions in 
Karimui and the Wosera. However, former drug pressure with antifolates in the course of 
previous mass drug administration campaigns has been higher in the latter two regions 
(McMahon, 1973; Spencer, 1992). Though parasite CQR at all three sites can be regarded as 
having reached a plateau level, resistance to SP evolved and spreads at a different speed and 
seems to be mainly dependent on both, former and present antifolate pressure, the latter being 
predominantly modulated by the level of implementation of the new drug policy. 
In view of the commonly accepted hypothesis that increasing drug pressure leads to the 
emergence and spread of drug resistant genotypes, how can we explain the intriguing 
observation of opposing in vivo and molecular resistance trends in the Karimui and the 
Wosera areas? Again, we believe that these results clearly reflect the fact that other important 
parameters, such as drug use patterns as well as immunity related to transmission intensity 
(Djimdé et al., 2003; Francis et al., 2006), play a significant role in determining the level and 
spread of parasite resistance in a given area. In Karimui, the conduct of our studies lead to an 
increased awareness of malaria and resulted in an overall change in health seeking behaviour. 
At the same time, health care provision generally improved due to better medical supply to 
the remote highland area. Moreover, missionaries, who represented the main source of 
chloroquine provision outside health facilities in previous years, left the area in 2003. Taken 
together, all these factors may have resulted in an overall adequate drug pressure (i.e., correct 
dosage of combination therapy to a higher proportion of malaria cases) acting on a relatively 
small parasite population, therefore preventing the further development and spread of parasite 
resistance in this moderate transmission area (Talisuna et al., 2002b; Talisuna et al., 2006). 
The inverse happened in the Wosera area during the same time period. Inadequate drug 
pressure (i.e., indiscriminate monotherapy with AQ or CQ) exerted on a large and 
heterogeneous parasite population originated not only from health systems management 
problems in the area which lead to an undersupply with SP (local health extension officer at 
the Kunjingini health centre, personal communication). Also drug consumption outside health 
facilities was frequent (10% and 12% of the survey populations in 2003 and 2004, 
respectively) with AQ or CQ monotherapy mainly distributed by so-called ‘marasin meris’, 
community health workers who were inadequately trained by a local NGO. These factors may 
have further enhanced parasite CQR which consequently lead to reduced capacity of CQ to 
protect the development of resistance to SP. 
Chapter 6   160
In summary, we have shown that a comprehensive baseline assessment of resistance markers 
including the investigation of their relationship with treatment response is important for the 
identification of appropriate marker sets. We could demonstrate that the molecular drug 
resistance profile of parasite populations in community samples represented the profile in 
clinical samples and was capable to reflect the longitudinal in vivo drug efficacy trends 
observed at the respective health centres. However, our community-based molecular 
monitoring approach will have to be further evaluated in geographical areas at both extremes 
of transmission intensity and different drug use patters (e.g., rural versus urban areas) in order 
to test its validity as complementary resistance monitoring tool. Furthermore, marker sets will 
have to be adapted to future monitoring purposes, such as the inclusion of markers for newly 
introduced or withdrawn drug classes. Our data confirm that the genetic drug resistance 
background of the parasite is only one of many factors determining clinical outcome and one 
which has evolved differently according to epidemiological characteristics as well as history 
and patterns of drug use in a given area. The frequently suggested surveillance indicator GFI, 
which is simply based on prevalence of mutated genotypes and treatment failure rate, does not 
seem to be comparably applicable in different epidemiological settings. Other proxy 
indicators for important determinants of antimalarial parasite as well as in vivo resistance, 
such as immunity, transmission intensity, and drug pressure, are necessary to be considered in 
future public health models for monitoring drug resistant malaria. 
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TABLE 1: Characteristics of study sites and survey populations between 2003 and 2005 
 
Study site Karimui area South Wosera area North Coast area 
Endemicity* mesoendemic mesoendemic mesoendemic 
Transmission intensity§ moderate high high 
Year 2003 2004 2005 2003 2004 2004 
Characteristics n=265 n=347 n=359 n=317 n=366 n=359 
Age (mean (95% CI, range), yrs) 18.9 (17.0-20.7, 0.5-60) 19.4 (17.7-21.2, 0.5-73) 15.4 (14.0-16.8, 0.5-66) 20.4 (18.7-22.2, 0.5-70) 21.3 (19.6-23.1, 0.5-69) 19.6 (17.8-21.5, 0.5-70) 
Sex: females/n (%) 137/265 (51.7) 192/347 (55.3) 186/359 (51.9) 159/317 (50.1) 189/366 (51.6) 182/359 (50.7) 
Temperature (mean (95% CI),°C) 36.1 (36.0-36.1) 36.1 (36.0-36.1) 36.4 (36.4-36.5) 36.6 (36.5-36.6) 36.5 (36.5-36.6) 36.4 (36.3-36.4) 
Hb (mean (95% CI), g/dl) 11.5 (11.2-11.8) 12.1 (11.8-12.3) 11.4 (11.2-11.7) 10.7 (10.5-10.9) 10.7 (10.6-10.9) 10.4 (10.3-10.6) 
Pf prevalence by microscopy (x/n (%, (95% CI)) 34/258 (13.2, 9.3-17.9) 64/346 (18.5, 14.5-23.0) 82/358 (22.9, 18.7-27.6) 55/314 (17.5, 13.5-22.2) 96/356 (27.0, 22.4-31.9) 82/358 (22.9, 18.7-27.6) 
Pf prevalence by msp2 nPCR (x/n (%, (95% CI)) 102/263 (38.8, 32.9-45.0) 71/347 (20.5, 16.3-25.1) 131/359 (36.5, 31.5-41.7) 129/317 (40.7, 35.2-46.3) 147/366 (40.2, 35.1-45.4) 115/359 (32.0, 27.2-37.1) 
Mean multiplicity of infection (MOI) (95% CI, range) 1.46 (1.32-1.60, 1-4) 1.59 (1.38-1.80, 1-4) 1.77 (1.62-1.92, 1-4) 1.77 (1.57-1.96, 1-6) 1.85 (1.68-2.02, 1-5) 1.54 (1.38-1.70, 1-5) 
* Pf prevalence age group 2-9 (x/n (%, (95% CI)) 13/93 (14.0, 7.7-22.8) 20/107 (18.7, 11.8-27.4) 44/138 (31.9, 24.2-40.4) 21/98 (23.6, 15.2-33.8) 36/110 (32.7, 24.1-42.3) 46/128 (35.9, 27.7-44.9) 
* Spleen rate age group 2-9 (%, (95% CI)) nd 17.65 (10.23-27.43) 26.85 (18.78-36.24) 17.65 (10.23-27.43) 17.27 (10.73-25.65) 41.13 (32.37-50.32) 
 
* determined according to P. falciparum prevalence and spleen rates (i.e., proportion of individuals with enlarged spleen) of 11-50% in children 
aged 2-9 years (WHO, 2003); § (Benet et al., 2004; Hii et al., 2001; Müller et al., 2004), n, total number of people surveyed; CI, confidence 
interval; Hb, haemoglobin; Pf, P. falciparum; msp2, merozoite surface protein 2; nPCR, nested polymerase chain reaction; nd, not determined 
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TABLE 2: Maximum likelihood estimates of mutant allele frequencies of polymorphic gene loci in pfmdr1, pfcrt, pfdhfr and pfdhps from all three 
sites assessed between 2003 and 2005 
Site Karimui area (Simbu Province) 
South Wosera 
(East Sepik Province) 
North Coast 
(Madang Province) 
Year 2003 2004 2005 2003 2004 2004 
TFR (%) 27.8 18.3 16.4 16.1 21.7 11.5 
SNP* n MAF 95%CI n MAF 95%CI n MAF 95%CI n MAF 95%CI n MAF 95%CI n MAF 95%CI 
pfmdr1 N86Y 93 0.99 (0.96, 1.00) 70 1.00   128 1.00   115 0.72 (0.65, 0.78) 139 0.69 (0.63, 0.75) 95 0.93 (0.89, 0.97) 
pfmdr1 Y184F 93 0.00   70 0.00   127 0.00   115 0.07 (0.04, 0.10) 139 0.06 (0.04, 0.10) 95 0.03 (0.01, 0.07) 
pfmdr1 N1042D 93 0.00   70 0.00   128 0.00   115 0.04 (0.02, 0.07) 140 0.06 (0.04, 0.10) 95 0.02 (0.00, 0.04) 
pfcrt K76T 93 0.97 (0.93, 0.99) 70 1.00   128 0.93 (0.89, 0.96) 115 0.94 (0.90, 0.96) 139 0.90 (0.86, 0.93) 95 0.99 (0.97, 1.00) 
pfcrt S163R 93 0.01 (0.00, 0.04) 69 0.00   125 0.00   115 0.00   137 0.00   95 0.01 (0.00, 0.03) 
pfcrt A220S 93 0.57 (0.49, 0.65) 70 0.63 (0.54, 0.71) 127 0.48 (0.44, 0.50) 115 0.61 (0.45, 0.76) 140 0.81 (0.77, 0.86) 95 0.95 (0.92, 0.98) 
pfcrt N326D 93 0.92 (0.87, 0.96) 70 nd   127 0.77 (0.71, 0.83) 115 0.82 (0.76, 0.87) 139 nd   95 0.97 (0.94, 0.99) 
pfcrt I356L 93 0.94 (0.89, 0.97) 70 0.91 (0.85, 0.96) 127 0.76 (0.70, 0.82) 115 0.83 (0.77, 0.87) 139 nd   95 0.98 (0.95, 1.00) 
pfdhfr S108N 93 0.83 (0.77, 0.89) 69 0.91 (0.85, 0.96) 128 0.94 (0.91, 0.97) 115 0.82 (0.76, 0.87) 139 0.86 (0.82, 0.90) 95 0.97 (0.94, 0.99) 
pfdhfr C59R 93 0.73 (0.65, 0.80) 69 0.91 (0.85, 0.96) 128 0.93 (0.89, 0.96) 115 0.75 (0.68, 0.81) 139 0.73 (0.67, 0.78) 95 0.95 (0.91, 0.98) 
pfdhps A437G 93 0.21 (0.15, 0.28) 68 0.10 (0.05, 0.16) 128 0.04 (0.04, 0.04) 115 0.00   139 0.03 (0.02, 0.06) 95 0.01 (0.00, 0.04) 
pfdhps K540E 93 0.01 (0.00, 0.05) 68 0.00   128 0.01 (0.00, 0.03) 115 0.00   139 0.01 (0.00, 0.03) 95 0.03 (0.01, 0.05) 
 
TFR, treatment failure rate; SNP, single nucleotide polymorphism; n, number of samples analysed; MAF, mutant allele frequency; CI, Bayesian 
confidence intervals for maximum likelihood estimates of MAF; nd, not determined; dark grey shading, significant increase in MAF between 
respective years; bright grey shading, significant decrease in MAF between respective years; * To simplify matters, only polymorphic loci are 
depicted in the table (i.e., all other gene loci analysed were never found as mutated allele) 
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TABLE 3: pfmdr1 genotype patterns assessed in community samples from all three sites between 2003 and 2005 
 
pfmdr1 
SNPs 
Karimui area 
Simbu Province 
South Wosera area 
East Sepik Province 
North Coast area 
Madang Province 
N86Y               
Y184F               
N1042D               
Year Treatment failure rates 
2003 27.8% 16.1%  
x/n 1/94 93/94 21/115 82/115 2/115  2/115 6/115 2/115  
    
% 1.1 99.0 18.3 71.3 1.7  1.7 5.2 1.7      
2004 18.3% 21.7% 11.5% 
x/n  67/67 20/137 98/137 3/137 2/137 7/137  5/137 2/137 3/95 88/95 2/95 2/95 
%  100.0 14.6 71.5 2.2 1.5 5.1  3.7 1.5 3.2 92.6 2.1 2.1 
2005 16.4%             
x/n  125/125 
            
%  100.0             
 
pfmdr1, Plasmodium falciparum multi drug resistance gene 1; white box, wild-type allele; shaded box, mutated allele; SNP, single nucleotide 
polymorphism; x, number of samples detected with a given genotype; n, total number of samples analysed in the respective site and year; 
(genotype patterns detected in one of all 633 samples only are not included in table 3) 
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TABLE 4: pfcrt genotype patterns assessed in community samples from all three sites between 2003 and 2005 
 
pfcrt 
SNPs 
Karimui area 
Simbu Province 
South Wosera area 
East Sepik Province 
North Coast area 
Madang Province 
K76T                
I356L                
N326D                
A220S                
Year Treatment failure rates 
2003 27.8% 16.1%   
x/n 2/94 2/94 1//94 1/94 29/94 1/94 56/94 9/115 7/115 1/115 2/115 17/115 79/115 
  
% 2.1 2.1 1.1 1.1 30.9 1.1 59.6 7.8 6.1 0.9 1.7 14.8 68.7   
2004 18.3% 21.7% 11.5% 
x/n  1/67 2/67  23/67  41/67 13/137    5/137 118/137 3/95 91/95 
%  1.5 3.0  34.3  61.2 9.5    3.7 86.1 3.2 95.8 
2005 16.4%         
x/n 8/125  1/125 1/125 44/125 1/125 68/125 
        
% 6.4  0.8 0.8 35.2 0.8 54.4         
 
pfcrt, Plasmodium falciparum chloroquine transporter gene; white box, wild-type allele; shaded box, mutated allele; SNP, single nucleotide 
polymorphism; x, number of samples detected with a given genotype; n, total number of samples analysed in the respective site and year; 
(genotype patterns detected in one of all 633 samples only are not included in table 4) 
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TABLE 5: pfdhfr/pfdhps genotype patterns assessed in community samples from all three sites between 2003 and 2005 
 
pfdhfr/dhps SNPs Karimui area Simbu Province 
South Wosera area 
East Sepik Province 
North Coast area 
Madang Province 
S108N               
C59R               
A437G               
K540E               
Year Treatment failure rates 
2003 27.8% 16.1%  
x/n 7/94 1/94 11/94 53/94 20/94 2/115 14/115 99/115  
     
% 7.5 1.1 11.7 56.4 21.3 1.7 12.2 86.1       
2004 18.3% 21.7% 11.5% 
x/n 5/67   55/67 7/67 20/137 12/137 99/137 5/137 2/95 1/95 88/95 1/95 3/95 
% 7.5   82.1 10.5 14.6 8.8 72.3 3.7 2.1 1.1 92.6 1.1 3.2 
2005 16.4%          
x/n 3/125  2/125 111/125 9/125 
         
% 2.4  1.6 88.8 7.2          
 
pfdhfr, Plasmodium falciparum dihydrofolate reductase; pfdhps, Plasmodium falciparum dihydropteroate synthase; white box, wild-type allele; 
shaded box, mutated allele; SNP, single nucleotide polymorphism; x, number of samples detected with a given genotype; n, total number of 
samples analysed in the respective site and year; (genotype patterns detected in one of all 633 samples only are not included in table 5) 
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TABLE 6: Genotype failure indices for combined dhfr/dhps genotypes for all three sites 
between 2003 and 2005 
 
Site 
Karimui 
Simbu Province 
South Wosera 
East Sepik Province 
North Coast 
Madang Province 
Year P GFI* P GFI P GFI 
2003                                 TFR 27.8% 16.1%   
G1: pfdhfr S108N+C59R + pfdhps A437G 21.3 0.8 0.0 0.0   
G2: pfdhfr S108N+C59R  56.4 2.0 86.1 5.3   
2004                                 TFR 18.3% 21.7% 11.5% 
G1: pfdhfr S108N+C59R + pfdhps A437G 10.4 0.6 3.6 0.2 1.1 0.1 
G2: pfdhfr S108N+C59R  82.1 4.5 72.3 3.3 92.6 8.0 
2005                                 TFR 16.4%     
G1: pfdhfr S108N+C59R + pfdhps A437G 7.2 0.4     
G2: pfdhfr S108N+C59R  88.8 5.4     
 
P, prevalence; GFI, genotype failure index; * GFIs are calculated as the ratio between 
prevalence of mutated genotype to treatment failure rate at a given site in the respective 
year; TFR, treatment failure rate; G, genotype (GFIs are shown for the two predominant 
dhfr/dhps genotypes only) 
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ABSTRACT 
 
BACKGROUND Molecular mechanisms and markers for sulphadoxine-pyrimethamine (SP) 
resistance in P. vivax have been reported. However, molecular correlates involved in 
resistance to 4-aminoquinolines and data on their relationship with in vivo treatment response 
are still scarce. 
METHODS We assessed P. vivax dhfr (F57L/I, S58R, T61M, S117T/N, and I173F/L) and 
mdr1 (Y976F and F1076L) mutations in pre-treatment samples from 104 patients with a P. 
vivax monoinfection who received amodiaquine (AQ) or chloroquine (CQ) in combination 
with SP in Papua New Guinea (PNG) and investigated the association between infecting 
genotype and treatment response. 
RESULTS Treatment failure rate reached 13% with the new combination regimen. 
Polymorphisms in pvdhfr codons F57L/I, S58R, T61M, S117T/N, and pvmdr1 codon Y976F 
were detected in 61%, 68%, 21%, 41%, and 39% of the samples, respectively. Taken 
independently, the single mutant pvdhfr 57 showed the strongest association with treatment 
failure (OR=9.31, p=0.01). Presence of the quadruple mutant pvdhfr 57L+58R+61M+117T 
with pvmdr1 mutation 976F best predicted treatment failure (OR=10.25, p<0.01). The 
difference in failure rates between sites was reflected in the genetic drug resistance profile of 
the respective parasite populations. 
CONCLUSIONS Our study identified a novel molecular marker in pvmdr1 to be associated with 
in vivo response to AQ or CQ plus SP. Our results suggest pvdhfr F57L/I, T61M, and 
S117T/N plus pvmdr1 Y976F as a suitable marker set for the molecular monitoring of P. 
vivax resistance against the current first-line therapy in PNG. 
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INTRODUCTION 
 
More than 50 % of all malaria cases outside Africa are caused by Plasmodium vivax and an 
estimated number of 70-80 million people are infected each year (Mendis et al., 2001). 
Plasmodium vivax has considerable clinical and socioeconomic impact in endemic countries 
and resurgence of the disease is mainly attributable to the emergence of parasite resistance to 
the commonly available and applied therapies (Baird, 2004; Sattabongkot et al., 2004). 
Moreover, research efforts lagged behind those for P. falciparum because of the lack of a 
continuous in vivo culture system and field studies being hampered by generally low 
parasitaemias in natural infections. 
Chloroquine (CQ) resistant P. vivax was first described in Papua New Guinea (PNG) in 1989 
(Whitby et al., 1989) and thereafter, reduced CQ sensitivity of P. vivax has been reported 
from several endemic countries including Indonesia (Baird et al., 1991; Schwartz et al., 
1991), Thailand and Myanmar (Myat et al., 1993; Tan-ariya et al., 1995), the Indian 
subcontinent (Dua et al., 1996; Garg et al., 1995), and South America (Garavelli et al., 1996; 
Soto et al., 2001). Because it has long been thought that antifolates, such as the fixed dose 
combination sulphadoxine-pyrimethamine (SP), are less active against P. vivax, an 
assumption which was mainly based on clinical studies failing to demonstrate SP efficacy 
against this species (Young & Burgess, 1959), SP has never been recommended for P. vivax 
malaria. Nevertheless, increasing levels of resistance of P. falciparum to CQ led to the 
adoption of SP as a cheap and safe alternative first-line-line option in many countries in South 
East Asia, Central and South America and Oceania, where both species are endemic, and P. 
vivax resistance to SP had developed rapidly in many areas within only a few years after its 
initial deployment as monotherapy (Baird, 2004; Peters, 1998; Pukrittayakamee et al., 2000). 
Hypnozoites, the latent liver stages of P. vivax, can give rise to a recurrent intra-erythrocytic 
infection between 3 weeks and several months after the initial infection depending on the 
strain. Therefore, in vivo assessment of drug efficacy is complicated by difficulties to clearly 
differentiate between treatment failures (true recrudescences originating from asexual blood 
stage parasites), relapses (red blood cell infection originating from hypnozoites) and newly 
acquired infections. Moreover, comparison of data is aggravated by the lack of studies 
following standardised protocols and classifications. Therefore, as in the case of P. 
falciparum, the assessment of molecular drug resistance markers could be a valuable 
complementary tool for the mapping and regular monitoring of drug resistant P. vivax malaria 
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(Plowe, 2003; WHO, 2006). Several genes related to resistance to the commonly used drugs 
have been described in P. falciparum. Orthologous genes of pfdhfr (Plasmodium falciparum 
dihydrofolate reductase), pfdhps (dihydropteroate synthase), pfcrt (chloroquine resistance 
transporter gene) and pfmdr1 (multidrug resistance gene 1) have been found in P. vivax, 
notably pvdhfr (Eldin de Pécoulas et al., 1998a), pvdhps (Korsinczky et al., 2004), pvcg10 
(Nomura et al., 2001) and pvmdr1 (Brega et al., 2005), respectively. Whereas no evidence 
could be found for an association between point mutations in both, pvcg10 and pvmdr1, and 
CQ resistance in P. vivax field isolates (Nomura et al., 2001; Sà et al., 2005), there are several 
laboratory studies which have clearly shown that pyrimethamine resistance is associated with 
a specific SNP accumulation in pvdhfr which leads to reduced enzyme affinity to the drug and 
corresponds to reduced sensitivity to pyrimethamine in vitro (Eldin de Pécoulas et al., 1998b; 
Hastings & Sibley, 2002; Hastings et al., 2005; Leartsakulpanich et al., 2002; Tahar et al., 
2001). Furthermore, this association could be confirmed in epidemiological studies 
investigating the relationship of the genetic pvdhfr background and in vivo response to 
antifolates (Hastings et al., 2004; Imwong et al., 2001; Tjitra et al., 2002). Likewise, reduced 
in vitro sensitivity to sulphadoxine (Chotinavich et al., 2004; Russell et al., 2003) and a 
relationship with clinical response to SP have been shown to be associated with SNPs in 
pvdhps (Imwong et al., 2005; Korsinczky et al., 2004). 
In PNG, where all four Plasmodium species that infect humans are found, the majority of 
infections are caused by P. falciparum and P. vivax and mixed infections are common (Müller 
et al., 2003). Antimalarial treatment in most health facilities in PNG is given based on 
presumptive clinical diagnosis without differentiation of the infecting species. Hence, after a 
long history of 4-aminoquinoline use against malaria, reports about reduced in vivo efficacy 
against P. falciparum and P. vivax malaria started to accumulate since the mid 1970s and the 
1980s, respectively (Grimmond et al., 1976; Rieckmann et al., 1989), which reached 
unacceptably high levels in both species in the 1990s (Al Yaman et al., 1996; Genton et al., 
2006). Despite the low use of SP in the country (only in combination with quinine against 
severe and treatment failure malaria), P. falciparum resistance to SP as well as reduced 
efficacy of SP against P. vivax has been described in the Madang province (Al Yaman et al., 
1994; Darlow et al., 1982a; Darlow et al., 1882b; Lamont & Darlow, 1982). First-line policy 
against uncomplicated malaria in PNG was changed to the combination of AQ or CQ plus SP, 
since this regimen showed initially satisfactory results against P. falciparum malaria 
(Jayatilaka et al., 2003). In order to assess the status of the clinical efficacy of the current 
first-line regimen against P. vivax malaria in PNG after its effective implementation in the 
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year 2000, we conducted in vivo drug efficacy studies in three different areas in the country 
between 2004 and 2005 using standard clinical classifications according to the revised World 
Health Organization (WHO) protocol (Marfurt et al. 2006, submitted, Chapter 2; WHO, 
2003). In the current study, we assessed P. vivax mutations in pre-treatment samples from 
patients with a monoinfection who received amodiaquine (AQ) or chloroquine (CQ) in 
combination with SP in PNG and investigated the association between infecting genotype and 
treatment response. 
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SUBJECTS, MATERIALS, AND METHODS 
 
Subjects and therapeutic classification 
In vivo drug efficacy studies were conducted between October 2004 and April 2005 in the 
Karimui area (Simbu Province), the South Wosera area (East Sepik Province), and the North 
Coast area of Madang (Madang Province) as described in detail elsewhere (Marfurt et al., 
2006, submitted, Chapter 2). Children between 6 months and 7 years of age were enrolled if 
they were presenting at the health centre with a clinically overt (axillary temperature ≥37.5°C 
or history of fever during the last 48 hours) and microscopically confirmed monoinfection 
with P. vivax (density >250 asexual parasites per microlitre of blood). Further inclusion 
criteria were the absence of danger signs for severe or complicated malaria (WHO, 2000), 
signs of any other disease, malnutrition or anaemia. Standard AQ or CQ plus SP first-line 
treatment (10 mg chloroquine or amodiaquine per kg on Day 0, 1 and 2, and 25 mg 
sulphadoxine per kg plus 1.25 mg pyrimethamine per kg on Day 0) was administered under 
supervision over the first three days. Follow-up visits were done on Day 1, 2, 3, 7, 14, and 28. 
On every visit, patients were clinically examined and a Giemsa-stained blood slide was taken 
for the microscopic assessment of parasitaemia. 
Patients were advised to come to the health centre on any day if symptoms occurred. 
Whenever a child was diagnosed as treatment failure, standard second line treatment (5 mg 
artesunate per kg on Day 1 followed by 2.5 mg artesunate per kg on Day 2 to 7, and a single 
dose of 25 mg sulphadoxine per kg plus 1.25 mg pyrimethamine per kg on Day 3) was given. 
Patients were classified as treatment failure (TF) when 1) clinical deterioration in the presence 
of P. vivax parasitaemia, or 2) parasitaemia between Day 3 and Day 28 with axillary 
temperature ≥37.5°C, or 3) parasitaemia between Day 7 and Day 28, irrespective of clinical 
conditions, was observed (WHO, 2001). Patients without clinical signs and without recurrent 
asexual parasites up to Day 28 were classified as adequate clinical and parasitological 
response (ACPR). 
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Laboratory analyses 
Finger prick blood samples were collected into EDTA Microtainer® tubes and DNA was 
extracted by using QIAamp® DNA Blood Kit (Qiagen, Hombrechtikon, Switzerland) 
according to the manufacturer’s instructions. 
Detection of single nucleotide polymorphisms in pvdhfr (F57L/I, S58R, T61M, S117T/N, and 
I173F/L) and pvmdr1 (Y976F and F1076L) was carried out with a LightCycler® system using 
FRET technology. Primers and probes were designed and synthesized by TIB® MOLBIOL 
(DNA synthesis service, Berlin, Germany) to detect five mutations in pvdhfr and two 
mutations in pvmdr1. The sequences of the primers and probes are listed in table 1. The PCR 
mixture (20 µl) contained 5 µl of DNA template, probes (0.2 µM), primers (0.5 µM), MgCl2 
(3 mM) and 2 µl of FastStart DNA Master Hybridization probes (Roche Molecular 
Biochemicals). For pvdhfr codons, the PCR program included 40 cycles of denaturation at 
95°C for 10 s, annealing of the primers and probes at 60°C for 10 s, and extension at 72°C for 
20 s. The temperature change rates were 20°C/s for denaturation and annealing and 1°C/s for 
extension. Fluorescence was measured at channel F2 of the LightCycler® system at the end of 
the annealing phase of each cycle. For pvmdr1 codons, PCR program was similar except that 
amplification was performed with 45 cycles. The melting curve phase, period added after the 
PCR, consisted of one cycle of 95°C for 2 s, 40°C (pvdhfr) or 30°C (pvmdr1) for 20 s, and 
heating at 80°C for 0 s. The temperature change rates were 20°C/s except for the final step 
which had a temperature transition rate of 0.1°C/s. Fluorescence was measured in continuous 
during the final step to determine a specific melting temperature of each genotype (Brega et 
al., 2004; Brega et al., 2005). A multi-clonal population could be identified by the presence of 
the two peaks simultaneously. DNA sequencing was used to confirm the presence of codon L 
or I at position 57 in pvdhfr. 
 
 
Statistics 
Statistical analyses were performed by the use of STATA software (version 8.2; Stata Corp., 
College Station, Texas). The strength of association was evaluated by calculating odds ratios 
(OR). We used χ2 test or Fisher’s exact test as applicable and logistical regression analysis to 
assess the relationship between single or multiple mutations and treatment failure, taking into 
account other explanatory variables known to be associated with treatment outcome. 
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RESULTS 
 
In vivo response to AQ or CQ plus SP 
Baseline characteristics of all the children with a P. vivax monoinfection on admission day are 
depicted in table 2. AQ plus SP was given to 98 (94.2%) children, CQ plus SP to 5 (4.8%) 
children, and one (1.0%) was treated with primaquine plus SP. P. vivax treatment failure, 
defined as recurrent parasitaemia after Day 3 up to Day 28, irrespective of clinical symptoms 
(WHO, 2001), was seen in 13 (12.5%) of all children (Table 2). The vast majority of cases 
(11/13=84.6%) were parasitological failures at Day 28, one patient failed at day 6 and one 
failed at day 14. There was a significant difference of failure rates between sites (χ2(2)=13.95, 
p=0.001): 10/34 (29.4%) P. vivax infections in the North Coast area of Madang and 3/46 
(6.5%) in the Karimui area failed treatment, whereas all 27 infections were successfully 
cleared in the Wosera area (for details: Marfurt et al., 2006, submitted, Chapter 2). 
 
 
Prevalence and relationship of pvdhfr and pvmdr1 mutations 
Mutation analyses were successfully accomplished in 100 (96.2%) of all pre-treatment 
samples from all the three study sites. Polymorphisms in pvdhfr codons F57L/I, S58R, T61M, 
S117T/N, and pvmdr1 codon Y976F were detected in 61%, 68%, 21%, 41%, and 39% of 
samples, respectively (Figure 1). Depending on the codon position, a pure mutant allele was 
found in most of the samples (15% to 59%), whereas in 6% to 16% of the samples, a mutant 
allele was found in conjunction with the wild-type allele. None of the other SNPs (i.e., pvdhfr 
I173F/L and pvmdr1 F1076L) was detected as mutated allele in any of the samples analysed. 
In all pre-treatment samples, nine different pvdhfr alleles were observed in single clone 
infections (78%), with the wild-type 57F+58S+61T+117S, the double mutant 57L+58R, and 
the quadruple mutant 57L+58R+61M+117L/I being the most prevalent haplotypes (28%, 
25%, and 15%, respectively). Twenty-two of all samples contained mixed alleles at varying 
codon positions indicating polyclonal infections (Table 3). It is worth mentioning that the 
mutation F57L/I was always linked to S58R, and the T61M mutation always linked to the 
triple mutation F57L/I+S58R+S117T. Furthermore, in contrast to S117T, which was found in 
single, double, triple and quadruple mutations in pvdhfr, S117N was only observed in relation 
to single or double mutations. 
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Association between pvdhfr and pvmdr1 alleles and treatment outcome 
To maximize our sample size, we pooled the data from all three study sites and evaluated the 
association between infections with single and combined mutant alleles in pvdhfr and pvmdr1 
and response to treatment. All patient isolates were coded according to presence or absence of 
mutant alleles and isolates showing both, wild-type and mutant allele, were treated as mutant. 
Likewise, infecting genotypes were coded according to the most highly mutated pvdhfr and 
pvmdr1 alleles present in the sample. 
In our study, explanatory variables such as fever, parasite density at day of enrolment or the 
combination regimen (SP plus CQ or AQ, respectively), were not associated with an 
increased risk of P. vivax treatment failure. However, risk of failure tended to decrease with 
increasing age (OR=0.60; 95% CI=0.36-1.00, p=0.05). Regarding single molecular markers in 
pvdhfr, the presence of mutated codon positions 57 (either 57L or 57I), 58R, 61M and 117T 
were independently associated with an increased risk of treatment failure (Table 4). The same 
was observed with infections harbouring the mutation pvmdr1 976F. This relationship was 
further confirmed by the observation of a significant association between infections 
containing the wild-type allele 976Y and a positive treatment response (OR=0.18, 95% 
CI=0.04-0.74, p<0.01). 
In a further step, we established the pvdhfr/pvmdr1 genotypes (i.e., combination of mutated 
alleles in both genes) of parasites for each patient sample. With regard to mutated gene loci, 
we could discriminate between 14 different genotypes (Table 5). Among those, seven were 
observed in treatment failure cases, whereas the remaining seven were exclusively found in 
patients with an adequate treatment response. Regarding pvdhfr genotypes alone, the risk of 
treatment failure was clearly related to the numbers of mutations present in an infection 
(OR=1.86, 95% CI=1.15-3.01, p=0.01). However, the only significant association with a 
negative treatment outcome was seen with infecting genotypes having pvdhfr quadruple 
mutations combined with the pvmdr1 mutation 976F (OR=10.25, 95% CI=2.44-43.11, 
p<0.01). 
Since treatment failure rate in the North Coast area (33%) was significantly higher than those 
of the Karimui area (7%) and the Wosera (0%), we investigated whether this difference in 
treatment outcome was reflected in the corresponding drug resistance marker profile of the 
parasite populations in the different sites (Table 6). Regarding polymorphisms in pvdhfr, there 
was a marked difference between sites for the mutated positions 57L (p (χ2(2)=0.01) and 58R 
(p (χ2(2)=0.01). Similarly, when compared with the two sites with lower treatment failure 
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rates, the prevalence of the mutated locus pvmdr1 976F was significantly higher in the North 
Coast area (p<0.001). Correspondingly, the prevalence of the wild-type allele 976Y was 
lowest at this site with the highest level of in vivo resistance (p=0.001). A similar picture was 
observed when frequencies of genotypes were compared. 
The different levels of treatment response were not only reflected in a varying prevalence of 
the number of mutations in pvdhfr (p (χ2(2)=0.03). There was a significant difference between 
sites in the prevalence of the wild-type pvdhfr/pvmdr1 genotype, which showed an increasing 
trend with decreasing treatment failure rate (p (χ2(2)=0.03). The inverse trend was observed 
with the two genotypes having a mutated pvmdr1 976F combined with the pvdhfr double 
(57L+58R) or quadruple (57L+58R+61M+117T) mutation, where prevalences were 
increasing with increasing levels of in vivo failure rates (p (χ2(2)=0.001 and 0.01, respectively; 
data not shown). 
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DISCUSSION 
 
Only four years after its effective implementation in PNG, the efficacy of the new first-line 
regimen of AQ or CQ plus SP against uncomplicated malaria has reached unacceptably low 
levels in both species (Marfurt et al., 2006, submitted, Chapter 2). In this study, we 
investigated the relationship between drug resistance markers in pvdhfr and pvmdr1 in pre-
treatment samples from patients with a P. vivax monoinfection and therapeutic outcome with 
the newly introduced combination regimen. We measured high prevalence rates of mutated 
key markers in both genes and demonstrated an association between infecting pvdhfr/pvmdr1 
genotype and in vivo treatment response. Furthermore, different levels of treatment failure 
rates observed at different study sites were reflected in the genetic drug resistance profile of 
the corresponding parasite populations. This finding is probably the most important one since 
it validates the usefulness of molecular markers to monitor P. vivax resistance to antimalarial 
drugs in order to aid policy makers to develop rationale treatment strategies. 
Regarding all single nucleotide polymorphisms analysed in pvdhfr (F57L/I, S58R, T61M, 
S117T/N, and I173F/L) and pvmdr1 (Y976F and F1076L), we found a high prevalence of 
infections harbouring parasites with mutated gene loci (i.e., between 20% and 70%, 
depending on the locus analysed). Furthermore, we observed a high degree of diversity of 
different pvdhfr genotypes in our sample set deriving from three different areas within the 
same country. In most of the samples, we detected pvdhfr wild-type alleles (28%), double 
(34%), and quadruple mutations (21%), whereas the rate of single and triple mutations were 
lower (6% and 11%, respectively). Among the genotypes having double and quadruple 
mutations, the occurrence of the allelic variants 57L+58R (29%) and 57L+58R+61M+117T 
(19%) were most common in PNG. Prevalence of infections with the mutation Y976F in 
pvmdr1 was also high (40%) and the mutation was found in all possible combinations with 
the different genotypes detected in pvdhfr. 
Our observations are consistent with the results from similar studies done in different 
countries in South East Asia, Central and South America and other parts of Oceania, where P. 
falciparum and P. vivax are sympatric and increasing levels of CQ resistance have led to a 
policy change to the alternative low cost option of SP. In these regions, in vivo resistance to 
SP in P. falciparum developed rapidly after its initial deployment as monotherapy (Baird, 
2004; Peters, 1998) and was paralleled by the development of in vivo resistance in P. vivax 
(Pukrittayakamee et al., 2000; Tjitra et al., 2002). Results which were further corroborated by 
Chapter 7   185
the more recent demonstration of a similar molecular mechanism of antifolate resistance in 
both species, one that is conferred by single point mutations in the target enzymes of 
antifolates (i.e., pvdhfr and pvdhps, respectively) and is driven by exertion of selective drug 
pressure and progresses rapidly (Imwong et al., 2003; Korsinczky et al., 2004; 
Leartsakulpanich et al., 2002; de Pécoulas et al., 1998a). Different epidemiological studies 
determining the molecular pvdhfr background in field isolates originating from various 
regions worldwide, such as Thailand (Brega et al., 2004; Imwong et al., 2001), Indonesia 
(Hastings et al., 2004; Hastings et al., 2005; Tjitra et al., 2002), Cambodia (Eldin de Pécoulas 
et al., 2004), Myanmar (Na et al., 2005), India (Kaur et al., 2006; Valecha et al., 2006), and 
Ethiopia (Schunk et al., 2006), have shown that previous SP use is correlated with the 
prevalence rates of resistant pvdhfr alleles. Moreover, the association between infecting 
pvdhfr alleles and treatment outcome with SP monotherapy could be demonstrated in 
Thailand (Imwong et al., 2001) and Indonesia (Hastings et al., 2004; Tjitra et al., 2002). 
A similar development of SP resistance in P. vivax seems to have taken place in PNG, though 
SP was introduced in combination with the 4-aminoquinolines AQ and CQ. The primary aim 
of combination therapy is the prevention of the development and spread of resistance and is 
dependent on the efficacy and pharmacokinetic properties of each partner drug (Kremsner & 
Krishna, 2002; White, 1999). 
Low sensitivity to SP in both species has been documented previously in PNG (Darlow et al., 
1982b), most probably been arisen because of former drug pressure exerted by mass treatment 
campaigns with pyrimethamine (in combination with CQ) in the late 1960s and 1970s 
(Spencer, 1994) and SP use in combination with quinine as second-line regimen against 
treatment failure and severe malaria. Therefore, the high frequency of pyrimethamine-specific 
molecular markers we measured in the P. vivax population is not surprising. Reports about 
moderate mutation rates of resistance markers in P. falciparum dhfr (i.e., S108N, C59R; 
Reeder et al., 1996), which had reached almost fixed levels in 2003 (Marfurt et al., 2006, in 
preparation, Chapter 4), provides further evidence for the hypothesis, that moderately resistant 
dhfr alleles had already occurred before the effective implementation of SP as part of the 
standard first-line treatment, and that the rapid emergence of high-level resistant alleles could 
not be curbed by its combination with AQ or CQ. The similar molecular mechanisms 
underlying antifolate resistance resulted in a similar course of the development of resistance 
in both Plasmodium species in PNG. Mainly because treatment in PNG is given based on 
presumptive clinical malaria diagnosis and therefore, both species are simultaneously under 
selection pressure of the same antimalarial drugs. 
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Though in vivo studies are still the gold standard for the determination of antimalarial drug 
efficacy, the assessment of molecular resistance markers has become an important 
complementary method for the monitoring of drug resistant P. falciparum malaria. However, 
since clinical treatment outcome is dependent on several environmental, host and parasite 
factors, the usefulness of marker sets can vary between areas and have to be established and 
evaluated for a given area (Alifrangis et al., 2003, Omar et al., 2001, Staedke et al., 2004). 
The supplementation of in vivo efficacy data with molecular correlates could also be a 
valuable tool in monitoring P. vivax resistance, particularly because unambiguous 
determination of treatment failure rates is aggravated by difficulties in distinguishing relapses 
and new infections. Recent advances in the understanding of the mechanisms underlying SP 
resistance in P. vivax have paved the way for the molecular monitoring of resistance against 
antifolates in this species. However, molecular resistance markers for 4-aminoquinolines have 
not been reported for P. vivax up to present. Though orthologous genes for pfcrt and pfmdr1, 
two important genes involved in CQ resistant falciparum malaria (reviewed in Bray et al., 
2005; Duraisingh & Cowman, 2005), have been discovered and non-synonymous point 
mutations have been described, an association between resistance and these SNPs or other 
genetic alterations, such as gene amplification or varying expression levels, could not be 
established until now (Brega et al., 2005; Nomura et al., 2001; Sà et al., 2005). Moreover, the 
elucidation of an association between molecular correlates and treatment outcome with 
combination regimens containing two drug classes being effective against different parasite 
targets may be more complex. 
In order to suggest useful markers for the molecular monitoring of P. vivax resistance to AQ 
or CQ plus SP, we did a baseline assessment of the molecular profile in P. vivax dfhr and 
mdr1 and investigated the association between infecting pvdhfr/pvmdr1 genotypes and in vivo 
treatment response. Regarding pvdhfr, single point mutations 57L or 57I, 58R, 61M, and 
117T, as well as the total number of mutations were all independently associated with an 
increased risk of treatment failure. These results are in concordance with previous results 
showing that 1) parasite reduction ratio 48 hours after initiation of treatment with SP was 
smaller in patients harbouring triple dhfr mutants than those harbouring double mutants 
(Imwong et al., 2001), and 2) people infected with quadruple dhfr mutants were at higher risk 
to fail treatment with SP (Hastings et al., 2004; Tjitra et al., 2002). Regarding the 
combinations of mutations in pvdhfr, the observations that 1) mutation 117N was never 
observed in dhfr triple or quadruple mutants, 2) triple and quadruple mutants had always the 
mutation 117T, 3) 57L/I was always linked to 58R, and 4) 61M was only seen in quadruple 
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mutants, were all in agreement with previous data. The most prevalent dhfr genotypes 
described in previous studies included single 117, double 58+117, triple 117+58+57, and 
quadruple 117+61+58+57 mutants and because of this frequently observed allele structure, 
the stepwise accumulation of mutations in pvdhfr was suggested to be similar to that in P. 
falciparum, where low level pyrimethamine resistance is conferred by the single pfdhfr 
mutation 108N (corresponding to pvdhfr 117N) and drug selection processes leading to the 
addition of 59R and/or 51I (corresponding to pvdhfr 58R and 57L/I) increase resistance to SP 
(Imwong et al., 2001; Sibley et al., 2001; Tjitra et al., 2002). Our data from PNG showing a 
high frequency of infections having the double mutant 57L+58R seem to be inconsistent with 
this hypothesis. Nevertheless, the same double mutant has been previously described in Thai 
and Indian field isolates (Imwong et al., 2001; Kaur et al., 2006) and Hastings et al. (2005) 
have reported prevalence rates of 5.3% in the Wosera area in 1999 and 8% in the North Coast 
area in 2000, respectively. Moreover, by using a yeast expression system for the investigation 
of in vitro drug sensitivity of different allelic pvdhfr variants, the same authors showed that 
the double mutant 57L+58R was less sensitive to pyrimethamine by a factor of seven when 
compared to the population expressing the wild-type allele. 
Regarding pvmdr1, we could confirm previous results that demonstrated the presence of the 
polymorphic mdr1 locus Y976F in field isolates (Brega et al., 2005). Furthermore, we found 
the mutation to be a strong independent predictor of treatment failure with AQ or CQ plus SP. 
To our knowledge, these are the first data that indicate pvmdr1 to play an important role in 
mediating drug resistance in P. vivax. This is in contrast with recent studies, where an 
association of pvmdr1 polymorphisms and P. vivax resistance to CQ and mefloquine could 
not be shown (Sà et al., 2005; Picot et al., 2005), the most likely reason being that these 
studies used very small sample sizes and were not specifically designed to demonstrate an 
association between pvmdr1 polymorphisms and in vivo treatment response. However, the 
role of pvmdr1 in conferring resistance to different drugs still remains to be clarified. On one 
hand, the situation may be equally complex as in falciparum malaria, where different SNPs 
and/or gene amplification were shown to be associated with resistance to 4-aminoquinolines, 
amino-alcohols and artemisinin derivates, respectively (Duraisingh & Cowman, 2005; 
Duraisingh & Refour, 2005). On the other hand, in consideration of the differences in biology, 
pathophysiology and evolutionary history between these two Plasmodium species, the 
principal function of pvmdr1 and its contribution to a drug resistant phenotype may be 
completely different. 
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The good predictive value of the single markers analysed in both genes were further 
confirmed by the investigation of the relationship of the combined pvdhfr/pvmdr1 genotype 
and treatment response, where the highest risk of failure was found to be significantly 
associated with an infecting genotype having a quadruple mutation in pvdhfr plus 976F 
mutation in pvmdr1. The observation of treatment failures with infections harbouring wild-
type alleles may well be a consequence of technical constraints due to the limitations of the 
present technology to differentiate true recrudescences from relapses and/or new infections, 
which may have lead to an overestimation of true failure rates. 
Though more elaborate, the application of sequencing methods would have been more 
informative, since the high plasticity of the P. vivax genome is known (Feng et al., 2003; 
Imwong et al., 2006) and a high diversity in pvdhfr alleles has already been reported from 
different geographic areas (Hastings et al., 2004; Imwong et al., 2003; Kaur et al., 2006; 
Tjitra et al., 2002). 
In spite of these limitations and the fact that a drug resistant P. vivax phenotype is most likely 
mediated by multigenic processes, we think that the set of SNPs included in our study is 
sufficient to monitor parasite resistance under the current first-line regimen. The difference in 
treatment failure rates between sites was not only reflected in different prevalence rates of key 
markers which have shown an association with treatment response, but was also reflected in 
different frequencies of highly mutated and/or wild-type pvdhfr/pvmdr1 genotypes circulating 
at the respective sites. These findings strongly support the usefulness of molecular markers to 
monitor the dynamics of P. vivax resistance and thus their important role in complementing in 
vivo efficacy data to decide on the most appropriate and feasible drug policy against vivax 
malaria. For the time being, we propose to use polymorphisms in pvdhfr F57L/I, T61M, and 
S117T/N plus pvmdr1 Y976F for the molecular assessment of P. vivax resistance against AQ 
or CQ plus SP in PNG. However, including other SP relevant markers (e.g. polymorphisms in 
pvdhps), and as yet unidentified markers involved in resistance to other antimalarials, may 
become necessary for the longitudinal monitoring of resistance in the future, in particular 
when a policy change will recommend new classes of drugs. 
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TABLE 1: Sequences of primers and oligonucleotide probes used for the detection of pvdhfr 
(F57L/I, S58R, T61M, S117T/N, and I173F/L) and pvmdr1 (Y976F and F1076L) mutations 
 
Gene Oligonucleotides Sequence (5' - 3') Position 
pvdhfr a
 Accession number: X98123 (PCR product: 422 bp) 
 
pvdhfr S 5’-TCTGGGCAATAAGGGGACT-3’ 114 - 132 
 
pvdhfr A 5’-AGTTTCTACTTAGGCATTCCCTAT-3’ 559 - 536 
 
Sensor 57/8  5’-GTAGGTCGTCACCGAGCTGAAGT FL-3’ 189 - 167 
 
Anchor 57/8  5’-CTTCATATCGACGGAGTTGCATTTCCATG PH-3’ 165 - 137 
 
Sensor [G] 5’-GATGCTCTCCCAGCTGCTTC FL-3’ 363 - 344 
 
Anchor 117 5’-CCCCATGACCACGACGTTTTGCAG PH-3’ 342 - 319 
 
Sensor 172V 5’-TGTGCTCCCCCAATGACGA FL-3’ 530 - 512 
 
Anchor 172/173 5’-GCATTTGTAGTACTTCAGCTTCTTTAAGAGC PH-3’ 510 – 480 
pvmdr1 a
 Accession number: AY618622 (PCR product: 763 bp) 
 
pvmdr1 5’-ATAGTCATGCCCCAGGATTG-3’ 2753-2772 
 
pvmdr1 447AS 5’-ACCGTTTGGTCTGGACAAGTAT-3’ 3535-3516 
 
Sensor Phe 5’-CATAAAAATGAAGAACGTTCCGGTC FL-3’ 2940-2916 
 
Anchor 976 5’-GTACAGCCGCCACGATAGGGCAGAA PH-3’ 2914-2890 
 
Sensor Leu 5’-AGTGCCCAACTTTTCATTAACAG FL -3’ 3217-3239 
 
Anchor 1076 5’-TTGCCTACTGGTTTGGTTCCTTCCT PH-3’ 3242-3266 
 
Pvdhfr, P. vivax dihydrofolate reductase; pvmdr1, P. vivax multidrug resistance gene 1; a 
GenBank™ database (http://www.ncbi.nlm.nih.gov) accession number; PCR, polymerase 
chain reaction; bp, base pairs 
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TABLE 2: Baseline characteristics of patients at enrolment and treatment outcomes for amodiaquine or chloroquine plus sulphadoxine-
pyrimethamine against P. vivax malaria 
 
Study site North Coast area (Madang Province) 
Karimui area 
(Simbu Province) 
South Wosera area 
(East Sepik Province) Total 
Characteristics n=34 n=43 n=27 n=104 
Weight (mean (95% CI), kg) 15.9 (8.0-23.8) 13.7 (12.2-15.2) 12.0 (10.6-13.5) 14.1 (11.2-16.9) 
Age (mean (95% CI), yrs) 2.3 (1.9-2.7) 3.5 (3.0-4.0) 3.2 (2.5-3.9) 3.0 (2.7-3.4) 
Sex: females/n (%) 20 (58.8) 17 (39.5) 9 (36.0) 47 (45.2) 
Temperature (mean (95% CI),°C) 37.1 (36.6-37.6) 38.6 (38.3-38.8) 37.0 (36.4-37.6) 37.7 (37.4-38.0) 
Haemoglobin (mean (95% CI), g/dl) 10.2 (9.4-11.0) 10.6 (10.0-11.2) 9.2 (8.6-9.8) 10.1 (9.7-10.5) 
Parasite density (geometric mean (range), per µl) 4677 (300-41280) 3437 (40-36600) 4964 (160-50640) 4182 (40-50640) 
Class no (%) 
Adequate clinical and parasitological response (ACPR) 24 (70.6) 40 (93.0) 27 (100) 91 (87.5) 
Treatment failure (TF) 10 (29.4) 3 (7.0) 0 (0) 13 (12.5) 
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FIGURE 1: Prevalence of mutations in pvdhfr (P. vivax dihydrofolate reductase) and pvmdr1 
(P. vivax multidrug resistance gene 1) assessed in pre-treatment samples from patients with a 
P. vivax monoinfection in Papua New Guinea. Each patient sample was determined as either 
pure mutant allele, or pure wild-type allele, or mixed allele infection, respectively. 
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TABLE 3: Pvdhfr haplotypes in pre-treatment samples from patients in Papua New Guinea 
who received amodiaquine or chloroquine plus sulphadoxine-pyrimethamine against P. vivax 
infection 
 
 
Pvdhfr, P. vivax dihydrofolate reductase; bold, mutated alleles 
 
 
 
Pvdhfr polymorphism No of samples 
57 58 61 117  
Samples with single pvdhfr haplotype 78 
F S T S 28 
F S T N 3 
F R T S 1 
F R T T 2 
F R T N 3 
L R T S 25 
L R T T 1 
L R M T 14 
I R M T 1 
Samples with mixed pvdhfr haplotypes 22 
F S/R T S 1 
F S T S/T 1 
L R T S/T 4 
L R T S/N 5 
L R T/M S/T 2 
L R T/M T 1 
F/L S/R T S 4 
F/L S/R T S/N 1 
F/L S/R T/M S/N 1 
F/L S/R T/M S/T 2 
Total number of samples 100 
Chapter 7   
 
199
TABLE 4: Association between single mutated gene loci in pvdhfr and pvmdr1 and treatment 
response to amodiaquine or chloroquine plus sulphadoxine-pyrimethamine 
 
Polymorphic SNP a sites in 
 Treatment outcome    
pvdhfr and pvmdr1 P(%)b ACPRc TFd ORe CIf pg 
pvdhfr Mut57h 61 49 12 9.31 1.16-74.75 0.01 
pvdhfr 57L 60 49 11 4.27 0.89-20.40 0.05 
pvdhfr 57I 1 0 1 *  0.01 
pvdhfr 58R 68 56 12 6.64 0.82-53.52 0.04 
pvdhfr 61M 21 15 6 4.11 1.21-13.99 0.02 
pvdhfr Mut117i 41 33 8 2.62 0.79-8.68 0.11 
pvdhfr 117T 28 20 8 5.36 1.58-18.23 0.01 
pvdhfr 117N 13 13 0 §  0.14 
pvmdr1 976Fk 39 30 9 4.28 1.22-15.04 0.02 
pvmdr1 976Yl 72 67 5 0.18 0.04-0.74 <0.01 
 
a
 SNP, single nucleotide polymorphism; pvdhfr, P. vivax dihydrofolate reductase; pvmdr1, P. 
vivax multidrug resistance gene 1; b P, prevalence; c ACPR, adequate clinical and 
parasitological response; d TF, treatment failure; e OR, odds ratio; f CI, 95% confidence 
interval; g calculated by standard χ2 analysis or Fisher’s exact test; h Mut57, either 57L or 57I; 
i
 Mut117, either 117T or 177N; k 976F represents mutated allele; l 976Y represents wild-type 
allele; * 57I polymorphism was found in only one patient who failed treatment; § 117N was 
not found in patients who failed treatment 
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TABLE 5: Association between infecting pvdhfr/pvmdr1 genotypes and treatment response to amodiaquine or chloroquine plus sulphadoxine-
pyrimethamine 
 
pvdhfr/pvmdr1 genotypesa 
 Treatment respose  
No of pvdhfr mutations pvmdr1 polymorphism No (x) ACPRb TFc ORd CIe p (LRTf) 
Wild-type 976Yg 19 18 1 0.32 0.04-2.62 0.22 
Wild-type 976Fh 9 9 0    
Single 117 976Y 3 3 0    
Single 117 976F 1 1 0    
Single 58 976Y 1 1 0    
Single 58 976F 1 1 0    
Double 57-58 976Y 18 17 1 0.34 0.04-2.82 0.26 
Double 57-58 976F 11 8 3 2.96 0.67-13.03 0.18 
Double 58-117 976Y 4 4 0    
Double 58-117 976F 1 1 0    
Triple 57-58-117 976Y 5 4 1 1.73 0.18-16.79 0.65 
Triple 57-58-117 976F 6 5 1 1.37 0.15-12.72 0.79 
Quadruple 57-58-61-117 976Y 11 10 1 0.64 0.08-5.47 0.67 
Quadruple 57-58-61-117 976F 10 5 5 10.25 2.44-43.11 <0.01 
Total (n) 100 87 13  
 
Pvdhfr, P. vivax dihydrofolate reductase; pvmdr1, P. vivax multidrug resistance gene 1; a the genotype is assigned according to the mutated alleles 
(i.e., mixed allele is coded as mutant); b ACPR, adequate clinical and parasitological response; c TF, treatment failure; d OR, odds ratio; e CI, 95% 
confidence interval; f LRT, likelihood ratio test; g wild-type allele; h mutated allele 
Chapter 7   
 
201
TABLE 6: Prevalence of polymorphisms in pvdhfr and pvmdr1 and corresponding treatment 
failure rates with amodiaquine or chloroquine plus sulphadoxine-pyrimethamine at three 
different sites in Papua New Guinea 
 
 Prevalence (%)  
Study site North Coast area Karimui area South Wosera area  
Mutated SNP a sites n=30 n=43 n=27 p (χ2(2)) 
pvdhfr Mut57 b 83.33 48.84 55.56 0.01 
pvdhfr 57L 83.33 46.51 55.56 0.01 
pvdhfr 57I 0.00 2.33 0.00 0.51 
pvdhfr 58R 90.00 55.81 62.96 0.01 
pvdhfr 61M 26.67 11.63 29.63 0.13 
pvdhfr Mut117 c 53.33 27.91 48.15 0.06 
pvdhfr 117T 40.00 18.60 29.63 0.13 
pvdhfr 117N 13.33 9.30 18.52 0.54 
pvmdr1 976F 70.00 25.58 25.93 <0.001 
Wild-type SNP sites     
pvdhfr 57F 30.00 55.81 51.85 0.08 
Pvdhfr 58S 23.33 51.16 44.44 0.05 
pvdhfr 61T 86.67 90.70 74.07 0.16 
pvdhfr 117S 73.33 83.72 62.96 0.14 
pvmdr1 976Y 46.67 81.40 85.19 0.001 
TF d rate (x/n (%)) 10 (33.3) 3 (7.0) 0 (0.0) <0.001 
 
a
 SNP, single nucleotide polymorphism; pvdhfr, P. vivax dihydrofolate reductase; pvmdr1, P. 
vivax multidrug resistance gene 1; b Mut57, either 57L or 57I; c Mut117, either 117T or 177N; 
d
 TF, treatment failure 
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Accurate diagnosis and effective treatment of malaria is still the mainstay in the control of the 
disease. However, the emergence and spread of parasite resistance to the commonly used 
drugs (i.e., 4-aminoquinolines and antifolates) has aggravated the burden of malaria during 
the last decades (Björkman & Bhattarai, 2005). The problem is complex, but several measures 
can be taken to restrain the scale and impact of parasite resistance: 
 
1) Adopt adequate methods to assess the level of parasite resistance 
2) Protect current drugs against resistance by using combination therapy 
3) Expand access to prompt and effective treatment for those in most need 
4) Promote evidence-based drug policies and sensible practices 
5) Encourage and sustain efforts for the development of new antimalarial compounds 
(Olliaro, 2005). 
 
The current studies gave clear consideration to point one: They investigated current and novel 
in vivo and molecular approaches in assessing parasite resistance of falciparum and vivax 
malaria in Papua New Guinea. 
This chapter will first give a general overview of common issues encountered with 
antimalarial drug policy in the face of drug resistance. The following paragraphs will then 
summarise again the main findings of the current studies, which are discussed in detail in the 
corresponding chapters 2 to 7, highlight their main implications for Papua New Guinea 
(PNG), and also discuss their relevance in the broader context of drug resistant malaria 
surveillance. The chapter will place emphasis on the main issues associated with in vivo and 
molecular assessment of parasite resistance, with a special focus on the feasibility and 
applicability of molecular monitoring approaches and their potential role in helping to 
monitor resistance and make decisions on rational treatment strategies against malaria. 
 
 
1. Evidence-based antimalarial drug policy 
Effective antimalarial drug policy should be characterised by clear formulation of objectives 
and targets, effective implementation and regular up-dates, and requires several components 
to be in place. These include: 
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• Regulations to support and enable the policy 
• Adequate drug supply 
• Guidelines on the use of antimalarial drugs 
• Training on diagnosis and treatment of malaria 
• Standardised mechanisms to regularly reassess the safety, efficacy and effectiveness 
of the implemented policy (Bloland & Ettling, 1999). 
 
Drug efficacy is commonly regarded as the most important determinant for effectiveness. 
However, if operational factors are not adequate, even a very efficacious drug regimen will 
not lead to good effectiveness on national level. Therefore, the evaluation of operational 
factors, as well as behavioural factors in the target population where policy has to be 
implemented, is important to be considered in the decision-making process. These include 
important aspects, such as 
• The quality of drugs 
• Adequate drug supply on central and peripheral levels 
• Appropriate health care provision by public and private sector 
• Access to health care facilities 
• Treatment-seeking behaviour in the communities 
• Acceptance of and compliance to treatment. 
 
Therefore, alongside the assessment of clinical efficacy in controlled studies, the 
measurement of process indicators of successful implementation of antimalarial drug policy 
are important additional data in order to estimate the likely effectiveness of the policy (Amin 
et al., 2004; Fevre & Barnish, 1999). 
Revision of antimalarial policy in previous years was mainly dependent on the country’s 
resources and its public-health infrastructure. Decisions to change treatment policy, especially 
in Sub-Saharan Africa, were mainly based on economical reasons (Amin et al., 2004; Fevre & 
Barnish, 1999; Schellenberg et al., 2006). The most important impediments to policy 
development include the lack of consensus on the methods to collect, analyse and present 
drug efficacy data, insufficient information on mechanisms of resistance and consequently, 
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the lack of consensus on tolerable levels of resistance. Hence, there is a strong need for 
evidence-based assessments in order to maximise the impact of the current policy and to 
decide on when and how a policy change should be initiated (Shretta et al., 2000). 
Finally, other measures and/or interventions of national malaria control programs which limit 
the development and spread of resistance include: 
• Treatment based on definitive malaria diagnosis 
• Measures to increase compliance (i.e., supervision of treatment, pre-packaged 
treatment doses) 
• Effective re-treatment of parasitological failures to prevent progress to clinical disease 
• Combination therapy with two different drug classes 
• Strategies to reduce transmission intensity by preventing human-to-vector contact (i.e., 
vector control measures, insecticide-treated bednet programs). 
 
Though the above mentioned malaria control activities may well benefit the effectiveness of 
treatment policy, special attention has to be given to more recently promoted drug-based 
intervention strategies, such as intermittent preventive treatment (IPT) for infants and/or 
pregnant women. Careful monitoring of drug-based interventions is critical in order to predict 
their potential impact on current and possible future antimalarial treatment strategies 
(Schellenberg et al., 2006). 
 
1.1 Indicators for policy change 
Only a few publications are available on the issue of antimalarial drug policy in the face of 
drug resistance and decision criteria on when and how drug policy should be changed are still 
controversial (Bloland & Ettling, 1999; Fevre & Barnish, 1999; Schapira et al., 1993; WHO, 
2005). It is apparent that there are several aspects to consider when making decisions on 
national drug policies. Among the many different factors, which include costs, availability 
and acceptability of drugs, prescribing practices of public- and private-sector facilities, patient 
and provider compliance with drug policies, and treatment-seeking behaviour of the 
communities, efficacy of both, current and proposed alternative treatment regimens, is of 
major importance (Bloland & Ettling, 1999). Since the principal objective of antimalarial 
treatment is the reduction of malaria morbidity, and especially mortality, it seems reasonable 
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to use morbidity and mortality rates as indicators to decide on whether a national treatment 
strategy is satisfactory. Unfortunately, a high proportion of the disease burden is not captured 
by data collected by routine surveillance at health facilities. Consequently, reliable data on 
drug efficacy are not available outside clinical and/or epidemiological studies (Winstanley et 
al., 2002). 
At the present time, in vivo drug efficacy studies are still the ‘gold standard’ method for the 
assessment of drug resistant malaria and in vivo drug efficacy is still accepted as one of the 
most important indicators for the initiation of a policy change. However, common indicators, 
which are applicable in different epidemiological settings and for various drugs, are difficult 
to define. Several criteria, based on outcome measures of in vivo drug efficacy studies have 
been suggested, such as the level of parasite resistance, i.e., RIII resistance between 5 and 
30% (Bloland et al., 1993; Sudre et al., 1992), or the level of in vivo failure rate >15-20%. 
Definitions based on in vivo failure rates were as yet primarily based on outcomes using the 
standardised Day 14 follow-up protocol (WHO, 1996). In order to provide evidence and 
guidance for required actions in the decision-making process, a systematic approach was 
suggested by Andrew Kitua (2000). The process was divided into four main periods which 
included: 
1) The grace period (clinical failure rate <5%), in which there is time for 
epidemiological, health systems, drug dynamics, and behavioural research, 
2) The alert period (clinical failure rate <15%), in which clear and systematic actions can 
be developed and planned,  
3) The action period, sub-divided into: 
i) Early action period (clinical failure rate 15-20%), and 
ii) Accelerated action period (clinical failure rate 21-24%), in which specific 
actions, such as the ascertainment of treatment failure rates and the 
evaluation of alternative treatment regimens (i.e., assessment of safety and 
efficacy profile and costs) are performed, and 
4) The change period (clinical failure rate ≥25%), where consensus based on relevant 
actions has been reached and respective policy change has to be implemented. 
 
However, this system was based on outcome measures with the WHO standard protocol from 
1996, which was drawn up primarily for high transmission areas. The protocol has been 
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challenged by several authors (Plowe et al., 2001; White, 2002) and has thereupon been 
recognized not to be sensible for low-to-moderate transmission areas (Ruebush et al., 2003; 
WHO, 2003). 
Recently published recommendations from WHO suggest that clinical, as well as 
parasitological resistance should be considered. The reason being that parasitological failure 
rates are likely to translate into clinical failure rates, either within a short-term in the infected 
individual depending on the immunological status, or within a long-term on population level 
as parasite resistance increases (Mutabingwa et al., 2001; Njama-Meya et al., 2004; WHO, 
2006). Moreover, asymptomatic parasitaemia after treatment is associated with an increased 
risk of anaemia, gametocyte carriage, and gametocyte-infectivity for mosquitoes (Hogh et al., 
1998; Price et al., 2001; Sowunmi et al., 2004). Therefore, the standard efficacy test protocol 
has been revised recently (WHO, 2001a; WHO, 2003) and can be applied for low-to-moderate 
and high transmission areas. Furthermore, the revised protocol uses a common classification 
scheme for all transmission areas and suggests duration of follow-up to be 28 days for drugs 
with elimination half-lives <7 days (AQ, CQ, QUIN, HAL, SP, and Malarone™), and 42 days 
for MEF and LUM (Stepniewska et al., 2004). The new WHO protocol takes into account 
both, clinical and parasitological results, and strongly suggests applying molecular techniques 
for the differentiation of recrudescences from new infections. However, different studies 
usually apply protocols that are based on different genotyping markers (i.e., polymorphic 
genes, such as msp1, msp2 and glurp, or microsatellite and/or SNP analysis). Since 
classification of genotyping results can have profound influence on the assessment of drug 
efficacy (Slater et al., 2005), there is a need for both, definitions for sensitivity of detection of 
molecular methods, as well as the classification and analysis of the resulting genotyping data. 
The current WHO guidelines recommend that a policy change should be considered when 
total failure rate is ≥25% and clinical failure rate is ≥15%. With combination regimens, a 
change is indicated at a level of a total failure rate at Day 28 of ≥10% (WHO 2005; WHO, 
2006). 
 
1.2 The role of molecular markers 
Systematic studies have shown that decreasing in vitro sensitivity in local field isolates can 
give an early indication for raising in vivo resistance (Brockman et al., 2000; Huong et al., 
2001). Similarly, where molecular correlates for resistance are known, the assessment of the 
prevalence of mutated alleles can serve as an early warning tool for the development of 
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resistance (Djimde et al., 2001a; Kublin et al., 2002). However, in vitro sensitivity tests and 
the assessment of molecular markers are still considered research tools. 
Molecular markers are recommended as complementary tool to the current ‘gold standard’ of 
in vivo drug efficacy tests. But because the number of laboratories with the required 
infrastructure and expertise is still small in developing countries, molecular monitoring is 
recommended to be restricted to reference centres at sentinel sites. Molecular methods have 
been successfully applied in various epidemiological settings, including countries with limited 
resources, and have produced a vast amount of valuable data. However, the assessment of 
molecular markers as a routine monitoring tool is still complicated due to several questions 
and issues which call for resolution and improvement: 
1) There is a lack of standardised guidelines for an appropriate design for molecular 
studies that can be used in different epidemiological settings and for different drug 
regimens. 
2) There is a need for molecular techniques that are easy to use, cheap, and allow high 
throughput of samples. In addition, standard operating procedures for blood sampling, 
DNA extraction, and further downstream molecular analyses are required. 
3) Molecular data do not relate directly to clinical treatment outcome. Apart from many 
host and environmental factors which determine in vivo treatment response, to what 
extent does parasite resistance play a role? 
4) Once the relationship of molecular correlates and in vivo treatment response is 
established for several drugs and combinations, how are these results translated into 
standardised parameters and/or indices for parasite resistance? 
5) Once these parameters and/or indices for parasite resistance are found, how relevant 
will they become for the decision-making process on antimalarial drug policies? 
 
2. In vivo assessment of antimalarial drug efficacy 
As in many malaria endemic areas in Africa, Asia, and South America, the development and 
spread of resistance to the commonly used antimalarial drugs represents a challenge for the 
control of the disease in Papua New Guinea (PNG). In response to the occurrence of 
widespread resistance to 4-aminoquinoline drugs, PNG decided to replace 4-aminoquinoline 
monotherapy with AQ or CQ plus SP in 1997. This decision against an artemisinin-based 
combination therapy (ACT) was not only taken because of economical reasons. The second 
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dominant Plasmodium species in PNG is P. vivax and malaria diagnosis at health facilities is 
usually based on clinical criteria. Therefore, effectiveness against both species was an 
important argument in favour of this combination because a) it was thought that SP, when 
used as monotherapy, would have reduced efficacy against P. vivax malaria, and b) 4-
aminoquinolines were still efficacious against non-falciparum malaria. When first efficacy 
trials with the new combination regimen conducted between 1998 and 1999 had shown good 
efficacy (treatment failure rates below 5%) against P. falciparum malaria (Jayatilaka et al., 
2003), the PNG Department of Health has replaced the standard first-line therapy with AQ or 
CQ against uncomplicated malaria with the combination of AQ or CQ plus SP in the year 
2000. 
In our in vivo efficacy studies conducted between 2003 and 2005 at three different sites in 
PNG we measured PCR-corrected treatment failure rates for P. falciparum malaria up to Day 
28 between 12% and 28%, depending on the region and the year of assessment. Overall 
treatment failure rate in P. vivax malaria was 12%. Unfortunately, comparison with previous 
data was hampered since former studies were using follow-up periods of 14 days and 
genotyping methods for the distinction between recrudescences and new infections were not 
applied. By restricting the analysis in our studies to the Day 14 outcomes based on clinical 
and parasitological criteria alone, we measured treatment failure rates between 2% and 18%. 
These data implied that there was a two to threefold decrease in efficacy of AQ or CQ plus SP 
only three years after effective implementation of the new first-line regimen in PNG. Though 
clinical failure rates were still low (<10% at all three sites), overall treatment failure rates 
exceeded 12% in all three sites. 
Our data clearly highlight recently raised controversial issues associated with the assessment 
of antimalarial drug efficacy (White, 2002) which are discussed in the following paragraphs. 
In concordance with previous data, our results demonstrate that in vivo studies with a follow-
up period of 14 days are not sensitive enough to assess the therapeutic efficacy of the current 
first-line regimen in the country (Mugittu et al., 2005; Stepniewska et al., 2004). Assessment 
up to Day 14 clearly underestimated the true failure rate. In our studies, in both, low-to-
moderate and high transmission areas, the majority of patients had recurrent parasitaemia after 
Day 14. Furthermore, late recurrences (i.e., appearing after Day 14) had to be expected for the 
current regimen including drugs with long elimination half-lives, such as SP (White, 2002). 
Our in vivo efficacy data, which were further corroborated by molecular data showing a 
highly CQ resistant and moderately SP resistant genetic profile in the parasite populations 
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(Chapters 4 to 7), indicate a relatively rapid loss of efficacy of the current first-line regimen in 
PNG and strongly argue for careful in vivo monitoring of drug efficacy in the country. The 
application of the newly revised WHO standard protocol (WHO, 2003) using a Day 28 
follow-up is essential to prevent potential underestimation of failure rates. Furthermore, the 
use of molecular genotyping methods for the determination whether treatment failure samples 
harbour recurrent or new infections, is inevitable to prevent potential overestimation of failure 
rates. 
Though the indication for genotyping methods is not open to debate, subsequent interpretation 
of results and data analysis can have significant effect on the outcome of a study. According 
to the newly revised WHO protocol (2003), cases of new infections with P. falciparum, as 
well as infections with P. vivax during the follow-up period, should be excluded from the 
study. The main reason being that rescue treatment given for a new infection could potentially 
mask a true recrudescence which was, in contrast to the new infection, not yet detectable by 
microscopy and PCR. The main problem with this recommendation is that the indication for 
rescue treatment is different for low-to-moderate and high transmission areas (i.e., rescue 
treatment is given to both, clinical and parasitologial failures in the former areas, but to 
parasitological failures not until the end of follow-up in the latter areas, respectively). This 
may be the reason why analysis of data is not done consistently in different studies. In 
addition, a recent report from Uganda, that investigated the effect of different classification 
schemes for genotyping data on the estimates of treatment failure rates, clearly shows the 
need for a standardised protocol (Slater et al., 2005). In our studies, we presented both, data 
unadjusted for genotyping, as well as PCR-corrected treatment failure rates. Adjustment for 
genotyping was done by classifying mixed genotypes (i.e., recrudescence plus new infection 
present) as treatment failures. Furthermore, cases whose recurrent parasites were identified as 
originating from a new infection, regardless whether mixed or pure, were not excluded from 
analysis. The main reason being that we used the current WHO recommendations for rescue 
treatment for high transmission areas at all three sites (i.e., patients were closely monitored up 
to Day 28 and rescue treatment was given at the end of the follow-up period). A similar 
approach (i.e., Kaplan-Meier analysis in conjunction with classifying new infections as 
adequate treatment responses) was also favoured recently by Guthmann and colleagues 
(2006), a decision which was based on the principle that as little information as possible 
should be discarded. 
In order to adapt a standardised protocol for all three study sites, which represent different 
settings with regard to transmission intensity, that is still compatible with local conventions 
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and health care practices and logistically feasible, a minor modification to the WHO standard 
protocol was made. In order to reach the required sample size (i.e., 120 subjects per study) 
within a reasonable time frame, we included children between 6 months and 7 years of age. 
Though older children are more likely to have partial immunity, we could not find an 
association between either age and treatment outcome, nor the treatment regimen (i.e., SP 
plus AQ or CQ), which partially depends on age (i.e., AQ is given to children <14 kg under 
current first-line policy in PNG), and treatment outcome (Chapter 4). Though the issue has 
been addressed by age-stratified analysis of data, which did not show a difference in treatment 
failure rate between the two treatment categories (i.e., SP plus AQ or CQ), one might still 
speculate that CQ is less efficacious than AQ, since the proportion of children which were 
able to clear CQ resistant parasites might have been larger in the CQ plus SP-group (i.e., on 
average older children). However, it was the principle aim of our in vivo studies to determine 
treatment failure rates under the current first-line policy in PNG, and not to compare clinical 
efficacy of AQ plus SP versus CQ plus SP. 
In view of the present situation in PNG, close monitoring is required of both, the current first-
line (AQ or CQ plus SP), as well as the second-line (Artesunate for 7 days plus SP on Day 3) 
regimen. Furthermore, careful evaluation of potential candidate regimens for replacement is 
urgently needed, so that appropriate measures with regard to future policy change can be 
taken in due time. Combination regimens currently recommended by WHO include: 
• Amodiaquine plus sulphadoxine-pyrimethamine, 
• Artesunate plus sulphadoxine-pyrimethamine, 
• Artesunate plus amodiaquine, 
• Artemeter-lumefantrine (Coartem®), or 
• Artesunate plus mefloquine (WHO, 2001b; WHO, 2006). 
 
There is strong advocacy for artemisinin-based combination therapy (ACT) because 
artemisinins have the added advantage of diminishing gametocyte carriage and lowering 
infectivity to mosquitoes, at least in low endemic countries (Hallett et al., 2004; Price et al., 
1996). 
Considering the facts, that 1) evidence for the success of the combination regimen of AQ or 
CQ plus SP was scarce at that time (McIntosh & Greenwood, 1998), and 2) the success of a 
combination regimen is dependent on the efficacy of each partner drug (Kremsner & Krishna, 
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2002), and 3) high levels of 4-aminoquinoline resistance and reduced sensitivity to antifolates 
were reported in PNG (Chapter 2), limited efficacy of AQ or CQ plus SP had to be expected. 
However, non-artemisinin-based combination therapy (NACT) with AQ plus SP has recently 
been shown to be equally or more efficacious than ACT with SP in northern Ghana 
(Mockenhaupt et al., 2005a) and Uganda (Sendagire et al., 2005; Yeka et al., 2005), the main 
reason being that resistance levels to SP and AQ were still low in these regions. Therefore, in 
certain regions where previous AQ and SP use was low, NACTs can still be considered as 
cost-effective interim options before full implementation of ACTs (Obonyo et al., 2006), 
though the cost-effectiveness of such an interim option versus direct implementation of ACT 
has to be carefully evaluated (Laxminarayan, 2004). In contrast, previous drug history in PNG 
was clearly different (i.e., constant AQ pressure for more than 20 years and sporadic use of 
SP) and the prospect for the combination of AQ plus SP to work was therefore low. 
ACTs have various advantages and disadvantages with respect to safety, tolerability, and 
efficacy, as well as risk of development of resistance, practicability and costs. The decision as 
to which treatment regimen to choose in PNG is therefore likely to be complex. Sound, 
locally acquired data will be necessary for this decision to be made in a sensible manner. But 
given the current in vivo and molecular resistance data in this report, this process becomes of 
utmost importance. 
Many of possible replacement regimens may be difficult to implement in PNG due to cost 
(e.g. mefloquine), pre-existing resistance (AQ, CQ, and SP), or practicability (e.g., 
Coartem®). 
Combination therapy with artesunate plus mefloquine has been successful against multi-drug 
resistant malaria in Thailand since 1995 (Wongsrichanalai et al., 2001) and mefloquine alone 
has recently been shown to be effective against treatment failure malaria in PNG (Genton et 
al., 2006), as well as against CQ resistant P. vivax malaria in Indonesian Papua (Maguire et 
al., 2006). However, a mefloquine-based ACT option would have to be carefully evaluated 
with regard to the current health infrastructures in PNG, as well as large differences in malaria 
epidemiology within the country (Müller et al., 2003; Wongsrichanalai et al., 2000). 
Other potential candidates include the combination of artesunate with the antifolate 
chlorproguanil plus dapsone (Lap-Dap™-plus) or dihydroartemisinin-piperaquine (Artekin®). 
Though the latter combination has been shown to be well tolerated and efficacious in phase 
III trials (Tran et al., 2004; Smithuis et al., 2006), there are still gaps in the knowledge with 
regard to their suitability in PNG, in particular since data about cross-resistance between 
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piperaquine and AQ/CQ are not yet available. The triple combination Lap-Dap™-plus is still 
under development, but similar concerns arise with regard cross-resistance between SP and 
the biguanide-dapsone combination Lap-Dap™. 
Final decisions on the exact choice of alternative drug regimens to be evaluated will most 
probably be based on availability and affordability and have to be made in consultation with 
PNG health policy makers. But as a matter of fact, in view of high-level resistance to AQ and 
CQ and rapidly progressing SP resistance, these drug classes should definitely not be 
considered as partner drugs in potential combination regimens in PNG. An artemisinin-based 
combination regimen should certainly be favoured and regarding the current status of 
antimalarial resistance in PNG, mefloquine seems to be one of the most promising partner 
drugs. 
 
3. Molecular monitoring of parasite resistance 
As all life functions of the malaria parasite, drug resistance is genetically determined and 
advanced understanding of the molecular basis of drug resistance have provided novel tools to 
study this phenomenon (Greenwood, 2002). The identification of several genes encoding drug 
targets of the most commonly deployed antimalarials (i.e., aminoquinolines, antifolates, and 
artemisinin derivates) and elucidation of genetic modifications conferring parasite resistance 
(i.e., primarily SNPs and in some instances, gene amplification) have led to the identification 
of several molecular markers for parasite resistance (described in detail in Chapters 4, 6 and 
7) and molecular monitoring of parasite drug resistance has become a complementary tool for 
long-term surveillance and for developing predictive models on malaria drug resistance 
(Plowe, 2003). 
 
3.1 Assessment of molecular markers: technical aspects 
A prerequisite for the use of molecular markers in an epidemiological context, such as the 
surveillance of parasite resistance to antimalarial drugs, is the availability of rapid and reliable 
techniques for their identification. There is a need for methods that facilitate parallel analysis 
of multiple SNPs and are affordable and enable analysis of large sample sets. To date, a 
number of techniques have been developed and applied in different settings, including 
laboratories in resource-restricted countries. The majority is based on PCR-RFLP or 
sequencing analysis, and more recently developed techniques include real-time PCR and 
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MALDI-TOF analysis. However, since most of these techniques are limited by low sensitivity 
and/or specificity, high costs, and are not suitable to be applied on an epidemiological scale, 
we have developed a parallel SNP analysis system, which is based on PCR, primer extension 
and DNA microarray technology, and allows the determination of all known SNPs in drug 
resistance associated P. falciparum genes. In relation to previously used techniques, costs are 
significantly lower and large numbers of samples can be analysed in a reasonably short time 
(Chapter 3). Advantages and disadvantages of currently used methods and the new DNA 
microarray-based technique are summarized again in table 1 and ranked with regard to 
sensitivity, specificity, ability to detect multiple clone infections (MOI), throughput, handling, 
and costs. 
 
Table 1: Comparison of different methods for SNP analysis 
 
Technique Sensitivity Specificity MOI Throughput Handling Costs 
PCR-RFLP +++ + + + intensive ++ 
Sequencing ++ +++ +/- ++ moderate ++ 
MALDI-TOF + +++ +/- +++ moderate +++ 
DNA microarray +++ ++/+++ ++ ++/+++ simple + 
 
 
The main advantage of the DNA microarray-based method is the possibility to analyse all 
known drug resistance associated SNPs at once. Hence, it might become possible to better 
elucidate the genetic background of drug failure, since phenotypic parasite resistance is likely 
to be mediated by multiple genes and as a consequence, conferred by SNPs from different 
loci. This underscores the need for linking individual SNPs into haplotypes. However, current 
algorithms and techniques are yet unable to generate true haplotypes of unlinked loci in 
samples containing multiple infections. The added advantage of the new DNA microarray-
based method to semi-quantify signal strength potentially allows the determination of the 
most dominant haplotype. 
By the successful application of our microarray system for molecular drug resistance 
monitoring in several sites over three years in Papua New Guinea, we could demonstrate that 
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standardised and comparable data could be produced at an affordable price. The flexibility of 
the system facilitates prompt inclusion of newly identified point mutations associated with 
parasite resistance in the future. Hence, the method offers unmatched capacity to provide 
evidence-based data on the dynamics of parasite resistance against antimalarial drugs in a 
cost-effective way. 
This platform can also be widely applied and adapted with ease to other genotyping tasks 
requiring parallel SNP analyses. These include for instance molecular markers for other 
important host-determinants for antimalarial treatment response, such as pharmaco- or 
immunogenetic markers (Meyer, 2004; Plebanski et al., 2002), as well as genetic 
determinants of susceptibility to disease (Williams, 2006). 
 
3.2 The role of molecular markers in predicting treatment response 
Though the relevance of genetic determinants of drug resistance to several drugs has been 
confirmed in vitro, a straightforward association of molecular markers with in vivo treatment 
response has rarely been found (Bloland, 2001). Epidemiological studies dealing with that 
subject were predominantly clinical drug efficacy trials and frequently applied the two 
following designs: 
i) Determination of drug resistance-associated SNPs in parasites circulating in pre-
treatment samples and the analysis of their relationship with treatment response, 
and/or 
ii) Comparison of parasite genotypes in samples before and after treatment in order to 
trace the genetic changes in the parasite gene(s) upon selective pressure exerted by 
the respective drug under investigation. 
 
These studies almost exclusively focused on the investigation of single drug classes as well as 
the analysis of single genes or markers. Hence, data on the association of multiple markers for 
different drug classes and studies evaluating their association with in vivo response to 
combination therapy are still scarce. Nevertheless, more recent molecular methods, such as 
our novel DNA microarray-based technique, greatly facilitate the parallel assessment of 
parasite resistance markers of several drug classes at once. The application of this method 
allows a more comprehensive assessment of the genetic resistance background of the parasite 
and hence, a more accurate elucidation of the specific role of different molecular markers 
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(i.e., direct mediation of resistance, modification of resistance, compensation for functional 
constraints or fitness costs) (Bray et al., 2005; Duraisingh & Cowman, 2005; Hayward et al., 
2005; Walliker et al., 2005). 
In our studies, we analysed the genetic profile of parasites collected from pre-treatment 
samples of 206 malaria patients attending two health facilities in PNG with known clinical 
and parasitological outcomes after treatment with AQ or CQ plus SP (Chapter 2). The 
analysis of twenty-four key markers in P. falciparum mdr1, pfcrt, pfdhfr and pfdhps, revealed 
a genetic background that was consistent with high-level resistance to CQ. In addition, 
mutation rates of molecular markers for pyrimethamine-resistance in pfdhfr were already high 
and sulphadoxine resistance-related SNPs in pfdhps started to emerge (Chapter 4). 
Our results showed that the strongest independent predictors for treatment failure with AQ or 
CQ plus SP were pfmdr1 N86Y and pfdhps A437G. Mutations found in CQ related markers 
(i.e., pfcrt K76T, A220S, N326D, and I356L) did not help to increase the predictive value, the 
most likely reason being that these mutations are almost fixed in the parasite population in 
PNG. Though mutations in SP related markers pfdhfr S108N and C59R were not associated 
with treatment failure, they increased the predictive value of pfdhps A437G. Consistent with 
the hypothesis that the genetic parasite resistance background in part determines in vivo 
treatment response, the most significant association with treatment failure with AQ or CQ 
plus SP was seen in patients who harboured the most highly mutated combined 
pfmdr1/pfcrt/pfdhfr/pfdhps genotype (Chapter 4). 
Our results are in agreement with previous data that have shown that the genetic drug 
resistance profile usually precedes the observation of in vivo resistance (i.e., mutation rates for 
resistance alleles are higher than corresponding treatment failure rates) (Djimde et al., 2001b; 
Kublin et al., 2002). Furthermore, mutations that have reached almost fixed levels in the 
parasite population have already been shown to be unsuitable as markers for resistance 
(Dorsey et al., 2001; Mayor et al., 2001; Rallon et al., 1999). 
A significant association between pfdhps A437G and treatment response with CQ plus SP 
was found in a recent study conducted in Laos (Berens et al., 2003). In contrast, the K540E 
mutation in pfdhps was shown to be a better indicator of treatment failure with the same 
combination regimen in Uganda (Dorsey et al., 2004). These contrasting reports clearly 
reflect that, apart from the genetic background of the parasite, there are several other factors 
which determine individual treatment outcome, the most important being the pharmacokinetic 
and pharmacodynamic properties of the drug(s) and the level of acquired immunity of the host 
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(White, 1998). Furthermore, former drug pressure as a major driving force for the 
development and spread of parasite resistance and hence, the determination of the genetic 
resistance profile of the parasite, is different between epidemiological settings. Therefore, the 
relevance of molecular markers in predicting treatment response varies between different 
regions accordingly. 
To summarize, extrapolation of results obtained in a given area to different epidemiological 
settings is risky, since both, important determinants of parasite resistance (e.g. drug pressure, 
population structure of parasites, transmission intensity, etc.) and host factors influencing 
treatment response (e.g. compliance to treatment, drug metabolism, transmission intensity as a 
major determinant for acquisition of immunity, etc.) are variable in different regions 
(Alifrangis et al., 2003; Djimde et al., 2003; Francis et al., 2006; Staedke et al., 2004). 
As in the case of P. falciparum, the molecular monitoring of drug resistant P. vivax malaria 
would be an equally valuable complementary tool to in vivo studies, the most important 
reason being that the assessment of drug efficacy against vivax malaria is complicated by 
difficulties in clearly differentiating between treatment failures (true recrudescences 
originating from asexual blood stage parasites), relapses (red blood cell infection originating 
from hypnozoites) and newly acquired infections. 
Orthologous genes of pfdhfr, pfdhps, pfcrt, and pfmdr1 have been found in P. vivax (i.e., 
pvdhfr, pvdhps, pvcg10 and pvmdr1, respectively). Though there is sound in vitro evidence 
for their role in conferring parasite resistance, their association with in vivo drug response has 
only been demonstrated for important SNPs in pvdhfr and pvdhps (Chapter 7). 
In the current study, we investigated the relationship between drug resistance markers in 
pvdhfr and pvmdr1 in pre-treatment samples from patients with a P. vivax monoinfection and 
therapeutic outcome with the newly introduced combination regimen in PNG. Thereby, we 
identified a novel molecular marker in pvmdr1 to be associated with in vivo response to AQ or 
CQ plus SP. We also measured high prevalence rates of mutated key markers in pvdhfr. As 
with falciparum malaria, an infection with the quadruple mutant pvdhfr 57L+58R+61M+117T 
plus pvmdr1 mutation 976F represented a significant risk of treatment failure with AQ or CQ 
plus SP. Our results demonstrating that the observed difference in failure rates between sites 
was reflected in the corresponding genetic drug resistance profile of the respective parasite 
populations, could further confirm the usefulness of our proposed marker set (i.e., pvdhfr 
F57L/I, T61M, and S117T/N plus pvmdr1 Y976F) as a supplementary monitoring tool for 
vivax malaria (Chapter 7). 
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Taken together, our results emphasis again that a careful baseline assessment of resistance 
markers including the investigation of their relationship with treatment response is important 
for the identification of appropriate marker sets in a given area. Moreover, though the internal 
validity of results from a given study may be good for the area where the assessments have 
been made, external validity may be heavily compromised because epidemiological 
characteristics (e.g. malaria endemicity, transmission intensity, drug use patterns, etc.) which 
are known to affect the development and spread of parasite resistance, can vary considerably 
between different geographic regions. Moreover, the interaction of these factors as well as 
their impact on the development and spread of resistance are still controversial issues (Ariey 
& Robert, 2003; Hastings, 2003; Hastings & D’Alessandro, 2000; Mackinnon & Hastings, 
1998; Talisuna et al., 2002a; Talisuna et al., 2003a). However, though once identified 
molecular markers are not absolutely reliable indicators for individual patient outcome, they 
may represent a useful public health tool for longitudinal monitoring of antimalarial resistance 
on population level (Sibley & Hunt, 2003). 
 
3.3 The role of molecular markers in monitoring parasite resistance 
Though molecular markers have been advocated as a rapid means for the surveillance of 
resistance in order to provide timely and evidence-based information for policy formulation, 
they are still rarely used for this purpose (Plowe, 2003, Plowe, 2005). This is most likely due 
to the lack of simple models that produce appropriate indicators to be applied in different 
epidemiological settings for various drugs and combinations. 
One possible model for CQ resistance, based on a genetic resistance index (GRI, ratio 
between prevalence of resistance genotype and prevalence of in vivo resistance) and a genetic 
failure index (GFI, ratio between prevalence of resistance genotype and incidence of in vivo 
treatment failure) has been proposed by Djimde et al. (2001a). Thereafter, similar models 
based on key molecular markers for SP resistance have been validated (Kublin et al., 2002; 
Kyabayinze et al., 2003). These models suggest that if GRIs and GFIs are stable over time 
(i.e., corresponding changes in parasite resistance and in vivo response), once established 
indices could be used for surveillance of resistance and molecular surveys could then provide 
a new epidemiological tool to extend the coverage of drug resistance monitoring beyond 
selected sentinel sites (i.e., include remote areas) (Plowe, 2003). 
Though the analysis of point mutations on population level and the establishment of 
correlations between the molecular drug resistance profile in parasites and in vivo outcome 
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could give a more comprehensive appraisal of the status and longitudinal dynamics of 
resistance, only a few studies have investigated the correlation between population-based 
molecular data and the level of clinical failure in health facilities of the same region. (Djimdé 
et al., 2001a; Djimdé et al., 2001b; Talisuna et al., 2002b; Talisuna et al., 2003b) 
Furthermore, these studies have mainly focused on single loci conferring resistance to a single 
drug class (i.e., CQ or SP). 
The current study in PNG aimed to bring together molecular data from community-based 
surveys and data derived from health centre-based studies collected over a time period of 
three years. After we had demonstrated in a first step, that there was no difference between 
the genetic drug resistance profile in clinical and community samples for two sites that are 
different with regard to epidemiological characteristics as well as drug use patterns (Chapter 
5), we investigated the potential of molecular marker frequencies and genotype patterns 
assessed on community level to reflect the longitudinal trends of failure rates with AQ or CQ 
plus SP at the corresponding health facilities. We finally evaluated the usefulness of the GFI 
model for surveillance of resistance under the current first-line regimen in PNG (Chapter 6). 
Treatment failure rates with the current combination regimen were reflected in the 
corresponding genetic resistance pattern of parasites from community samples. Frequencies 
of mutated alleles of AQ/CQ relevant markers in pfcrt and pfmdr1 were high and did not 
show significant changes over time. Also mutant allele frequencies in the pyrimethamine 
relevant gene pfdhfr, which were still moderate, were not significantly variable over time. In 
contrast, mutations in pfdhps, involved in resistance to sulphadoxine, were still low, but had 
started to emerge with variable degree at all three sites. The opposing longitudinal trends in 
clinical response observed at two sites (i.e., decreasing in Karimui and increasing in the 
Wosera) were best reflected by the frequencies and genotype patterns of mutations in SP 
relevant genes pfdhfr (S108N plus C59R) and pfdhps (A437G). Though the GFI based on the 
prevalence of the combined pfdhfr S108N+C59R plus pfdhps A437G genotype was most 
reliably predicting longitudinal in vivo trends at a given site, it was less useful for the 
comparison of different sites (i.e., different epidemiological settings) at a given time point. 
On one hand, these data further corroborated our previous findings that demonstrated this 
genotype to be the best predictor for treatment failure on individual level (Chapter 4) and 
suggest this genotype to be a valuable marker for the level of clinical failure on population 
level over time at a given site. On the other hand, our results are not consistent with African 
studies that had shown the pfdhps genotype not to be indicative for treatment failure with SP 
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monotherapy in Ghana and Tanzania (Mockenhaupt et al., 2005b; Mugittu et al., 2004; 
Mutabingwa et al., 2001). However, other authors had suggested the quintuple mutation 
(triple pfdhfr 108+59+51 plus double pfdhps 473+540) as important predictor for treatment 
failure with SP in Uganda and Malawi (Kyabayinze et al., 2003; Kublin et al., 2002). Other 
studies had reported pfdhps mutations to be good predictors for unsuccessful treatment 
response to combination therapy with CQ plus SP (Berens et al., 2003; Dorsey et al., 2004). 
These conflicting reports underscore the need for a careful baseline assessment of the 
molecular marker profile in parasite populations in a given epidemiological setting, the 
investigation of its relationship with in vivo treatment response, and the monitoring of its 
dynamics over time. They clearly indicate that former drug history is an important 
determinant of the genetic resistance background in parasites and that SP resistance may 
emerge and spread very differently according to whether SP was used as monotherapy or 
introduced as partner component in a combination regimen. In addition, other important 
parameters, such as drug use patterns as well as immunity related to transmission intensity 
(Djimdé et al., 2003; Francis et al., 2006; Talisuna et al., 2006) play a significant role in 
determining the level and spread of parasite resistance in a given area. Hence, indicators 
based on molecular data have to be considered with caution with regard to prior drug use and 
key epidemiological characteristics (e.g. malaria endemicity, intensity and seasonality of 
transmission, etc.) and interpreted in the local context where they had been assessed and will 
be used in the future. 
The importance, that also other factors have to be considered in the validation of molecular 
markers and hence, the establishment of putative models for surveillance, was also reflected 
in our findings with the GFI model in PNG. In contrast to previous reports, which showed this 
indicator to be constant over time and postulated a stable relationship between the prevalence 
of pfcrt K76T and therapeutic failure with CQ (Djimde et al., 2001a), we found that GFIs 
based on CQ relevant genotypes were highly variable and did not reflect the corresponding in 
vivo failure trends, the most likely explanation being that a highly CQ resistant genetic 
background is quasi fixed in the parasite population in PNG. Likewise, GFIs based on 
prevalence rates of pfdhfr genotypes were also not able to reflect the corresponding in vivo 
trends, with frequencies of the most predominant double pfdhfr mutant (S108N+C59R) being 
stable over time (i.e., GFIs reflected an inverse in vivo trend). In contrast, GFIs based on the 
combined pfdhfr/pfdhps genotype have proven to be the best indicators for the longitudinal 
trends of failure rates observed at all the three sites. 
Chapter 8: Discussion   221
To conclude, the currently suggested GFI model remains to be validated in other areas 
representing settings with wide variations in epidemiological characteristics and drug use 
history, as well as for different drugs and drug combinations. Molecular data on antimalarial 
parasite resistance from different continents and/or countries are rich, but they show that the 
development and suggestion of a universal approach seem to be difficult. However, the 
appraisal we used in the current study (i.e., community-based surveys and the analysis of the 
whole array of drug resistance-associated molecular markers), which provides a tool for a 
more comprehensive assessment of the situation in a given area, may open the avenue to 
make better decisions on molecular monitoring approaches in a given area. 
Fortunately, mutations in pfATPase6, the gene encoding a putative target for artemisinin 
derivates (Eckstein-Ludwig et al., 2003; Jambou et al., 2005), were as yet not detected in 
PNG. This finding is important seeing that artesunate has already been officially introduced as 
partner drug with SP for second-line treatment against severe and treatment failure malaria, 
and a policy change to ACT as potential replacement option to AQ or CQ plus SP has to be 
taken into consideration in the near future. 
Taken together, our in vivo and molecular data from PNG demonstrate 1) a highly mutated 
CQ resistance background, 2) a frequency of pfdhfr mutations consistent with a moderately 
pyrimethamine resistant phenotype, and 3) the emergence of key mutations in pfdhps. The 
latter was not surprising in view of former drug use history in PNG (Chapter 2). Furthermore, 
they suggest that SP, and more specifically sulphadoxine, is the effective component in the 
current first-line regimen and hence, molecular monitoring of resistance to this component is 
important under constant treatment policy in PNG. However, future marker sets will have to 
be adapted according to possible policy changes, such as the introduction of entirely new drug 
classes, as well as the cessation of drugs with unacceptably low levels of efficacy. Further 
monitoring of molecular markers of withdrawn drugs is an important issue, especially in the 
view of the limited drug armamentarium against malaria. Recent studies showed that the 
cessation of CQ was followed by re-emergence of CQ sensitive P. falciparum (Kublin et al., 
2003). Moreover, increasing clinical efficacy trends were reflected in the corresponding drug 
resistance profile of the parasites (i.e., disappearance of the CQ resistant pfcrt K76T 
genotype) (Mita et al., 2003). These observations are promising and the possibility of rotating 
the limited number of safe, effective and affordable antimalarials could be considered (Laufer 
& Plowe, 2004). 
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3.4 Implications for future research and recommendations 
Though a vast amount of molecular data on antimalarial parasite resistance has been produced 
during the last two decades, there are many questions and issues which have to be addressed 
in the future. Not only for a better understanding of the molecular mechanisms conferring 
parasite resistance to several drug classes and combinations, but also to develop and validate 
simple but comprehensive models, so that molecular data can be used as a source for 
establishing indicators for resistance. The most important issue being that these indicators can 
be used by health authorities in the decision-making process on drug policy in malaria 
endemic countries. 
 
The present study has highlighted again several critical and in part controversial issues of 
current methods of in vivo, as well as molecular assessment of drug resistant malaria, the most 
important being: 
• The drawbacks of the current in vivo drug efficacy study protocol, especially the lack 
of consensus on how genotyping data for the differentiation between recrudescences 
and new infections are generated and analysed. 
• The difficulties in comparing molecular resistance data in general, and more 
specifically in extrapolating the findings from one epidemiological setting to another. 
The main reasons being: 
• The absence of standardised protocols for a comprehensive baseline assessment of 
the genetic drug resistance profile in parasites that enables more accurate selection 
of relevant markers for subsequent monitoring, as well as better comparability of 
data from studies conducted in different areas. 
• Limited information about the progression of parasite resistance in areas which 
differ with regard to several characteristics, such as demographic and ecological 
parameters, malaria endemicity, level and pattern of disease transmission, and drug 
usage. 
• The lack of simple models that may provide reliable indices based on molecular data 
in order to be helpful to several potential users, such as scientist, health care 
professionals and policy makers. 
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Some of the questions will have to be addressed by ongoing activities in basic research 
investigating: 
I) The molecular mechanisms underlying anti-plasmodial action of several drug 
classes. These include old and new generation aminoquinolines and antifolates, as 
well as artemisinin derivates and entirely new compounds that will be discovered 
in the future. 
II) The molecular basis determining parasite resistance to different drug classes. 
Future in silico and in vitro research will lead to the identification and 
characterisation of other genes, as well as other genetic modification and/or 
epistatic interactions between genes to be involved in conferring parasite 
resistance. 
 
Further insight into the role and relevance of molecular markers in predicting in vivo 
treatment response, as well as the validation of their usefulness as a public health tool for 
monitoring resistance will be obtained by the following studies: 
I) The investigation of genetic determinants of parasite resistance in the field, an 
important issue being the elucidation of the role of the molecular parasite 
background in determining in vivo response. This will also include the 
development of proxy indicators for other determinants of resistance, such as host 
drug metabolism, host immunity, transmission intensity and drug pressure, which 
have to be considered in the analysis. 
II) Validation of the applicability of presently proposed marker sets for different drug 
classes and combination regimens (e.g. pfcrt K76T for CQ, triple pfdhfr 
(S108N+C59R+N51I) or quadruple pfdhfr/pfdhps (plus A437G+K540E) for SP as 
suggested in certain areas in Africa, or triple pfdhfr/pfdhps (S108N+C59R plus 
A437G) for AQ/CQ plus SP as suggested in the present study) in different 
epidemiological settings. 
III) The search for new approaches in dealing with the problem of multiclonal P. 
falciparum infections. These include the assessment of the relationship between 
mutations within and between genes (linkage disequilibrium), as well as the 
development of novel probabilistic models possibly providing estimates of 
genotypes and/or haplotype frequencies in a patient sample. Further refinement of 
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our novel DNA microarray-based technology, which already allows a semi-
quantitative assessment of several SNPs, combined with a genotyping method 
capable of quantifying MOI, may potentially enable the determination of the most 
dominant resistance genotype/haplotype in a patient sample in the future. 
IV) The molecular analysis of archived blood samples which will provide valuable 
information about 1) genetic changes in the parasite even after a new drug has 
been introduced and/or a previously inefficacious drug has been withdrawn, and 2) 
the time lag between the occurrence of parasite resistance and in vivo treatment 
failure which will allow better predictions about the likely progression of 
resistance in a given area. 
V) The validation of currently suggested models and concepts for molecular 
monitoring of antimalarial resistance (e.g. GFIs) in various epidemiological 
settings. Previous studies evaluating the GFI model, including the investigations in 
the present study, indicate this model to be too simplistic. Hence, additional 
parameters for other determinants of parasite resistance (e.g. drug pressure) and 
the level of host immunity (e.g. transmission intensity) may have to be taken into 
account in future public health models. 
 
More specific recommendations for future research and resistance monitoring activities in 
PNG include: 
1) Selection and comparative evaluation of potential replacement options, preferably 
artemisinin-based combination regimens (with the current first- and second-line 
regimens being included as control arms in the studies). Apart from safety and 
efficacy, important aspects to consider include pre-existing and putative cross-
resistance to potential partner drugs, acceptability in the communities, practicability 
within the health infrastructure in PNG, and costs. 
2) Molecular monitoring of parasite resistance at representative sentinel sites. Under 
constant drug policy in PNG, we suggest to use the marker sets for P. falciparum and 
P. vivax proposed in the present study. In view of artesunate being used as partner 
drug with SP in the current second-line regimen, we strongly recommend to include 
the currently proposed pfATPase6 SNPs as additional markers. However, marker sets 
will have to be adapted according to future drug policy change(s) (e.g. inclusion of 4-
aminoquinoline markers after withdrawal of CQ and AQ). 
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3) After careful evaluation in PNG, our community-based molecular monitoring 
approach has been shown to be feasible under current treatment strategy in the areas 
where the assessment has been done. Therefore, molecular monitoring using this 
approach and applying the proposed marker set can be recommended for the short-
term (i.e., under constant treatment policy) in these areas. However, the validity of this 
community-based approach has to be proven for other drug(s) and drug combinations 
in different epidemiological settings, especially with regard to differences in 
transmission intensity and drug use patterns, before a similar approach can be 
propagated for other areas within PNG, as well as in other malaria endemic countries. 
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Abstract 
With a renewed interest in large-scale malaria interventions knowledge about the possible 
long-term effects of such interventions on the nature of malaria transmission is essential. We 
document complex changes in malaria epidemiology over the last 40 years associated with 
changing malaria control activities in Karimui, an isolated area in Papua New Guinea. An 
initially equal distribution of P. falciparum, P. vivax and P. malariae changed to currently 
68% P. falciparum, after passing through a phase of transitory P. vivax dominance, when 
control started to fail. Initial drops in malaria prevalence proved difficult to sustain and 
present post-control levels are significantly higher than pre-control levels. The example of 
Karimui indicates that unsustained control can lead to changes in malaria patterns that may 
leave a population worse off. 
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Introduction 
Renewed awareness of the immense human and economic costs of malaria has brought 
malaria control once again to prominence on the international public health agenda. There has 
been extensive discussion of the possible effects of malaria interventions on protective 
immunity and patterns of morbidity1,2, but less attention has been given to the long-term 
effects on malaria transmission itself, especially in areas outside Africa that have complex 
malaria patterns. 
In Africa, a massive resurgence of malaria was seen after cessation of control in many areas3, 
but the absence of significant levels of non-falciparum malaria preclude investigation of 
differential control effects on individual malarial species. Following the cessation of DDT 
spraying in Sri Lanka in 1964, P. vivax quickly re-established itself causing major epidemics4. 
Control was reintroduced and, following the switch from vector control to exclusive treatment 
of malaria cases and the first reports of chloroquine resistance, a steep rise in P. falciparum 
cases was observed4, although P. vivax remained the dominant parasite5. In areas of Asia and 
South America with ongoing malaria control programs, for instance Thailand and Brazil, a 
shift from P. falciparum to P. vivax preponderance occurred in the last 20 years6,7, despite 
rising levels of drug resistant P. falciparum. The contrary trend of P. falciparum replacing P. 
vivax was, however, observed in parts of India with high levels of drug and insecticide 
resistance8. These patterns indicate complex relationships between control activities and the 
transmission of different malaria species in different parts of the world. 
In Papua New Guinea, where all 4 human Plasmodium species and a multitude of vectors 
occur, the malaria control program that lasted from 1960 to the early 1980s was associated 
with a notable shift from P. vivax to P. falciparum predominance9,10. In Karimui, an isolated 
area without road access, located approximately 1000 m above sea-level (settlement range 
900-1200 m) to the south of the main highland cordillera, control started later and lasted 
longer than elsewhere in PNG. Good, detailed malariological data from pre-control (1965,11), 
early into control (1971,12), breakdown of control (1981,13) and current, post-control times 
(2001/0214) are available from a series of large malaria surveys in this area. Furthermore, the 
history of control is relatively well documented14. This offers an exceptional opportunity to 
investigate changes in malaria epidemiology in relation to malaria control activities. 
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Materials & Methods 
This paper used results from four major malaria surveys, conducted between 1965 and 2002, 
in the Karimui and Daribi area on the Karimui Plateau, South Simbu. These surveys published 
in reports or scientific paper contained detailed description of sample locations and population 
and presented data in ways that allowed collating samples that were comparable in areas and 
age groups covered. A number of other malaria surveys, in particular from the control period, 
could not be used for this comparison as they lacked sufficient detail and/or documentation. 
Most were only available from field research note from one author (R. Hide) and either only 
covered parts of the Karimui area or did not contain sufficient detail on populations covered. 
The comparison was thus restricted to the 4 published surveys. 
Following an initial malaria mass blood survey of the Karimui area in 1962, a major pre-
control survey was conducted in August 1965 by the Malaria Control Service and included 
3937 people in both Karimui and Daribi census districts (CD)11. Control measures began in 
early 1968, and included indoor residual spraying with DDT (IRS, two spray rounds annually) 
and mass drug administration (CQ and pyrimethamine, administered during the spray rounds 
from 1968 to 1970 only, Figure 1). Regular mass blood surveys were carried out twice a year 
to assess control efficacy, and a scientific assessment of the malaria situation under control 
was conducted in October-November 197112. The 1971 study assessed 978 people on the 
Karimui Plateau. 
A decade later, following reports of high levels of child malnutrition, in-depth 
epidemiological surveys were carried out in Karimui during August-September 1981 by 
members of the Simbu Land Use Project, the Provincial Department of Health and the 
PNGIMR. The aim of these surveys was to determine the prevalence of malnutrition, malaria 
and intestinal parasites13. Malarial infections and spleen rates were assessed in a total of 1591 
individuals from 7 villages in Karimui and Daribi CD. Twice-yearly spraying was continued 
until 1978, when control was scaled back.  Spraying continued at irregular intervals and 
decreasing coverage until the early 1980s (15, Figure 1). The 1981 survey thus coincided with 
the period of failing control characterised by erratic interventions and decreasing coverage 
and effectiveness. 
In 1984, vector control was officially abandoned and until 2002 treatment of all presumptive 
malaria cases with chloroquine and primaquine has been the mainstay of malaria control 
throughout PNG. Although insecticide treated bednets (ITN) have become increasingly 
available in PNG in recent years, they were virtually absent in Karimui villages. As part of a 
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larger study into the epidemiology of malaria throughout the PNG highlands, 765 individuals 
in 4 villages were examined for malarial infections and morbidity between July 2001 and May 
200214. In addition, a further 263 individuals were surveyed in December 2002 in 3 additional 
villages surrounding Karimui Station as part of an ongoing study in molecular markers of 
drug resistance.  For the present analysis, results from the latter study were included with 
those from the wider 2001-2 survey. 
Although the same villages were not included in each of the four main studies used here, all 
studies conducted cross-sectional community surveys across the same areas of the Karimui 
Plateau, and comprised all age groups in similar proportions. As original data was only 
available from the 2001/02 surveys, age categories were set to provide maximum 
correspondence between tabulations in the published studies. The data from the most recent 
surveys were then reanalysed to fit these categories. All comparisons between and within 
studies were done using Chi-square tests and logistical regression. 
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Results 
The first detailed survey in 1965, prior to control measures, found a malaria prevalence of 
19.4% across Karimui, with similar amounts of P. falciparum, P. vivax and P. malariae 
present (Table 1 & Figure 1). After malaria control started in 1968, overall malaria levels 
were rapidly brought down to 7.1% by 1971, with P. falciparum dominating over P. vivax 
(PR: 4.5% vs. 2.8%, p = 0.05, Figure 1). P. malariae was permanently reduced. The age 
distribution of cases was little affected during the early phase of control, with parasite 
prevelance peaking at 1-4 yr both in 1965 and 1971 (Figure 2). 
The faltering of the control program in the late 1970s and early 1980s resulted in a massive 
surge in malaria transmission. In 1981, overall prevalence had climbed over 30%, 
significantly exceeding pre-control levels (Table 1, p < 0.001). The increase was strongest in 
P. vivax (PR: Pf 13.9%, Pv 15.8%, Pm 4.4%, Figure 1) and peak prevalence shifted to the 5-
9yr (Pv) and 10-14 yr (Pf, Pm) age groups (Figure 2). 
By 2001, some 20 years after the breakdown of control, the overall prevalence of malaria had 
not risen significantly (p > 0.5). However, there has been a major shift in species composition 
(Table 1). While the overall prevalence of P. vivax decreased to pre-control levels (6.9%), the 
prevalence of P. falciparum increased to 22.1% and now accounts for 67.6% of infections. 
Peak prevalence of parasitemia has shifted back towards younger age groups (Figure1), most 
notable in P. vivax infections. 
In the 2001/02 surveys there is a highly significant difference both in overall prevalence and 
age distribution of cases in relation to the distance of the surveyed village to a health centre. 
In villages within 1 hour walk of Karimui and Negabo health centres, overall prevalence was 
22.5% compared to 35.6% in those further away (p < 0.001, Table 2) and age of peak 
prevalence was significantly higher (Χ2 = 12.6, df = 3, p = 0.006). Such differences were not 
observed (p > 0.2) in the 1981 surveys, with overall prevalence of 33.6% and 36.0% in the 1-
9 year and 24.0% and 20.2% in the over 15 year age groups in villages within or beyond 1 
hour walking distance from the nearest health centre, respectively. 
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Discussion 
The data from Karimui not only show that the impressive initial reductions in malaria 
transmission achieved by control measures were difficult to sustain, but that the epidemiology 
of malaria in the area has been significantly changed over the course of these interventions. 
The slight shift to P. falciparum early during the control period was probably due to mass 
drug administration, as has been seen in other parts of the country16. Surprisingly, the roles 
were reversed when the control efforts were breaking down. Between 1971 and 1981, 
irregular spraying and cessation of mass drug administration favoured P. vivax transmission. 
Several factors may have contributed to this change: its long-lasting liver stages, short 
extrinsic cycle and faster production of gametocytes17 make P. vivax easier to transmit in 
marginal or fluctuating circumstances. Additionally, prolonged DDT spraying elsewhere in 
PNG led to a shift in vectors towards early- and outdoor-biting mosquitoes18. Early-biting 
mosquitoes in PNG tend to be younger and more likely to carry P. vivax sporozoites19, thus 
favouring transmission of P. vivax. 
The resurgence of malaria following collapse of regular control was very rapid. Mass blood 
surveys in the same areas conducted by the malaria control services (usually at time of spray 
activities) in the 6-18 months preceding the 1981 survey, found a significantly lower overall 
prevalence (14-15%) with a similar predominance of P. vivax as in the 1981 survey (Hide 
pers. comm.). 
As elsewhere in PNG, P. falciparum became the dominant malaria species in Karimui after 
the complete cessation of vector control in the 1980s, while P. vivax fell back to pre-control 
levels (Figure1) with a comparable age distribution (Figure 2). Indiscriminate use of 4-
aminoquinolines in combination with poor compliance and the advent of resistant P. 
falciparum9 are the likely reasons for this shift. Both result in poor clearance of infections and 
increased gametocyte production, thus fuelling P. falciparum transmission. Ongoing in vivo 
follow-up and molecular drug resistance markers studies show high levels of 4-
aminoquinolines resistance in Karimui (Marfurt & Mueller, unpublished data). P. malariae, 
with the longest extrinsic cycle and still full susceptibility to 4-aminoquinolines, never fully 
recovered. 
During the period that these changes in malaria epidemiology occurred, other significant 
changes in human-environment relations took place in the Karimui area that may have 
influenced malaria transmission.  Most importantly, these included substantial population 
increase (a doubling between 1962 and 1990), and a shift in settlement pattern from dispersed 
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longhouses to centralised nucleated villages. These trends resulted in larger, more clustered 
areas of cultivation and human use. Such conditions favour vectors such as An. punctulatus 
that breed in open, sunlit pools18 that result from agriculture and other human activity, thus 
increasing the chance of transmission.. 
It has been argued that a change to a sedentary, agricultural life style favoured the 
transmission of P. falciparum over P. vivax and contributed to the worldwide P. falciparum 
dominance20,21. It cannot be ruled out, therefore, that changes in population density, 
agriculture and settlement pattern at Karimui may have contributed to the dramatic shift 
towards P. falciparum following the collapse of control activities. It may also have helped to 
seal the fate of P. malariae, a parasite well adapted to endemicity in sparse and mobile human 
populations20. 
Malaria control may also have affected immune status causing shifts in the age of peak 
prevalence. Early on, age distribution was little affected, but during the breakdown of control 
there was a clear shift towards older children, as shown by the 1981 survey. In the 20 years 
since cessation of vector control, peak prevalence of malarial infections has shifted back to 
younger age groups, except in areas with ready access to antimalarial drug treatment. This 
indicates, that 13 years of control, even if imperfectly done, reduced immunity in children. 
Similar shifts in distribution of malaria cases to older age groups with decreasing transmission 
were also seen in Africa where they were linked to increases in bednet coverage and changes 
in first line-treatment2. 
This Karimui example demonstrates that, as elsewhere in areas with complex malaria 
patterns4, 5, 6, 7, 8, 9, major control interventions not only result in temporary reductions in levels 
of transmission but may be associated also with significant, unpredictable and possibly long-
term shifts in malaria epidemiology. Such shifts might be especially marked if control is not 
properly maintained and, as in the case of Karimui and PNG in general, may leave an area 
worse off than before control. While the Karimui experience does not contraindicate renewed 
malaria control efforts, it highlights the importance of monitoring changes in malaria 
epidemiology, as well as the need to sustain successful interventions once started. 
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Table 1: Malaria prevalence rates (PR), species composition and spleen rates (SR) in Karimui 
from 1965-2002 
 
          
     Species composition   
Year n  PR  P. f. P. v. P. m.  SR 
          
          1965 3,937  764 (19.4%)  36.7% 34.6% 28.7%  - 
1971 978a    69 (7.1%)  56.2% 34.3% 9.6%  262 (26.8%) 
1981 1,591  482 (30.3%)  40.7% 46.4% 12.9%  488 (30.7%) 
2001/02 1,028  314 (31.2%)  68.4% 21.1% 10.5%  400 (38.9%) 
          a
 Sample size for spleen rate 1084 
 
 
Table 2: Age-specific prevalence of all malaria infection in 2001/02 surveys in relation to 
distance from nearest health centre 
 
        
Age  With 1 hour walk  > 1 hour walk  
 (years) 
 N % pos  N % pos  
        
        
< 1  8 0.0  57 36.8  
1 – 4  50 18.0  84 57.1  
5 – 9  75 33.3  101 50.5  
5 – 15   57 35.1  119 46.2  
> 15  153 15.0  324 21.3  
        
All  343 22.4  685 35.6  
        
 
 
Appendix I 9 
Figure 1: Changing prevalence of malarial infection in relation to control interventions in 
Karimui from 1965 – 2002. 
P. falciparum (Pf): black bars: P. vivax: grey bars, P. malariae: open bars. Abbreviations: 
IRS, indoor residual spraying with DDT; MDA, mass drug administration; CQ, chloroquine; 
SP sulphadoxine-pyremethamine. 
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Figure 2: Age-prevalence of different malarial infections in Karimui 1965 – 2002. 
Data from 1965 survey did not allow differentiating into 5-9 and 10-14 age groups and date 
are thus given for age group 5-14 only. 
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Study forms and questionnaires 
 
 
 
In vivo drug efficacy study: DAY 0 
 
1 
               
 
In vivo drug efficacy study: 
 
 
 
Date of health centre attendance:     (Day, Month, Year) 
 
 
 
Identification: 
 
 
ID number:       
 
Kristen nem 
 
 Village  
Nem bilong 
papa 
 Hamas christmas 
bilong yu 
 
Nem bilong 
mama 
 Sex: F=female 
        M=male 
 
 
If a child is less than 6 months old, he/she must be excluded from the study! 
 
 
 
Checklist for enrollement: 
 
Exclusion criteria Y/N 4. Co-infection with any other disease  
1. Age <6 months  * 5. Current treatment with antibiotics  
2. Severe malnutrition 
    (MUAC < 12 cm) 
 * 6. Antimalarial treatment within 
       the last 28 days 
 
3. Haemoglobin < 5g/dl  7. Danger signs of complicated Pf 
    malaria 
 
 
* Check the information with the health book of the patient. 
 
If there is ‘YES’ for any of these criteria, the patient cannot be included in the 
study! 
 
               
 
In vivo drug efficacy study: DAY 0 
 
2 
History of disease: 
 
Wanem dei sik i kamap (1=Nau; 2=Asde; 3=Asde bipo; 4=Tripela dei i go pinis; 
5=Foapela dei i go pinis; 6=Fivepela dei i go pinis) 
 
Wanem kain sik i kamap 
 
 
 
 
 
If a patient reports YES for cough and/or diarrhoea, he/she must be excluded from the study! 
 
Check the health book: 
Date of last antimalarial treatment:       (Day, Month, Year) 
 
If a patient had an antimalarial treatment within the last 28 days, he/she must be excluded from the study! 
 
Clinical assessment: 
 
Weight kg 
Axillary temperature °C 
Current level of consciousness (F = fully, D = drowsy, C = coma) 
Respiratory rate / min 
Chest indrawing Y/N 
Spleen grade (Hackett’s grading system) 0-5; 8=not possible; 9=not done 
Other signs:  
 
If there are clinical signs of the following conditions: 
• Severe malnutrition (MUAC < 12 cm) 
• Febrile conditions due to any other disease 
• Severe P. falciparum malaria 
the patient must be excluded from the study! 
 
 
Haematology: 
 
Bleedcode:       
 
Microtainer™:   Y/N   IsoCode® Stix:  Y/N 
 
Haemoglobin:   . g/dl 
 
If the haemoglobin reading is below 5.0 g/dl, the patient must be excluded from the study! 
 
 
 
 
Skin hat o skin kol o skin guria Y/N 
Het pen Y/N 
Kus Y/N 
Pekpek wara Y/N 
Arapela kain sik: Y/N 
In vivo drug efficacy study: DAY 0 
 
3 
 
 
Malaria slide: compulsory! Immediate reading in the afternoon! 
 
 
 
 
 
 
 
 
Drugs (1st dose) administered on DAY 0: 
The patient received: (tick two if received in combination) 
 
Chloroquine Y/N 
Camoquin Y/N 
Primaquine Y/N 
Amodiaquine Y/N 
Fansidar Y/N 
Other drug: Y/N 
 
 
 
 
 
 
 
               
 
 
Please check on DAY 1: 
 
Drugs (2nd dose) administered on DAY 1:  Y/N 
 
Chloroquine Y/N 
Camoquin Y/N 
Primaquine Y/N 
Amodiaquine Y/N 
Fansidar Y/N 
Other drug: Y/N 
 
 
 
 
 
 
 
 
Pf / 200 WBC     
Pv / 200 WBC     
Pm / 200 WBC     
Po / 200 WBC     
P. gam.     
In vivo drug efficacy study: DAY 2 
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Date of health centre attendance:     (Day, Month, Year) 
 
Identification: 
ID number:        
 
Kristen nem  Village  
Nem bilong papa  Hamas christmas bilong yu  
Nem bilong mama  Sex (F=female, M=male)  
 
History of disease:   
 
 
 
 
 
 
 
 
Clinical assessment: 
 
Axillary temperature °C 
Current level of consciousness (F = fully, D = drowsy, C = coma) 
Other signs:  
 
Haematology: 
 
Bleedcode:       
 
Malaria slide: compulsory! Immediate reading in the afternoon! 
 
 
 
 
 
 
 
 
Drugs (3rd dose) administered on DAY 2: 
The patient received: (tick two if received in combination) 
 
Chloroquine Y/N 
Camoquin Y/N 
Primaquine Y/N 
Amodiaquine Y/N 
Fansidar Y/N 
Other drug: Y/N 
 
 
Asde yu kisim marasin pinis Y/N 
Nau yu sik Y/N 
Nau yu gat skin hot o skin col o skin guria Y/N 
Nau yu gat het pen Y/N 
Nau yu gat traut Y/N 
Nau yu gat pekpek wara Y/N 
Arapela kain sik: Y/N 
Pf / 200 WBC     
Pv / 200 WBC     
Pm / 200 WBC     
Po / 200 WBC     
P. gam.     
In vivo drug efficacy study: DAY 3 
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Date of health centre attendance:     (Day, Month, Year) 
 
Identification: 
ID number:        
 
Kristen nem  Village  
Nem bilong papa  Hamas christmas bilong yu  
Nem bilong mama  Sex (F=female, M=male)  
 
 
 
History of disease:   
 
 
 
 
 
 
 
 
 
Clinical assessment: 
 
Axillary temperature °C 
Current level of consciousness (F = fully, D = drowsy, C = coma) 
Other signs:  
 
 
 
Haematology: 
 
Bleedcode:       
 
Malaria slide: compulsory! Immediate reading in the afternoon! 
 
 
 
 
 
 
 
 
 
 
Nau yu sik Y/N 
Nau yu gat skin hot o skin col o skin guria Y/N 
Nau yu gat het pen Y/N 
Nau yu gat traut Y/N 
Nau yu gat pekpek wara Y/N 
Arapela kain sik: Y/N 
Pf / 200 WBC     
Pv / 200 WBC     
Pm / 200 WBC     
Po / 200 WBC     
P. gam.     
In vivo drug efficacy study: DAY 7 
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Date of follow-up:       (Day, Month, Year) 
 
Identification: 
ID number:        
 
Kristen nem  Village  
Nem bilong papa  Haumas christmas bilong yu  
Nem bilong mama  Sex (F=female, M=male)  
 
History of disease: 
 
Taim mipela kisim blut yu bin sik gen:  Y/N 
 
Sapos ‘YES’: (1=Nau; 2=Asde; 3=Asde bipo; 4=Tripela dei i go pinis) 
 
 
 
Taim yu kisim las tablet yu gat skin hot oskin kol o skin guria:    Y/N 
 
Sapos ‘YES’: (1=Nau; 2=Asde; 3=Asde bipo; 4=Tripela dei i go pinis) 
 
 
Taim yu kisim las tablet yu gat: 
 
 
 
 
 
 
Taim mipela kisim blut yu yet bin go gen long: 
 
 
 
 
 
 
Sapos ‘YES’: Date:      (D, M, Y) 
 
Yu bin kisim marasin long hap:   Y/N 
 
Yu bin kisim marasin long arapela ples:  Y/N 
 
Sapos ‘YES’: Stori long marasin: Drugs:          
 
     Full treatment: Y/N 
 
Data should be checked with the health book! 
 
Het pen Y/N 
Traut Y/N 
Pekpek wara Y/N 
Arapela kain sik: Y/N 
Ait post Y/N 
Helt Senta Y/N 
Haus Sik Y/N 
In vivo drug efficacy study: DAY 7 
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Clinical assessment: 
 
Axillary temperature °C 
Current level of consciousness (F = fully, D = drowsy, C = coma) 
Other signs:  
 
 
Haematology: 
 
Bleedcode:       
 
Malaria slide: compulsory! Immediate reading in the afternoon! 
 
 
 
 
 
 
 
 
 
 
Pf / 200 WBC     
Pv / 200 WBC     
Pm / 200 WBC     
Po / 200 WBC     
P. gam.     
In vivo drug efficacy study: DAY 14 
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Date of follow-up:       (Day, Month, Year) 
 
Identification: 
ID number:        
 
Kristen nem  Village  
Nem bilong papa  Hamas christmas bilong yu  
Nem bilong mama  Sex (F=female, M=male)  
 
 
History of disease: 
 
Taim mipela kisim blut yu bin sik gen:  Y/N 
 
Sapos ‘YES’: (1=Nau; 2=Asde; 3=Asde bipo; 4=Tripela dei i go pinis;5=Foapela dei i 
go pinis; 6=Fivepela dei i go pinis; 7=Sixpela dei i go pinis) 
 
 
Taim yu kisim las tablet yu gat skin hot oskin kol o skin guria:    Y/N 
 
Sapos ‘YES’: (1=Nau; 2=Asde; 3=Asde bipo; 4=Tripela dei i go pinis;5=Foapela dei i 
go pinis; 6=Fivepela dei i go pinis; 7=Sixpela dei i go pinis) 
 
 
Taim yu kisim las tablet yu gat: 
 
 
 
 
 
 
Taim mipela kisim blut yu yet bin go gen long: 
 
 
 
 
 
Sapos ‘YES’: Date:      (D, M, Y) 
 
Yu bin kisim marasin long hap:   Y/N 
 
Yu bin kisim marasin long arapela ples:  Y/N 
 
Sapos ‘YES’: Stori long marasin: Drugs:          
 
     Full treatment: Y/N 
 
Data should be checked with the health book! 
Het pen Y/N 
Traut Y/N 
Pekpek wara Y/N 
Arapela kain sik: Y/N 
Ait post Y/N 
Helt Senta Y/N 
Haus Sik Y/N 
In vivo drug efficacy study: DAY 14 
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Clinical assessment: 
 
Axillary temperature °C 
Current level of consciousness (F = fully, D = drowsy, C = coma) 
Other signs:  
 
 
Haematology: 
 
Bleedcode:       
 
Malaria slide: compulsory! Immediate reading in the afternoon! 
 
 
 
 
 
 
 
 
 
 
Pf / 200 WBC     
Pv / 200 WBC     
Pm / 200 WBC     
Po / 200 WBC     
P. gam.     
In vivo drug efficacy study: DAY 28 
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Date of follow-up:       (Day, Month, Year) 
 
Identification: 
ID number:        
 
Kristen nem  Village  
Nem bilong papa  Hamas christmas bilong yu  
Nem bilong mama  Sex (F=female, M=male)  
 
 
History of disease: 
 
Taim mipela kisim blut yu bin sik gen:  Y/N 
 
Sapos ‘YES’:  Insait tupela wik i go pinis   Y/N 
   Insait onepela wik i go pinis   Y/N 
 
 
Taim yu kisim las tablet yu gat skin hot oskin kol o skin guria:    Y/N 
 
Sapos ‘YES’:  Insait tupela wik i go pinis   Y/N 
   Insait onepela wik i go pinis   Y/N 
 
 
 
Taim yu kisim las tablet yu gat: 
 
 
 
 
 
 
Taim mipela kisim blut yu yet bin go gen long: 
 
 
 
 
Sapos ‘YES’: Date:      (D, M, Y) 
 
Yu bin kisim marasin long hap:   Y/N 
 
Yu bin kisim marasin long arapela ples:  Y/N 
 
Sapos ‘YES’: Stori long marasin: Drugs:          
 
     Full treatment: Y/N 
 
Data should be checked with the health book! 
Het pen Y/N 
Traut Y/N 
Pekpek wara Y/N 
Arapela kain sik: Y/N 
Ait post Y/N 
Helt Senta Y/N 
Haus Sik Y/N 
In vivo drug efficacy study: DAY 28 
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Clinical assessment: 
 
Axillary temperature °C 
Current level of consciousness (F = fully, D = drowsy, C = coma) 
Other signs:  
 
 
Haematology: 
 
Bleedcode:       
 
Malaria slide: compulsory! Immediate reading in the afternoon! 
 
 
 
 
 
 
 
 
Pf / 200 WBC     
Pv / 200 WBC     
Pm / 200 WBC     
Po / 200 WBC     
P. gam.     
In vivo drug efficacy study: DAY SICK 
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Date of health centre attendance:     (Day, Month, Year) 
 
Identification: 
ID number:        
 
Kristen nem  Village  
Nem bilong papa  Hamas christmas bilong yu  
Nem bilong mama  Sex (F=female, M=male)  
 
 
History of disease: 
Wanem dei sik i kamap (1=Nau; 2=Asde; 3=Asde bipo; 4=Tupela dei i go pinis; 5=Tripela dei i 
go pinis; 6=Foapela dei i go pinis; 7=Fivepela dei i go pinis) 
 
Wanem kain sik i kamap 
Skin hat o skin kol o skin guria Y/N 
Het pen Y/N 
Kus Y/N 
Pekpek wara Y/N 
Arapela kain sik: Y/N 
 
 
Check with the health book: 
 
The patient received on DAY 0: (tick two if received in combination) 
 
Chloroquine Y/N 
Camoquin Y/N 
Primaquine Y/N 
Amodiaquine Y/N 
Fansidar Y/N 
Artemether/Artesunate Y/N 
Other drug: Y/N 
 
 
 
Clinical assessment: 
 
Axillary temperature °C 
Current level of consciousness (F = fully, D = drowsy, C = coma) 
Spleen grade (Hackett’s grading system) 0-5; 8=not possible; 9=not done 
Other signs:  
 
 
 
 
 
In vivo drug efficacy study: DAY SICK 
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Haematology: 
 
Bleedcode:       
 
 
Malaria slide: compulsory! Immediate reading in the afternoon! 
 
 
 
 
 
 
 
 
Presumptive diagnosis:            
 
 
Drugs administered: 
 
The patient received on DAY SICK: (tick two if received in combination) 
 
 
 
Sapos ‘YES’:  oral dose  Y/N 
 
   Shot I.M.  Y/N 
 
   Shot I.V.  Y/N 
 
 
Pf / 200 WBC     
Pv / 200 WBC     
Pm / 200 WBC     
Po / 200 WBC     
P. gam.     
Chloroquine Y/N Full treatment Y/N 
Camoquin Y/N Full treatment Y/N 
Primaquine Y/N Full treatment Y/N 
Amodiaquine Y/N Full treatment Y/N 
Fansidar Y/N Full treatment Y/N 
Artemether/Artesunate Y/N Full treatment Y/N 
Quinine Y/N Full treatment Y/N 
Other drug: Y/N Full treatment Y/N 
Community-based cross-sectional surveys: Household questionnaire 
 1 
Date:      (Day / Month / Year) 
 
Village:        Province:         
 
Village Number:       Province Number:        
 
Household (HH) Number:      Name of the head of the HH:       
 
Members of the HH: 
Name Date of birth 
(Day / Month / Year) 
Reported age 
(Years or months) 
Sex 
(F / M) 
Present 
(Y / N) 
If no (N), where? ID number 
      XA     
      XA     
      XA     
      XA     
      XA     
      XA     
      XA     
      XA     
      XA     
      XA     
      XA     
      XA     
      XA     
 
Community-based cross-sectional surveys: Individual questionnaire 
 
2 
Village number:     ID number: XA      
 
Village:      Household number:      
 
Kristen nem:      Sex:   (F=female; M=male) 
 
Pikinini: Nem bilong mama      
 
  Nem bilong papa:      
 
Date of birth or approximate age:      (Day / Month / Year)) 
 
Malaria questionnaire 
Insait long onepela wik I go pinis, yu bin sik?  Y/N 
 
• Sapos ‘YES’: Wanem kain sik i kamap? 
Skin hat o skin kol o skin guria Y/N 
Het pain Y/N 
Kus Y/N 
Pekpek wara Y/N 
Arapela kain sik Y/N 
Wanem kain sik? 
 
• Wanem dei sik i kamap?   
(0=Nau; 1=Asde; 2=Asde bipo; 3=Tripela dei i go pinis; 4=Foapela dei i go pinis; 5=Fivepela  
dei i go pinis; 6=Sixpela dei i go pinis, 7=Sevenpela dei i go pinis; 8=Etpela dei i go pinis;  
9=Ninepela dei i go pinis; 10=Tenpela dei i go pinis; 13=not known) 
 
• Wanem dei sik i go pinis?   
(0=Nau; 1=Asde; 2=Asde bipo; 3=Tripela dei i go pinis; 4=Foapela dei i go pinis; 5=Fivepela  
dei i go pinis; 6=Sixpela dei i go pinis; 7=not finished; 9=not known) 
 
Insait long onepela wik I go pinis, yu yet bin go gen long: 
 
 
 
 
• Sapos YES’: Yu bin kisim malaria marasin long hap?  Y/N 
 
Sapos YES’: Wanem taim yu kisim las tablet    (Date) 
Wanem taim yu kisim las sut:     (Date) 
 
If the health book of the patient is available,       Y/N     it should be checked for the following data: 
 
Date of the last anti-malarial treatment:     (Day / Month / Year) 
 
Treatment course:       Full treatment   Y/N  
Ait post Y/N 
Helt Senta Y/N 
Haus Sik Y/N 
Community-based cross-sectional surveys: Individual questionnaire 
 
3 
Number of anti-malarial treatment courses during the preceding year:    
No Date (Day / Month / Year) Course (Note two drugs if received in combination!) Full 
course? 
1   Y/N 
2   Y/N 
3   Y/N 
4   Y/N 
5   Y/N 
 
Yu bin kisim malaria marasin long arapela ples?  Y/N 
 
• Sapos YES’: Wanem ples yu kisim malaria marasin: 
 
 
 
 
 
 
 
 
 
• Stori long marasin: Drugs:        
 
Clinical assessment: 
 
Axillary temperature °C 
Respiratory rate / min 
Current level of consciousness (F = fully, D = drowsy, C = coma) 
Chest indrawing Y/N 
Spleen grade (Hackett’s grading system) 0-5; 8=not possible; 9=not done 
Other signs                                          Y/N Specify: 
 
Haematology: 
 
Bleedcode: XA   = ID number!  Haemoglobin:   . g/dl 
 
Microtainer™:   Y/N    Vacutainer™:  Y/N 
 
Malaria slide: compulsory! 
 
 
 
 
 
 
Whenever a subject is sick (clinical evidence and patient’s report) or has a haemoglobin reading below 5.0 
g/dl, she/he must be advised to go to the next health centre (assistance for transportation has to be 
provided!)
Haus marasin Y/N 
Stoa Y/N 
Maket Y/N 
Ples dokta Y/N 
Wantoks Y/N 
Arapela ples Y/N 
Wanem ples? 
Pf / 200 WBC     
Pv / 200 WBC     
Pm / 200 WBC     
Po / 200 WBC     
P. gam.     
Informed consent form: English 
 
A 
INFORMED CONSENT 
(adapted from WHO/MAL/96.1077) 
 
We are from the PNG Institute of Medical Research and we are interested in knowing how 
well the current treatment for malaria is working in this region of PNG. To do this, we are 
carrying out a study in which we are treating a group of children for malaria and then 
following them for 28 days to see if their infection is cured. 
 
If you agree to participate the study, we would like to see your child 5 more times over the 
next 28 days (i.e. on day 2, 3, 7 14 and 28), so that we can monitor the progress of the 
treatment. At each visit your child will receive a full medical examination and we will take a 
small amount of blood by finger-prick to make blood smears to see if your child still has 
malaria parasites. It is very important that we see your child on these days, so if you feel that 
you cannot agree with this procedure, please let us know now. 
 
Your participation is completely voluntary. If you do not want your child to participate in this 
study, he/she will receive treatment as usual at this health centre. Participation in this study 
will not cost you or your family anything. You may also withdraw your child from the study 
at any time and for any reason. 
 
Your child will benefit from participating in this study because he/she will be closely 
followed over the next 28 days. If your child continues to suffer from malaria, he/she will 
receive an alternative treatment which will cure the illness. There will be someone here at the 
health centre every day so that, even on days between scheduled visits and on week-ends, you 
may bring your child for a check-up if you feel that he/she is ill. 
 
Do you have any questions about the study? 
 
 
Informed consent form: Tok pisin 
 
B 
INFORMED CONSENT 
(Tok Pisin) 
 
Mipela wokman bilong PNG IMR i kam long wokim malaria research (risets). Mipela painim 
aut malaria marasin i wok long bodi long kilim i dai binatang bilong malaria or nogat. 
 
Long stadi bai mipela i lukim ol pikinini antap long sixpela mun na moa, husait i save kisim 
bagarap long sik malaria. 
Taim mipela enrolim yu long stadi na mipela i painim aut olsem yu gat sik malaria, em taim 
mipela i sekim blut bilong yu. Bai yu kisim tritmen long tripela dei. Bihain bai mipela lukim 
yu gen long las dei bilong marasin. Mipela bai mekim follow up insait onepela wik bihain, 
tupela wik bihain gen, na gen onepela mun bihain. Mipela bai kam bek gen long hauslain na 
kisim blut bilong yu long lukim sapos yu sik gen or olrait. Bihain long olgeta follow up, 
dispela wok bilong sekim yu i pinis. 
 
As tingting bilong dispela wok em bilong helpim yu na olgeta kominiti insait long PNG na tu 
em bilong helpim gavman long kamapim gutpela marasin plen long daunim sik malaria. 
 
Sapos yu wan bel orait, mipela bai enrolim yu long dispela stadi. 
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1. DNA preparation 
 
DNA is isolated from whole blood (anti-coagulated with EDTA) or red blood cell pellets using QIAamp® 96 
DNA Blood Kit (Qiagen, Hombrechtikon, Switzerland) according to the manufacturer’s instructions. 
[http://www1.qiagen.com/literature/protocols/QIAamp96DNABlood.aspx] 
 
 
 
2. Amplification of target sequences 
 
2.1 Primary PCR 
 
2.1.1 Primary PCR mix 
 
Reagents 1 reaction 104 reactions (96 patients) final conc.
H2O 30.0 µl 3120 µl 
10 x PCR buffer (without MgCl2) 5.0 µl 520 µl 1 x
dNTP mix (2mM) 5.0 µl 520 µl 200 µM
MgCl2 (25mM) 6.0 µl 624 µl 3 mM
Primary PCR primer mix (10 µM each) # 1.0 µl 104 µl 200 nM each
Taq polymerase 5U/µl 0.50 µl 52 µl 0.05 U/µl
Final volume 47.5 µl 4940 µl 
DNA  2.5 µl  
Final volume 50 µl  
 
# Primary PCR primer mixes (sequence information: see Appendix): 
 
1. P 1-1 (pfmdr1 PCR I: P 1-1 for / P1-1 rev, 10 µM each in TE buffer) 
2. P 3-1 (pfmdr1 PCR II: P 3-1 for / P3-1 rev, 10 µM each in TE buffer) 
3. P 5-1 (pfdhfr PCR: P 5-1 for / P5-1 rev, 10 µM each in TE buffer) 
4. P 8-1 (pfdhps PCR: P 8-1 for / P8-1 rev, 10 µM each in TE buffer) 
5. P 10-1 (pfcrt PCR I: P 10-1 for / P10-1 rev, 10 µM each in TE buffer) 
6. P 11-1 (pfcrt PCR II: P 11-1 for / P11-1 rev, 10 µM each in TE buffer) 
7. P 12-1 (pfcrt PCR III: P 12-1 for / P12-1 rev, 10 µM each in TE buffer) 
8. P 16-1 (pfcrt PCR IV: P 16-1 for / P16-1 rev, 10 µM each in TE buffer) 
9. P 17-1 (pfATPase6 PCR: P 17-1 for / P17-1 rev, 10 µM each in TE buffer) 
10. P 18-1 (pfcrt PCR V: P 18-1 for / P18-1 rev, 10 µM each in TE buffer) 
 
 
2.1.2 Primary PCR program 
 
96 °C 180 sec 
 
96 °C   30 sec 
52 °C   90 sec  20 cycles for clinical (symptomatic) samples 
72 °C   90 sec  25 cycles for community (asymptomatic) samples 
 
Hold at 4 °C 
 
Appendix III 3 
2.2 Nested PCR 
 
2.2.1 Nested PCR mix 
 
Reagents 1 reaction 104 reactions (96 patients) final conc.
H2O 60.0 µl 6000 µl 
10 x PCR buffer (without MgCl2)  10.0 µl 1000 µl 1 x
dNTP mix (2mM) 10.0 µl 1000 µl 200 µM
MgCl2 (25mM) 12.0 µl 1200 µl 3 mM
Nested primer mix (10µM each)§ 2.0 µl 200 µl 200 nM each
Taq polymerase 5U/µl 1.0 µl 100 µl 0.05 U/µl
Final volume 95 µl 9500 µl 
Primary PCR product 5.0 µl   
Final volume 100 µl  
 
§ Nested PCR primer mixes (sequence information: see Appendix): 
 
11. P 1 (pfmdr1 PCR I: P 1 for / P1 rev, 10 µM each in TE buffer) 
12. P 3 (pfmdr1 PCR II: P 3 for / P3 rev, 10 µM each in TE buffer) 
13. P 5 (pfdhfr PCR: P 5 for / P5 rev, 10 µM each in TE buffer) 
14. P 8 (pfdhps PCR: P 8 for / P8 rev, 10 µM each in TE buffer) 
15. P 10 (pfcrt PCR I: P 10 for / P10 rev, 10 µM each in TE buffer) 
16. P 11 (pfcrt PCR II: P 11 for / P11 rev, 10 µM each in TE buffer) 
17. P 12 (pfcrt PCR III: P 12 for / P12 rev, 10 µM each in TE buffer) 
18. P 16 (pfcrt PCR IV: P 16 for / P16 rev, 10 µM each in TE buffer) 
19. P 17 (pfATPase6 PCR: P 17 for / P17 rev, 10 µM each in TE buffer) 
20. P 18 (pfcrt PCR V: P 18 for / P18 rev, 10 µM each in TE buffer) 
 
2.2.2 Nested PCR program 
 
96 °C 180 sec 
 
96 °C   30 sec 
52 °C   90 sec  20 cycles for clinical (symptomatic) samples 
72 °C   90 sec  25 cycles for community (asymptomatic) samples 
 
Hold at 4 °C 
 
 
 
3. SAP (Shrimp Alkaline Phosphatase) digest of PCR products 
 
3.1 Preparation of PCR products 
 
By using a multichannel pipette, pool 10 µl of all the 10 nested PCR reactions from each patient into a new 
96 well plate. Mix and centrifuge briefly. = PCR pool plate 
 
Transfer 10 µl of each well into a new 96 well plate and add 90 µl of H20 to each well. 
Mix and centrifuge briefly. = PCR pool plate 1:10 
 
Appendix III 4 
3.2 SAP digest 
 
NOTE Each PCR pool from PCR pool plate 1:10 has to be SAP digested in duplicate because we have 
 to perform 2 extension reactions per patient! 
 
 
3.2.1 SAP master mix 
 
Reagents 1 reaction 104 reactions (48 patients) 
H2O 4.0 µl 416 µl 
10 x SAP buffer 1.0 µl 104 µl 
Shrimp Alkaline Phosphatase (SAP) 1U/µl 2.0 µl 208 µl 
Final volume 7.0 µl 728 µl 
PCR pool 1:10 5.0 µl  
Final volume 12.0 µl 
 
 
 
• Using a multichannel pipette, transfer 5 µl of the PCR pool 1:10 to the SAP plate. 
 Remember: you need two wells per patient (i.e., 1 SAP plate contains 48 patients). 
 
• Add 7 µl of the SAP master mix to each well. 
 
• Mix and centrifuge briefly, start SAP program. 
 
 
SAP plate 
 
SAP plate 1 2 3 4 5 6 7 8 9 10 11 12
A) SAP 1 Patient1 Patient2 Patient3 Patient4 Patient5 Patient6 Patient7 Patient8 Patient9 Patient10 Patient11 Patient12
B) SAP 2 Patient1 Patient2 Patient3 Patient4 Patient5 Patient6 Patient7 Patient8 Patient9 Patient10 Patient11 Patient12
C) SAP 1 Patient13 Patient14 Patient15 Patient16 Patient17  etc.             
D) SAP 2 Patient13 Patient14 Patient15 Patient16 Patient17  etc.             
E) SAP 1                         
F) SAP 2                         
G) SAP 1                     Patient47 Patient48
H) SAP 2                     Patient47 Patient48
 
 
 
3.2.2 SAP program 
 
SAP digest:   1 hour at 37 °C 
Inactivation of SAP digest: 15 min at 90 °C 
 
NOTE This reaction is performed in a PCR machine. 
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4. Primer extension 
 
4.1 Preparation of ddNTP mixes 
 
Combination 1 
 
Combination 2 
ddATP Cy3 
 
ddUTP Cy3 
ddCTP Cy3 
 
ddCTP Cy3 
ddGTP Cy5 
 
ddATP Cy5 
ddUTP Cy5 
 
ddGTP Cy5 
 
• To get a 2.5 µM final concentration of ddNTP mixes (Combination 1, Combination 2), dilute Cy3- 
and Cy5-labelled ddNTP’s stock solutions (100 µM at -80°C) 1:40 in TE buffer: 
 
1. 4 x 25 µl 100 µM ddNTP stock = 100 µl. Add 900 µl TE buffer = 1 ml 2.5 µM ddNTP mix. 
2. Make aliquots and store 2.5 µM ddNTP mix at -20°C! 
 
 
4.2 Preparation of extension primer mixes 
 
Gene Combination 1 (25 oligos)  Combination 2 (15 oligos) 
Pfdhps 437, 540, 581, 613, 640  436, 613B, 645 
Pfdhfr 16, 51, 59, 108, 164  108B, 164B 
Pfmd1r 86, 184, 1034, 1042  1246 
Pfcrt 72, 75B1, 152, 271, 326, 326B, 356, 356B  74, 76, 97, 163, 220, 371 
PfATPase6 538, 769, 769B  574, 623, 683 
 
 
• To get a 62.5 nM final concentration of extension primer mixes (Combination 1, Combination 2), 
dilute extension primer stock solutions (10 µM in TE buffer) 1:160 in TE buffer: 
 
1. Combination 1: 25 x 2 µl = 50 µl plus 270 µl TE buffer 
2. Combination 2: 15 x 2 µl = 30 µl plus 290 µl TE buffer 
 Store extension primer mixes at +4°C! 
 
 
4.3 Reaction mix combination 1 
 
Combination 1 1 reaction 52 reactions (48 patients) final conc.
H2O 1.6 µl 83.2 µl 
10 x Sequenase buffer 2 ul 104 ul 1 x
Extension primer mix Combination 1 (62.5 nM) 2 ul 104 ul 6.25 nM
ddNTP mix Combination 1 (2.5 µM) 2 ul 104 ul 0.25 µM
Thermo Sequenase (5U/µl) 0.4 µl 20.8 µl 0.1 U/µl
Final volume 8 ul 416 ul 
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4.4 Reaction mix combination 2 
 
Combination 2 1 reaction 52 reactions (48 patients) final conc.
H2O 1.6 µl 83.2 µl 
10 x Sequenase buffer 2 ul 104 ul 1 x
Extension primer mix Combination 2 (62.5 nM) 2 ul 104 ul 6.25 nM
ddNTP mix Combination 2 (2.5 µM) 2 ul 104 ul 0.25 µM
Thermo Sequenase (5U/µl) 0.4 µl 20.8 µl 0.1 U/µl
Final volume 8 ul 416 ul 
 
 
• Add 8 µl of the extension reaction mixes Combination 1 and Combination 2 to the SAP digested 
PCR products in the SAP plate = EXTENSION plate (Final volume = 20 µl) 
 
• Start extension program 
 
 
EXTENSION plate 
 
SAP→EXTENSION 1 2 3 4 5 6 7 8 9 10 11 12 
A) COMB 1 Patient1 Patient2 Patient3 Patient4 Patient5 Patient6 Patient7 Patient8 Patient9 Patient10 Patient11 Patient12 
B) COMB 2 Patient1 Patient2 Patient3 Patient4 Patient5 Patient6 Patient7 Patient8 Patient9 Patient10 Patient11 Patient12 
C) COMB 1 Patient13 Patient14 Patient15 Patient16 Patient17  etc.             
D) COMB 2 Patient13 Patient14 Patient15 Patient16 Patient17  etc.             
E) COMB 1                         
F) COMB 2                         
G) COMB 1                     Patient47 Patient48 
H) COMB 2                     Patient47 Patient48 
 
 
 
4.5 Primer extension program 
 
94 °C 60 sec 
 
94 °C 10 sec  35 cycles 
50 °C 40 sec 
 
Hold at 4 °C 
 
 
Appendix III 7 
4.6 Denaturation 
 
• Pool extension reaction mixes Combination 1 and Combination 2 with a multichannel pipette 
(Final volume = 40 µl). 
 
• Add 6 µl of denaturing solution: 0.5 µl 0.5M EDTA pH 8.0 
 2.0 µl 10% SDS 
 3.5 µl H20  (Final volume: 46 µl) 
 
• Incubate at 94 °C for 60 sec 
• Chill on ice for 2 min 
 
 
 
5. Hybridisation of extended primers 
 
5.1 Preparation of the spotted microarray 
 
• Add 23 µl of the extension reaction mix on the chip 
• Add 6 µl 20 x SSC to each well of the slide 
 
5.2 Hybridisation 
 
• Incubate the chip in a opaque humid chamber at 50 °C for 60-90 min 
 
 
5.3 Washing procedure after hybridisation 
 
1. 2x SSC + 0.2% SDS: 20 min at room temperature (RT) 
2. 2x SSC:   20 min at RT 
3. 2x SSC + 2% EtOH:   2 min at RT 
 
• Dry the chip with compressed air and store at RT in the dark 
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6. Data acquisition and analysis 
 
6.1  Base calling 
 
 Slides can be scanned by the use of any laser scanner. 
 
IMPORTANT: 
 
1. Cy3 (wavelength: 532 nm) and Cy5 (wavelength: 635 nm) signals have to be acquired! 
2. Single signal or combined signal images have to be stored as tif-files for further analysis! 
3. File names have to include a unique study, slide, experiment and operator identification 
code 
 
 
6.2  Short guide for data analysis 
 
a) Prior to analysis, patient/study identification numbers and their respective position on the slide(s) 
have to be entered using the galDesigner software: 
 
1. Open galDesigner software 
2. Load template = malaria.sti 
3. Enter all 12 patient/study identification numbers in the respective fields on each slide 
4. Save each slide (containing 12 patients) as separate gal-file 
 
Important: file names have to include a unique study, slide, experiment and operator identification code 
 
 
b) Slide images are analysed using the Axon GenePix® Pro (version 6.0) software (www.axon.com): 
 
5. Open GenePix® Pro software 
 
 “Image” menu: 
6. Open image = tif-file (Ctrl+O)) 
7. Open array list = gal-file (Alt+Y) 
8. Align array list (by using Block Mode and/or Feature Mode) 
9. Analyse slide (creates image) (Alt+A) 
 
 “Results” menu: 
10. Save results as GenePix Results Files = gpr-file (Alt+U) 
 
 “Report” menu: 
11. Run report: by using the script: Triplicates, ratios, with 6 parameters 
12. Start (creates the STI chip report) 
13. Export the STI chip report as tab-delimited txt-file 
 
Important: file names have to include a unique study, slide, experiment and operator identification code 
 
 
c) Data are converted into a format compatible with any statistical package using fileConverter 
software: 
 
14. Open fileConverter software 
15. Transfer results as tab-delimited txt-files into the data folder 
16. Run fileConverter 
17. Rename and save the outTable.txt file in your personal data folder 
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7. Appendix 
 
7.1 Buffers 
 
• 500 mM EDTA pH 8.0 
• 180 mM phosphate buffer pH 8.0 
• 20 x SSC pH 7.0 
• 2 x SSC 
• 2 x SSC + 0.2% SDS 
• 2 x SSC + 2% EtOH 
• 10% SDS 
• 1 x TE buffer (= 10 mM Tris/HCl pH 8.0) 
• 10 mM Tris/HCl pH 7.4 
 
1. Prepare all buffers/solutions according to the protocols in: 
  Molecular Cloning (a laboratory manual; Sambrook J., Fritsch E.F. and Maniatis T. 
  2nd edition; Cold Spring Harbor Laboratory Press, 1989) 
2. Store all buffers at RT! 
 
 
7.2 Reagents 
 
• 10 x PCR buffer (=buffer B)   Solis BioDyne, Tartu, Estonia 
• 25 mM MgCl2     Solis BioDyne, Tartu, Estonia 
• Taq polymerase (Firepol®; 5 U/µl)   Solis BioDyne, Tartu, Estonia 
• dNTP mix (2mM each): 
 
 Dilute 100 mM stock solutions 1:50 in 10 mM Tris/HCl pH 7.4 
 
 dATP 100 mM     Amersham Biosciences: 272050 
 dTTP 100 mM     Amersham Biosciences: 272080 
 dCTP 100 mM     Amersham Biosciences: 272060 
 dGTP 100 mM     Amersham Biosciences: 272070 
 
• 10 x SAP buffer     Amersham Biosciences: 70103 
• Shrimp Alkaline Phospothase (SAP; 1U/µl)  Amersham Biosciences: 70092Z 
• 10 x Sequenase buffer    Amersham Biosciences: 93-79222 
• Thermo Sequenase (Termipol®; 5 U/µl)  Solis BioDyne, Tartu, Estonia 
 
 NOTE Store all reagents at -20°C! 
 
• Cy3 /Cy5 labelled ddNTP    Perkin Elmer: NEL999 
 
 NOTE Store 100 µM ddNTP stock solutions at -80°C! 
 
 
7.3 Oligonucleotides 
 
A. C-7 oligos (Spotting) 
 
500 µM stock solutions in 180 mM phosphate 
buffer pH 8.0 (aliquots at -20°C)   Operon (Amino C-7 linker at the 3’ end!!!) 
 
B. Extension oligos 
 
 100 µM stock solutions in TE buffer pH 8.0 
 (aliquots at -20°C)    Operon (HPLC-purified!!!) 
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7.4 Sequence information 
 
NOTE: 
• All primers and sequences are listed from the 5’ to the 3’ end of the sequence 
• Sequences in italic/underlined denote flexible primer sequences (=flexi tag) 
• Neg1-Neg4: negative control oligonucleotides (=conserved sequence stretches from the 
respective genes) 
 
 
7.4.1 Pfdhfr 
 
Pfdhfr primary PCR primer (Size PCR product: 677 bp) 
 
P5-1 for:  TTTATGATGGAACAAGTCTGC 
P5-1 rev:  TAAATGATAAAATCCAATGTTGTAT 
 
 
Pfdhfr nested PCR primer (Size PCR product: 637 bp) 
 
P5 for:  ACAAGTCTGCGACGTTTTCGATATTTATG 
P5 rev:  AGTATATACATCGCTAACAGA 
 
 
Pfdhfr C-7 primer 
 
DHFR Neg1 C-7: AAATATAAGAGATGTAAATATTTAAACAA 
 
16 C-7:  CACATATGGCATAAATATCGAAAACGTC 
51 C-7:  TACATTTCCATGGTAATACTCCTTTATTTC 
59 C-7:  GTGCAGTTACAACATATGTGAA 
10/108 C-7:  GCAGGGAAGCGGGAGCGAAACAGC 
11/108B C-7:  AAAACGGGGCACAGCGCGGCGGAA 
06/164 C-7:  GGGAGAGCGCAGCAGGCAACAGAG 
07/164B C-7:  GACCGCCACCAAGAACAGCACCGG 
 
 
Pfdhfr extension primer 
 
16:   GACGTTTTCGATATTTATGCCATATGTG 
51:   GAAATAAAGGAGTATTACCATGGAAATGTA 
59:   TTCACATATGTTGTAACTGCAC 
10/108:  GCTGTTTCGCTCCCGCTTCCCTGCCAAAATGTTGTAGTTATGGGAAGAACAA 
11/108B:  TTCCGCCGCGCTGTGCCCCGTTTTAAAGGTTTAAATTTTTTTGGAATGCTTTCCCAG 
06/164:  CTCTGTTGCCTGCTGCGCTCTCCCGGGAAATTAAATTACTATAAATGTTTTATT 
07/164B:  CCGGTGCTGTTCTTGGTGGCGGTCTTCTTGATAAACAACGGAACCTCCTA 
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Pfdhfr sequence (Accession number: J04643) 
 
P5-1 for 
P5 for 
P5 rev 
P5-1 rev 
 
C-7 and extension primer for dhfr 16, dhfr 51, dhfr 59, dhfr 108, dhfr 164 
SNP 
 
         TTTATGATGGAACAAGTCTGC 
                    ACAAGTCTGCGACGTTTTCGATATTTAT 
         01 ATGATGGAACAAGTCTGCGACGTTTTCGATATTTATGCCATATGTGCATGTTGTAAGGTT 
         61 GAAAGCAAAAATGAGGGGAAAAAAAATGAGGTTTTTAATAACTACACATTTAGAGGTCTA 
        121 GGAAATAAAGGAGTATTACCATGGAAATGTAATTCCCTAGATATGAAATATTTTTGTGCA 
        181 GTTACAACATATGTGAATGAATCAAAATATGAAAAATTGAAATATAAGAGATGTAAATAT 
        241 TTAAACAAAGAAACTGTGGATAATGTAAATGATATGCCTAATTCTAAAAAATTACAAAAT 
        301 GTTGTAGTTATGGGAAGAACAAACTGGGAAAGCATTCCAAAAAAATTTAAACCTTTAAGC 
        361 AATAGGATAAATGTTATATTGTCTAGAACCTTAAAAAAAGAAGATTTTGATGAAGATGTT 
        421 TATATCATTAACAAAGTTGAAGATCTAATAGTTTTACTTGGGAAATTAAATTACTATAAA 
        481 TGTTTTATTATAGGAGGTTCCGTTGTTTATCAAGAATTTTTAGAAAAGAAATTAATAAAA 
        541 AAAATATATTTTACTAGAATAAATAGTACATATGAATGTGATGTATTTTTTCCAGAAATA 
        601 AATGAAAATGAGTATCAAATTATTTCTGTTAGCGATGTATATACTAGTAACAATACAACA 
        661 TTGGATTTTATCATTTATAAGAAAACGAATAATAAAATGTTAAATGAACAAAATTGTATA 
        721 AAAGGAGAAGAAAAAAATAATGATATGCCTTTAAAGAATGATGACAAAGATACATGTCAT 
        781 ATGAAAAAATTAACAGAATTTTACAAAAATGTAGACAAATATAAAATTAATTATGAAAAT 
        841 GATGATGATGATGAAGAAGAAGATGATTTTGTTTATTTTAATTTTAATAAAGAAAAAGAA 
        901 GAGAAAAATAAAAATTCTATACATCCAAATGATTTTCAAATATATAATAGCTTGAAATAT 
        961 AAATATCATCCTGAATACCAATATTTAAATATTATTTATGATATTATGATGAATGGAAAT 
       1021 AAACAAAGTGATCGAACGGGAGTAGGTGTTTTAAGTAAATTCGGATATATTATGAAATTT 
       1081 GATTTAAGTCAATATTTCCCATTATTAACTACGAAGAAATTATTTTTAAGAGGAATTATT 
       1141 GAAGAATTGCTTTGGTTTATTAGAGGAGAAACAAATGGTAATACGTTGTTAAATAAGAAT 
       1201 GTAAGGATATGGGAAGCTAATGGTACTAGGGAATTTTTAGATAATAGAAAATTATTTCAT 
       1261 AGAGAAGTTAACGATTTAGGACCTATTTATGGTTTTCAATGGAGACATTTCGGTGCTGAA 
       1321 TATACAAATATGTATGATAATTATGAAAATAAAGGAGTGGATCAATTAAAAAATATAATA 
       1381 AATTTAATTAAAAATGATCCTACAAGTAGAAGAATTCTTTTGTGTGCATGGAATGTAAAA 
       1441 GATCTTGACCAAATGGCATTACCTCCTTGTCATATTTTATGTCAGTTTTATGTTTTCGAT 
       1501 GGGAAATTATCATGTATTATGTATCAAAGATCATGTGATTTAGGGCTAGGAGTACCTTTT 
       1561 AATATTGCTTCTTATTCTATTTTTACTCATATGATTGCACAAGTCTGTAATTTGCAACCT 
       1621 GCGCAGTTCATACACGTTTTAGGAAATGCACATGTTTATAATAATCACATTGATAGTTTA 
       1681 AAAATTCAACTTAACAGAATACCCTATCCATTCCCAACACTTAAATTAAATCCAGATATT 
       1741 AAAAATATTGAAGATTTTACAATTTCGGATTTTACAATACAAAATTATGTTCATCATGAA 
       1801 AAAATTTCAATGGATATGGCTGCTTAA 
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7.4.2 Pfdhps 
 
Pfdhps primary PCR primer (Size PCR product: 756 bp) 
 
P8-1 for:  ATTTTTGTTGAACCTAAACGTGCTGTTCA 
P8-1 rev:  CTTGTCTTTCCTCATGTAATTCATCT 
 
 
Pfdhps nested PCR primer (Size PCR product: 686 bp) 
 
P8 for:  TTGAAATGATAAATGAAGGTGCTAGT 
P8 rev:  CCAATTGTGTGATTTGTCCA 
 
 
Pfdhps C-7 primer 
 
DHPS Neg4 C-7: AACAAAAATTACATGATGAACAACAAAAT 
 
436 C-7:  GGATTCTCCACCTATATCTATAA 
437 C-7:  TCCTTTTGTTATACCTAATCCAA 
540 C-7:  ATCCATTGTATGTGGATTTCCA 
581 C-7:  CAAATCCTAATCCAATATCAAATAGTATCC 
613 C-7:  AATAAATCTTTTTCTTGAATATCC 
09/613B C-7:  CGCGCACAGAAGGGCGAGAGACGA 
640 C7:  TTGTGGACAAATCACACAATTG 
645 C7:  GTGATTTGTCCACAATATTTTTAT 
 
 
Pfdhps extension primer 
 
436:   TTATAGATATAGGTGGAGAATCC 
437:   TTGGATTAGGTATAACAAAAGGA 
540:   AGGAAATCCACATACAATGGAT 
581:   GGATACTATTTGATATTGGATTAGGATTTG 
613:   GGATATTCAAGAAAAAGATTTATT 
09/613B:  TCGTCTCTCGCCCTTCTGTGCGCGATTTTGATCATTCATGCAATGGG 
640:   CAATTGTGTGATTTGTCCACAA 
645:   ATAAAAATATTGTGGACAAATCAC 
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Pfdhps sequence (Accession Number: Z30659) 
 
P8-1 for 
P8 for 
P8 rev 
P8-1 rev 
 
C-7 and extension primer dhps 436, dhps 437, dhps 540, dhps 581, dhps 613, dhps 640, dhps 645 
SNP 
 
         01 TGATACCCGAATATAAGCATAATGTTTTAAATAATACCATCAGATGTTTATATAACAAAT 
         61 ATGTGAGTAGGATGAAAGAACAATATAATATAAATATTAAAGAAAATAATAAAAGGATAT 
        121 ATGTATTAAAAGATAGAATTTCTTATTTAAAAGAAAAAACAAATATTGTTGGAATATTAA 
        181 ATGTTAATTATGATTCTTTTTCAGATGGAGGTATTTTTGTTGAACCTAAACGTGCTGTTC 
        241 AAAGAATGTTTGAAATGATAAATGAAGGTGCTAGTGTTATAGATATAGGTGGAGAATCCG 
        301 CTGGTCCTTTTGTTATACCTAATCCAAAAATTAGTGAAAGAGATTTAGTAGTACCTGTAT 
        361 TACAATTATTTCAAAAAGAATGGAATGATATAAAAAATAAAATTGTTAAATGTGATGCGA 
        421 AACCAATTATAAGTATTGATACAATTAACTATAATGTTTTTAAAGAATGTGTTGATAATG 
        481 ATTTAGTTGATATATTAAATGATATTAGTGCTTGTACAAATAATCCAGAAATTATAAAAT 
        541 TATTAAAAAAAAAAAACAAATTCTATAGTGTAGTTCTAATGCATAAAAGAGGAAATCCAC 
        601 ATACAATGGATAAACTAACAAATTATGATAATCTAGTTTATGATATAAAAAATTATTTAG 
        661 AACAAAGATTAAATTTTCTTGTATTAAATGGAATACCTCGTTATAGGATACTATTTGATA 
        721 TTGGATTAGGATTTGCGAAGAAACATGATCAATCTATTAAACTCTTACAAAATATACATG 
        781 TATATGATGAGTATCCACTTTTTATTGGATATTCAAGAAAAAGATTTATTGCCCATTGCA 
        841 TGAATGATCAAAATGTTGTAATAAATACACAACAAAAATTACATGATGAACAACAAAATG 
        901 AAAATAAAAATATTGTGGACAAATCACACAATTGGATGTTTCAGATGAATTACATGAGGA 
        961 AAGACAAGGATCAACTTTTATATCAAAAAAATATATGTGGTGTGTTTAAAAAAAAAAAAA 
       1021 AATTCAAATGAGTATACAAAAGTAACAATTCTATATATGTTACATATAAAATATAAATAA 
       1081 TATATATTCATGTATATGTATTTATGTATTTCTTTTCAGGTGGATTAGCAATTGCTTCCT 
       1141 ACAGCTATTATAAAAAGGTAGATCTAATAAGAGTTCATGACGTTTTAGAAACAAAATCGG 
       1201 TTTTGGATGTTTTAACAAAAATAGACCAAGTGTAATTTACAAAAGGAAAGTGCAAACATG 
       1261 TGATTAAAC 
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7.4.3 Pfmdr1 
 
PCR I: 
 
Pfmdr1 primary PCR I primer (Size PCR product: 613 bp) 
 
P1-1 for:  TTAAATGTTTACCTGCACAACATAGAAAATT 
P1-1 rev : CTCCACAATAACTTGCAACAGTTCTTA 
 
 
Pfmdr1 nested PCR I primer (Size PCR product: 526 bp) 
 
P1 for:  TGTATGTGCTGTATTATCAGGA 
P1 rev:  CTCTTCTATAATGGACATGGTA 
 
 
Pfmdr1 I C-7 primer 
 
MDR Neg2 C-7:  AAAACTACAGCAATCGTTGGAGAAACAGGT 
 
86 C-7:  CATGTTCTTTAATATTACACCAAA 
13/184 C-7:  GGGAACGACACAGACAAGCCGGGG 
 
 
Pfmdr1 I extension primer 
 
86:   TTTGGTGTAATATTAAAGAACATG 
13/184:  CCCCGGCTTGTCTGTGTCGTTCCCTGCCAGTTCCTTTTTAGGTTTAT 
 
 
Pfmdr1 sequence I (Accession Number: from S53996) 
 
P1-1 for 
P1 for 
P1 rev 
P1-1 rev  
 
C-7 and extension primer mdr 86, mdr 184 
SNP 
 
         01 ATGGGTAAAGAGCAGAAAGAGAAAAAAGATGGTAACCTCAGTATCAAAGAAGAGGTTGAA 
         61 AAAGAGTTGAACAAAAAGAGTACCGCTGAATTATTTAGAAAAATAAAGAATGAGAAAATA 
        121 TCATTTTTTTTACCGTTTAAATGTTTACCTGCACAACATAGAAAATTATTATTTATATCA 
        181 TTTGTATGTGCTGTATTATCAGGAGGAACATTACCTTTTTTTATATCTGTGTTTGGTGTA 
        241 ATATTAAAGAACATGAATTTAGGTGATGATATTAATCCTATAATATTATCATTAGTATCT 
        301 ATAGGTTTAGTACAATTTATATTATCAATGATATCAAGTTATTGTATGGATGTAATTACA 
        361 TCAAAAATATTAAAAACTTTAAAGCTTGAATATTTAAGAAGTGTTTTTTATCAAGATGGA 
        421 CAATTTCATGATAATAATCCTGGATCTAAATTAAGATCTGATTTAGATTTTTATTTAGAA 
        481 CAAGTGAGTTCAGGAATTGGTACGAAATTTATAACAATTTTTACATATGCCAGTTCCTTT 
        541 TTAGGTTTATATATTTGGTCATTAATAAAAAATGCACGTTTGACTTTATGTATTACTTGC 
        601 GTTTTTCCGTTAATTTATGTTTGTGGTGTCATATGTAATAAGAAAGTAAAATTAAATAAA 
        661 AAAACATCTTTGTTATATAATAACAATACCATGTCCATTATAGAAGAGGCTTTAATGGGA 
        721 ATAAGAACTGTTGCAAGTTATTGTGGAGAAAAGACTATATTAAACAAATTTAATTTGTCC 
        781 GAAACTTTTTATAGTAAATATATTTTAAAAGCTAATTTTGTAGAAGCATTACATATAGGT 
        841 TTAATAAATGGTTTAATTTTAGTTTCTTATGCATTCGGTTTTTGGTATGGTACAAGAATT 
        901 ATTATAAATAGTGCAACGAATCAATACCCCAATAATGATTTTAATGGTGCCTCAGTTATA 
        961 TCCATTTTATTAGGTGTACTTATTAGTATGTTTATGTTAACAATTATCTTACCAAATATA 
       1021 ACAGAATATATGAAAGCTTTAGAAGCAACAAATAGTTTATATGAAATAATAAATCGAAAA 
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PCR II: 
 
Pfmdr1 primary PCR II primer (Size PCR product: 880 bp) 
 
P3-1 for:  AATTTGATAGAAAAAGCTATTGATTATAA 
P3-1 rev:  TATTTGGTAATGATTCGATAAATTCATC 
 
 
Pfmdr1 nested PCR II primer (Size PCR product: 799 bp) 
 
P3 for:  GAATTATTGTAAATGCAGCTTTA 
P3 rev:  GCAGCAAACTTACTAACACG 
 
 
Pfmdr1 II C-7 primer 
 
1034 C-7:  GAATCCCCATAAAGCTGCATTTACAAT 
1042 C-7:  ATAGTTTTGCCTATTGGTTTGGATCCTTCT 
1246 C-7:  TCTTAAGTTATAATCACATATATTA 
 
 
Pfmdr1 II extension primer 
 
1034:   ATTGTAAATGCAGCTTTATGGGGATTC 
1042:   AGAAGGATCCAAACCAATAGGCAAAACTAT 
1246:   TAATATATGTGATTATAACTTAAGA 
 
 
Pfmdr1 sequence II (Accession Number: from S53996) 
 
P3-1 for 
P3 for 
P3 rev 
P3-1 rev 
 
C-7 and extension primer mdr 1034, mdr 1042, mdr 1246 
SNP 
 
       2701 AAAACGGGTTTAGTAAATAATATTGTTATTTTCTCTCATTTCATAATGCTCTTTCTGGTT 
       2761 AGCATGGTTATGTCCTTTTATTTTTGTCCAATTGTTGCAGCTGTATTAACTTTTATATAT 
       2821 TTTATTAATATGCGTGTATTTGCTGTAAGAGCTAGATTAACCAAAAGTAAAGAAATTGAG 
       2881 AAAAAAGAAAATATGTCAAGCGGAGTTTTTGCATTTAGTTCAGATGATGAAATGTTTAAA 
       2941 GATCCAAGTTTTTTAATACAGGAAGCATTTTATAATATGCATACTGTTATTAATTATGGT 
       3001 TTAGAAGATTATTTCTGTAATTTGATAGAAAAAGCTATTGATTATAAAAATAAAGGACAA 
       3061 AAAAGAAGAATTATTGTAAATGCAGCTTTATGGGGATTCAGTCAAAGCGCTCAATTATTT 
       3121 ATTAATAGTTTTGCCTATTGGTTTGGATCCTTCTTAATTAAAAGAGGTACTATATTAGTT 
       3181 GATGACTTTATGAAATCCTTATTTACTTTTATATTTACTGGTAGTTATGCTGGAAAATTA 
       3241 ATGTCCTTAAAAGGAGATTCAGAAAATGCAAAATTATCATTTGAGAAATATTATCCATTA 
       3301 ATGATTAGAAAATCAAATATTGATGTAAGAGATGATGGTGGAATAAGAATAAATAAAAAT 
       3361 TTAATAAAAGGTAAAGTTGATATTAAAGATGTAAATTTCCGTTATATTTCAAGACCAAAT 
       3421 GTACCTATTTATAAAAATTTATCTTTTACATGTGATAGTAAAAAAACTACAGCAATCGTT 
       3481 GGAGAAACAGGTAGTGGAAAATCAACTTTTATGAATCTCTTATTAAGATTTTATGACTTG 
       3541 AAAAATGATCACATTATATTAAAAAATGATATGACAAATTTTCAAGATTATCAAAATAAT 
       3601 AATAATAATTCATTGGTTTTAAAAAATGTAAATGAATTTTCAAACCAATCTGGATCTGCA 
       3661 GAAGATTATACTGTATTTAATAATAATGGAGAAATATTATTAGATGATATTAATATATGT 
       3721 GATTATAACTTAAGAGATCTTAGAAACTTATTTTCAATAGTTAGTCAAGAACCCATGTTA 
       3781 TTTAATATGTCCATATATGAAAATATCAAATTTGGAAGAGAAGATGCAAATTGGAAGATC 
       3841 GTTAAACGTGTTAGTAAGTTTGCTGCTATAGATGAATTTATCGAATCATTACCAAATAAA 
       3901 TATGATACAAATGTTGGACCATATGGTAAAAGCTTATCAGGTGGACAAAAACAGAGAATA 
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7.4.4 Pfcrt 
 
PCR I: 
 
Pfcrt primary PCR I primer (Size PCR product: 280 bp) 
 
P10-1 for:  TTGTCGACCTTAACAGATGGCTCAC 
P10-1 rev:  AATTTCCCTTTTTATTTCCAAATAAGGA 
 
Pfcrt nested PCR I primer (Size PCR product: 200 bp) 
 
P10-for:  CTTGTCTTGGTAAATGTGCTC 
P10-rev:  GAACATAATCATACAAATAAAGT 
 
Pfcrt I C-7 primer 
 
CRT Neg 3 C-7: AAACTTATTTTTAAAGAGATTAAGGATAA 
 
01/72 C-7*:  ACGCCGGAACGCCGGAACGCCGGA 
75B1 C-7*:  AATTACACATACACTTAAATAAATAATACTTAA 
02/74 C-7*:  ACGGGGCAACGGGGCAACGGGGCA 
76 C-7:  AATTTTTGCTAAAAGAACTTTAAACAAA 
97 C-7:  TGAGTTTCGGATGTTACAAAAC 
 
Pfcrt I extension primer 
 
01/72*:  TCCGGCGTTCCGGCGTTCCGGCGTTTTTAAGTATTATTTATTTAAGTGTA 
75B1*:   TTAAGTATTATTTATTTAAGTGTATGTGTAATT 
02/74*:  TGCCCCGTTGCCCCGTTGCCCCGTTATTATTTATTTAAGTGTATGTGTAAT 
76:   TTTGTTTAAAGTTCTTTTAGCAAAAATT 
97:   GTTTTGTAACATCCGAAACTCA 
(* currently in test stage) 
 
Pfcrt sequence I (Accession Number: from AF030694) 
 
P10-1 for 
P10 for 
P10 rev 
P10-1 rev 
 
C-7 and extension primer crt 72, crt 74, crt 75, crt 76, crt 97 
SNP 
 
        01 AAATTCGCAAGTAAAAAAAATAATCAAAAAAATTCAAGCAAAAATGACGAGCGTTATAGA 
        61 GAATTAGATAATTTAGTACAAGAAGGAAGTAAGTATCCAAAAATGGAAATATTGAATGAT 
       121 ATAAATGAATAGATAAATCAACCTATTGGATATATATATATATATATATATATATATATA 
       181 TATGTATACCCATATGTATTAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCC 
       241 CTTGTCGACCTTAACAGATGGCTCACGTTTAGGTGGAGGTTCTTGTCTTGGTAAATGTGC 
       301 TCATGTGTTTAAACTTATTTTTAAAGAGATTAAGGATAATATTTTTATTTATATTTTAAG 
       361 TATTATTTATTTAAGTGTATGTGTAATTGAAACAATTTTTGCTAAAAGAACTTTAAACAA 
       421 AATTGGTAACTATAGTTTTGTAACATCCGAAACTCACAACTTTATTTGTATGATTATGTT 
       481 CTTTATTGTTTATTCCTTATTTGGAAATAAAAAGGGAAATTCAAAAGTAAGATAAATCAA 
       541 TATATTAAAATGATGGATTTATAAGAGAATCTATTCCACCTACCAATATAAAACATTACA 
       601 CATATATATATATATATATATATATATATATGTATGTATGTTGATTAATTTGTTTATATA 
       661 TTTATATTTATTTCTTATGACCTTTTTAGGAACGACACCGAAGCTTTAATTTACAATTTT 
       721 TTGCTATATCCATGTTAGATGCCTGTTCAGTCATTTTGGCCTTCATAGGTCTTACAAGAA 
       781 CTACTGGAAATATCCAATCATTTGTTCTTCAATTAAGTATTCCTATTAATATGTTCTTCT 
       841 GCTTTTTAATATTAAGATATAGGTAAGTATACTATTTTAAATTACAAAAAAAAAAAAAAA 
       901 AAAAAAAAAAAAAAAAATATAAAATATATATATATATATATATATATATATATATATATA 
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PCR II: 
 
Pfcrt primary PCR II primer (Size PCR product: 605 bp) 
 
P18-1 for:  ACTTTATTTGTATGATTATGTTC 
P18-1 rev:  TAACTGCTCCGAGATAATTGT 
 
Pfcrt nested PCR II primer (Size PCR product: 548 bp) 
 
P18 for:  TCCTTATTTGGAAATAAAAAGGGAAATT 
P18 rev:  TAAGTGATATCTAAAAAGGAGTAAAT 
 
 
Pfcrt II C-7 primer 
 
152 C-7:  AGTTCTTGTAAGACCTATGAAGG 
163 C-7:  CTTAATTGAAGAACAAATGATTGGAT 
 
 
Pfcrt II extension primer 
 
152:   CCTTCATAGGTCTTACAAGAACT 
163:   ATCCAATCATTTGTTCTTCAATTAAG 
 
 
Pfcrt sequence II (Accession Number: from AF030694) 
 
P18.1 for 
P18 for 
P18 rev 
P18.1 rev 
 
C-7 and extension primer crt 152, crt 163 
SNP 
 
        421 AATTGGTAACTATAGTTTTGTAACATCCGAAACTCACAACTTTATTTGTATGATTATGTT 
        481 CTTTATTGTTTATTCCTTATTTGGAAATAAAAAGGGAAATTCAAAAGTAAGATAAATCAA 
        541 TATATTAAAATGATGGATTTATAAGAGAATCTATTCCACCTACCAATATAAAACATTACA 
        601 CATATATATATATATATATATATATATATATGTATGTATGTTGATTAATTTGTTTATATA 
        661 TTTATATTTATTTCTTATGACCTTTTTAGGAACGACACCGAAGCTTTAATTTACAATTTT 
        721 TTGCTATATCCATGTTAGATGCCTGTTCAGTCATTTTGGCCTTCATAGGTCTTACAAGAA 
        781 CTACTGGAAATATCCAATCATTTGTTCTTCAATTAAGTATTCCTATTAATATGTTCTTCT 
        841 GCTTTTTAATATTAAGATATAGGTAAGTATACTATTTTAAATTACAAAAAAAAAAAAAAA 
        901 AAAAAAAAAAAAAAAAATATAAAATATATATATATATATATATATATATATATATATATA 
        961 TATATTTATATATATTTATTTATATATTTATTTATTTATTTATTTATATTTATTTATTTA 
       1021 CTCCTTTTTAGATATCACTTATACAATTATCTCGGAGCAGTTATTATTGTTGTAACAATA 
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PCR III: 
 
Pfcrt primary PCR III primer (Size PCR product: 360 bp) 
 
P11-1 for:  ATTTACTCCTTTTTAGATATCACTTA 
P11-1 rev:  TTATATTTTTTAAAAACTATTTCCCTTG 
 
Pfcrt nested PCR III primer (Size PCR product: 304 bp) 
 
P11-for:  ACAATTATCTCGGAGCAGTTA 
P11-rev:  CATGTTTGAAAAGCATACAGGC 
 
 
Pfcrt III C-7 Primer 
 
220 C-7: ACTAATTAAGACAAGATTAAATATGATAGAA 
 
 
Pfcrt III extension primer 
 
220:   TTCTATCATATTTAATCTTGTCTTAATTAGT 
 
 
 
Pfcrt sequence III (Accession Number: from AF030694) 
 
P11-1 for 
P11 for 
P11 rev 
P11-1 rev 
 
C-7 and extension primer crt 220, 
SNP 
 
 
        961 TATATTTATATATATTTATTTATATATTTATTTATTTATTTATTTATATTTATTTATTTA 
       1021 CTCCTTTTTAGATATCACTTATACAATTATCTCGGAGCAGTTATTATTGTTGTAACAATA 
       1081 GCTCTTGTAGAAATGAAATTATCTTTTGAAACACAAGAAGAAAATTCTATCATATTTAAT 
       1141 CTTGTCTTAATTAGTTCCTTAATTGTAAGAAAACAAAATATATAAATAAATAAATATATA 
       1201 TATATATATATATATATATATATATTGTAATATTTAATATATATTAACACTTAAACTTTG 
       1261 TTTTTATTATATTAATTTATATTCTTTATCATTTTTTTTTTTTTTTTCCTTCTTTTTTTT 
       1321 TTTAGCCTGTATGCTTTTCAAACATGACAAGGGAAATAGTTTTTAAAAAATATAAGATTG 
       1381 ACATTTTAAGATTAAATGTAAGAAGAAATATATAATAATAATAATATATATATTATATAT 
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PCR IV: 
 
Pfcrt primary PCR IV primer (Size PCR product: 697 bp) 
 
P16-1 for:  TCTGTTATTTTTATTTCTTATAGGCTAT 
P16-1 rev:  CTTGTATGTATCAACGTTTTTCATCC 
 
 
Pfcrt nested PCR IV primer (Size PCR product: 630 bp) 
 
P16-for:  CTTTTTCCAATTGTTCACTTCTTG 
P16-rev:  TCTTACATAGCTGGTTATTAAAT 
 
 
Pfcrt IV C-7 primer 
 
271 C-7:  TTTTAAAAATGGAAGGGTGTATA 
326 C-7:  AAAGAAGGAAAACAATGCGAAGGTTT 
326B C-7:  CATTTGTGATAATTTAATAACCAGCTATGT 
 
 
Pfcrt IV extension primer 
 
271:   TATACACCCTTCCATTTTTAAAA 
326:   AAACCTTCGCATTGTTTTCCTTCTTT 
326B:   ACATAGCTGGTTATTAAATTATCACAAATG 
 
 
 
Pfcrt sequence IV (Accession Number: from AF030694) 
 
P16-1for 
P16 for 
P16 rev 
P16-1 rev 
 
C-7 and extension primer crt 271, crt 326, crt 326B 
SNP 
 
       1441 ATATTTCCTTTTTTACCACTTTTTTTTTTTTTATTCCTATAACGCATTATAATTATTTCT 
       1501 GTTATTTTTATTTCTTATAGGCTATGGTATCCTTTTTCCAATTGTTCACTTCTTGTCTTA 
       1561 TATTACCTGTATACACCCTTCCATTTTTAAAAGAACGTAAGAATTAATTAGGAAAGAAAA 
       1621 AATAAATAAATGAATGTGCCCATATATATATATATATATATATATATATATATGTATGTA 
       1681 TGTATAATTTTCCCTTTTTAGTTCATTTACCATATAATGAAATATGGACAAATATAAAAA 
       1741 ATGGTTTCGCATGTTTATTCTTGGGAAGAAACACAGTCGTAGAGGTAAAATAGGATTTTC 
       1801 ATTATATATTAAAAATTACTACTTATTATGTTAATAAAAAAATATGTTTTTTAATGTTCA 
       1861 ATTTGTTTTATTTTAATTATTTTTTTTTTTTTGTTTTGTTTCCTCTTCAGAATTGTGGTC 
       1921 TTGGTATGGCTAAGTTATGTGATGATTGTGACGGAGCATGGGTAAGAAGCTTATAATAAA 
       1981 ATTTCAAAATTATAAGAGACATTTATATATATTTTAACAATAATAATTAAATAAAACAAT 
       2041 ATTATATATATTATATATATTATTATTTTATTTATTATTTTTTTTTTTTTTTTTTTAGAA 
       2101 AACCTTCGCATTGTTTTCCTTCTTTAGCATTTGTGATAATTTAATAACCAGCTATGTAAG 
       2161 AATAAAAAGGATGAAAAACGTTGATACATACAAG 
 
 
 
Appendix III 20 
PCR V: 
 
Pfcrt primary PCR V primer (Size PCR product: 626 bp) 
 
P12-1 for:  AGGAAATAAATATGGGAATGTTTAATTGA 
P12-1 rev:  TTCTAAGATAATATTTCCTACACGGT 
 
 
Pfcrt nested PCR V primer (Size PCR product: 476 bp) 
 
P12-for:  ACCATGACATATACTATTGTTAG 
P12-rev:  TTATAGAACCAAATAGGTAGCC 
 
 
Pfcrt V C-7 primer 
 
356 C-7:  TGCTGGACCTTGTATACAACTAACAA 
356B C-7:  AGCAATTGCTTATTACTTTAAATTCTTAGCC 
371 C-7:  TTACAACATCACCCTATAAAATTAAAAAG 
 
 
Pfcrt V extension primer 
 
356:   TTGTTAGTTGTATACAAGGTCCAGCA 
356B: GGCTAAGAATTTAAAGTAATAAGCAATTGCT 
371:   CTTTTTAATTTTATAGGGTGATGTTGTAA 
 
 
 
Pfcrt sequence V (Accession Number: from AF030694) 
 
P12-1 for 
P12 for 
P12 rev 
P12-1 rev 
 
C-7 and extension primer crt 356, crt 356B, crt 371 
SNP 
 
                                       AGGAAATAAATATGGGAATGTTTAAT 
       2221 TGAATTAAGATATATATATATATATATATATATATATATGTAACCATATAATTTTTCATT 
       2281 TTCTATCTTTTTTATAGATTATCGACAAATTTTCTACCATGACATATACTATTGTTAGTT 
       2341 GTATACAAGGTCCAGCAACAGCAATTGCTTATTACTTTAAATTCTTAGCCGTAAGAATTA 
       2401 AAAAGATATAAATATATAAATATATATGTGAAATATATGATATATATGATATATATTTTT 
       2461 TATATGTAATGTTTTTTTTTTTTTTTCACAATATACATTTAAATGTTTATGATGGTACAA 
       2521 CGTATCATATTTTATAATAATTTTATGCATTCATGTATATTATTTTTACTTTTTAATTTT 
       2581 ATAGGGTGATGTTGTAATAGAACCAAGATTATTAGATTTCGTAACTTTGGTAAGTGTGAA 
       2641 ATTAAAAAATGAATTTTTTTTTTTTTTTTTTTTTTTATGAACAAAATAATGTGTATATAA 
       2701 TATGTGTGTAATATCAAATGGCTTGTTCGTTATAAATATTATATTTTTTTTTTTTTTTTT 
       2761 TTACAGTTTGGCTACCTATTTGGTTCTATAATTTACCGTGTAGGAAATATTATCTTAGAA 
       2821 AGTAATACAAAAATAAGATAAAAAAATATAATATATAAAATATGTATATTGTTCTTATAT 
       2881 ATTTTGTTCATATATATATATATATATATATATATTTTTATATTTCCATCTGTCTTTTTA 
       2941 TTCTATTGTTATAATTTATCATAAATTTTTTTTAAATTTGTTTACATTAGGAAAAAAAAT 
       3001 GAGAAATGAAGAAAATGAAGATTCCGAAGGAGAATTAACCAACGTCGATTCAATTATTAC 
       3061 ACAATAA 
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7.4.5 PfATPase6 
 
PfATPase6 primary PCR primer (Size PCR product: 896 bp) 
 
P17-1 for  AATATTGTTATTCAGAATATGATTATAA 
P17-1 rev  TGGATCAATAATACCTAATCCACCTA 
 
 
PfATPase6 nested PCR primer (Size PCR product: 798 bp) 
 
P17 for  AGCAAATATTTTCTGTAACGATAATA 
P17 rev  TGTTCTAATTTATAATAATCATCTGT 
 
 
PfATPase6 C-7 primer 
 
538 C-7:  ACCGAATTAGCTTTATTACATTT 
574 C-7:  GTACAGGTGTTGTATTTTTTTCA 
623 C-7:  CCTGAGCTGTAGTATAATTAGAATGGTT 
683 C-7:  TTTCTCCAAGAAGAAATACATTCA 
769 C-7:  TTAATTTTTTATAAGCAAAGCTAAGT 
769B C-7  TAGTAAAGATTTAAATATTAAGAATACAG 
 
 
PfATPase6 extension primer 
 
538:   AAATGTAATAAAGCTAATTCGGT 
574:   TGAAAAAAATACAACACCTGTAC 
623:   AACCATTCTAATTATACTACAGCTCAGG 
683:   TGAATGTATTTCTTCTTGGAGAAA 
769:   ACTTAGCTTTGCTTATAAAAAATTAA 
769B   CTGTATTCTTAATATTTAAATCTTTACTA 
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PfATPase6 sequence (Accession Number: AJ532679) 
 
P17-1 for 
P17 for 
P17 rev 
P17-1 rev 
 
C-7 and extension primer ATPase6 538, ATPase6 574, ATPase6 623, ATPase6 683, ATPase6 769 
SNP 
 
          1 AATATATATATATATATATATATATATATATATATATATATGTGTTTATTTTATATTATT 
         61 TAATTTATTTCGTTGAACTTATTATATCTTTGTCATTCGTGAAATTATTTATTATTATAC 
        121 ATAATATTTTGGTTTGTATATAAAGAATGGAAGAGGTTATTAAGAATGCTCATACATACG 
        181 ATGTTGAGGATGTACTAAAATTTTTGGATGTAAACAAAGATAATGGTTTAAAGAATGAGG 
        241 AATTGGATGATAGAAGATTAAAATATGGTTTGAATGAATTAGAAGTAGAAAAGAAGAAAA 
        301 GTATTTTTGAATTGATATTAAATCAATTTGATGATTTATTAGTAAAGATATTATTACTAG 
        361 CTGCATTCATTAGTTTCGTGTTAACTTTATTAGATATGAAACATAAAAAAATAGAAATAT 
        421 GTGATTTTATTGAACCATTAGTTATAGTATTAATATTAATATTAAATGCTGCCGTAGGTG 
        481 TATGGCAAGAATGTAATGCTGAAAAATCTTTAGAAGCTTTAAAAGAATTACAACCTACCA 
        541 AAGCTAAAGTATTACGAGATGGGAAGTGGGAAATTATTGATAGTAAATATTTATATGTTG 
        601 GTGATATTATTGAATTGAGTGTTGGTAATAAAACTCCCGCTGATGCAAGAATAATTAAAA 
        661 TATATTCAACAAGTTTAAAAGTTGAACAGAGTATGTTAACAGGAGAATCCTGTTCAGTTG 
        721 ACAAATATGCTGAAAAAATGGAAGATAGTTATAAAAATTGTGAAATACAGTTGAAAAAAA 
        781 ATATTTTATTTTCATCTACCGCTATTGTATGTGGTAGATGTATAGCTGTTGTAATCAACA 
        841 TAGGTATGAAGACTGAAATAGGTCATATTCAGCATGCTGTTATAGAATCAAATAGTGAAG 
        901 ATACTCAAACACCTTTACAAATAAAAATCGATTTATTTGGTCAACAATTATCAAAAATCA 
        961 TTTTTGTAATATGTGTAACTGTATGGATTATTAATTTTAAACATTTCTCAGATCCAATTC 
       1021 ATGGTTCATTTTTATATGGTTGTTTATATTATTTTAAAATTAGTGTTGCTTTAGCTGTTG 
       1081 CTGCTATACCAGAAGGATTGCCAGCAGTCATAACAACTTGTTTAGCTTTAGGAACAAGAA 
       1141 GAATGGTAAAAAAAAATGCTATAGTAAGAAAATTACAAAGTGTTGAGACGTTAGGATGTA 
       1201 CAACGGTTATATGTTCTGATAAAACAGGTACCCTTACAACAAATCAAATGACAACAACCG 
       1261 TGTTTCATTTGTTTAGAGAATCTGATTCTTTAACAGAATACCAACTATGTCAAAAAGGGG 
       1321 ATACCTATTACTTTTATGAAAGTTCAAACTTAACAAATGATATATATGCAGGTGAATCAT 
       1381 CTTTTTTTAATAAATTAAAAGATGAAGGAAATGTTGAAGCTTTAACGGATGATGGAGAAG 
       1441 AAGGATCAATTGATGAAGCTGATCCATATAGTGATTATTTTTCTAGTGATAGTAAGAAAA 
       1501 TGAAAAATGATTTAAACAACAACAATAATAATAATAATAATAGTAGTAGGAGTGGTGCTA 
       1561 AGAGGAATATTCCTTTAAAAGAAATGAAATCAAATGAAAATACAATAATAAGTAGAGGTA 
       1621 GTAAAATATTAGAAGATAAAATTAATAAATATTGTTATTCAGAATATGATTATAATTTTT 
       1681 ATATGTGTTTAGTAAATTGTAATGAAGCAAATATTTTCTGTAACGATAATAGTCAAATAG 
       1741 TAAAAAAATTTGGAGACAGTACCGAATTAGCTTTATTACATTTTGTACATAATTTTGATA 
       1801 TATTACCAACATTCTCTAAAAATAATAAAATGCCAGCAGAATATGAAAAAAATACAACAC 
       1861 CTGTACAATCATCAAATAAGAAGGATAAATCACCAAGGGGTATCAACAAATTCTTTAGTT 
       1921 CAAAAAATGATAACAGTCATATTACCAGTACATTGAATGAAAATGATAAGAATTTAAAGA 
       1981 ATGCTAACCATTCTAATTATACTACAGCTCAGGCAACAACAAATGGATATGAAGCTATAG 
       2041 GAGAAAATACATTTGAGCATGGCACAAGTTTTGAAAATTGTTTCCACTCAAAATTGGGTA 
       2101 ATAAAATAAATACCACATCAACACATAATAATAATAACAACAATAATAATAATAGTAATA 
       2161 GTGTTCCAAGTGAATGTATTTCTTCTTGGAGAAATGAATGTAAACAAATAAAAATTATTG 
       2221 AATTCACTAGAGAAAGGAAACTTATGAGTGTTATTGTTGAAAATAAAAAAAAAGAAATAA 
       2281 TATTGTATTGTAAAGGTGCACCTGAGAATATAATAAAAAATTGTAAATATTATTTAACGA 
       2341 AAAATGATATACGTCCATTAAATGAAACTTTAAAAAATGAAATTCATAATAAGATTCAAA 
       2401 ATATGGGAAAAAGAGCATTAAGAACACTTAGCTTTGCTTATAAAAAATTAAGTAGTAAAG 
       2461 ATTTAAATATTAAGAATACAGATGATTATTATAAATTAGAACAAGATTTAATTTATTTAG 
       2521 GTGGATTAGGTATTATTGATCCACCACGTAAATATGTAGGAAGAGCAATTAGATTATGCC 
       2581 ATATGGCTGGTATACGTGTATTTATGATTACAGGTGATAATATTAATACGGCCAGAGCTA 
       2641 TAGCTAAAGAAATTAATATATTAAATAAAAATGAAGGAGATGATGAAAAGGATAATTATA 
       2701 CAAATAATAAAAATACACAAATATGTTGTTATAATGGAAGAGAATTTGAAGATTTTTCAT 
       2761 TAGAAAAGCAAAAACATATTTTAAAAAATACACCAAGAATTGTTTTCTGTAGAACTGAAC 
       2821 CTAAACATAAAAAACAAATAGTAAAAGTATTAAAAGACTTAGGAGAAACAGTTGCTATGA 
       2881 CAGGTGATGGTGTAAATGATGCACCAGCATTGAAATCAGCTGACATAGGAATAGCTATGG 
       2941 GTATTAATGGAACGGAGGTAGCTAAAGAAGCATCAGATATTGTTTTAGCTGATGATAATT 
       3001 TTAATACTATAGTTGAAGCAATTAAAGAAGGAAGATGTATATATAATAATATGAAAGCAT 
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7.4.6 Position controls 
 
BIN CONTROL Cy3: TAATTATGAAAATAAAGGAG 
 
BIN CONTROL Cy5: TAATTATGAAAATAAAGGAG 
 
 
 
7.4.5 Flexible primers 
 
NOTE: 
• Regular: C-7 flexi tags free 
• Italic: flexi extension tags free 
• Bold: flexi C-7 tags in use!!! 
• Italic underlined: flexi extension tags in use!!! 
 
• Flexible C-7 primers 
 
01 C-7:  ACGCCGGAACGCCGGAACGCCGGA (crt 72) 
02 C-7:  ACGGGGCAACGGGGCAACGGGGCA (crt 74) 
03 C-7:  CAAGGCGCCAAGGCGCCAAGGCGC 
04 C-7:  CAGCGGCACAGCGGCACAGCGGCA 
05 C-7:  CCACACGGCCACACGGCCACACGG 
06 C-7:  GGGAGAGCGCAGCAGGCAACAGAG (dhfr 164) 
07 C-7:  GACCGCCACCAAGAACAGCACCGG (dhfr 164B) 
08 C-7:  GCGCCAACGCAGACCGGAAGACCA 
09 C-7:  CGCGCACAGAAGGGCGAGAGACGA (dhps 613B) 
10 C-7:  GCAGGGAAGCGGGAGCGAAACAGC (dhfr 108) 
11 C-7:  AAAACGGGGCACAGCGCGGCGGAA (dhfr 108B) 
12 C-7:  CCCCGAGAACGCCCGAAGCACAAG 
13 C-7:  GGGAACGACACAGACAAGCCGGGG (mdr1 184) 
14 C-7:  GGCGGGAACCGAAGACAGGGGAAG 
15 C-7:  GACAACGGGCAGCGACCGGACCAA 
16 C-7:  CCCAAAGCCCGCAACCCGACCAAC 
17 C-7:  CAGGAACCAAGCCAGCCAGAGGCC 
18 C-7:  ACACCACAGGACACACGCCCCAGG 
 
 
• Flexible extension primers 
 
01/72*:  TCCGGCGTTCCGGCGTTCCGGCGTTTTTAAGTATTATTTATTTAAGTGTA 
02/74*:  TGCCCCGTTGCCCCGTTGCCCCGTTATTATTTATTTAAGTGTATGTGTAAT 
03/:   GTTCCGCGGTTCCGCGGTTCCGCG 
04/:   GTCGCCGTGTCGCCGTGTCGCCGT 
05/:   GGTGTGCCGGTGTGCCGGTGTGCC 
06/164:  CTCTGTTGCCTGCTGCGCTCTCCCGGGAAATTAAATTACTATAAATGTTTTATT 
07/164B:  CCGGTGCTGTTCTTGGTGGCGGTCTTCTTGATAAACAACGGAACCTCCTA 
08/:   TGGTCTTCCGGTCTGCGTTGGCGC 
09/613B:  TCGTCTCTCGCCCTTCTGTGCGCGATTTTGATCATTCATGCAATGGG 
10/108:  GCTGTTTCGCTCCCGCTTCCCTGCCAAAATGTTGTAGTTATGGGAAGAACAA 
11/108B:  TTCCGCCGCGCTGTGCCCCGTTTTAAAGGTTTAAATTTTTTTGGAATGCTTTCCCAG 
12/:   CTTGTGCTTCGGGCGTTCTCGGGG 
13/184:  CCCCGGCTTGTCTGTGTCGTTCCCTGCCAGTTCCTTTTTAGGTTTAT 
14/:   CTTCCCCTGTCTTCGGTTCCCGCC 
15/:   TTGGTCCGGTCGCTGCCCGTTGTC 
16/:   GTTGGTCGGGTTGCGGGCTTTGGG 
17/:   GGCCTCTGGCTGGCTTGGTTCCTG 
18/:   CCTGGGGCGTGTGTCCTGTGGTGT 
(* currently in test stage) 
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7.5 Oligonucleotide array on the chip 
 
 
• galDesigner software: Template saved as malaria.sti 
 
 
7.5b Oligonucleotide array on the chip 
 
 (Intermediate batch designed by Jutta, May-July 2006) 
 
 
• galDesigner software: Template saved as genopole_May06.sti 
 
For slide printing, 0.5 nl of a 50 µM solution of the C-7 primers are used per spot 
(Prior to printing, the 500 µM C7-primer stock solutions have to be diluted 1:10 in 180 mM 
phosphate buffer pH 8.0). 
 
 
Cy5 cont. 86 13/184 1034 1042 1246 436 437 540 581 613 
09/613B 640 645 16 51 59 10/108 11/108B 06/164 07/164B 01/72 
DHFR Neg1 75B1 76 97 152 163 220 271 326 326B 371 
356 356B 538 574 623 683 769 MDR Neg2 CRT Neg3 DHPSNeg4 Cy3 cont. 
769B 02/74 Empty! Empty! Empty! Empty! Empty! Empty! Empty! Empty! Empty! 
Cy5 cont. 86 13/184 1034 1042 1246 436 437 540 581 613 
09/613B 640 645 16 51 59 10/108 11/108B 06/164 07/164B 01/72 
DHFR Neg1 75B1 76 97 152 163 220 271 326 326B 371 
356 356B 538 574 623 683 769 MDR Neg2 CRT Neg3 DHPSNeg4 Cy3 cont. 
769B 02/74 Empty! Empty! Empty! Empty! Empty! Empty! Empty! Empty! Empty! 
Cy5 cont. 86 13/184 1034 1042 1246 436 437 540 581 613 
09/613B 640 645 16 51 59 10/108 11/108B 06/164 07/164B 01/72 
DHFR Neg1 75B1 76 97 152 163 220 271 326 326B 371 
356 356B 538 574 623 683 769 MDR Neg2 CRT Neg3 DHPSNeg4 Cy3 cont. 
769B 02/74 Empty! Empty! Empty! Empty! Empty! Empty! Empty! Empty! Empty! 
Cy5 cont. 86 184 1034 1042 1246 436 437 540 581 613 
613B 640 645 16 51 59 108 108B 164 164B 01/72 
DHFR Neg1 75B1 76 97 152 163 220 271 326 326B 371 
356 356B 538 574 623 683 769 MDR Neg 2 CRT Neg 3 DHPS Neg 4 Cy3 cont. 
769B 02/74 13/184/ 09/613B 10/108 11/108B 06/164 07/164B 12/ Empty! Empty! 
Cy5 cont. 86 184 1034 1042 1246 436 437 540 581 613 
613B 640 645 16 51 59 108 108B 164 164B 01/72 
DHFR Neg1 75B1 76 97 152 163 220 271 326 326B 371 
356 356B 538 574 623 683 769 MDR Neg 2 CRT Neg 3 DHPS Neg 4 Cy3 cont. 
769B 02/74 13/184/ 09/613B 10/108 11/108B 06/164 07/164B 12/ Empty! Empty! 
Cy5 cont. 86 184 1034 1042 1246 436 437 540 581 613 
613B 640 645 16 51 59 108 108B 164 164B 01/72 
DHFR Neg1 75B1 76 97 152 163 220 271 326 326B 371 
356 356B 538 574 623 683 769 MDR Neg 2 CRT Neg 3 DHPS Neg 4 Cy3 cont. 
769B 02/74 13/184/ 09/613B 10/108 11/108B 06/164 07/164B 12/ Empty! Empty! 
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7.6 SNPs on the chip 
 
Pfdhps Polymorphisms CHIP 
436 TCT→GCT/TTT Ser→Ala/Phe S→A/F TCT→GCT CII S→A Cy3=WT Cy5=MUT1 
437*** GCT→GGT Ala→Gly A→G GCT→GGT CI A→G Cy3=MUT Cy5=WT 
540 AAA→GAA Lys→Glu K→E AAA→GAA CI K→E Cy3=WT Cy5=MUT 
581 GCG→GGG Ala→Gly A→G GCG→GGG CI A→G Cy3=WT Cy5=MUT 
613 GCC→ACC Ala→Thr A→T GCC→ACC CI A→T Cy3=MutA Cy5=WT or MutB 
613B*** GCC→TCC Ala→Ser A→S GCC→TCC CII A→S Cy3=WT or MutA Cy5=MutB 
640*** ATT→TTT Ile→Phe I→F ATT→TTT C l I→F Cy3=MUT Cy5=WT 
645 CAC→CCC His→Pro H→P CAC→CCC CII H→P Cy3=MUT Cy5=WT 
Pfdhfr Polymorphisms CHIP 
16 GCA→GTA Ala→Val A→V GCA→GTA CI A→V Cy3=WT Cy5=MUT 
51 AAT→ATT Asn→Ile N→I AAT→ATT CI N→I Cy3=WT  Cy5=MUT 
59*** TGT→CGT Cys→Arg C→R TGT→CGT CI C→R Cy3=WT Cy5=MUT 
108 AGC→AAC Ser→Asn S→N AGC→AAC CI S→N Cy3=MutA or MutB Cy5=WT 
108B*** AGC→ACC Ser→Thr S→T AGC→ACC CII S→T Cy3=WT or MutA Cy5=MutB 
164 ATA→TTA Ile→Leu I→L ATA→TTA CI I→L Cy3=WT Cy5=MUT 
164B*** ATA→TTA Ile→Leu I→L ATA→TTA CII I→L Cy3=WT Cy5=MUT 
Pfmdr1 Polymorphisms CHIP 
86 AAT→TAT Asn→Tyr N→Y AAT→TAT CI N→Y Cy3=WT Cy5=MUT 
184 TAT→TTT Tyr→Phe Y→F TAT→TTT CI Y→F Cy3=WT Cy5=MUT 
1034 AGT→TGT Ser→Cys S→C AGT→TGT CI S→C Cy3=WT Cy5=MUT 
1042*** AAT→GAT Asn→Asp N→D AAT→GAT CI N→D Cy3=MUT Cy5=WT 
1246 GAT→TAT Asp→Tyr D→Y GAT→TAT CII D→Y Cy3=MUT Cy5=WT 
Pfcrt Polymorphisms CHIP 
72 TGT→AGT Cys→Ser C→S TGT→AGT CI C→S Cy3=MUT Cy5=WT 
74 ATG→ATT Met→Ile M→I ATG→ATT CII M→I Cy3=MUT Cy5=WT 
75B1 AAT→GAT/GAA Asn→Asp/Glu N→D/E AAT→GAT/GAA CI N→D or E Cy3=WT Cy5=MUT 
76*** AAA→ACA Lys→Thr K→T AAA→ACA CII K→T Cy3=WT Cy5=MUT 
97 CAC→CAA His→Gln H→Q CAC→CAA CII H→Q Cy3=WT Cy5=MUT 
152 ACT→GCT Thr→Ala T→A ACT→GCT CI T→A Cy3=WT Cy5=MUT 
163 AGT→AGG Ser→Arg S→R AGT→AGG CII S→R Cy3=WT Cy5=MUT 
220 GCC→TCC Ala→Ser A→S GCC→TCC CII A→S Cy3=MUT Cy5=WT 
271 CAA→GAA Gln→Glu Q→E CAA→GAA CI Q→E Cy3=WT Cy5=MUT 
326 AAC→GAC Asn→Asp N→D AAC→GAC CI N→D Cy3=WT Cy5=MUT1 
326B*** AAC→AGC Asn→Ser N→S AAC→AGC CI N→S Cy3=MUT2 Cy5=WT 
356 ATA→TTA Ile→Leu I→L ATA→TTA CI I→L Cy3=WT Cy5=MUT1 
356B*** ATA→ACA Ile→Thr I→T ATA→ACA CI I→T Cy3=WT Cy5=MUT2 
371 AGA→ATA Arg→Ile R→I AGA→ATA CII R→I Cy3=MUT Cy5=WT 
PfATPase6 Polymorphisms CHIP 
538*** AGT→AGC Ser→Arg S→R AGT→AGC CI S→R Cy3=MUT Cy5=WT 
574 CAA→CCA Gln→Pro Q→P CAA→CCA CII Q→P Cy3=MUT Cy5=WT 
623 GCA→GAA Ala→Glu A→E GCA→GAA CII A→E Cy3=WT Cy5=MUT 
683 AAT→AAG Asn→Lys N→K AAT→AAG CII N→K Cy3=WT Cy5=MUT 
769 AGT→AAT Ser→Asn S→N AGT→AAT CI S→N Cy3=MUT Cy5=WT 
769B*** AGT→AAT Ser→Asn S→N AGT→AAT CI S→N Cy3=WT Cy5=MUT 
 
(*** = extension on antisense strand) 
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7.7 PCR conditions for QIAGEN® Taq polymerase 
 
7.7.1 Primary PCR mix 
 
Reagents 1 reaction 14 reactions
H2O 33.25 µl 465.5 µl
10 x buffer (containing 15 mM MgCl2!) 5.0 µl 70.0 µl
dNTP mix (2mM) 5.0 µl 70.0 µl
MgCl2 (25mM) 3.0 µl 42.0 µl
Primary PCR primer mix (10 µM each) 1.0 µl 14.0 µl
Taq Polymerase 5U/ µl 0.25 µl 3.5 µl
Final Volume 47.5 µl 665.0 µl
DNA  2.5 µl 
Final Volume 50.0 µl 
 
 
6.7.2 Primary PCR program 
 
96 °C 180 Sec  
 
96 °C   30 sec 
52 °C   90 sec  20 cycles for clinical (symptomatic) samples 
72 °C   90 sec  25 cycles for community (asymptomatic) samples 
 
Hold at 4 °C 
 
 
 
7.7.3 Nested PCR mix 
 
Reagents 1 reaction 14 reactions
H2O 66.5 µl 931.0 µl
10 x buffer (containing 15 mM MgCl2!) 10.0 µl 140.0 µl
dNTP mix (2mM) 10.0 µl 140.0 µl
MgCl2 (25mM) 6.0 µl 84.0 µl
Nested PCR primer mix (10 µM each) 2.0 µl 28.0 µl
Taq Polymerase 5U/ µl 0.5 µl 7.0 µl
Final Volume 95.0 µl 1330.0 µl
Primary PCR product 5.0 µl  
Final Volume 100.0 µl 
 
 
6.7.4 Nested PCR program 
 
96 °C 180 sec 
 
96 °C   30 sec 
52 °C   90 sec  20 cycles for clinical (symptomatic) samples 
72 °C   90 sec  25 cycles for community (asymptomatic) samples 
 
Hold at 4 o C 
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SITE Karimui area 
PROVINCE Simbu 
HEALTH FACILITY Sigimaru health centre 
CATCHMENT AREA 6’000-7’000 
YEAR 2003 2004 2005 
TOTAL NUMBER OF INDIVIDUALS SURVEYED n=265 n=347 n=359 
Characteristics of study population    
Sex (x/n (%)) F: 137/265 (51.70) F: 192/347 (55.33) F: 186/359 (51.81) 
 M: 128/265 (48.30) M: 155/347 (44.67) M: 173/359 (48.19) 
Age (mean (95% CI), yrs) 18.85 (16.98-20.71) 19.43 (17.72-21.15) 15.41 (14.01-16.81) 
Endemicity    
Spleen rate all age groups (%, (95% CI)) nd 12.79 (9.45-16.79) 21.43 (17.24-26.10) 
Spleen rate 2-9 years (%, (95% CI)) nd 26.85 (18.78-36.24) 35.82 (27.73-44.55) 
Spleen rate adults (>20 years) (%, (95% CI)) nd 4.96 (2.02-9.96) 6.25 (2.55-12.45) 
Pf prevalence in children 2-9 years (x/n (%, (95% CI)) 13/93 (13.98, 7.66-22.72) 20/107 (18.69, 11.81-27.38) 44/138 (31.88, 24.21-40.35) 
Prevalence by microscopy    
Pf prevalence (x/n, (%)) 34/258 (13.18) 64/346 (18.50) 82/358 (22.91) 
Pv prevalence (x/n, (%)) 14/258 (5.43) 39/346 (11.27) 41/358 (11.45) 
Pm prevalence (x/n, (%)) 5/258 (1.94) 10/346 (2.89) 9/358 (2.51) 
Po prevalence (x/n, (%)) 0/258 (0.00) 0/346 (0.00) 0/358 (0.00) 
Overall malaria prevalence (all species, (x/n, (%)) 49/258 (18.99) 106/346 (30.64) 119/358 (33.24) 
Mixed infections    
0=no infection (x/n, (%)) 209/258 (81.01) 240/346 (69.36) 239/358 (66.76) 
Pf single infection (x/n, (%)) 31/258 (12.02) 57/346 (16.47) 71/358 (19.83) 
Pv single infection (x/n, (%)) 11/258 (4.26) 32/346 (9.25) 29/358 (8.10) 
Pm single infection (x/n, (%)) 4/258 (1.55) 10/346 (2.89) 6(358 (1.68) 
Pf plus Pv double infection (x/n, (%)) 2/258 (0.78) 7/346 (2.02) 10/358 (2.79) 
Pf plus Pm double infection (x/n, (%)) 0/258 (0.00)  1/358 (0.28) 
Pv plus Pm double infection (x/n, (%)) 0/258 (0.00)  2/358 (0.56) 
Pf plus Pv plus Pm triple infection (x/n, (%)) 1/258 (0.39)   
Pf density (geometric mean (range), per µl) 782 (0-43800) 357 (0-81600) 571 (0-138160) 
 
Appendix IV 
 
3 
 
SITE Karimui area 
PROVINCE Simbu 
YEAR 2003 2004 2005 
TOTAL NUMBER OF INDIVIDUALS SURVEYED n=265 n=347 n=359 
Prevalence by PCR    
Pf prevalence by microscopy (x/n (%, (95% CI)) 34/258 (13.18, 9.30-17.92) 64/346 (18.50, 14.54-22.97) 82/358 (22.91, 18.65-27.61) 
Pf prevalence by msp2 nPCR (x/n (%, (95% CI)) 102/263 (38.78, 32.86-44.96) 71/347 (20.46, 16.34-25.09) 131/359 (36.49, 31.50-41.70) 
Mean multiplicity of infection (MOI) (95% CI, range) 1.46 (1.32-1.60, 1-4) 1.59 (1.38-1.80, 1-4) 1.77 (1.62-1.92, 1-4) 
Pattern of MOI (msp2 genotypes)    
Single (x/n, (%)) 65/102 (63.73) 44/71 (61.97) 61/131 (46.56) 
Double (x/n, (%)) 29/102 (28.43) 16/71 (22.54) 45/131 (34.35) 
Triple (x/n, (%)) 6/102 (5.88) 7/71 (9.86) 19/131 (14.50) 
Quadruple (x/n, (%)) 2/102 (1.96) 4/71 (5.63) 6/131 (4.58) 
Quintuble (x/n, (%))    
Sextuple (x/n, (%))    
Prevalence 3D7 allele family (x/n, (%)) 70/102 (68.63) 48/71 (67.60) 93/131 (70.99) 
Prevalence FC27 allele family (x/n, (%)) 57/102 (55.88) 42/71 (59.15) 91/131 (69.46) 
Symptoms    
Temperature (mean (95% CI),°C) 36.06 (36.00-36.13) 36.09 (36.02-36.16) 36.42 (36.36-36.49)  
Fever cases (temperature =37.5°C), x/n, (%, 95% CI) 3/264 (1.14, 0.23-3.28) 8/347 (2.31, 1.00-4.49) 16/359 (4.46, 2.57-7.14) 
Hb (mean (95% CI), g/dl) 11.47 (11.19-11.76) 12.05 (11.83-12.27) 11.44 (11.22-11.66) 
Anaemia (Hb <7.5 g/dl, x/n, (%, 95% CI) 12/263 (4.56, 2.38-7.83) 6/344 (1.74, 0.64-3.76) 10/359 (2.79, 1.34-5.06) 
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SITE Karimui area 
PROVINCE Simbu 
YEAR 2003 2004 2005 
TOTAL NUMBER OF INDIVIDUALS SURVEYED n=265 n=347 n=359 
Drug pressure    
Consumption at health facilities    
Health book checked (x/n, (%)) 8/265 (3.02%) 37/347 (10.66) 119/359 (33.15) 
Antimalarial treatment courses in previous year (mean, (95%CI)) 1.37 (0.12-2.63) 1.81 (1.22-2.40) 1.39 (1.17-1.60) 
Antimalarial treatment courses in previous year (median, (range)) 1 (1-5) 1 (0-6) 1 (0-4) 
Combination therapy last course (x/n, (%)) 8/8 (100%) 28/35 (80.00) 95/107 (88.79) 
Consumption outside health facilities    
Consumption of drugs outside health facilities (x/n=y, (%)) 28/265 (10.57) 3/347 (0.86) 0/359 (0.00) 
       Pharmacy (x/y, (%)) 11/28 (39.28) 0/3 (0.00)  
       Store (x/y, (%)) 3/28 (10.71) 0/3 (0.00)  
       Market (x/y, (%)) 0/28 (0.00) 0/3 (0.00)  
       Healer (x/y, (%)) 0/28 (0.00) 0/3 (0.00)  
       Relatives (x/y, (%)) 0/28 (0.00) 0/3 (0.00)  
       Other places (x/y, (%)) 18/28 (64.28) 3/3 (100.00)  
              Missionary 17/28 (60.71) 3/3 (100.00)  
              Marasin meri    
              Local aid post    
              Home supply (staff health facility, friends) 1/28 (3.57)   
Reported drugs consumed outside health facilities    
Antimalarials (x/y, (%))  15/28 (83.33) 1/3 (33.33)  
Pain killers (e.g., Paracetamol, Aspirin, etc.) (x/y, (%))  14/28 (50.00)   
Unknown drugs (x/y, (%))  5/28 (17.86) 2/3 (66.67)  
Local herbs (x/y, (%))  1/28 (3.57)   
Antibiotics (x/y, (%))     
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SITE South Wosera North Coast area 
PROVINCE East Sepik Madang 
HEALTH FACILITY Kunjingini health centre (HC) Mugil HC 
CATCHMENT AREA 12'000-15'000 15'000-20'000 
YEAR 2003 2004 2004 
TOTAL NUMBER OF INDIVIDUALS SURVEYED n=317 n=366 n=359 
Characteristics of study population    
Sex (x/n (%)) F: 159/317 (50.16) F: 189/366 (51.64) F: 182/359 (50.70) 
 M: 158/317 (49.84) M: 177/366 (48.36) M: 177/359 (49.30) 
Age (mean (95% CI), yrs) 20.68 (18.84-22.53) 21.33 (19.57-23.08)  20.06 (18.12-21.99)  
Endemicity    
Spleen rate all age groups (%, (95% CI)) 7.46 (4.74-11.07) 7.44 (4.96-10.64) 25.36 (20.86-30.28) 
Spleen rate 2-9 years (%, (95% CI)) 17.65 (10.23-27.43) 17.27 (10.73-25.65) 41.13 (32.37-50.32) 
Spleen rate adults (>20 years) (%, (95% CI)) 0.00 (0.00-3.02) 0.67 (0.02-3.66) 10.96 (6.39-17.19) 
Pf prevalence in children 2-9 years (x/n (%, (95% CI)) 21/98 (23.60, 15.24-33.78) 36/110 (32.73, 24.08-42.33) 46/128 (35.94, 27.65-44.89) 
Prevalence by microscopy    
Pf prevalence (x/n, (%)) 55/314 (17.52) 96/356 (26.97) 82/358 (22.91) 
Pv prevalence (x/n, (%)) 31/314 (9.87) 62/356 (17.42) 48/358 (13.41) 
Pm prevalence (x/n, (%)) 20/314 (6.37) 12/356 (3.37) 11/358 (3.07) 
Po prevalence (x/n, (%)) 0/314 (0.00) 0/356 (0.00) 0/358 (0.00) 
Overall malaria prevalence (all species, (x/n, (%)) 97/314 (30.89) 151/356 (42.42) 120/358 (33.52) 
Mixed infections    
0=no infection (x/n, (%)) 217/314 (69.11) 205/356 (57.58) 238/358 (66.48) 
Pf single infection (x/n, (%)) 47/314 (14.97) 78/356 (21.91) 63/358 (17.60) 
Pv single infection (x/n, (%)) 24/314 (7.64) 46/356 (12.92) 30/358 (8.38) 
Pm single infection (x/n, (%)) 17/314 (5.41) 8/356 (2.25) 7/358 (1.96) 
Pf plus Pv double infection (x/n, (%)) 6/314 (1.91) 15/356 (4.21) 16/358 (4.47) 
Pf plus Pm double infection (x/n, (%)) 2/314 (0.64) 3/356 (0.84) 2/358 (0.56) 
Pv plus Pm double infection (x/n, (%)) 1/314 (0.32) 1/356 (0.28) 1/358 (0.28) 
Pf plus Pv plus Pm triple infection (x/n, (%))   1/358 (0.28) 
Pf density (geometric mean (range), per µl) 461 (0-18800) 513 (0-153680) 1156 (0-65680) 
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SITE South Wosera North Coast area 
PROVINCE East Sepik Madang 
YEAR 2003 2004 2004 
TOTAL NUMBER OF INDIVIDUALS SURVEYED n=317 n=366 n=359 
Prevalence by PCR    
Pf prevalence by microscopy (x/n (%, (95% CI)) 55/314 (17.52, 13.48-22.18) 96/356 (26.97, 22.42-31.90) 82/358 (22.91, 18.65-27.61) 
Pf prevalence by msp2 nPCR (x/n (%, (95% CI)) 129/317 (40.69, 35.24-46.32) 147/366 (40.16, 35.10-45.38) 115/359 (32.03, 27.23-37.13) 
Mean multiplicity of infection (MOI) (95% CI, range) 1.77 (1.57-1.96, 1-6) 1.85 (1.68-2.02, 1-5) 1.54 (1.38-1.70, 1-5) 
Pattern of MOI (msp2 genotypes)    
Single (x/n, (%)) 71/129 (55.04) 73/147 (49.66) 73/115 (63.48) 
Double (x/n, (%)) 32/129 (24.81) 36/147 (24.49) 27/115 (23.48) 
Triple (x/n, (%)) 18/129 (13.95) 28/147 (19.05) 12/115 (10.43) 
Quadruple (x/n, (%)) 2/129 (1.55) 7/147 (4.76) 1/115 (0.87) 
Quintuble (x/n, (%)) 5/129 (3.88) 3/147 (2.04) 2/115 (1.74) 
Sextuple (x/n, (%)) 1/129 (0.78)   
Prevalence 3D7 allele family (x/n, (%)) 81/129 (62.79) 106/147 (72.11) 87/115 (75.65) 
Prevalence FC27 allele family (x/n, (%)) 91/129 (70.45) 88/147 (59.86) 60/115 (52.17) 
Symptoms    
Temperature (mean (95% CI),°C) 36.55 (36.50-36.60) 36.52 (36.47-36.57) 36.40 (36.34-36.45) 
Fever cases (temperature =37.5°C), x/n, (%, 95% CI) 7/316 (2.22, 0.89-4.51) 8/266 (2.19, 0.89-4.02) 9/358 (2.51, 1.15-4.72) 
Hb (mean (95% CI), g/dl) 10.70 (10.51-10.89) 10.74 (10.59-10.89) 10.44 (10.26-10.62) 
Anaemia (Hb <7.5 g/dl, x/n, (%, 95% CI) 11/310 (3.55, 1.78-6.26) 30/363 (2.75, 1.33-5.01) 13/35 (3.63, 1.95-6.13) 
 
 
Appendix IV 
 
7 
 
SITE South Wosera North Coast area 
PROVINCE East Sepik Madang 
YEAR 2003 2004 2004 
TOTAL NUMBER OF INDIVIDUALS SURVEYED n=317 n=366 n=359 
Drug pressure    
Consumption at health facilities    
Health book checked (x/n, (%)) 241/317 (76.03) 277/366 (75.68) 292/359 (81.34) 
Antimalarial treatment courses in previous year (mean, (95%CI)) 1.20 (1.02-1.37) 1.47 (1.26-1.68) 1.37 (1.16-1.58) 
Antimalarial treatment courses in previous year (median, (range)) 1 (0-7) 1 (0-9) 1 (0-11) 
Combination therapy last course (x/n, (%)) 170/215 (79.07) 235/257 (91.44) 201/267 (75.28) 
Consumption outside health facilities    
Consumption of drugs outside health facilities (x/n=y, (%)) 36/317 (11.36) 38/366 (10.38) 81/359 (22.56) 
       Pharmacy (x/y, (%)) 0/36 (0.00) 8/38 (21.05) 22/81 (27.16) 
       Store (x/y, (%)) 1/36 (2.78) 9/38 (23.68) 7/81 (8.64) 
       Market (x/y, (%)) 0/36 (0.00) 0/38 (0.00) 0/81 (0.00) 
       Healer (x/y, (%)) 0/36 (0.00) 2/38 (5.26) 4/81 (4.94) 
       Relatives (x/y, (%)) 8/36 (22.22) 6/38 (15.79) 27/81 (33.33) 
       Other places (x/y, (%)) 31/36 (86.11) 25/38 (65.79) 36/81 (44.44) 
              Missionary    
              Marasin meri 31/36 (86.11) 24/38 (63.16)  
              Local aid post   19/81 (23.46) 
              Home supply (staff health facility, friends)  1/38 (2.63) 15/81 18.52) 
Reported drugs consumed outside health facilities    
Antimalarials (x/y, (%))  35/36 (97.22) 36/38 (94.74) 65/81 (80.25) 
Pain killers (e.g., Paracetamol, Aspirin, etc.) (x/y, (%))  1/36 (2.78) 6/38 (15.79) 34/81 (41.97) 
Unknown drugs (x/y, (%))  1/36 (2.78) 1/38 (2.63) 1/81 (1.23) 
Local herbs (x/y, (%))    4/81 (4.94) 
Antibiotics (x/y, (%))    9/81 (11.11) 
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